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The aim of this research was to identify factors associated with and assess 
the efficacy of preventative strategies in the treatment of diabetic 
nephropathy from data collected at nephrological out-patient follow-up visits. 
A study of mortality, over a ten year period, in 1,421 diabetic and 26,990 
non-diabetic people in Wolverhampton identified cardiovascular disease as 
the predominant cause of death in both groups, with female diabetic patients 
having an increased risk of dying from cardiovascular disease in comparison 
to male diabetic and female non-diabetic people. Diabetic nephropathy 
accounted for 4% of deaths in diabetic people. From 220 patients referred 
for nephrological assessment, diabetic nephropathy was diagnosed in 149. 
Comparison of nephropathy patents with control subjects, without 
nephropathy, and people with non-diabetic renal disease identified poor 
glycaemic control, hypertension, smoking history and defaulting from clinic 
visits as factors associated with nephropathy. The onset of nephropathy, 
retinopathy and hypertension, from diagnosis of diabetes, appeared to be 
accelerated in Type 2 patients, especially in Indo-Asian people. 
Assessment of the efficacy of preventative treatment strategies was made by 
determining survival in 141 nephropathy patients over eleven years. Seven- 
year survival was better in a subgroup of patients with serum creatinine 
levels within normal limits at nephrological assessment in comparison to the 
main group. Five year survival of patents on renal replacement therapy was 
better than observed in other studies. Un6ontrolled hypertension, which was 
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a hazard to survival, was common, and in many patients was untreated. 
Initial reduction of blood pressure after nephrological referral was not 
sustained in the majority of patients. Black patients had the worst 
hypertension control. The inability to speak English contributed to defaulting 
from routine clinic visits, was a risk for developing nephropathy and was a 
specific hazard for survival in Indo-Asian patents, especially in men, as was 
current cigarette smoking in Black patients. 
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1.1 Diabetes Mellitus 
Diabetes mellitus is a chronic incurable disease which affects over 30 million 
people in Europe alone and more than 100 million world wide (Fuller, 1991; 
DECODE study group, 1998). There are two types of diabetes. Typel 
(insulin dependent diabetes) presents in people of up to 35 years of age and 
requires treatment with both diet and insulin. Type 2 diabetes (non-insulin 
dependent diabetes) typically presents later in life but may start as early as 
35 years, and can be treated with diet alone, diet and oral therapy or diet 
and insulin. Diabetes and its accompanying complications are major causes 
of morbidity and mortality throughout the western world and increasingly, in 
developing countries. 
Type 1 diabetes is an auto-immune disease; the aetiology of which is 
unknown. Genetic research has shown that susceptibility to Type 1 diabetes 
is associated with alleles HLA-DQA1, DQB1 and DRB1 of the Human 
Leukocyte Antigen (HLA) region on chromosome 6 and the insulin-IGF2 
region on chromosome 11 (Todd et al, 1987; Julier et al, 1991; Davies et al, 
1994; Bain, 1995; Chauffert et al, 1997; Zevaco-Mattei et al, 1999). Although 
genetic susceptibility is present, diabetes does not develop until a trigger 
initiates the cell-mediated auto-immune response. The triggers are thought 
to be environmental which may include exposure to childhood viruses or 
toxins. The beta cells in the Islets of Langerhans in the pancreas, which 
normally produce insulin, are attacked and destroyed by the immune system. 
Subsequently, insulin secretion decreases and eventually stops (The Expelit 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1999). 
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Proinsulin, the precursor of insulin, is synthesised by the endoplasmic 
reticulum of the pancreatic beta cells. It is a single chain peptide which is 
cleaved during proteolysis to form insulin and C-peptide (Drury, 1979). 
Insulin is essential for the stimulation of the uptake of glucose by the brain, 
liver, gut and peripheral muscles; for the suppression of glucose production 
by the liver; and the formation and storage of glycogen in cells. It is released 
from beta cells when blood glucose levels rise above normal and is 
controlled by a negative feedback mechanism (Schmidt-Nielsen, 1983). In 
1922, Banting and Macleod first used insulin to treat diabetes and the 
prognosis for patients with the disease changed from a few years to 
potentially a full life span. However, although the last surviving patient of 
Professor Banting's original trial of insulin died in 1993 after 71 years of 
successfully treated diabetes, the prognosis for many patients with Type 1 
diabetes is of high morbidity and early mortality from the complications of the 
disease (Bliss, 1995). 
Type 2 diabetes is a more complex disease in which there is insulin 
resistance with varying degrees of insulin deficiency. This results in the 
occurrence of hyperglycaemia with an over-production of insulin leading to 
hyped nsu linaernia in the initial stages (DeFronzo et al, 1992; The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1999). 
Although insulin is produced, it does not appear to function adequately. This 
may be due to abnormalities in the post prandial secretion of insulin where 
the initial pulse release of insulin is decreased but the subsequent consistent 
release is near normal. The reasons for this are not fully understood but it 
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may be the result of beta cell dysfunction (Leahy, 1990; DeFronzo et al, 
1992). As blood glucose levels rise, the beta cells continue to produce 
insulin. Eventually, the production of insulin will stop and blood levels fall. As 
this happens, the level of glucose in the blood increases producing the same 
physiological effects of hyperglycaemia as in Type 1 diabetes. A number of 
studies in Type 2 diabetic patients, following oral glucose tolerance testing, 
have shown a deficient insulin response when compared to plasma glucose 
concentration, some suppression of glucose uptake by the liver and 
decreased suppression of hepatic glucose production (DeFronzo et al, 
1992). 
The onset of Type 2 diabetes is more insidious than Type 1 and often Type 2 
patients are unaware that they are ill. The symptoms occur gradually over a 
period of time and can vary in severity, depending on what proportion of beta 
cells are still functioning. Type 2 diabetes is frequently diagnosed during 
routine medical examinations for work or for insurance purposes. Some 
patients present with the complications which are detected by doctors, 
opticians and chiropodists. Often patients are unaware that they have Type 2 
diabetes because they do not associate the symptoms with the disease 
(Jackson etal, 1991; Singh etal, 1992). 
The complications of diabetes are the end result of badly controlled blood 
gl ucose levels often exacerbated by defaulting from routine diabetic clinic 
assessment (Harnmersley et al, 1985). The complications can be divided 
into two categories, acute metabolic and chronic. The acute metabolic 
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complications can either be the result of uncontrolled high blood glucose 
levels e. g.: diabetic ketoacidosis or hyperosmolar coma, or secondary to 
excess treatment with insulin where hypoglycaernia may lead to coma. 
The chronic complications can be subdivided into macrovascular, those 
affecting the large blood vessels, and microvascular, those affecting the 
small blood vessels. The macrovascular complications affect the heart, brain 
and the large blood vessels of the legs (Figure 1.1). Intensive insulin 
treatment has been shown to reduce the risk factors of cardiovascular 
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Figure 11.11: Macrovascular complications of diabetes 
Patients with both types of diabetes have an increased risk of developing 
and dying from cardiovascular disease in comparison to non-diabetic people 
(Kannel and McGee, 1979; Moss et al, 1991; de Grauw et al, 1995; Gatling 
et al, 1997). 
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The microvascular complications affect the small blood vessels in the retina, 
the kidney and the nervous system (Figure 1.2). 
Eyes 110- Retinopathy 




Figure 1.2: Microvascular complications of diabetes 
The Diabetes Control and Complication Trial in the USA and the EURODIAB 
IDDM Complications study in Europe have confirmed the direct link between 
poor blood glucose control and the development of microvascular 
complications (Diabetes Control and Complications Trial Study Group, 1993; 
Stephenson et al, 1994). 
The cost of diabetes and subsequent complications is high in terms of both 
the individual patient's quality of life and in the provision of health care for 
diabetic patents, in Europe alone the cost of diabetes care is thought to be 
5.8% of the total expenditure on healthcare (DECODE Study Group, 1998). 
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1.2 Microvascular Complications 
1.2.1 The Kidneys 
The kidneys are paired organs located in the posterior aspect of the 
abdomen behind the peritoneum. The blood supply for each kidney comes 
from a single renal artery; occasionally there are accessory renal arteries. 
The kidneys are excretory organs that remove waste products and toxins 
from the blood plasma during a process of filtration, reabsorption and tubular 
secretion. The nephron is the functional unit of the kidney. It has been 
estimated that in humans there are over one million nephrons per kidney 
(Brenner and Rector, 1986). 
0 
The nephron is composed of the Malpighian body, the proximal tubule, the 
loop of Henle, the distal tubule and the collecting duct. Within the Malpighian 
body, a small artery splits into a bundle of capillaries known as the 
glomerulus. Fluid is forced through the glomerular basement membrane by 
the blood pressure, a process known as glomerular ultrafiltration. For this to 
occur the blood pressure must be greater than the osmotic pressure of the 
blood proteins (Schmidt-Nielson, 1983; Brenner and Rector, 1986). The 
function of the glomerular basement membrane is to allow filtration of water 
and low molecular weight positively charged molecules while preventing loss 
of negatively charged molecules including plasma proteins, which in the 
normal kidney remain in the plasma after passing through the glomerular 
capillary network. Serum proteins of low molecular weight are filtered by the 
glomerulus but are then reabsorbed by the cells of the proximal tubule (Noth 
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et al, 1989). Following filtration, the fluid enters the proximal tubule where 
reabsorption of solutes, glucose and water occurs. Further reabsorption 
takes place in the loop of Henle, the distal tubule and the collecting ducts 
resulting in increasingly concentrated urine. Urine passes from the collecting 
ducts to the renal pelvis and is excreted via the ureters and bladder 
(Schmidt-Nielsen, 1983). 
The capillary network within the glomerulus is lined by endothelial cells, has 
a central region of mesangial cells With a surrounding matrix, and finally 
there is a layer of epithelial cells. The central region has three layers; the 
lamina rara externa, the lamina densa and the lamina rara interna (Brenner 
and Rector, 1986). The glornerular basement membrane contains a 
glycoprotein matrix, composed of type IV collagen in the form of a triple helix 
with three identical chains, and carbohydrate units. The function of these 
carbohydrate units may be to hold the peptide chains apart and determine 
porosity of the membrane (Keen and Jarret, 1982). Laminin is another 
glycoprotein present in the glomerular basement membrane. It is composed 
of three sub-chains linked by disulphide bonds to form a cross shape. The 
majority of the membrane is composed of type IV collagen and laminin which 
is thought to act as a link unit between the epithelial cells, collagen and 
heparan sulphate proteoglycan (Tariso et al, 1988; Deckert et al, 1992). 
Heparan sulphate proteoglycans have been identified in the three layers of 
the mesangium and in the mesangial matrix and are the major anionic 
component which maintain the charge selectivity of the membrane, thus 
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preventing filtration of negatively charged plasma proteins (Deckert et al, 
1992). 
1.2.2 Aefiblogy of Diabetic Nephropathy 
Diabetic nephropathy is the kidney disease that develops in individuals 
following years of poorly controlled diabetes. It can affect patients with either 
Type 1 or Type 2 diabetes. There appears to be a subset of patients who are 
particularly susceptible to developing nephropathy. It has been reported that 
35% of Type 1 patents will develop nephropathy (Krolewski et al, 1985). 
In 1989, Seaquist and co-workers demonstrated 82% clustering of 
nephropathy in families where one member had nephropathy in comparison 
to 17% in families free from the complication. Clustering of hypertension and 
cardiovascular disease has been shown in families of people with 
nephropathy (Chowdhbry et al, 1995). It is unlikely that a single gene is 
responsible for the development of nephropathy. A number of potential 
genes have been examined in relation to nephropathy; the DD allele of the 
ACE gene has been implicated with decline in glomerular filtration rate in 
nephropathy patients (Dudley et al, 1995; Tarnow, 1996; Vleming et al, 
1999). Other genes such as those encoding heparan sulphate 
proteoglycans, type IV collagen, insulin, aldose reductase, HLAB62 and 
HLADR9 genes have all been proposed as contributing to nephropathy 
(Tarnow, 1996; Chowdhury et al, 1995). Although, so far, these studies are 
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inconclusive. A number of genetic studies are in progress with the aim of 
addressing this question. 
1.2.2.1. Cellular Changes in Diabetic Nephropathy 
The damage to the small blood vessels of the kidney which leads to the 
development of nephropathy is complex and is probably due to a 
combination of factors at a cellular level accompanied by haemodynamic 
changes. The cellular events in diabetic nephropathy involve changes to the 
glomerular basement membrane, alterations in coagulation and fibrinolysis 
plus increased activity of the polyol pathway accompanied by 
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Figure 1.3: Possible mechanisms of damage to the small blood vessels of the 
kidney 
1.2.2.2 The Glomerular Basement Membrane 
Increased porosity of the glomerular basement membrane and loss of 
plasma proteins during ultrafiltration occurs following loss of the mechanisms 
maintaining the negative selective charge. This is related to thickening of the 
membrane and loss of heparan sulphate proteoglycan. In 1989, Noth and 
colleagues postulated that the basement membrane contains pores of 
different sizes, the majority of which are small (5.1-5.7nm), that allow normal 
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selective filtration of solutes plus a small number of larger pores which 
permit unselective filtration of larger proteins. 
In the presence of hyperglycaemia, blood proteins are known to undergo 
glycation (glycation is used instead of glycosylation to indicate that the 
reaction is not catalysed by an enzyme). This reaction occurs between 
glucose and a protein, in the absence of an enzyme, whereby the aldehyde 
group of the glucose molecule binds to the NI-12 of a protein forming a Schiff 
base which is unstable. The Schiff base rearranges to form a more stable 
Amadori product. In theory, both of these reactions are still reversible, but 
the Amadori product forms cross links with other molecules and the glycated 
protein formed in this irreversible reaction will remain in the body until it is 
naturally broken down (Cerami et al, 1987; Brownlee et al, 1988). In diabetic 
patients, the measurement of glycylated haemoglobin (HbA1 or HbAlc) is 
routinely used to assess diabetic control over the previous six weeks, as it 
gives an indication of mean blood glucose concentrations over this period. 
The effects of glycation on the glomerular basement membrane have been 
investigated; when type IV collagen and laminin were incubated in high 
concentrations of glucose, there was increased glycation of both proteins 
(Tarisio et al, 1988). It has also been demonstrated in streptozotocin-induced 
diabetic rats that increase in blood glucose results in the loss of glomerular 
anionic sites, which represents a decrease in heparan sulphate proteoglycan 
in the glomerular basement membrane. However, this may or may not be the 
result of glycation (Modya et al, 1993). 
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Advanced glycation end products (AGEs) and Amadori products have been 
found in the glomeruli of patients with nephropathy (Sakai et al, 1996). 
AGEs With modified proteins are known to stimulate mesangial cells to 
synthesise matrix proteins and up-regulate the production of type IV collagen 
(Sugiyama et al, 1996). The presence of glycated proteins may contribute to 
thickening of the glomerular basement membrane and other functional 
changes. 
Glycation of deoxyribonucleic acid (DNA) has been demonstrated in 
bacterial plasmids and may occur in eukaryote cells in vivo (Cerami et al, 
1987). More recently, the administration of AGEs to normal adult mice 
resulted in increased expression of the genes for type IV collagen and 
laminin (Striker and Striker, 1996). Hyperglycaernia in diabetic mice also 
resulted in increased expression of the messenger ribonucleic acid (mRNA) 
for type IV collagen and laminin but in dwarf mice carrying a mutated gene 
for growth hormone, there was no increase in expression of mRNA. for these 
extracellular membrane proteins, suggesting a possible role for growth 
hormone in increased production of extracellular proteins and subsequent 
thickening of the glomerular basement membrane (Striker et al, 1996). It is 
also known that in human cell cultures, mesangial cells synthesise, secrete 
and bind insulin-like growth factor (IGF-1); this in turn stimulates cell 
production (Kojima et al, 1988; Aron et al, 1989). 
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1.2.2.3 Free Radicals 
Free radicals are highly reactive cytotoxic atoms with unpaired electrons in 
the outer shell of their electron orbit. They are short lived because they 
scavenge and bind to spare electrons from a nearby atom to restore the 
paired electron balance; they are strong oxidants (Figure 1.4) (Jennings and 
Barneft, 1988). Free radical production occurs in many reactions in the body 
including oxidative metabolism and the electron transport chain but there are 
mechanisms which control free radical activity. These include detoxifying 
enzymes (superoxide dismutase and catalase) and antioxidants (Vitamins C 
and E, glutathione and carotene). 
02+ e- 0-2 (Superoxide) 
02+ e' + 2H+ H202 (Hydrogen peroxide) 
H202+6-+ H+ H20+ OH (Hydroxyl radical) 
OH + e"+ H+ 10 H20 
(Anonymous, From Current Debates on Diabetes, 1992) 
Figure 1.4: Free radical production 
The sorbitol pathway is affected by hyperglycaernia in that high glucose 
levels result in increased use of NADPH and sorbitol accumulation (Section 
1.2.2.4). This use of NADPH eventually results in reduced synthesis of 
antioxidants (Barnett and Dobson, 1990). People with diabetes are known to 
have decreased levels of the antioxidants glutathione and Vitamin C. 
Oxidation of lipoprotein by free radicals produce lipid peroxides. These 
stimulate platelet aggregation and fibrin formation while decreasing 
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prostaglandin synthesis by endothelial cells. Hyperglycaernia is thought to 
promote lipid peroxidation, thereby increasing the risk of vascular damage. 
Non-enzymatic glycation alters the activity of enzymes, affects co-enzymes 
and ultimately leads to the production of free radicals. Glycation of 
superoxide dismutase results in an Amadori product which generates 
superoxide (0-2) and hydrogen peroxide (H202) which in turn produces the 
hydroxyl radical (OH) (Fujii et al, 1996). Extracellular superoxide is 
transported into the cell which causes an increase in intracellular calcium 
ions which in turn activates synthesis of nitric oxide (Ido et a/, 1996). 
Combination of superoxide and nitric oxide produces the reactive 
peroxynitrite ion, this decomposes to form hydroxyl free radicals 
(Bruckdorfer, 1993). Increased nitric oxide synthesis by endothelial cells 
results in vasodilation and vascular permeability and production of hydroxyl 
free radicals leads to oxidative damage to cells (Tomlinson, 1994; Ido et al, 
1996) 
1.2.2.4 The Polyol (Sorbitol) Pathway 
It has been suggested that the polyol pathway is intimately involved in the 
mechanisms which cause microvascular disease in the kidney, eyes and the 
nerves. In the presence of hyperglycaernia, there is increased production of 
aldose reductase, possibly as a means of regulating osmolarity in the 
extracellular fluid. AJdose reductase catalyses the reaction where D-glucose 
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Figure 1.5: Sorbitol pathway (Tomlinson, 1994) 
The consumption of NADPH during this reaction by aldose reductase is 
high. NADPH is needed to produce antioxidants, therefore their production is 
decreased during hyperglycaernia leaving tissues susceptible to damage by 
free radicals. 
1.2.2.5 Alterations to Blood Coagulation and Fibrinolysis 
It has been suggested that thickening of the glomerular basement 
membrane is a response to capillary endothelial damage or raised capillary 
pressure (Tooke, 1987). However, other factors affecting endothelial cells 
may contribute to the changes in nephropathy. Interleukin-1 has an inhibitory 
effect on the synthesis by endothelial cells of tissue plasminogen activator (t- 
PA), an essential component of fibrinolysis - the breakdown of fibrin in blood 
clots (Gough and Grant, 1991). 
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Endothelial cells have a number of important functions in regulating 
haernostasis including: 
(a) synthesis of. 
plasminogen (the substrate of the fibrolytic system) 
von Willebrand factor (promotes platelet adhesion) 
platelet activating factor (PAF) (stimulates aggregation of platelets) 
prostacyclin (an inhibitor of platelet aggregation) 
(b) contributing to thrombus formation by binding fibrinogen 
(c) producing thrombomodulin (which binds thrombin while simultaneously 
binding heparan sulphate, an essential co-factor for anti-thrombin III and is 
also important in the protein C anticoagulant system) 
(d) producing endothelial relaxing factor (EDRF) (which controls local 
vascular tone). 
Abnormalities of production of EDRF may contribute to the haemodynamics 
found in nephropathy (Tooke, 1987; Remuzzi and Rossi, 1989). Thus 
damage to the endothelial layer of the glomerulus produces abnormalities of 
haemostasis which may in turn contribute to further renal pathology. 
In the presence of hyperglycaemia, platelets demonstrate increased 
adhesiveness and aggregation (Jones and Peterson, 1981). In 1979, 
Waitzman proposed that there is disruption to the production of 
prostaglandins, including prostacyclin, in diabetic patients with microvascular 
disease. It is postulated that this disruption alters the mechanisms which 
normally prevent platelet aggregation. Increased activity of platelets may 
damage endothelial cells thus stimulating abnormal production of platelet 
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activating factor (PAF) and plasminogen activator inhibitor I (PAI-1) leading 
to the release of platelet derived growth factor (PDGF) and Interleukin-1. 
A recent study comparing Type 2 diabetic patents with non diabetic controls 
demonstrated that platelet aggregation was the same for both groups (Jokl 
et al. 1995). However, in the diabetic patients platelets released significantly 
more PAM, which correlated with low levels of very low density lipoprotein 
(VLDL) cholesterol and high plasma triglyceride levels (Jokl et al, 1995). A 
number of studies of diabetic patients with reduced renal function, varying 
from microalburninuria to overt nephropathy, have shown increased 
concentrations of lipids and plasma fibrinogen and enhanced platelet activity 
and aggregation (Rylance et al, 1986; Jensen et al, 1988; Jones et al, 1989 
and O'Donnell et al, 1991: Omoto et al, 1999). 
1.2.2.6 Upids in Diabetic Nephropathy 
Patients with well controlled Type 1 diabetes have similar lipid profiles to 
non-diabetic people, whereas those with poorly controlled diabetes have 
elevated lipid levels (Befteridge, 1989). In contrast, Type 2 patients tend to 
have low HDL cholesterol and raised total and very low density lipoprotein 
triglyceride levels (Befteridge, 1989). Hyperlipidaemia has been 
demonstrated to be linked with hyperinsulinaemia and may be an integral 
part of the development of Type 2 diabetes (Frayn, 1993). 
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It has been demonstrated that in both types of diabetes, patients with 
microalbuminuria and those with proteinuria have raised levels of total 
cholesterol, low density lipoprotein (LDL) cholesterol and triglyceride (Eckel 
et al, 1981; Wafts et al, 1988; Seghieri et al, 1990). 
1.2.2.7 The Role of the Renin-Angiotensin System in Diabetic 
Nephropathy 
Much research had been undertaken looking at the role of the renin- 
angiotensin system (RAS) in diabetic nephropathy (Figure 1.6). 
Angiotensi 
Renin 




Angiotensin 11 (All) 
Binding to All Receptor 
(adapted from Barnett and Dobson, 1990) 
Figure 1.6: Renin-Angiotensin System 
The RAS works by a negative feedback mechanism in the kidney and is 
designed to maintain sodium balance and circulating blood volume (Padfield, 
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1988; Davidson et al, 1998). It is activated by reduced blood pressure, 
decreased blood volume, Na+ depletion and sympathetic stress. Renin, a 
proteolyfic enzyme, is released in response to the stimulants previously 
mentioned, and acts on angiotensinogen which is converted to angiotensin I 
(AI). This is turn is converted to angiotensin 11 (All) by the action of 
angiotensin converting enzyme (ACE). The effects of All binding to specific 
All receptors are to produce systemic vasoconstriction and stimulate the 
following: 
" aldosterone synthesis and secretion (by the adrenal cortex) which 
promotes sodium reabsorption by the proximal tubule of the kidney 
" hypophyseal vasopressin secretion 
" inhibit the release of renin in the kidneys. 
The RAS is inactivated when these conditions return to normal. The 
synthesis of RAS components occurs in a variety of cells relevant to 
nephropathy: renin and angiotensinogen are synthesised in endothelial, 
vascular smooth muscle cells and the liver; ACE is produced in vascular 
endothelial cells and All in the vasculature. All receptors are found in several 
organs including the vasculature smooth muscle, endothelial cells, the 
kidney and the heart (Osbakken, 1995). 
Diabetic patients, even with moderately good diabetic control, have an 
increased blood volume. This is due to the co-transport of sodium ions to the 
extracellular fluid which occurs with reabsorption of glucose by the renal 
tubules, leading to dilatation of the small blood vessels (Anderson and 
Brenner, 1988). This in turn causes adaptive hyperfiltration and 
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hyperperfusion in the micro-circulation of the glomerulus. The specific affect 
of All in the kidney is to increase the glomerular capillary pressure. 
Glomerular hyperfiltration is found in the early stages of diabetic 
nephropathy and is caused by a combination of elevated glomerular plasma 
flow and increased glomerular capillary hydraulic pressure (Zatz et al, 1986). 
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1.3 Clinical Aspects of Diabetic Nephropathy 
1.3.1 Clinical Presentation of Diabetic Nephropathy 
Five stages have been described in the development of diabetic 
nephropathy in Type I diabetic patients (Selby et al, 1990). The first stage 
occurs within the first five years following diagnosis of diabetes. There is 
hyperfunction of the kidney demonstrated by an increased glomerular 
filtration rate (GFR). On microscopic examination of renal biopsy specimens, 
the structure of the kidney appears to be normal, the albumin excretion rate 
(AER) and the blood pressure are both normal. The link between kidney 
function and blood pressure control is intimate; within the kidney are the 
components of several biochemical pathways including the RAS whose 
reactions influence vasoconstriction and vasodilation of blood vessels and 
ultimately the level of arterial blood pressure (Castiglioni and Savazzi, 1988; 
Selby etal, 1990). 
As the disease progresses to stage two, the glomerular structure alters and 
the glomerular basement membrane starts to thicken. The GFR may remain 
raised or return to normal while the AER and blood pressure remain normal. 
By stage three, the loss of small amounts of protein in the urine, known as 
microalbuminuria, becomes detectable. Microalbuminuria is defined as AER 
of 20-200 pg of protein minute-' or 30-300 mg 24hrl (Castiglioni and 
Savazzi, 1988; Deckert et al, 1991). The GFR may still be raised, normal or 
starting to decline as the kidney function deteriorates while the blood 
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pressure will be near the upper levels of normal or slightly raised. It was 
once thought that microalbuminuria rarely occurred in Type 1 patients before 
five years duration of diabetes (Castiglioni and Savazzi, 1988). However, 
recently the results of two studies, the EURODIAB IDDM Complications 
study and the WHO Multinational Study of Vascular Disease in Diabetes, 
have demonstrated that 19% (EURODIAB Study) and 15% (WHO study) of 
Type 1 patients had microalbuminuria within five years of diagnosis of 
diabetes (Stephenson et al, 1994). 
The progression to stage four of the disease is marked by the excretion of 
increasing amounts of protein in the urine until frank persistent proteinuria 
occurs, detectable on dipstick testing. At this point the AER is greater than 
200 jig protein minute-' or greater than 300mg of protein excreted every 24 
hours. The blood pressure will now have risen to hypertensive levels and 
require therapy. Proteinuria is thought to reach a peak after sixteen years 
duration of diabetes in susceptible Type I patients (Viberti, 1988). 
Stage five is the final progression to end stage renal failure (ESRF), by 
which time the GFIR will have declined to less than 10 ml minute-'. The AER 
may either be high, indicating continuing renal damage, or low as a result of 
loss of kidney function. Without renal replacement therapy (RRT), death 
would rapidly occur. 
In the past the development of microalbuminuria in Type 2 diabetes was 
regarded as a sign of incipient cardiovascular disease as often the diagnosis 
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of ischaemic heart disease or death from myocardial infarction frequently 
occurred within a relatively short time of detection of microalbuminuria 
(Mogensen, 1984; Viberti, 1988). It is possible that a more aggressive 
approach to the treatment of both Type 2 diabetes and ischaemic heart 
disease has resulted in patents surviving for longer after microalburninuria is 
detected allowing renal disease to progress to proteinuria. The diagnosis of 
diabetic nephropathy in Type 2 diabetes is less easily diagnosed in that 
older patients may have other types of renal disease, including renal artery 
stenosis, accompanying nephropathy. However, there are contradictory 
reports on this topic and even histological evidence is not always definitive 
(Waldherr et al, 1992; Ritz et al, 1995). In Wolverhampton, a diagnosis of 
diabetic nephropathy is made on clinical grounds based on a history of 
diabetes, the presence of diabetic retinopathy and hypertension which has 
developed around the same time as proteinuria. This excludes renal disease 
secondary to hypertensive changes in the kidney. 
Type 2 patents may present at diagnosis of diabetes with proteinuria, due to 
nephropathy, accompanied by diabetic retinopathy and other complications 
(Turner et al, 1996). Many Type 2 patents are unaware of the symptoms of 
diabetes which, if untreated, can result in hyperglycaemia over a 
considerable period of time which in turn leads to microvascular damage and 
the resultant complications (Jackson et al, 1991; Singh et al, 1992). It is 
probable that the early disease process of nephropathy in Type 2 patients 
follows the same course as in Type 1 patents. It has been reported that in 
Type 2 patients the time to onset of proteinuria is shorter and that the 
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progression of renal disease is slower than in people with Type 1 diabetes 
(Ritz and Stefanski, 1996; Christensen et al, 1999). 
1.3.2 Treatment and Prevention of Diabetic Nephropathy 
1.3.2.1 Glycaemic Control 
An early review article on the relationship between poor glycaemic control 
and microvascular complications concluded that there were no definitive 
results from studies in humans which demonstrated this relationship, 
although animal studies had strongly suggested a link between the two 
(Tchobroutsky, 1978). However, in 1987, Nyberg and co-workers 
demonstrated that glycaemic control was related to GFR in patients with 
diabetic nephropathy. The use of intensified insulin therapy and 
subcutaneous insulin infusion has resulted in retardation of established 
microvascular complications and prevention of the development of these in 
Type 1 patients as has the use of intensive oral therapy in Type 2 patients 
(Feldt-Rasmussen et al, 1986; Reichard et al, 1993; Diabetes Control and 
Complications Trial Research Group, 1993; American Diabetes Association, 
1999). As a result, improvement in glycaemic control is regarded as the most 
important preventative measure in relation to all microvascular 
complications. 
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1.3.2.2 Anti-Hypertensive Therapy 
The use of angiotensin converting enzyme inhibitors (ACEI) in the treatment 
of early diabetic nephropathy in animals and humans has shown that 
alterations in renal haemodynamics, occur even when the drugs do not affect 
the systemic blood pressure (Zatz et al, 1986; Marre et al, 1991). Reddi and 
colleagues have demonstrated that treatment of diabetic rats with an ACEI, 
enalapril, improved albumin excretion rate by preventing loss of heparan 
sulphate proteoglycan. From this it can be concluded that ACE inhibition 
restored the negative selective charge of the glomerular basement 
membrane (Reddi et al, 1991). 
Two early studies demonstrated irrevocably that controlling hypertension in 
patients with nephropathy, using different types of anti-hypertensive 
medication, had a beneficial effect by preventing a reduction in GFIR and by 
reducing albumin excretion rate and arterial blood pressure (Mogensen, 
1982; Parving et al, 1983). The introduction of ACE inhibitors (ACEI) for the 
treatment of hypertension and the encouraging results of studies in diabetic 
rats with nephropathy have led to research in diabetic patients with 
microalburninuria or normalburninuria with or without hypertension which 
showed beneficial effects on renal function (Pedersen et al, 1988; Marre et 
al, 1988; Marre etal, 1991; Lewis etal, 1993; Viberti etal, 1994; the EUCLID 
Study Group, 1997). ACEI are now routinely used in the treatment of diabetic 
patients with proteinuria and those with microalburninuria and hypertension. 
A meta-analysis of 100 studies of anti-hypertensive therapy has confirmed 
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the beneficial effects of ACEI on improving GFR and decreasing albumin 
excretion rates in nephropathy patients (Kasiske et al, 1993). 
1.3.2.3. Prognosis in Diabetic Nephropathy 
Once overt proteinuria is established most patients will reach ESRF within 
10 years (Viberti, 1988; Ritz and Stephanski, 1996). Between 1975-1984, 
only 762 diabetic patents received RRT in the U. K.; less than 6% of new 
patients who received dialysis (Cameron and Challah, 1986). These findings 
prompted a study to assess whether the numbers being offered RRT had 
increased since 1984. The results indicated that one third of diabetic patients 
with ESRF died; the majority from untreated renal failure (Joint Working 
Party of the Renal Association et al, 1989). The recommendations from this 
study were that diabetic patents in ESRF should be offered dialysis and 
kidney transplantation. 
The number of diabetic patents receiving RRT throughout the world varies 
considerably; in France in 1989,6.9% of dialysis patients had diabetes in 
comparison to Japan with 40% in 1990 (Zmirou et al, 1992; Watanabe et al, 
1993). However, the incidence of diabefic end-stage renal disease varies in 
different countries and in different ethnic groups within the same country 
(Ritz and Stephanski, 1996). 
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1.4 Other Microvascular Complications 
1.4.1 Diabetic Refinopathy 
Retinopathy is the microvascular disease which affects the small blood 
vessels of the retina and is due to damage to vascular endothelial cells. The 
disorder causes a variety of events which can be detected on the retina: new 
blood vessels form; ucotton wool spots' appear (these are the distended 
stumps of the ganglion-cell axons in the nerve cells supplying the retina) and 
exudates form which are composed of extracellular fluid, extracellular lipids 
and macrophages (Kohner et al, 1982). Retinopathy is graded according to 
the severity of the disease; background retinopathy includes a small number 
of exudates, "cotton wool spots", microaneurysms or small intra-retinal 
haemorrhages; maculopathy includes the above abnormalities spread 
through the macula and finally proliferative retinopathy includes the 
formation of new blood vessels outside the retina (Liang and Goldberg, 
1980). 
Retinopathy is recognised as one of the major causes of blindness in the 
western world. Visual loss from retinopathy is dependent on the duration of 
and age of onset of diabetes and the severity of the complication. After 10- 
15 years of Type 1 diabetes, 50% of patients will develop some degree of 
retinopathy. Patients with proliferative retinopathy have an increased risk of 
blindness due to macular oedema and vitreous haemorrhage. Macular 
oedema causes loss of visual acuity in greater numbers of diabetic patients 
than does vitreous haemorrhage; vitreous haemorrhage occurs when the 
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new blood vessels proliferate outside the retina into the vitreous cavity and 
haernorrhage occurs (Liang and Goldberg, 1980). However, when vitreous 
haernorrhage does occur, there is greater severity of visual loss. 
In the EURODIAB IDDM Complications study, 46% of the 3,250 patients had 
retinopathy, 26% with mild background, 10% with moderate to severe 
background and 10% with proliferative (Sjolie et al, 1997). In Type 1 
patients, nephropathy is usually accompanied by the other microvascular 
complications, retinopathy, which is often proliferative, and neuropathy. The 
EURODIAB study has also shown that the prevalence of retinopathy in 
patients with raised AER increased significantly with diastolic blood pressure 
above 85 mm Hg in comparison to people with normal albumin excretion rate 
(Stephenson et al, 1995). Another study in Sweden has shown that patients 
with retinopathy were older, the duration of diabetes was longer, the 
glycaemic control was worse, systolic blood pressure was higher than those 
people without retinopathy, they had higher albumin excretion levels and 
serum creatinine was elevated in patients with severe retinopathy (Agardh et 
al, 1989). Both the Diabetes Control and Complications Trial (1993) and the 
United Kingdom Prospective Diabetes Study (1994) have demonstrated that 
intensive treatment to reduce blood glucose levels has a beneficial effect on 




Long-term hyperglycaernia can affect the small blood vessels which supply 
the nervous system resulting in peripheral and / or autonomic neuropathy. 
There is a high morbidity from foot problems secondary to peripheral 
neuropathy and sudden death in diabetic patients may be associated with 
QT interval prolongation in people with autonomic neuropathy (Ward, 1999; 
Veglio et al, 1999). The mechanisms which cause neuropathy are not fully 
understood and as yet there is no treatment for neuropathy (Ward, 1999). 
The results of the EURODIAB Study have suggested a link between 
neuropathy, diastolic blood pressure and microalburninuria (Tesfaye et al, 
1996). - 
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1.5 Cardiovascular Disease 
Cardiovascular disease is a major cause of mortality in diabetic people 
(Kannel and McGee, 1979; Moss et al, 1991). Several factors contribute to 
the risk of cardiovascular disease developing in diabetic patients including 
hyperglycaernia, insulin resistance, presence of hypertension and 
abnormalities in coagulation, fibrinolysis and lipid profiles (Deckert et al, 
1991; Kng and Wakasaki, 1999; Sowers and Lester, 1999). The presence of 
microalburninuda in diabetic patients is predictive of early death from 
cardiovascular disease (Deckert et al, 1992). Diabetic women have an 
increased risk of developing and dying from cardiovascular disease, 
especially coronary heart disease (Manson et al, 1991; Moss et al, 1991). It 
has been postulated that an interaction between hyperglycaernia and 
oestradiol reduces the production of nitric oxide from endothelial cells 
(normally mediated by oestradiol), as nitric oxide may be associated with the 
protective effects of antioxidants, a reduction in the concentration of nitric 
oxide could lead to the development of atherosclerosis (Bruckdorfer, 1993; 
Sowers and Lester, 1999). Cardiovascular disease is associated with 
nephropathy and it has been suggested that the mechanisms underlying 
both conditions may be similar (Deckert et al, 199 1). 
Hypertension contributes to the morbidity and mortality from cardiovascular 
disease and nephropathy in patients with diabetes. Between 30-75% of 
diabetic complications are related to hypertension (Consensus Statement, 
1993). Both Type I and Type 2 patients are at risk of developing 
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hypertension and as previously described much research has been 
performed to find the most effective anti-hypertensive treatments in 
nephropathy (Maki et a/, 1995). 
-55- 
1.6 The Epidemiology of Diabetic Nephropathy 
In a diabetic clinic population based study of 982 patients in Denmark, the 
prevalence of microalbuminuria was 22% and of macroalbuminuria was 
19%. The patents with nephropathy were predominantly men and the 
prevalence was higher in people in whom diabetes had been diagnosed 
before 20 years of age (Parving et al, 1988). In the Wisconsin study, a large 
population based study, 18% of people on insulin treatment and 12% of 
patients not being treated with insulin had proteinuria, and the prevalence 
was found to increase with advancing age (Klein et al, 1988). The same 
study identified that proteinuria was associated with hypertension, systolic 
blood pressure, increasing severity of retinopathy and, as in the Danish 
study, was found predominantly in men (Klein et al, 1988). 
The Rochester study demonstrated an incidence of nephropathy in non- 
insulin dependent diabetic people of 133 per 100,000 person-years and in 
insulin dependent patients: 170 per 100,000 person-years and showed the 
cumulative risk of Type 2 patients developing chronic renal failure within 10 
years after diagnosis of proteinuria to be 11 % (Humphrey et al, 1989). 
The Steno study in Type I patients showed the cumulative incidence of 
nephropathy to be 45% after 40 years duration of diabetes and that there 
were two distinct incidence peaks for the onset of proteinuria at different 
durations of diabetes: the first occurred after 16 years and the second after 
32 years (Andersen et al, 1983). The same study demonstrated a 
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prevalence of nephropathy of 21% after 20-25 years duration of diabetes 
which then declined to 10% after 40 years of diabetes (Andersen et al, 
1983). In the EURODIAB study (Type 1 diabetic patients, n=3,250) the 
prevalence of macroalbuminuria ranged from 18-25% at five year intervals of 
diabetes duration and 19% of patients with a short duration of diabetes 
(between 1-5 years) had microalbuminuria (Stephenson et al, 1994). 
The prevalence of macroalburninuria has been shown to be higher in the 
USA (27%) than in Europe (12%) although prevalence of microalbuminuria 
was similar between the two continents (USA: 22 % and Europe: 25%) 
(Lloyd et al, 1996). There are differences in the incidence of end-stage renal 
failure (ESRF) in people of different ethnic groups within the same country: 
Pima Indians and Black people have a higher incidence of ESRF than White 
people in the USA, as do Aborigines in Australia and Indo-Asian people in 
the UK (Burden et al, 1992; Ritz and Stefanski, 1996). Perneger and co- 
workers found a 7.4 increased odds ratio for ESRF associated with Black 
people in the USA and Cowie and colleagues found a 2.6 greater incidence 
of ESRF in Black patients than in White people (Cowie et al, 1989; Perneger 
et al, 1994). 
Although data from other centres are of a value, a key purpose of the 
research herein was to identify factors which could inform and improve 
clinical practice in a multi-ethnic community in the West Midlands region of 
the United Kingdom. 
-57- 
Chapter 2 




2.1.1 Methods Used in The Mortality Study 
This was a retrospective analysis of underlying causes of death in a sample 
of diabetic patents in comparison to non-diabetic people in the general 
population of Wolverhampton over a ten year period (1981-1990). Data on 
the diabetic sample and the non-diabetic general population (source: Office 
of Population Censuses and Surveys; SD 25,1981-1990) were obtained 
from the Department of Public Health, Wolverhampton Health Authority; the 
data on deaths in diabetic people originated from death certificates 
(including all causes recorded in Parts I and 11 of the certificate) and were 
provided on a regular basis as typed lists of deaths. One hundred and ten 
deaths from diabetes in the OPCS data were not accounted for in the data 
on deaths in people with diabetes indicating that the data in diabetic patients 
did not include all of the diabetic population who died during the time period 
studied. For the analysis, information on all deaths with diabetes as the 
underlying cause was removed from the general population data to acquire a 
population free from diabetes, as far as could be ascertained from the death 
certificate. 
Underlying causes of death were grouped and classified in accord with the 
recommendations of the World Health Organisation in the Ninth Revision of 
International Classification of Disease (World Health Organisation, 1977). 
These were then referred to as disease groups: cardiovascular (CVD) (ICD-9 
390-459); this included all cardiac, vascular and cerebro-vascular disease; 
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respiratory (ICD-9 460-519), malignant neoplasms (ICD-9 140-208), liver 
(ICD-9 571), renal (ICD-9 580-589) and gastro-intestinal (G. I. ) (ICD-9 520- 
579). All other causes of death were grouped together as "others". The 
disease group diabetes (ICD-9 250) (see Appendix 4) included diabetes, 
diabetic ketoacidosis (DKA), hyperosmolar coma (HOC), hypoglycaemia 
(HG), diabetic nephropathy and gangrene. Disease groups were subdivided 
into specific causes for deaths from diabetes, coronary heart disease ([CHD] 
and cerebrovascular accidents [CVA]). 
Data obtained on diabetic patients from 1983 onwards were corrected 
according to the change in death certification known as "Rule 3', whereby 
any death certificate with pneumonia as the sole cause of death in Part I but 
with diabetes in Part 11, had the Part 11 entry transferred to Part I Le.: diabetes 
was recorded as the underlying cause of death (Williams, 1993). The 
general population data would have been subjected to "Rule 3' before 
publication. 
Information on age, gender and underlying cause of death was collected for 
each year for both the diabetic sample and the general population. Initially, 
comparison was made of underlying causes of death in both groups over the 
ten year period. Then subjects were stratified according to age bands (15- 
34,35-44,45-54,55-64,65-74,75-84 and > 85 years) and gender to permit 
comparisons based on age and to identify differences between men and 
women. 
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Causes of Death 
Diabetic Group Age Groups Male/Female 
versus versus versus 
Non-Diabetic Group--* Age Groups Male/Female 
Figure 2.11: Flow diagram of mortality study 
To fully assess the extent of coronary heart disease all cases with underlying 
causes of death recorded as ischaernic heart disease or myocardial 
infarction were added together in both groups of data. Deaths from the acute 
metabolic complications of diabetes, DKA, HOC, HG, were compared over 
the ten years as were those from diabetic nephropathy. 
2.1.2 Methods Used to Study The Prevalence of and Factors Associated 
with Diabetic Nephropathy 
This was a cross-sectional study using data collected retrospectively to 
determine the prevalence of diabetic nephropathy and accompanying 
diabetic complications in a cohort of diabetic patients with persistent 
proteinuria on albusfix testing (BM-Test-5L, Boehringer-Mannheim; 
proteinuria = 5g 1-1) or raised serum creatinine concentrations (>120 11mol 1-1 ) 
referred from the diabetic clinic for nephrological assessment between 1987- 
1995. This study was a pragmatic piece of research based on routine clinical 
practice and therefore assessments which may otherwise have been 
performed as part of a structured research protocol were not performed 
unless they were part of routine medical care. 
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Patients were identified by consultant nephrologists and copies of letters 
generated after the assessment examination were kept in a separate file by 
medical secretaries to ensure that patents were identified for this study and 
none omitted from the analysis. Diabetic nephropathy was diagnosed on 
clinical grounds Le.: presence of persistent proteinuria plus the presence of 
diabetic retinopathy or diagnosis was confirmed by renal biopsy where there 
was any doubt using the clinical definition. Data were collected from patients' 
hospital records on age, gender, diabetes history including complications 
and treatment, renal history, blood pressure measurements and anti- 
hypertensive therapy, smoking, family history of diabetes and physical 
parameters e. g.: body mass index, glycaemic control as measured by HbAll 
and total blood cholesterol levels. Details of regular defaulting from routine 
diabetic clinic visits (i. e.: missing more than two consecutive clinic visits in 
more than one year since diagnosis of diabetes) were also collected. 
Patients were divided into Type 1 and Type 2 diabetes groups and a 
comparison was made between the two. Type I was defined as diagnosis 
before the age of 35 and requiring insulin treatment; Type 2 was defined as 
diagnosis after 35 years of age and treated with either diet, oral therapy or 
insulin treatment. For patents with proteinuria at diagnosis of diabetes the 
duration of diabetes was recorded as zero, only to give a numerical value, as 
it was accepted that Type 2 patients presenting with complications will have 
had diabetes for some time before diagnosis. 
Renal function was assessed using serum creatinine levels and urinary 
protein excretion (as measured by 24 hour urine saves). Measurement of 
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creatinine clearance (the excretion of creatinine through the kidneys as 
measured using a 24 hour urine sample and a single blood sample taken 
during the time of the urine collection) would have given a more accurate 
assessment of glomerular filtration rate (Forrester et al, 1985). However, 
creatinine clearance was not performed in all nephropathy patients whereas 
serum creatinine concentrations were. 
Retinopathy was defined as background (cotton wool spots and dot or blot 
haernorrhages) and severe retinopathy was defined as proliferative changes 
(e. g.: presence of new blood vessels) haernorrhage or loss of visual acuity 
not due to other conditions. Ischaemic heart disease was defined as 
documented evidence of angina symptoms or electrocardiographic evidence. 
Hypertension was defined as systolic pressure > 140 mm Hg and / or 
diastolic pressure > 90 mm Hg or receiving anti-hypertensive therapy as 
defined by the Working Group on Hypertension in Diabetes (1987). Severe 
peripheral vascular disease was defined as the presence of intermittent 
claudication or amputation. 
Blood pressure was measured using a single sitting reading with a standard 
mercury Hawksley sphigrnomanometer. Routine measurement of height and 
weight were made in the diabetic clinic; height if measured in inches was 
converted to centimetres, weight was measured in kilograms to permit 
calculation of body mass index. 
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All laboratory measurements were performed by the Clinical Chemistry 
Department, New Cross Hospital, Wolverhampton according to departmental 
standard operating procedures (Appendix 5). HbAl was measured using the 
automated high performance liquid chromatography method by Bibmen (in 
the same manner as HbAl c is now measured). Serum creatinine levels were 
measured using the Jaffe reaction (alkaline picrate) on Bayer Diagnostics 
Chem I and latterly on DAX Twenty four hour urinary protein excretion was 
measured using the pyrogallol red method on Bayer Diagnostics RAIOOO 
and total cholesterol was Measured using the cholesterol oxidase method on 
Bayer Diagnostics Chem I and latterly on Dax (Appendix 5). 
Initially an analysis of all patients referred with renal disease was made to 
determine the point prevalence (prevalence at one point in time Le.: 
nephrological assessment) of diabetic nephropathy and non-diabetic renal 
disease and the prevalence of diabetic complications in Type 1 and Type 2 
patients. Comparisons were made between the groups to assess if there 
were differences in other parameters e. g: glycaemic control and blood 
pressure. A similar analysis was performed in Type 1 and 2 patients with 
nephropathy and in Type 2 nephropathy patients compared to Type 2 
patients with non-diabetic renal disease. 
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Indo-Aslan versus Black versus White 
Figure 2.2: Flow diagram of diabetic nephropathy studies 
Duration of diabetes to the onset of proteinuria, retinopathy and 
hypertension was also determined and compared in a subgroup of Type 1 
and Type 2 patients with nephropathy who had all three complications, those 
without either retinopathy or hypertension were omitted. Only patients with a 
diagnosis of diabetes greater than three years were included, in order to 
exclude patients with established retinopathy and proteinuria before 
diagnosis of diabetes and to reduce the 'unknown" duration of diabetes 
before diagnosis in Type 2 patients. A similar subgroup analysis was 
performed in the comparison of Type 2 patients with nephropathy and those 
with non-diabetic renal disease. 
2.1.3 Methods Used in The Case-Controlled Compadsons of Nephropathy 
Patients with Type I and Type 2 Diabetes 
Two case-controlled comparisons was made (1) between White Type 1 
nephropathy patents and White Type 1 control subjects closely matched for 
age, gender, duration of diabetes and diabetic treatment (matching for age 
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and duration of diabetes was achieved by using bands of 5 years) and (2) 
between Type 2 patients with matched Type 2 control subjects, in this study 
matching also included ethnic groups. The large number of variables used to 
match the control subjects with nephropathy patents was to ensure that the 
groups were as similar as possible but also to remove these variables from 
the comparison (i. e.: to remove potentially confounding variables). 
Control subjects were selected from 909 patents who attended the diabetic 
clinic for annual review examination between 1992-1995; the patients were 
identified by nursing staff and a medical secretary working in the diabetic 
clinic. The same type of data were collected from patients' hospital records 
in control subjects as previously described for patients with renal disease. 
Control subjects had no overt evidence of renal disease Le.: they did not 
have proteinuria on "albusfix" testing or raised serum creatinine levels. As 
routine testing for microalbuminuria was not performed in the diabetic clinic, 
it was not known whether control subjects had microalburninuria. Only 
patients who had had serum creatinine concentrations measured were 
included in the control group and none had had creatinine clearance 
measured. The process of matching control subjects to those with 
nephropathy was performed after all data had been recorded on Smart 
databases, one for renal patients and the other for annual review patients. 
All computer data was checked for accuracy by comparison with the original 
collected written data. 
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In the study of Type I nephropathy patients versus controls, all nephropathy 
patients with serum creatinine concentrations > 200 gmol 1-1 or who had 
reached ESRF were excluded. In the study of Type 2 nephropathy patients 
versus controls, all nephropathy patients with serum creatinine 
concentrations > 300 Amol 1-1 or who had reached ESRF were excluded. 
Type 2 nephropathy patents were only included if they had a duration of 
diabetes greater than two years, had no retinopathy at presentation of 
diabetes and no proteinuria within the first three years after diagnosis of 
diabetes. These inclusion criteria were selected in order to identify a discrete 
group with nephropathy and decrease the likelihood that patients had 
undiagnosed diabetes for many years before diagnosis (although most Type 
2 patients have a silent pre-diagnosis phase of diabetes). Control subjects in 
both of these studies had serum creatinine concentrations within the normal 
limits (60-1201, mol 1-1). Type 1 controls were selected from 266 Type 1 
patients and Type 2 controls from 643 Type 2 patients. 
In both case-controlled studies comparisons were made between the groups 
which included diabetic complications, smoking history, defaulting from 
routine clinic attendance, blood pressures, anti-hypertensive therapy and 
HbAll results for a four year period before nephrological referral. Subgroup 
comparisons were made between patients who were hypertensive and were 
or were not receiving anti-hypertensive therapy within and between the 
nephropathy and control groups. 
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2.1.4 Methods Used to Compare Type 2 Nephropathy Patients From 
D#ferent Ethnic Groups 
Type 2 patents with nephropathy were divided into three groups dependent 
on ethnic origin; White (defined as people with genetic origins in Europe, 
irrespective of place of birth), Indo-Asian (defined as people with genetic 
origins from the Indian subconfinent, irrespective of place of birth) and Black 
(defined as people with genetic origins from Africa irrespective of place of 
birth) and matched according to age, gender, duration of diabetes and 
diabetes treatment. For the initial analysis, patients on renal replacement 
therapy or with serum creatinine levels greater than 300 gmol 1-1 were 
omitted from the analysis to remove bias due to advanced disease. A further 
analysis was performed to validate the results of Chi2 tests by using larger 
numbers of patients; this included patients with serum creatinine 
concentrations above 300 pmol 1-1 and those on RRT. 
A point prevalence Le.: prevalence at a single examination (nephrological 
assessment) was determined for diabetes complications and other factors 
that may be associated vvith nephropathy in the different ethnic groups. 
Duration of diabetes to the onset of proteinuria, retinopathy and 
hypertension were also determined and compared between the groups to 
assess whether there were any differences in development of these 
complications. 
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A comparison was made between patients with treated and untreated 
hypertension to determine whether there were factors which contributed 
towards lack of anti-hypertensive therapy which were specific to any of the 
ethnic groups. 
2.1.5 Methods Used to Assess the Effectiveness of Routine Clinical Care 
on Survival (Preventative Study) 
Patients with nephropathy referred for nephrological assessment were 
followed up over a maximum period of twelve years (1987-1998) to assess 
the effect of normal clinical practice on survival. Normal clinical practice was 
defined as treatment determined by consultant nephrologists for individual 
patients and individual medical problems on an "intention to treat" basis; 
there was no written pre-determined protocol for treatment which could be 
followed by junior medical staff, although individual cases were discussed 
with the consultant. Follow up was defined as regular attendance at the out- 
patient clinic, though the number of visits per year varied according to the 
clinical condition of the patent. Patients were excluded from the study if they 
were receiving renal replacement therapy at the study onset or if they had 
only one functioning kidney, as this may have affected the rate of decline of 
renal function. As patents were referred at different times over the twelve 
year period, length of follow up time varied from patient to patent. 
Data were collected from patients' hospital records on blood pressure 
measurements, serum creatinine concentrations, urinary protein levels, and 
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glycaemic control as measured by HbAl (both pre- and post-referral), over 
the time period since referral, as well as demographic data. Information on 
end points was also collected. The end points were: survival without 
reaching ESRF, need for renal replacement therapy (RRT), survival on RRT, 
death, death following RRT and lost to follow up. Cause of death was also 
recorded. In some cases, the causes of death could not be determined due 
to inability to locate patients' hospital records after death. Data collected at 
referral were the baseline data used to compare data collected annually in 
subsequent years up to year 7, from this time point numbers of patients were 
too low to reliably perform statistical analysis. 
A number of different parameters were examined to find the potential effect 
of these on survival. Hypertension was defined as a systolic pressure > 140 
mm Hg or diastolic pressure > 90 mm Hg and this decided the "need for 
treatment7. Age at renal referral, duration of diabetes, time from onset of 
overt proteinuria to renal referral, duration of diabetes until onset of 
proteinuria, systolic and diastolic blood pressures, serum creatinine, 24 hour 
urinary protein excretion, anti-hypertensive treatment (as measured by point 
scale, see Appendix 1) and presence or absence of this at baseline. All of 
the above were compared in all of the Type 1 and Type 2 groups and, in 
addition, two other analyses were performed: 1) in three ethnic groups: Indo- 
Asian (people with ethnic origins in the Indian subcontinent whether born 
there or elsewhere): Black (people with ethnic origins in either Africa or the 
Caribbean, irrespective of place of birth): and White patients and 2) a 
subgroup analysis of Type 1 and Type 2 patients with serum creatinine 
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levels below 120 gmol 1-1 (upper limit of normal) to remove bias due to 
advanced renal disease. 
Type 1 Type 1 (subgroup) 
Diabetic 
Nephropathy versus versus 
Patients < 11 years 
follow up) Type 2 Type 2 (subgroup) 
I 
Indo-Asian versus Black versus White 
Figure 2.3: Flow diagram of study assessing the effectiveness of routine clinical 
care and survival analysis in nephropathy patients. 
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2.2 Statistical Analysis 
2.2.1 Analysis of Mortality Study 
Analysis was restricted to a direct comparison using Chi2 tests of proportion 
of deaths in diabetic compared to non-diabetic people and then according to 
age stratification and gender. The odds ratio (OR) was calculated as an 
estimate of the relative risk of one group dying from a specific cause in 
comparison to the other group; the actual relative risk could not be 
performed as the data did not include the full population of deaths in people 
with diabetes (Silman, 1995; Gordis, 1996). 
The calculation used for the odds ratio was: OR = axd 
bxc 
where a= number of diabefic people dying from a specific underlying cause 
b= number of non-diabetic people dying from the same specific cause 
c= number of diabetic people dying from other underlying causes 
d= number of non-diabefic people dying from other underlying causes 
Confidence intervals were calculated for the odds ratios using Woolf s 
Method (Silman, 1995). For 95% confidence intervals (C. I. ) the following 
calculation was used: 
95% C. 1. = exp (10geOR +1.96 
Vlla+llb+llc+lld) 
where a, b, c, d were defined as above. 
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e. g: for deaths with cardiovascular disease as the underlying cause. 
Lower 95% C. I.: 
= exp (logeOR - 1.96rl/a+l/b+l/c+l/d) 
= exp (log 1.27 -1.96XO. 0545) 
= exp (0.238-0.107) 
= exp (0.131) 
= 1.14 
Upper 95% C. I. 
exp (IogeOR + 1.9W 1/a+l/b+I/C+l/d) 
exp (logl. 27 +1.96XO. 0545) 
exp (0.238+0.107) 
exp (0.345) 
1.41 Therefore, 95% Confidence Interval = (1.14,1.41) 
The odds ratio has logarithmic properties, therefore, it does not lie 
mathematically in the centre, of the lower and upper confidence intervals 
(Silman, 1995). 
To achieve 80% power for this study with a significance level of P<0.05, 
the sample size was calculated using the following formula for two 
proportions: N=8[p, (I - p, )+ P2 0- P2 )1/( PI-P2 )2 per group (Lowe, 1993). 
The proportion of deaths from CVD in diabetic and non-diabetic people in 
the Aberdeen study were used to give an indication of likely proportions of 
deaths from the same cause in this study: deaths from CVD in diabetic 
people (56%) and non-d iabetic people (41 %) (Wong et al, 199 1): 
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N= 8[(0.56)(0.44)+(0.41)(0.59)]/(0.56-0.41) 2 per group 
N=1174 per group. This result was confirmed using a computerised sample 
size calculator (Brant, 1999). 
Once data was collected the power of the study was determined using the 
proportion of deaths from CVD in each group at a statistical power P<0.05 
for a two sided test. However, as the numbers in each group were not equal, 
the harmonic mean was calculated using the formula: 
Nhý-- 2JN-lN-21 
Ni +N2 
and substituted for the sample size using a computerised power calculator, 
(Brant, 1999). 
Z2.2 Analysis of Diabetic Nephropathy Studies 
Data analysis was performed using SPSS and Excel statistics packages. 
Descriptive statistics (mean, L+standard deviation), median, minimum, 
maximum and inter-quartile ranges] were obtained and presented in tables 
or as boxplots (box-and whisker-plots). The chosen level of statistical 
significance was P<0.05 in one and two-tailed tests. The statistical power of 
the studies was determined once the number of patients in each of the 
groups were known, at the start of the research the final numbers could be 
not be anticipated as a pilot study was not performed. 
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Quantitative data were analysed using Student t test for parametric (e. g.: 
age or duration of diabetes) or Mann-Whitney U test for non-parametric (e. g.: 
serum creatinine concentrations) where two sets of data were compared. 
One-way analysis of variance was used if there were more than two sets of 
data (e. g.: HbAl over four years) to determine how reliable the mean 
differences were (Tabachnick and Fidell, 1996). Scatterplots were produced 
to assess whether the relationship between two variables was linear (e. g.: 
time to development of retinopathy and proteinuria). The strength of the 
linear relationship between two variables was then compared, after any 
outlying points (maximum n=3) were removed, using the Pearson correlation 
coefficient (Kinnear and Gray, 1994; Tabachnick and Fidell, 1996; SPSS 
inc., 1999). Linear regression was used to determine whether one variable 
could predict another and the multiple correlation coefficient (R 2) was used 
to determine the variance of the dependent variable predicted by the 
independent variable (e. g.: age as a predictive variable for diastolic blood 
pressure) (Johnson and Tsui, 1998). 
Multiple regression analysis was used to determine the predictive 
relationship between several independent variables and one dependent 
variable (e. g.: time to onset of hypertension and retinopathy, as a 
combination of independent variables, to determine whether together they 
increased the prediction of time to onset of proteinuria). Multiple regression 
analysis was dependent on the linear relationship (ascertained by 
scatterplots) between the dependent variable and the independent variables 
which were either continuous or dichotomous variables (Tabachnick and 
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Fidell, 1996). Sequential and stepwise multiple regression analyses were 
also performed (time to onset of hypertension and retinopathy as predictors 
of onset of proteinuria were also used in sequential and stepwise multiple 
regression analysis). The sequential multiple regression allowed the addition 
of different independent variables in a particular order (with the variables 
considered to have the greatest predictive value first) whereas in stepwise 
multiple regression the order in which variables were added into the 
regression equation was dependent on statistical considerations alone 
(determined by the statistical software and not necessarily in the order the 
researcher would have chosen). Variables were also removed when these 
were found to have no predictive effect during the stepwise multiple 
regression technique (Tabachnick and Fidell, 1996; SPSS inc., 1999). The 
removal of outlying results not only increased the accuracy of the Pearson 
correlation coefficient but also the various regression techniques used, as all 
forms of regression analysis are very sensitive to outlying results 
(Tabachnick and Fidell, 1996). 
Logistic regression analysis was used to determine whether a set of 
variables could predict a single variable (e. g.: variables such as defaulting 
from clinic visits, anti-hypertensive therapy, smoking status, gender, systolic 
and diastolic blood pressures were assessed as predictors of serum 
creatinine). This technique was used in preference to other methods of 
multivariate analysis because it was more flexible Le.: predictive variables do 
not have to have a linear relationship with the dependent variable or be of 
normal distribution and no assumption was made concerning equality of the 
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variance plus any type of variable (dichotomous, discrete or continuous) 
could be used (Tabachnick and Fidell, 1996). Both direct (all variables added 
simultaneously) and sequential (variables added one after the other) logistic 
analysis were performed. 
The odds ratio was calculated as an estimate of the relative risk of the 
presence of different variables for developing nephropathy; the actual 
relative risk could not be performed as these were case controlled studies 
(Silman, 1995; Gordis, 1996). 
The power of the various studies at P<0.05 were determined after data 
collection using a computerised power calculator (Brant, 1999; UCLA, 1999). 
Where the standard deviations of two populations (cr) were needed to 
calculate the power, the harmonic mean of a was calculated. 
All qualitative data e. g.: presence of complications, gender or smoking 
status, were changed into dichotomous variables by assigning either yes =1 
or no =0 in order to perform Chi2 tests to assess differences between groups 
(Tabachnick and Fidell, 1996). Where the expected frequencies obtained 
during Chi2 test were < 5, Fischer's exact test was performed in 2x2 
contingency tables only; if the number of variables were such that the 
degrees of freedom were >1, Fischer's exact test was not performed (SPSS 
Inc, 1999). 
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2.2.3 Analysis of the Effectiveness of Routine Clinical Care and Survival 
Analysis (Preventative Strategies) 
Descriptive statistics were determined at baseline (nephrological 
assessment examination), repeated measures analysis of variance was 
used to determine differences in mean values between the groups and 
within the groups, when parameters from different years were compared 
(e. g.: serum creatinine concentrations, systolic and diastolic blood 
pressures). Chi2 test were used to compare categorical descriptive variables. 
Cumulative survival was determined using Kaplin-Meier survival curves and 
the difference in the equality of the survival distribution was compared using 
the Logrank test The mean and median values were presented along with 
standard error and 95% confidence intervals. End points were death, 
survival, lost to follow up (patent stopped attending nephrology and diabetic 
clinics) and renal replacement therapy (RRT). Data on patients who survived 
or were lost to follow up were censored as they had not reached the other 
two end points. 
The Kaplin-Meier estimate of survival is the successive overall probability of 
survival over a period of time, usually expressed in graph form, where at the 
baseline time point all subjects are assumed to be still living Le.: at fime=O, 
there is 100% survival (Parmar and Machin, 1995). The Logrank test was 
used to compare two survival curves to determine whether the survival 
distributions of the curves were equal Le.: was there a statistical difference in 
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survival between the curves? Prior to calculation of this, all data were ranked 
with censored data having a higher rank than deaths. The Logrank test 
involved calculating observed and expected deaths, a formula similar to the 
Ch i2 tests: - 
X2 Logrank ý (OA7E A)2+ (OB-EB)2 where A =data set I and B= data set 2. 
EA EB 
Degrees of freedom =1 (Parmar and Machin, 1995). 
The Cox proportional hazard model was used to determine the effect of 
different variables as a hazard for survival in the form of hazard ratios 
(prognostic significance). Hazards which are not constant Le.: they can vary 
within a patent group, are proportional hazards to survival (whereas hazard 
rate is assumed to be constant). The Cox proportional hazard model is a 
model which allows non-constant variables to be assessed in terms of 
hazard to survival that does not make assumptions about the distribution of 
the hazard in the groups tested (Pamar and Machin, 1995). The only 
assumption is that the hazard is proportional in each group throughout the 
study. The hazard ratio for the Cox proportional model when comparing two 
groups of patients equals T: h)Fexp(px), where T represents the model which 
is being examined and x represents the difference between the two groups, 
which is equivalent to HR= exp (P), where HR is the hazard ratio. The Cox 
model uses regression analysis as the formula used to determine HR = exp 
(P) is in the form of a straight-line regression model (Pamar and Machin, 
1995; Johnson and Tsui, 1998). An HR<1 signifies a better risk (reduced 
hazard) and HR>I signifies increased hazard. Data were adjusted for 
various characteristics (to remove any effect due to these variables) prior to 
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analysis. All hazard ratios greater than 1, were presented in table form, 
along with standard error, 95% confidence intervals and level of statistical 
significance. 
For the survival analysis, the sample size for the whole study was calculated 
based on a number of assumptions: 
0 The anticipated difference between the groups: 80: -- 7CTWe V 71 Type 2'ý 0 for 
Ho. 
0A fixed survival time was used: 5 years (1826 days) 
11 The statistical significance = 0.05 
0 The power of the study = 80% 
As the only available results of previous studies were in patients who were 
receiving RRT, it was decided that it would not be appropriate to use these 
to calculate the numbers required in a study of patents who were not on 
dialysis. 
Therefore, based on the assumptions that 
10 both Type 1 and Type 2 patients were at risk of death from similar causes 
e. g.: cardiovascular disease 
c' the rate of deterioration of renal function is similar in both groups 
(Beisenbach et al, 1994) 
" Type 2 patients were older 
" Type 2 patients were less likely to receive RRT 
" Cumulative survival in Type 2 patients would be lower than in Type 1 
patients over 5 years 
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it was assumed that an anticipated difference in survival between the groups 
would be 8=0.20 with 50% of Type 1 patients and 30% of Type 2 patients 
surviving for 5 years, giving a required sample size of 91 in each group, with 
P <0.05 and 80% power (Parmar and Machin, 1996). 
Literature searches were performed using Medline, the Cochrane database, 
the Citation Index and the Index Medicus. Some references were obtained 
from the bibliographies of published articles. 
A system for allocating points to anti-hypertensive medication and dosages 
is described fully in Appendix 1. 
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2.3 Ethical Considerations 
This study was approved by the Wolverhampton District Research Ethics 
Committee in 1992. Patients' consent was not obtained as all information 
was extracted from hospital records and all interventive, treatments were part 
of normal clinical care rather than as part of a research project. For the same 
reason General Practitioners were not informed that their patients were 
participating. Patient confidentiality was maintained throughout the study by 
the use of identification codes rather than patients' names during the data 
collection process and when data were recorded on computer databases. A 
separate written record of patients names and identification codes was 
maintained to allow follow up for the survival analysis. 
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2.4 The Aims of This Study 
The overall aims of this research were: 
1 To determine whether diabetic nephropathy is a significant cause of 
mortality in people with diabetes in Wolverhampton. 
2 To identify factors which were associated diabetic nephropathy . 
3 To identify factors which place diabetic patients at risk of developing 
nephropathy. 
To assess how effective routine clinical care was on survival in 
patients with nephropathy, following nephrological referral and follow 
up. 








Mortality and morbidity from diabetes mellitus have long been recognised as 
a major health problem. The cardiovascular complications of diabetes are 
known to contribute to a significant proportion of deaths in diabetic patients 
(Kannel and McGee, 1979; Turnbridge et al, 1981; Moss et al, 1991). 
Research has shown that the majority of cardiovascular deaths are due to 
coronary heart disease (CHD) and that diabetic patients have an increased 
relative risk of developing CHD in comparison to non diabetics (Manson et 
A 1991; Folsom et al, 1997). End stage renal failure (ESRF) secondary to 
diabetic nephropathy has been identified as a microvascular complication 
that does not necessarily result in death. In 1989, recommendations were 
made that diabetic patients in ESRF should be given renal replacement 
therapy at an earlier stage of renal failure than non-diabetics (Joint Working 
Party British Diabetic Association et al, 1989). Cardiovascular disease is still 
the major cause of death in diabetic patients and a world wide study has 
shown excess mortality in patients with both types of diabetes, proteinuria 
and hypertension (de Grauw et al, 1995; Wang et al, 1996). 
Wolverhampton is a large industrial town in the West Midlands with a 
population of 242,190 recorded at the last census of mixed ethnic groups, 
primarily White (81.4%), Indian (11.4%) and Black-Caribbean (4.1 %) (Office 
of Population Censuses and Surveys, 1992). The question as to whether the 
results of studies in diabetic patients in other towns, cities or countries apply 
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in Wolverhampton has not been answered. The aim of this study was to 
provide retrospectively an overview of mortality in the diabetic population of 
Wolverhampton in comparison to the general population by the use of 
information on deaths in diabetic patients between 1981 and 1990. This 
study will act as an introduction to further research investigating factors 




The objectives of this study were: 
(a) To determine whether there was a difference in the underlying 
causes of death recorded in diabetic and non-diabetic people. 
(b) To assess whether there were differences in the underlying causes of 
death between men and women with and without diabetes. 
(c) To assess whether there were differences in the underlying causes of 
death between people with and without diabetes of different age 
groups. 
(d) To determine the relative contribution of nephropathy to mortality in 
diabetic patients in Wolverhampton. 
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3.3 Hypotheses 
I Ho: There was no difference in underlying causes of death between 
people with diabetes and those without diabetes. 
Hi: There was a difference in underlying causes of death between 
people with diabetes and those without diabetes. 
2 Ho: There was no difference in underlying causes of death between 
men and women with diabetes. 
Hi: There was a difference in underlying causes of death between 
men and women with diabetes. 
Ho: There was no difference in underlying causes of death in people 
With diabetes of different ages. 
Hi: There was a difference in underlying causes of death in people 
with diabetes of different ages. 
4 Ho: Diabetic nephropathy was not a major underlying cause of death 
in people mfith diabetes. 
Hi: Diabetic nephropathy was a major underlying cause of death in 
people with diabetes. 
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3.4 Methods 
Details of deaths (as recorded in Parts I and 11 of the death certificate) (See 
Appendix 3) in diabetic patients and the general population in 
Wolverhampton over a ten-year period (1981-1990) were supplied by the 
Department of Public Health, Wolverhampton Health Authority; the data on 
diabetic people originated from death certificates (including all causes 
recorded in Parts I and 11 of the certificate) from the office of the Registrar of 
Births, Deaths and Marriages, Wolverhampton. 
Underlying causes of death were coded and grouped in accord with that 
recommended by the World Health Organisation in the Ninth Revision of the 
International Classification of Disease (World Health Organisation, 1977). 
These were then referred to as disease groups: cardiovascular (CVD) (ICD- 
9 390-459); this included all cardiac, vascular and cerebro-vascular 
disease; respiratory (ICD-9 460-519), malignant neoplasms (ICD-9 140- 
208), liver (ICD-9 571), renal (ICD-9 580-589) and gastro-intestinal (G. I. ) 
(ICD-9 520-579). All other causes of death were grouped together as 
Nothers'. The disease group diabetes (ICD-9 250) (see Appendix 4) included 
diabetes, diabetic ketoacidosis (DKA), hyperosmolar coma (HOG), 
hypoglycaemia (HG), diabetic nephropathy and gangrene. Disease groups 
were subdivided into specific causes for diabetes and coronary heart 
disease ([CHDI and cerebrovascular accidents [CVA]). 
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The underlying causes of death in diabetic people were compared to 
underlying causes of death in the general population of Wolverhampton 
from data published by the Office of Population Censuses and Surveys over 
the same period (OPCS: SD 25 1981-1990). One hundred and ten deaths 
from diabetes in the OPCS data were not accounted for in the data on 
deaths in people with diabetes. Therefore, this data in diabetic patients did 
not include all of the diabetic population who died during the time period 
studied. For the analysis, information on all deaths with diabetes as the 
underlying causes was removed from the general population data to acquire 
a population free from diabetes, as far as could be ascertained from the 
underlying causes of death. Information on age, gender and underlying 
cause of death was collected for each year for both the diabetic sample and 
the non-diabetic general population. 
Data obtained on diabetic patients from 1983 onwards were corrected 
according to the change in death certification known as "Rule 3", whereby 
any death certificate with pneumonia as the sole cause of death in Part I but 
with diabetes in Part 11, had the Part 11 entry transferred to Part I Le.: 
diabetes was recorded as the underlying cause of death (Williams, 1993). 
The general population data would have been subjected to "Rule 3" before 
publication. 
Comparisons were made of all underlying causes of death in all subjects 
over the ten years followed by a comparison based on gender and age 
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stratification to identify significant differences between men and women and 
in different age bands. To fully assess the extent of coronary heart disease 
all cases with underlying causes of death recorded as ischaemic heart 
disease or myocardial infarction were added together in both groups of data. 
Deaths from the acute metabolic complications of diabetes, DKA, HOC, HG, 
were compared over the ten years as were those from diabetic nephropathy. 
Chi 2 tests were used to compare differences between the groups. The 
estimated relative risk of one group dying from a specific cause in 
comparison to the other group was determined using the odds ratio (OR). 
The level of significance was P<0.05 for one and two tailed tests. 
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3.5 Results 
Data on 28,411 deaths in the Wolverhampton population between 1981- 
1990 were used in this study; 26,990 deaths were classified as having 
occurred in non-diabetic people and 1,421 in people with diabetes. The 
non-diabetic group was composed of 13,835 men (51 %) and 13,155 women 
(49%) in comparison to 680 (48%) men and 741 (52%) women in the 
diabetic group. There were significantly more women in the diabetic group 
(P <0.05). 
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Figure 3.1: Undedying causes of death in the diabetic group: 1981-1990 
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Figure 3.2: Underlying causes of death in the non-diabetic group: 1981-1990 
Cardiovascular disease (CVD) remained the commonest underlying cause 
of death in both groups for each of the ten years and accounted for 
approximately half of the deaths (53% in diabetic group and 47% in non- 
diabetic people; P <0.001) (Figures 3.1 to 3.4, Table 3.1). The estimated 
relative risk (as determined by odds ratio [OR]) of people with diabetes 
dying from CVD was OR=1.3. 
Over the ten years, malignant neoplasms were consistently the second 
commonest cause of death in the non-diabetic group followed by respiratory 
disease in comparison to the diabetic group where diabetes was the second 
commonest cause also followed by respiratory disease (Figures 3.1 and 
3.2). 
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Figure 3.4: Underlying causes of death in the non-diabetic group 
The highest proportion of deaths in diabetic patients were from CVD, 
diabetes and respiratory disease in comparison to non-diabetic people 
where the highest proportion were from CVD, malignant neoplasms and 
respiratory disease (Figures 3.3 and 3.4; Table 3.11). 
There was no significant difference in deaths from respiratory and renal 
diseases between the groups (Table 3.1). The estimated relative risk of 
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15% 
... 401 AA oil 
death from liver disease was Increased in people with diabetes (OR=2.9) 
whereas there was a reduced estimated relative risk of dying from malignant 
neoplasms (OR=0.3), gastrointestinal disease (OR=0.2) and from other 
causes (OR=0.1) (Table 3.11). 
Causes of 
Death 
Number of Deaths 
Diabetic Group 
0 (%) E 
Number of Deaths 
Non-Diabetic Group 








CVD 755 (53) 675 12735 (47) 12815 <0.001 1.27 - 1.14.1.41 
Respiratory 210 (15) 186 3510 (13) 3534 N. S. 1.16 1.03.1.39 
Neoplasm 118 (8) 340 6688 (25) 6466 <0.001 0.27 0.25,0.36 
Uver 18 (1) 7 120 (<I) 131 <0.001 2.87 2.55,3.29 
Renal 12 (1) 10 197 (<I) 199 N. S. 1.16 0.67.2.15 
G. I. 9 (1) 44 862 (3) 827 <0.001 0.19 0.10,0.37 
Others 12 (1) 145 2878 (11) 2764 <0.001 0.07 0.04.0.12 
Diabetes 287 (20) 14 0 (0) 272 N. A. N. A. N. A. 
Totals 1421 (100) 26,990 (100) 1 
- 
L; VL): L; arcliovascular Disease GI: Gastro-intestinal Disease Q: Observed E: Expected 
N. A.: Not applicable as all deaths from diabetes removed from general population data 
Level of significance: F! 50.05 N. S.: Not significant N. D.: Not done C. I.: Confidence 
Interval 
Table 3.1: Underlying causes of death in people with diabetes and those without 
diabetes. 
Using the proportion of deaths from CVD In each group, the sample size 
was recalculated to confirm the power of the study, as the numbers in the 
groups were unequal, the harmonic mean of n was determined (2700) and 
used in the calculation. At a significance level of P _< 
0.05, the power of the 
study was calculated at 99% (Brant, 1999). 
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When total deaths from CVD were compared in women, there was no 
difference between the groups (diabetic: n=376 [51%] versus non-diabetic: 
n=6367 [48%]; P--N. S. ). However, the age stratified comparison 
demonstrated that a higher proportion of deaths in female diabetic patients 
were due to CVD in certain age bands: 15-34 (however, actual numbers 
were very small; OR=5.3,95% CI: 0.45,62.80), 45-54 (OR=4.1) and 55-64 
(OR=2.5) years (Table 3.2). A smaller proportion of diabetic women died 
from CVD between 35-44 years and from 75 years of age onwards than 



















>85 62 (45) 85 1849 (62) 1826 <0.001 0.50 0.35,0.70 
75-84 128 (47) 166 2591 (62) 2553 <0.001 0.55 0.43,0.70 
65-74 121 (56) 108 1409 (54) 1413 N. S. 1.08 0.81,1.43 
55-64 52 (60) 34 484 (38) 502 <0.001 2.47 1.59,3.85 
45-54 11 (58) 5 108 (25) 114 <0.001 4.09 1.60,10.43 
35-44 0 (0) 3 32 (84) 29 N. A. N. A. N. A. 
15-34 2 
-(67) 
1 15 (27) 16 N. A. 5.33 0.45,62.80 
Totals 376 6367 
u: uDservea tz: Lxpectea %: Percentage ot total aeatns in eacn age Dana N. b.: Not signiticant 
Level of significance: Fý0.05 N. A.: Not applicable (expected frequency <5 for X2 test) 
N. D.: Not done C. I.: Confidence Interval 
Table 3.2: Deaths in women from cardiovascular disease 
Three hundred and seventy-six (54%) diabetic men died from CVD in 
comparison to 6,312 (46%) non-diabetic men (P <0.001). A higher 
proportion of men with diabetes between the ages of 45-54 (OR=2.4) and 
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55-64 years (OR=1.8) died from CVD than non-diabetic men (Table 3.3). 
These results suggest that women with diabetes between the ages of 45-64 
years have a greater estimated relative risk of dying from CVD than diabetic 




Number of Deaths 
from CVD 
Diabetic Men 
0 (%) E 
Number of Deaths 
from CVD 
Non-Diabetic Men 








>85 16 (41) 20 574 (51) 570 N. S. 0.67 0.35.1.28 
75-84 103 (50) 107 2021 (53) 2017 N. S. 1.02 0.77,1.35 
65-74 145 (56) 132 2017 (50) 2086 N. S. 1.32 1.02,1.69 
55-64 80 (63) 63 1127 (49) 1144 <0.005 1.77 1.23,2.57 
45-54 24 (73) 18 411 (53) 476 <0.001 2.37 1.09.5.17 
35-44 8 (53) 8 116 (54) 116 N. S. 0.97 0.33,2.81 
15-34 0 (0) 0 46 (46) N. A. N. A. N. A. N. A. 
Totals 376 6312 
U. UDservea E: Lxpectecl %: Percentage of total deatns in eacn age band N. 5.: Not significant 
Level of significance: P <0.05 N. A.: Not applicable N. D.: Not done Cl: Confidence Interval 
Table 3.3: Deaths in men from cardiovascular disease 
When CVD was divided into deaths from CVA and CHD, there was no 
difference between the groups with CVA as the underlying cause of death: 
diabetic: (n=149,11%) and non-diabetic(n =2,998,11%) (P--N. S. ). Diabetic 
men had a higher than expected number of deaths from CVA (observed = 
72, expected = 61: 10%) than non-diabetic men (observed = 1,240, 
expected=1250: 9%), with diabetic men having an increased odds ratio 
(1.2) (P--N. S). CVA was the underlying cause of death in 1,907 non-diabetic 
women and in 79 diabetic women (reducing the estimated relative risk for 
diabetic women: OR=0.9) (P <0.05). 
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Four hundred and twenty-four (30%) diabetic people in comparison to 
12,559 (46%) non-diabetic people died of CHD (P <0.001). However, fewer 
women with diabetes (n=198: 27%) died from CHD than non-diabetic 
women (n=5,573,42%) (P <0.001); women with diabetes had an increased 
estimated relative risk of dying from CHD between the ages of 45-54 years 
(OR=1.3) and 55-64 years (OR=1.4) but reduced risk from 65 years of age 




Number of Deaths 
from CHD in 
Diabetic Women 
0 (%) E 
Number of Deaths 







95% C. I. 
Odds 
Ratio 
>85 19 (14) 33 1161 (34) 1113 <0.001 0.30 0.18,0.49 
75-84 56 (21) 81 2157 (46) 2091 <0.001 0.30 0.22.0.40 
65-74 77 (36) 62 1373 (49) 1346 <0.001 0.57 0.43,0.76 
55-64 41 (47) 20 552 (39) 558 N. S 1.36 0.88,2.10 
45-54 5 (26) 3 101 (21) 102 N. A. 1.29 0.46,3.68 
35-44 0 (0) N. A. 30 (17) N. A. N. A. N. A. N. A. 
<1-34 0 (0) N. A 1 (2) N. A N. A N. A. N. A. 
Totals 198 5375 
v. uoserveo t:: Lxpectea -/o: ijercentage at totai aeatns in eacn age Dana N. b.: Not signiticant 
Level of significance: P<O * 
05 N. A.: Not applicable (expected frequency <5 for X2 test) N. D.: Not done 
Cl: Confidence Interval 
Table 3.4: Deaths in women from coronary heart disease 
There were no differences in deaths from CHD in men between the groups 
(diabetic: n=226 [33%] and non-diabetic: n=4150 [30%]) (P--N. S. ). 
Fewer people with diabetes [men: n= 59 (9%) and women: n= 59 (8%)] died 
from malignant neoplasm as the underlying cause of death than expected 
when compared to non-diabetic people [men: n=3,638 (26%) and women: 
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n=3,050 (23%)] (P <0.001) (Table 3.5 and 3.6). The estimated relative risk 
of dying from malignant neoplasm was greatly reduced in both men and 
















95% C. I. 
Odds 
Ratio 
>85 5 (13) 6 170 (15) 169 N. S. 0.83 0.32,2.15 
75-84 12 (6) 48 930 (24) 895 <0.001 0.20 0.11,0.37 
65-74 23 (9) 82 1363 (33) 1304 <0.001 0.53 0.35,0.82 
55-64 15 (12) 44 835 (36) 806 <0.001 0.23 0.14.0.41 
45-54 1 (<J) 10 245 (32) 236 <0.001 0.07 0.01,0.50 
35-44 3 (20) 4 60 (28) 59 N. S. N. D. N. D 
15-34 0 (0) 0 35 (35) 35 N. A N. D N. A. 
Totals 59 3638 
0: Observed E: Expected W Percentage of total deaths in each age band N. S.: Not significant 
Level of significance: P-<0.05 N. A.: Not applicable N. D.: Not done C. I.: Confidence Interval 














0 (%) E 
P Odds 
Ratio 
95% C. I. 
Odds 
Ratio 
>85 3 (2) 15 333 (11) 321 <0.001 0.18 0.06,0.56 
75-84 15 (<1) 51 817 (19) 781 <0.001 0.24 0.14,0.41 
65-74 27 (13) 71 903 (35) 859 <0.001 0.27 0.18,0.40 
55-64 11 (13) 40 626 (49) 597 <0.001 0.15 0.08.0.28 
45-54 3 (16) 11 253 (60) 245 <0.001 0.13 0.04.0.45 
35-44 0 (0) 3 96 (65) 93 N. A. N. A. N. A. 
15-34 0 (0) 1 22 (40) 21 N. A. N. A. N. A. 
Totals 59 3050 
U: UDSerVea t: upectea I/o: Percentage ot totai aeams in eacn age Dana N. S.: Not signiticant 
Level of significance: Fý<0.05 N. A.: Not applicable N. D.: Not done C. I.: Confidence Interval 
Table 3.6: Deaths in women from malignant neoplasms 
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In certain age bands there were fewer deaths from gastro-intestinal disease 
and 80ther" underlying causes in comparison to non-diabetic people in both 
men and women (Table 3.7). 
Causes of Death Age 
Bands 
(years) 
Numbers of Deaths 
Diabetic Group 
0 (%) E 
Numbers of Deaths 
Non-Diabetic Group 
0 (%) E 
P 
G. I. (Men) 75-84 1 (0.5) 7 139 (4.0) 133 <0.05 
65-74 1 (0.4) 7 125 (3.0) 119 <0.05 
G. I. (Women) 74-84 3 (1.0) 9 143 (3.0) 137 <0.05 
65-75 0 (0.0) 7 90 (3.0) 83 <0.01 
Others (Men) 75-84 2 (1.0) 14 299 (7.0) 287 <0.001 
65-74 0 (0) 12 218 (5.0) 206 <0.001 
55-64 1 (0.8) 7 133 (5.0) 127 <0.05 
Others (Women) >85 1 (0.7) 15 387 (11.0) 373 <0.001 
75-84 3 (1.0) 26 462 (10.0) 439 <0.001 
65-74 2 (0.9)15 200 (7.0) 190 <0.001 
U: uDserved E: Expected W Percentage of total deaths in each age band N. S.: Not significant 
Level of significance: F! 50.05 G. I.: Gastro-Intestinal 
Table 3.7: Other underlying causes of death in different age groups 
However, there was a higher proportion of deaths from liver disease in 
diabetic men from the ages 55-64 years (1.5%) compared to 0.5% in non- 
diabetic men and 65-74 years (diabetic men: 1.5% and non-diabetic men: 
0.4%), and in diabetic women from 75-84 years (1.00%) and >85 years 
(1.00%) compared to 0.01% and 0 03% respectively in non-diabetic women 
of the same age group. The numbers in diabetic people were very small. 
Two hundred and eighty seven (20%) of the diabetic group died from 
diabetes and there was no significant difference between males and 
females. Twenty died from "acute diabetesm i. e. DKA, HOC and HG, 50 from 
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nephropathy, and the rest from diabetes, intercurrent infection or gangrene 
(Table 3.8). 
Causes of Death 
(Diabetes) 
Number of Deaths 
Male 
0 (%) E 
Number of Deaths 
Female 
0 (%) E 
p 
Acute 13 (10) 9 7 (5) 11 N. S. 
Nephropathy 20 (15) 23 30 (19) 27 N. S. 
Others Diabetes 100 (75) 101 117 (76) 116 
- 
N. S. 
- - - Total Diabetes 133 (100) 137 154 (100) 149 
ý 
N. S .ý 
0: Observed E: Expected N. S.: Not significant Level of significance: P<u. u, 5 
Table 3.8: Deaths from diabetes. 
More women (n=96) than men (n=59) died of diabetes from the age of 75 
years onwards (P<0.005) but there was no significant difference between 
the sexes under 75 years of age. In the sub-group of acute diabetes there 
were more male deaths (n=9) between 65-74 years than expected (n=6) 
(P<0.05) and only 2 deaths under the age of 55 years. When nephropathy 
was compared to other causes within the diabetic group, it was not a 
significant underlying cause of death. The only notable difference in deaths 
from nephropathy, was that men died of nephropathy from the age of 35 
years onwards, whereas the women were older, 45 years and above. 
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3.6 Discussion 
All studies of mortality that rely on information recorded on death certificates 
(or in this case usecond-hand' information with death certificates as the 
original source) are potentially subject to inaccuracy secondary to what is 
actually written as the cause of death in Part 1 of the certificate, which at 
times, may not reflect the underlying diseases which have contributed to the 
death (Fuller et al, 1983; Panzram, 1987). A study in Minnesota identified 
that diabetes was not mentioned in 46% of 274 death certificates of people 
known to have diabetes (Sprafka et al, 1993). It is likely that under reporting 
of diabetes as the underlying cause of death also applied to the data in this 
study. 
Under reporting of diabetes on death certificates can bias the results of a 
study, especially in diabetic people who have macrovascular complications, 
including coronary heart disease. The other potential source of bias could 
be inaccuracy on recording the cause of death in nephropathy patients. This 
was observed in a study into the availability of RRT in diabetic patients, 
where it was noted that in some patients congestive cardiac failure was 
recorded on the death certificate. The authors commented that ESRF would 
have been more appropriate as the terminal stages of ESRF include the 
symptoms of cardiac failure (Working Party of the Renal Association et al, 
1989). 
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The most common underlying cause of deaths in both diabetic (53%) and 
non-diabetic groups (47%) was CVD. The proportion of deaths from CVD in 
diabetic people was lower than in a Dutch study but similar to other studies 
in this country (de Grauw et al, 1994; Gatling et al, 1997). The higher 
percentage of deaths from CVD in both male groups can be compared with 
a study in Sweden, where it was shown that 11.6% of diabetic and 2.7% of 
non-diabetic men died from CVD (Rosengren et al, 1989). This can be 
interpreted as indicating that death rates for CVD in people with diabetes in 
Wolverhampton are exceptionally high. This comparison also shows that 
more diabetic men die from CVD than non-diabetic men, similar to the 
present study. The Wolverhampton results are comparable with those of a 
study in Minnesota, USA, which looked specifically at mortality in Type 2 
diabetic patients, where CVD accounted for 63% of deaths in men and 62% 
on women (Sprafka et al, 1993). 
It has been demonstrated previously that people with diabetes have an 
increased risk of death from CHD (Kannel and McGee, 1979; Waine, 1989). 
The present study has shown that CHD was the major cause of death in 
both diabetic and non-diabetic groups in Wolverhampton. There was no 
difference in deaths from CHD between the male diabetic and non-diabetic 
groups while the smaller proportion of deaths from CHD in diabetic women 
was in contrast to a study in Aberdeen where diabetic women had a higher 
than expected death rate from CHD than non-diabetic women (Wong et al, 
1991). It has been reported that diabetic women are six times more likely to 
develop CHD than non-diabetic women (Manson et al, 1991). In 
-103- 
Wolverhampton diabetic women between the ages of 45 and 64 years had 
an increased estimated relative risk of dying from CHD than non-diabetic 
women, but this estimated risk was far lower than the risk of developing 
CHD that was suggested by Manson and co-workers (1991). A report 
published in 1994 stated that Wolverhampton had one of the highest death 
rates from CHD in the UK (Kelleher et al, 1994). Extrapolating that this may 
be typical of mortality in the town over several years, it may (a) explain the 
lower proportion of deaths with CHD as the underlying cause of death in 
diabetic women found in the present study in comparison to studies 
elsewhere and (b) complicate the comparison of deaths in Wolverhampton 
with studies from other places which have a lower population mortality rate 
from CHD. CVA represented a small proportion of cardiovascular deaths in 
both groups (similar to the findings of Wong and colleagues, 1991). 
The small proportion of deaths from malignant neoplasms in both male (9%) 
and female (8%) diabetic patients were consistent with the findings of Fuller 
and co-workers (1983). The Minnesota study demonstrated that deaths from 
neoplasms occurred in almost equal percentages in male and female 
diabetic patients; this was consistent with the Wolverhampton study 
(Sprafka et a/, 1993). Few other studies have looked at mortality from liver 
and gastro-intestinal diseases. The small proportion of deaths from gastro- 
intestinal disease (9%) in diabetic patients was interesting but was also 
consistent with the findings in a study by Kessler published in 1971 of over 
10,000 diabetic deaths, where the numbers of deaths from liver and 
gastrointestinal disease were very small and those from cancer accounted 
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for only 9% of deaths (Kessler, 1971). It is possible that the reduced 
mortality from both malignant neoplasm and gastro-intestinal disease is due 
to acompetitive risk' Le.: one predominant cause of mortality e. g.: CVD, in a 
group of people results in reduced mortality from other causes (Fuller et al, 
1983). The higher proportion of deaths from liver disease (18%) in diabetic 
people in comparison to non-diabetic people (<I%) may be secondary to a 
number of factors e. g.: in people with diabetes, the metabolic functions of 
the liver are abnormal in terms of gluconeogenesis, insulin metabolism and 
lipid metabolism (Type 2) which may eventually result in liver damage. 
Diabetic patients may also be taking a number of drugs for diabetes and the 
complications of the disease, which potentially could have damaging effects 
on the liver over time. However, the numbers of deaths from liver disease in 
each of the groups was relatively small. Further investigation of the role of 
liver disease in diabetic deaths may be an interesting area for future 
research. 
Mortality directly attributable to diabetes represented a fifth of all diabetic 
deaths. Only a small number of these deaths were due to the acute 
metabolic complications of diabetes with 10% of the "acute" diabetic deaths 
occurring under the age of 50 years. This contrasts to the findings of 
Turnbridge's group in 1981, who found that 19% of diabetic deaths under 50 
years were due to diabetic ketoacidosis and hypoglycaemia. More recently, 
Tattersall and Gill outlined the difficulties in establishing the cause of 
sudden death in diabetic patients which included how unreliable 
measurement of post-mortem blood glucose can be and the reluctance of 
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pathologists to attribute cause of death to metabolic rather than pathological 
causes (Tattersall and Gill, 1991). The data presented here should be 
assessed in this light. 
In relation to other causes of death in this study, diabetic nephropathy was 
not a significant underlying cause of death. However, as previously 
discussed, cardiovascular disease may be recorded as the underlying 
cause of death in patients in ESRF either secondary to renal failure or 
because many patients in ESRF die of ischaernic heart disease (Joint 
Working Party of the Renal Association et al, 1989; Wong et al, 1991). The 
Aberdeen study found that 32% of deaths in patients with nephropathy were 
due to ischaemic heart disease which was not surprising as people with 
nephropathy often have accompanying macrovascular complications (Wong 
et al, 1991). It has also been suggested that mortality rates from 
nephropathy in people below 45 years of age may be reduced due to the 
increasing numbers of diabetic patients receiving renal replacement therapy 
(Stephenson et al, 1992). However, Moss and colleagues in Wisconsin, 
found excess mortality in both younger and older diabetic patients due to 
renal disease and have suggested that if nephropathy had been classified 
under diabetes using ICD-09 coding, the excess mortality would in fact be 
greater than they found (Moss et al, 1991). More recently, excess mortality 
associated with proteinuria and accompanying hypertension in both insulin 
dependent and non-insulin dependent diabetic patients has been shown on 
a world wide scale (Wang et al, 1996). 
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Despite reservations about the reliability of data from death certificates, this 
section of the thesis provided an interesting background to the causes of 
death in diabetic patients in Wolverhampton and specifically as to whether 
diabetic nephropathy was significant in terms of mortality. However, there 
were a number of flaws with the design of this study. Firstly, the data used 
on deaths in the diabetic group were not obtained directly from death 
certificates but through a "mediator", the Department of Public Health, which 
produced two specific problems: There was no guarantee that data on all 
deaths in diabetic patients had been obtained and when comparison was 
made with the OPCS data it became evident that a proportion of deaths in 
diabetic people had been omitted from the data source provided by the 
Department of Public Health. This was not entirely surprising as this data 
had been provided to inform the diabetic physicians about deaths in their 
patient population and not specifically for research purposes. The other 
problem with this data was that the only method of validating the accuracy of 
the information was to compare some of the data with death certificates. 
Unfortunately, the Registrar of Births, Deaths and Marriages would only 
agree to this if copies of the death certificates were purchased at E5.00 
each; to validate 5% of this data would have cost over E350 and there was 
no funding available for this project. 
During the years 1981-1986, there was no information on the total 
population attending the diabetic clinic. This limited the types of analysis 
which could be performed and essentially excluded performing annual and 
standardised mortality rates in the diabetic group although these could have 
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been calculated in the general population (Gordis, 1996). As the data did 
not include information on deaths of all people with diabetes calculation of 
proportionate mortality rates (PMR) would have been inaccurate. However, 
this could have been calculated for the sample of diabetic deaths, out of 
interest, but a direct comparison of the PMR in the general population would 
not have been valid due to the missing data (Gordis, 1996). 
Although a comparison of causes of death in different age groups has been 
made, again due to the incomplete data on deaths in diabetic people and 
the lack of information on the total diabetic population, it was impossible to 
calculate age-specific or age-standardised death rates (Gordis, 1996). 
The present study was retrospective using available data gathered for other 
purposes. In order to obtain more robust data, a prospective cohort study 
over ten years would have allowed for efficient project management, 
development of a sound scientific protocol, removal of possible biases, 
collection of data from a well documented group of diabetic patients (and 
the general population if wished) and the potential to analyse the data in a 
more comprehensive manner. This type of study was not possible in the 
lifetime of this thesis. 
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3.7 Conclusions 
I The majority of deaths in both diabetic and non-diabetic people in 
Wolverhampton were due to CVD with CHD being the main 
underlying cause of death. 
2 Female diabetic patients had a 4.0 times increased risk of dying from 
CVD than non-diabetic females between the ages of 45-54 years and 
a 2.5 times increased risk between ages of 55-64 years in 
comparison to diabetic men where the risk was 2.4 times increased at 
ages 45-54 years and 1.6 times increased between 55-64 years. 
Therefore accept Ho(2): There was no difference in underlying 
causes of death between men and women with diabetes; but with the 
caution that diabetic women had an increased risk of developing 
CVD. 
3 Diabetic patients were less likely to die from malignant neoplasms, 
gastro-intestinal disease and other causes than non-diabetics. 
Therefore accept Hi(l): There was a difference in underlying causes 
of death in people with and without diabetes. 
4 Diabetes was responsible for 20% of deaths within the diabetic 
group. 
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5 Diabetic nephropathy was not a significant cause of death. Therefore, 
accept Ho(4): Diabetic nephropathy was not a major underlying cause 
of death in people %Mth diabetes. 
The results obtained neither proved or disproved the third hypothesis: That 
there was no difference in underlying causes of death in people with 
diabetes of different ages. 
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Chapter 4 
Renal Disease in Patients Attending the Wolverhampton 
Diabetic Clinic: 1987-1995 
- ill - 
4.1 Introduction 
The aim of the clinician is to provide diabetic care, education and support to 
ensure that patents manage their diabetes in a way that will prevent the 
occurrence of severe complications. Diabetic nephropathy is one of those 
complications which becomes devastating when patients reach end stage renal 
failure and the only alternatives are dialysis, kidney transplantation or death. 
Several large studies; population based, clinic based and across Europe, have 
been undertaken to determine the extent of nephropathy within a specified 
population; comparisons have also been made between the USA and Europe 
(Klein et al, 1988; Humphrey et al, 1989; Stephenson et al, 1994; Lloyd et al, 
1996). However, from a clinical perspective it is more interesting to know how 
many local diabetic patients have nephropathy in order to provide adequate 
provision of care for these patients. 
In 1988-1989, the Wolverhampton hospital diabetic clinic served a population of 
289,200 plus approximately 31,000 diabetic people from surrounding areas 
(South and Mid-Staffordshire, Shropshire, Dudley and Walsall) (Office of 
Population Censuses and Surveys, 1990). The number of patents attending the 
clinic between 1988-1989 was 2,047 from a total diabetic population in the town 
of 5,155 (Wolverhampton Diabetes Register, 1990). The extent of renal disease 
and particularly diabetic nephropathy in the clinic was not known although 
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increasing numbers of patents were being referred from the diabetic clinic for 
nephrological assessment. The aim of this study was to establish the extent of 
diabetic nephropathy in patients attending the hospital clinic. 
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4.2 The Objectives 
I To determine the prevalence of nephropathy in the index diabetic 
population. 
2 To determine the prevalence of other causes of renal disease in the index 
diabetic patients. 




1 Ho: The majority of patients being referred for nephrological assessment 
do not have diabetic nephropathy. 
Hi: The majority of patents being referred for nephrological assessment 
have diabefic nephropathy. 
2 Ho: There was no difference in prevalence of diabetic complications 
between Type 1 and Type 2 patents with renal disease. 
Hi: There was a difference in prevalence of diabetic complications 
between Type 1 and Type 2 patients with renal disease. 
-115- 
4.4 Methods 
Data on the numbers of patents (n=2047) attending the diabetic clinic in 1988- 
1989, obtained from the Wolverhampton Diabetic Clinic computerised register, 
were used to determine the prevalence of patients with renal disease in the clinic 
population, as data for subsequent years was not available. Data were collected 
from the hospital records of all diabetic patients referred from the diabetic clinic 
for nephrological assessment over an eight-year period between 1987-1995. This 
included patients with proteinuria and raised serum creatinine levels, with or 
without proteinuria, and patents presenting with end stage renal failure who had 
defaulted from routine clinic visits. Data on age, sex, ethnic group, family history 
of diabetes, smoking history, diabetes, diabetes treatment and diabetic control 
(as measured by HbAl), and complications including renal disease (as measured 
by 24 hour urinary protein and serum creatinine concentrations) were collected. 
Details of regular defaulting from routine diabetic clinic visits (i. e.: missing more 
than two consecutive clinic visits in more than one year since diagnosis of 
diabetes) were also collected. Patients were divided into Type I and Type 2 
diabetes groups and a comparison was made between the two. Type 1 was 
defined as diagnosis before the age of 35 and requiring insulin treatment; Type 2 
was defined as diagnosis after 35 years of age and treated with either diet, oral 
therapy or insulin treatment. Normal blood pressure was defined as a systolic 
pressure of < 140 mm Hg and a diastolic < 90 mm Hg as recommended by the 
Working Group on Hypertension in Diabetes (1987). 
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Diabetic nephropathy was diagnosed on clinical grounds: the presence of 
proteinuria and diabetic retinopathy. Renal biopsy was only performed where 
there was insufficient clinical evidence to give a definitive diagnosis. For patients 
with proteinuria at diagnosis of diabetes the duration of diabetes was recorded as 
zero, only to give a numerical value, as it was accepted that Type 2 patients 
presenting with complications will have had diabetes for some time before 
diagnosis. 
Diabetic retinopathy, peripheral neuropathy and peripheral vascular disease were 
graded according to severity, as recorded in patients notes. Ischaernic heart 
disease was assessed by either documented evidence of angina symptoms or on 
electrocardiographic evidence. 
Descriptive statistics, two-tailed Student t tests, Chi2 tests (Fisher Exact test was 
used if n<5) and Mann-Whitney U tests for non-parametric data were performed 




All percentages relate to patients referred for nephrological assessment (index 
group) unless otherwise stated. Over eight years, 220 people (11% of the 
hospital diabetic population) were referred for nephrological assessment, of 
these 49 (22%) were Type 1 and 171 (78%) were Type 2 diabetic patients. All 
Type I and 84 (49%) Type 2 patients were treated with insulin (it was 
inapplicable to perform statistical tests to compare differences in treatment). 
Seventy-seven (35%) were female and 143 (65%) were male (Table 4.1). There 
were 153 (70%) White, 44 (20%) Indo-Asians and 23 (10%) Black. Two Type 1 
Indo-Asian patents (33% of all Type 1 Inclo-Asians) and 21 Type 2 Inclo-Asian 
patients (55% of all Type 2 Inclo-Asians) spoke little or no English. 





TOTAL 49(22) 171(78) 
GENDER 
male 35(71) 108(63) N. S. 
Female 14(29) 63 (37) 
ETHNIC GROUP 
White 40(82) 113(66) 
Indo-Asian 6(12) 38 (22) <0.005 
Black 3(6) 20 (12) 
TREATMENT 
Insulin 9(100) 84 (49) 
Oral 0 75 (44) N/A 
Diet 0 12(7) 
N. b.: NOt bigniticant N/A: Not Applicable Level of signiticance: P <U. U5 
Table 4.1: Demographics of diabetic patients with renal disease. 
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The age range in both groups was wide, with a mean age of 43 (SID +12) years in 
Type 1 patients compared to 63 (SID +8) years in the Type 2 group; this was 
significantly different (P<0.001). The mean duration of diabetes at referral was 23 
(SID +10) years in the Type 1 group and 11 (SID +7) years for Type 2 patients 
(P<0.001) and the mean duration of diabetes at the onset of proteinuria was 
longer in Type 1 patients: 19 years (SID +8) years versus Type 2: 11 (SID +7) 
years (P<0.001). 
Renal biopsies were performed in 21 cases where there was doubt as to the 
diagnosis on clinical grounds alone, only three were in Type 1 patients. Diabetic 
nephropathy was diagnosed in 47 (96%) of Type 1 patients and 102 (60%) of the 
Type 2 group. Chronic renal failure secondary to hypertension was diagnosed in 
38 (22%) of Type 2 patients while 31 had renal disease due to other causes, 
including four with confirmed renal artery stenosis (Figure 4.1). Four (2%) Type 2 
patients had proteinuria at diagnosis of diabetes. 
CiDiabetic N: phropathy : GloMeruloscierosis ciPyelonephritis 
ON: phro I cl rosis Ren I Artery Stenosis : Hypertension 
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Figure 4.11: Causes of renal disease in Type 2 diabetic patients 
50% 
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The power of the study was calculated as 99% using the proportion of patents in 
each group with a diagnosis of diabetic nephropathy (0.96 in Type 1 patients and 
0.60 in Type 2 patients), P<0.05 and the harmonic mean of the number in each 
group (as the sample sizes were unequal in the two groups). 
4.5.1. Renal Function 
The mean urinary protein excretion over 24 hours was the same in both groups 
although the range was greater in Type 2 patients. There was a Wide range of 
serum creatinine levels with a bimodal distribution in both groups; however, the 
means were similar although the standard deviation in the Type 2 group was 
smaller and the median for Type 1 patients was within the normal limit (Table 
4.2). 
NormalRange Typel Type 2 P 
SERUM CREATININE (ýLnlol 1-1) 
Range 60-120 40-1070 57-1140 
Mean (+SD) 209 L+235) 206 L±185) N. S. 
Median 105 137 
PROTEINURLA (g 24hou(') 
Range 0.00-1.10 0.10-16.00 0.07-21.0 
Mean (+SD) 2.98L+3.13) 2.86L+3.78) N. S. 
Median 1.89 1.52 
zw.: blanaara Ueviation N. S.: Not Significant Level ot signiticance: t,, ýu. uo 
Table 4.2: Renal function in Type 1 and 2 diabetic patients 
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4.5.2 Microvascular Complications 
Of the 146 (66%) patients With retinopathy, 90 (62% of retinopathy patients) had 
severe refinopathy. There was a higher prevalence of retinopathy in the Type I 
group (92%) than in Type 2 patients (59%) (P<0.001); Type I patients had 
significantly more severe retinopathy (P<0.05). Forty-nine percent of patients With 
retinopathy were treated by laser photocoagulation. Fifty patients (23%) had 
cataracts, 23 (10%) were blind in one eye and 10 (4%) were blind in both eyes; 







Retinopathy 45 (92) 101 (59) <0.001 
Severe Retinopathy 39 (87*) 51 (51 *) <0.05 
Laser Photocoagulation 29 (64*) 43 (43*) N. S. 
Cataracts 14 (29) 36 (21) N. S. 
Blind One Eye 13 (27) 10 (6) <0.001 
Blind Both Eyes 5 (10) 4 (2) <0.005 
NERVOUS SYSTEM 
Peripheral Neuropathy 23 (47) 57 (33) N. S. 
Autonomic Neuropathy 4 (8) 3 (2) <0.01 
KIDNEYS 
I Diabetic Nephropathy 47 (96) 1 10 (60) 1 <0.001 
-: Yo ot patients VAth retinopathy N. S.: Not significant Level of significance: P< 0.05 
Table 4.3: Microvascular complications in diabetic patients with renal disease 
Peripheral neuropathy was identified in 80 (36%) patients, in seven this was 
severe, while autonomic neuropathy was found in seven (3%) patients. The Type 
group had a higher prevalence of peripheral neuropathy (N. S. ) and autonomic 
neuropathy (P<0.01) (Table 4.3). 
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4.5.2. Macrovascular Complications 
Ischaernic heart disease (IHD) was found in 41 (19%) patients and 26 (12%) had 
had myocardial infarctions (MI). The Type 1 group had a slightly lower 
prevalence of IHD and MI than Type 2 patients had but this was not statistically 
significant. Transient ischaernic attacks (TIA) had occurred in 8 (4%) patients and 
cerebrovascular accidents (CVA) in 22 (10%). The Type I patents had a non- 
significant higher prevalence of CVA (Table 4.4). Total cholesterol levels (Type 1: 
mean: 6.8 (S. D. + 2.0); Type 2: mean: 6.6 (S. D. + 2.0) mmol/1) and diabefic 
control (Type 1: mean HbAl 11.5 (S. D. + 2.2) %; Type 2: mean 10.9 (S. D. + 2-5) 
%) were similar in both groups (P--N. S. for both). Peripheral vascular disease 
(PVD) was present in 68 (31 %) patients and was severe in 24 of these. Twenty- 







Ischaernic Heart Disease 8 (16) 33 (19) N. S. 
Myocardial Infarction 4 (8) 22 (13) N. S. 
BRAIN 
Transient Ischaernic Attack 2 (4) 6 (4) N. S. 
Cerebrovascular Accident 6 (12) 16 (9) N. S. 
VASCULAR 
Peripheral Vascular Disease 19 (39) 49 (29) N. S. 
Ulcers 5 (10) 20 (12) N. S. 
Leg Amputations (1 only) 3 (6) 6 (4) N. S. 
n. o.. Not signincam Levej ot signincance: výýu. uo 
Table 4A Macrovascular complications in diabetic patients with renal disease 
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There was no statistically significant difference between the groups for any of 
these complications (Table 4.4). 
Hypertension was present in 202 (92%) patients; the prevalence in both groups 
was similar. Only 95 patients with hypertension were being treated with anti- 
hypertensive medication at referral (Table 4.5). The mean and median systolic 
blood pressures, which were higher in Type 2 patients, demonstrated that 
systolic hypertension was common in both groups. The mean and median 
diastolic pressures for both groups were 90mmHg. Of those receiving anti- 
hypertension medication, around a half had hypertension that was resistant to 







Hypertension 44(90) 158(92) N. S. 
Anti-hypertensive Therapy 20(46*) 75(47*) N. S. 
Systolic Pressure (mm Hg) 
Range 70-240 110-260 
Mean L+SD) 160 L+30) 168 L+26) N. S. 
Median 160 163 
Diastolic Pressure (mm Hg) 
Range 40-120 50-120 
Mean L+ SD) 90 L+15) 90 L+14) N. S. 
Median 90 90 
ZS-U.: Standard deviation N. S.: Not significant Level ot signiticance: P <U. Ub 
*: % of patents with hypertension 
Table 4.5: Blood pressure of diabetic patients with renal disease 
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Sixty-two patients smoked cigarettes, 76 had a family history of diabetes and 75 
had defaulted from routine diabetic clinic follow up. There were no significant 
differences between the groups for any of these factors. 
4.5.4. Outcomes 
Over eight years, 82 (37%) patients reached end stage renal failure (ESRF) or 
died. Of those who received renal replacement therapy (RRT): 16 had Type 1 
and 26 had Type 2 diabetes. Of the Type 1 patients on RRT, 11 received 
continuous ambulatory peritoneal dialysis (CAPD), five had haemodialysis (HID) 
and seven eventually received kidney transplants. In comparison, 13 Type 2 
patients received CAPD, 13 HID and only two had kidney transplants: one went to 
India to be transplanted (Figure 4.2). 
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Figure 4.2: Type of renal replacement therapy received by diabetic patients 
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Of the 40 patients who died, 15 (38%) died from ESRF either following or without 
having received RRT, 17 (42%) from cardiovascular disease and eight (20%) 
from other causes. 
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4.6 Discussion 
Seven percent of the diabetic clinic population had nephropathy and 4% had 
renal disease due to other causes. These results can be compared with two 
studies in Type 1 patients; the EURODIAB study where prevalence was 12% and 
the Epidemiology of Diabetes Complications study where prevalence was 27% 
(Lloyd et al, 1996). The large numbers of Type 2 patients with nephropathy in this 
study, 102 (60%), confirms the findings of Humphrey and co-workers (1989). In a 
population-based study in Minnesota, they found that Type 2 patients had an 
eight times greater chance of developing chronic renal failure than people with 
Type I diabetes. 
The higher prevalence of renal disease in men than women was to be expected. 
Previous studies of nephropathy in Type 1 and Type 2 patients have 
demonstrated a preponderance of males (Andersen et al, 1983; Humphrey et al, 
1989). In a study detailing the progression of proteinuria in both types of 
diabetes, Cooper and colleagues (1988) showed that the ratio of men to women 
in Type 1 patients was 2: 1 and in Type 2 was 1.51. In this study the ratio of men 
to women was higher in Type I patients: 2.51 and marginally so in the Type 2 
group: 1.71. 
The difference in age at referral for nephrological assessment can be explained 
by the later onset of Type 2 diabetes. The shorter duration of diabetes in the 
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Type 2 group both at referral and onset of proteinuria in comparison to Type I 
patients was reflective of the unknown duration of diabetes prior to diagnosis (the 
silent phase pre-diagnosis). Many Type 2 patients are unaware of the symptoms 
of diabetes and that by the time the disease is diagnosed, after several years of 
untreated hyperglycaemia, complications, including nephropathy, have 
developed. In this study, the 2% of Type 2 patients with proteinuria at diagnosis 
of diabetes supports this argument and is consistent with the findings of the 
United Kingdom Prospective Diabetes Study, where they also found 2% of newly 
diagnosed Type 2 patients to have microvascular complications (UK Prospective 
Diabetes Study Group, 1994). In 1991, Friedman and Gross demonstrated that 
the decline in glomerular filtration rate in Type 2 patients is at a slower rate than 
in Type I patients. 
Type I patients had more microvascular complications than the Type 2 group but 
this was to be expected, as there was a higher prevalence of nephropathy in the 
Type I group. It has been suggested that a sub-group of diabetic patients are 
susceptible to both nephropathy and retinopathy (Agardh et al, 1989). The 
EURODIAB study clearly demonstrated the association between retinopathy, 
nephropathy and raised diastolic blood pressure in a subgroup of Type 1 patients 
(Stephenson et al, 1995). The higher incidence of blindness In Type I patients in 
this study was consistent with the findings of Parving and colleagues (1988), 
where the prevalence of proliferative retinopathy increased by 36% and 
blindness by 11 % in patients with proteinuria. 
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The prevalence of peripheral neuropathy in diabetic patients without proteinuria 
has been shown to be 11 % in Type 1 patients and 26% in Type 2 patients 
(Boulton et a/, 1985; Franklin et al, 1990). It has also been demonstrated that 
insulin-dependent patients with proteinuria have an increased risk of peripheral 
neuropathy (Parving et al, 1988). This study has shown that Type 2 patients had 
a relatively high prevalence of peripheral neuropathy (33%) and that there was 
no significant difference in this complication between the two groups. Peripheral 
neuropathy, like the other microvascular complications, is the result of poor 
diabetic control over many years. In this study, HbAl results at referral were 
higher than ideal in both the groups. 
The prevalence of macrovascular complications were the same in both groups 
which was surprising considering the younger age of the Type 1 patients. It has 
been suggested that Type I patients with proteinuria have an eight times 
increased Incidence of myocardial infarctions and Ischaernic heart disease 
(Deckert et al, 1992). It has been postulated that the mechanisms involved In 
reducing the density of heparan sulphate proteoglycan which occur in the 
glomerular basement membrane of patients with proteinuria may also occur In 
plasma membranes and myornedial cells and thus contribute to atherosclerosis 
and macrovascular disease (Deckert et al, 1992). The relatively high prevalence 
of cerebrovascular accidents and peripheral vascular disease in Type 1 patients 
also reflects the high risk of atherosclerosis in these patients. 
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Hypertension is twice as common in diabetic as in non-diabetic individuals 
(Working Group on Hypertension in Diabetes, 1987). Rising blood pressure is 
known to contribute to the progression of diabetic nephropathy (Microalbuminuria 
Collaborative Study Group, United Kingdom, 1993). The importance of effective 
blood pressure control in preventing the decline of renal function in diabetic 
patients was first observed in the early 1980s and various strategies have been 
used to keep blood pressure within normal limits and decelerate the progression 
of renal disease (Mogensen, 1982; Parving et al, 1983; Hommel et al, 1986; 
Lewis et al, 1993; Mogensen, 1995; EUCLID Study Group, 1997). In this study 
blood pressure levels were similar in both Type I and Type 2 patients. Both 
groups had systolic hypertension and diastolic pressures were at the upper limits 
of normal. Systolic hypertension has been associated with a decline in renal 
function in both types of diabetes and diastolic hypertension (> 95mmHg) with 
the progression of nephropathy in Type 1 patients (Cooper et al, 1988; Klein et 
a/, 1988; Nielsen et al, 1993, Deckert et al, 1991). Less than half of both groups 
who were hypertensive were receiving anti-hypertensive medication at referral, 
which was surprising as over 90% of patients had hypertension. Of those on 
treatment, around a half had hypertension that was resistant to treatment with 
one drug only and were receiving a combined adjunct therapy. As renal function 
deteriorates the blood pressure tends to rise correspondingly and becomes more 
difficult to control. The need for combined adjunct anti-hypertensive regimes may 
be indicative of the advanced stage of renal disease of many of these patients. 
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Renal funcbon varied from within normal levels for serum creatinine to end stage 
renal failure in both groups and there was no difference between the groups in 
this respect. 
The relatively high default rates from routine diabetic clinic attendance support 
previous research performed in Wolverhampton which demonstrated that 
patients defaulting from regular clinic visits had a higher complication rate than 
regular attendees (Hammersley et al, 1985). 
This was a prospective study of a cohort of patients with nephropathy which 
included patients with already established renal disease. This meant that the 
number of new cases / population/ year (the incidence) could not be calculated 
but the extent of renal disease in the diabetic clinic could be determined using 
point prevalence. Point prevalence was used as opposed to period prevalence 
because diabetic nephropathy is a chronic disease state during which there are 
rarely periods of remission (Silman, 1995). 
In Type 2 patients there has been much debate about using clinical definitions to 
diagnose nephropathy instead of using renal biopsies to confirm the diagnosis. 
Without having performed renal biopsy, there is a potential source of biasing the 
diagnosis in Type 2 patients although previous research has indicated that the 
diagnosis of nephropathy on histological examination is not as clear-cut as In 
Type 1 patients (Ritz et al, 1995). 
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Observer bias was probably present in the examination of physical parameters 
by different clinicians as no specific examination protocol was followed and no 
training was performed prior to the study to reduce individual variation in 
techniques. Using data obtained at routine clinic visits without using a specific 
protocol provided an insight into the real practice of clinical medicine in a way 
that the use of a formal examination and treatment protocol designed for 
research purposes would not have given. It could be argued that the results of 
this project are more relevant to evidence based practice than those from a 
formal research protocol. 
Serum creatinine concentrations were used to assess renal function instead of 
creatinine clearance; this being a more accurate assessment of renal function 
that serum creatinine concentration. This was for pragmatic reasons as 
creatinine clearance was not assessed in all patients but serum creatinine was. 
In a study based on a structured research protocol as opposed to one based on 
normal clinical practice, measurements of (a) urinary albumin excretion (b) 
albumin: creatinine ratio (c) glomerular filtration rate by excretion of radio isotopes 
and (d) renal plasma flow could have been used to give a more accurate 
assessment of renal function than serum creatinine levels. 
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4.7 Conclusions 
1 Diabetic nephropathy was the major cause of renal disease in both Type I 
and Type 2 patients, therefore accept H1(1): the majority of patients 
referred for nephrological assessment have diabetic nephropathy. 
However, a significant minority of patients with Type 2 diabetes have 
either renal failure due to hypertension or to other causes. 
2 Type 1 patients in this index population had a higher prevalence of 
microvascular complications, therefore, accept Hi(2): there was a 
difference in prevalence of diabetic complications between Type I and 
Type 2 patients. 
3 There was no difference in renal function between the two groups. 
4 Uncontrolled hypertension was common in both groups. 
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Chapter 5 
Comparison of (1) Type I and Type 2 Diabetic 
Patients with Nephropathy and (ii) Type 2 Patients 




The previous chapter compared the point prevalence of diabetic 
complications and the pattern of renal disease in Type I and Type 2 patients 
with all causes of renal disease. Whether there are significant differences 
between (a) Type 1 and 2 patients with nephropathy and (b) between Type 2 
patients with nephropathy and those with non-diabetic renal disease needs 
further elucidation. 
There have been many studies looking at the natural history of nephropathy 
in Type 1 patients (Parving et al, 1988; Mathiesen et al, 1995). Until it 
became evident that Type 2 patients, formed the majority of people with 
diabetes and nephropathy receiving renal replacement therapy (RRT), less 
research had been done to identify the course of nephropathy in this group 
of patients ( Humphrey et a/, 1989). 
A German study has shown that 21 % of Type 2 diabetic patients at autopsy 
had renal disease from causes other than nephropathy in comparison to 
dialysis populations where 32% of Type 2 patients In London, and 52% in 
France had non diabetic renal disease (Grenfell et al, 1988; Waldherr et al, 
1992; Zmirou et al, 1992). Within the financial, ethical and time constraints of 
providing clinical care, it is not always feasible or possible to perform renal 
biopsies on all Type 2 patients with renal disease to provide a definitive 
diagnosis. However, by direct comparison of the diabetes and renal histories 
of Type I and Type 2 patients with nephropathy and non-diabetic renal 
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disease, it is possible to identify characteristics in each group that are 
predictive of the diagnosis without renal biopsy. 
The aim of this part of the study was to determine differences In renal and 
diabetes parameters between a) Type I and Type 2 patients with 
nephropathy and b) Type 2 patients with nephropathy and patients with 




I(a) To ascertain whether there were significant differences in renal 
function between Type 1 and Type 2 patients with nephropathy. 
l(b) To ascertain whether there were any significant differences in the 
prevalence of diabetic complications between Type 1 and Type 2 
patients with nephropathy. 
1(c) To identify factors that might be predictive of the development of 
nephropathy in the two groups. 
1(d) To determine whether there were differences in renal outcomes 
between Type 1 and Type 2 patients with nephropathy. 
2(a) To determine whether there were significant differences In renal 
function between Type 2 patients with nephropathy and non-diabetic 
renal disease. 
2(b) To determine if there were significant differences In prevalence of 
diabetic complications between Type 2 patients with nephropathy and 
non-diabetic renal disease. 
2(c) To determine whether there were differences in renal outcomes 




1 Ho: The rate of progression of nephropathy was the same in Type 1 
patients and in Type 2 patients. 
Hi: The rate of progression of nephropathy is different in Type 1 patients 
to that in Type 2 patients. 
2 Ho: Diabetic complications were similar in Type I and Type 2 patients 
with nephropathy 
Hi: Diabetic complications were different in Type 1 and Type 2 patients 
with nephropathy. 
3 Ho: Diabetic complications were similar in Type 2 patients vvith 
nephropathy compared to patients with non-diabetic renal disease. 
Hi: Diabetic complications were different in Type 2 patients with 
nephropathy compared to patients with non-diabetic renal disease. 
4 Ho: The progress of renal disease in patients with nephropathy was the 
same as that of patients with non-diabetic renal disease. 
Hi: The progress of renal disease in patients with nephropathy was 
faster than that of patients with non-diabetic renal disease. 
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1-12: The progress of renal disease in patients with nephropathy was 
slower than that of patients with non-diabetic renal disease. 
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5.4 Methods 
Data collected from the hospital records of patients referred for nephrological 
assessment (as in Chapter 4: information on diabetes, diabetes history, 
treatment and complications and renal function) were used to investigate 
differences between Type 1 and Type 2 patients with nephropathy and Type 
2 patients with nephropathy and Type 2 patients with non-diabefic renal 
disease. Point prevalence was determined for diabetic complications at the 
nephrological assessment visit. 
Duration of diabetes to the onset of proteinuria, retinopathy and 
hypertension was also determined and compared in a subgroup of patients 
with these three complications. The subgroup was composed of patients with 
all three complications, those without either retinopathy or hypertension were 
omitted. Only patients with a diagnosis of diabetes greater than three years 
were included, in order to exclude patients with established retinopathy and 
proteinuria before diagnosis of diabetes and to reduce the possible 
Munknown" duration of diabetes before diagnosis. 
Renal function was assessed using revised results for serum creatinine and 
24 hour urinary protein excretion. The revised results were those with 
outliers" removed. The *outliers' for creatinine results represented patients 
with serum creatinine greater than 300 pmol 1"' and for proteinuria those with 
protein excretion greater than 10g 24h". Data are presented comparing 
results for all patients, revised and moutliers% 
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Comparisons were made between (a) Type 1 and Type 2 patients with 
nephropathy and (b) Type 2 patients with nephropathy and Type 2 patients 
with non-diabetic renal disease. 
Descriptive statistics, two-tailed Student t tests, Chi2 tests, Mann-Whitney U 
tests for non-parametric data, the Pearson test for correlation (a maximum of 
two outlying points were removed per test to make correlation more 
accurate, when necessary), linear regression and stepwise multiple 
regression analysis were performed using SPSS and Excel statistics 
packages. The chosen level of statistical significance was P ýý0.05. 
-140- 
5.5 Results 
5.5.1 Compadson of Type I and Type 2 Patients with Nephropathy 
There were 149 patients with nephropathy, 47 Type I and 102 Type 2. 
Renal biopsies were performed in two Type 1 patients and seven of the Type 
2 group to confirm diagnosis in those patients where clinical findings were 
inconclusive. The ratio of males to females was just over 2: 1 with the Type 1 
group being predominantly White (83%) in comparison to only 57% White 
patients in the Type 2 group. Sixty eight (67%) of Type 2 patients were 
insulin treated (Table 5.1). Diabetic control was poor at referral in both 
groups. 





TOTAL NUMBER 47(100) 102(100) 
GENDER 
Male 33(70) 70 (69) N. S. 
Female 14(30) 32 (31) 
ETHNic GROUP 
White 39 (83) 58 (57) 
Indo-Aslan 5 (11) 30 (29) <0.01 
Black 3 (6) 14 (14) 
TREATMENT 
Insulin 47(100) 68 (67) 
Oral 0 32 (31) N. A 
Diet 0 2 (2) 
DLABETIC CONTROL 
HbAll (%) 
Range 7.4-16.3 6.7-20.0 
Mean (+SD) 11.9(2.1) 11.2(2.5) N. S. 
NOT signiticant NA.: Not applicable Level ot signiticance P_<U. 0 
Table 5.1: Demography of Type I versus Type 2 patients with diabetic 
nephropathy 
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The age range at referral was wide with a twenty year difference in mean 
ages: Type 1: range: 18-71, mean: 43 (SD+12) years and Type 2: range: 41- 
83, mean: 62 (SD+8) years (P<0.001). The mean duration of diabetes was 
twelve years shorter in the Type 2 group than in Type 1 patents and this 
was statistically significant: Type 1: 24 (+ 8) years versus Type 2: 12 L+7) 
years (P<0.001). 
In each of the two sub-groups of patients with nephropathy and retinopathy 
(n= 36, Type 1 and n= 40, Type 2) the mean duration of diabetes before 
onset of proteinuria was shorter in the Type 2 group than in Type 1 patients 
(Table 5.2). Duration of diabetes until onset of retinopathy and hypertension 
was also shorter in the Type 2 sub-group In comparison to the Type 1 sub- 
group and these differences were statistically significant. The statistical 
power of the sub-study, calculated after collection of data, was low (<18%), 
therefore, this sub-study could be regarded as a pilot study. In order to 
achieve 80% power a minimum of 780 patients would be needed. 
Complication Time to Onset Time to Onset P 
Mean (+SD) [years] Mean(+SD) [years] 
Type I Type 2 
Retinopathy 17(6) 11(6) <0.001 
Proteinuria 20(8) 14(6) <0.001 
Hypertension 21(8) 13(4) <0.001 
eu. ötanaara ueviation Levei ot signiiicance; P-_u. a Lim. LAauele3 Mtmillus 
Table 5.2: Duration of diabetes to onset of complications 
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However, the medians for duration of diabetes to onset of all three 
complications were shorter than the means in the Type 1 sub-group while 
the range was also larger than the Type 2 sub-group (Figure 5.1). 
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Figure 5.1: Comparison of time to onset of complications: Type 1 versus Type 2 nephropathy 
patients. 
The difference of six years in the mean length of time between development 
of retinopathy (Type 1- 17 (+8) years compared to Type 2: 11 (6+) years) 
was statistically significant (P<0.001), as was the difference of six years in 
mean length of time to development of proteinuria (Type 1: 20 (+8) years 
versus Type 2: 14 (±6) years) (P<0.001). When these differences were 
compared between the two sub-groups, Type 1 patients had retinopathy for 
1 year longer than Type 2 patients before developing proteinuria (P<0.001). 
There was a positive correlation between these two parameters in Type 2 
patients (r=0.74, P<0.001) but less so in Type 1 patients (r=0.65, P<0.001) 
-143- 
(one outlying point was removed which increased the correlation coefficient 
from r=0.52 to r=0.65) (Figure 5.2 and 5.3). 
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Figure 5.2: Relationship between development of retinopathy and proteinuria in Type 
2 nephropathy patients 
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y=0- . 856x + 0.65 r--0.65 P <0.001 
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Figure 6.3: Relationship between development of retinopathy and proteinuria 
in Typel nephropathy patients 
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There was a significant difference in the mean length of time from diagnosis 
of diabetes to development of hypertension between the groups: Type 1: 21 
(±8) years compared to Type 2: 13 (+6) years (P<0.001). Again, there was 
one year of difference in the time to development of proteinuria and 
hypertension (Type 1- hypertension developed 1 year after proteinuria; in 
Type 2 patients hypertension developed 1 year before proteinuria) (P=N. S. ). 
There was a positive correlation between the time to development of 
proteinuria and hypertension in Type 1 patients (r=0.44, P<0.01) (the 
correlation coefficient increased from r=0.40 to r=0.44 after one outlying 
point had been removed) and a much more significant correlation in Type 2 
patients (this increased from r=0.79 to r=0.91, after two outlying points had 
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Figure 5.4: Relationship between the development of hypertension and proteinuria in 
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Figure 5.5: Relationship between development of hypertension and proteinuria in 
Type 2 nephropathy patients 
In Type 1 patients linear regression analysis demonstrated that the individual 
relationships between the length of time to development of retinopathy was 
43% predictive of the variance in time to development of proteinuria 
(P<0.001) and the time to development of hypertension was 19% predictive 
of the time to the variance in development of proteinuria (P<0.01). A 
stepwise multiple regression analysis showed that the relationship between 
time to development of retinopathy and hypertension was 33% predictive to 
time to development of proteinuria (P<0.005) with retinopathy having greater 
statistical significance (P <0.01) than hypertension (P--N. S. ). 
In Type 2 patients the individual relationships between time to development 
of retinopathy was 55% predictive of the variance in time to development of 
proteinuria (P<0.001) while the time to development of hypertension was 
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83% predictive of the variance in time to development of proteinuria 
(P<0.001). A stepwise multiple regression analysis showed that these two I 
factors together were 69% predictive of the time to development of 
proteinuria (P<0.001) with time to onset of hypertension (P<0.001) having 
greater statistical significance than retinopathy (P<0.005). 
5.5.1.1 Renal Function 
The ranges of urinary protein and serum creatinine were wide with bimodal 
distribution for creatinine results and similar means for both parameters in 
both groups (P--N. S. ). However, the medians were much lower than the 
means (Table 5.3). 
Normal 
Range 
Type I Type 2 P 
SERUM CREATININE (gmoi fl) 
Range 60-120 69-774 65-680 
Mean (+SD) 188(187) 183(137) N. S. 
Median 105 131 
PROTEINURIA (g 24hours-1) 
Range 0.00-0.10 0.10-16.00 0.07-21.00 
Mean (_+SD) 3.06(3.28) 2.72(3.46) N. S. 
Median 1.96 1.79 
mo.. imm signincam Lem oT signiticance: t---u. uo -), u: stanciara ceviation 
Table 5.3: Renal function: Type 1 versus Type 2 patients with nephropathy 
When the "outliers" were removed from the creatinine results (revised 
results) the means were greatly reduced in both groups (P--N. S. ) while the 
medians were lower than previously (Figure 5.6). The results for the 
a outliers', clearly showed that these Type 1 patients were in end stage renal 
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failure (ESRF) and that the Type 2 group were progressing towards ESRF 
(P<0.05) (Figure 5.6). 
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Figure 5.6: Comparison of creatinine levels in nephropathy patients 
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Figure 5.7: Comparison of proteinuria in nephropathy patients 
The revised proteinuria results demonstrated a smaller reduction in the 
means and medians for both groups (P = N. S. )(Figure 5.7). 
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5.5.1.2 Microvascular Complications 
Retinopathy was present in 46 (96%) of Type I and 81 (79%) of Type 2 
patients with 75 having severe retinopathy: 31 Type 1 and 44 Type 2 
(P--N. S. ). Type 1 patients were more likely to be blind in one eye but there. 
was no statistical difference in prevalence of blindness in both eyes (Table 
5.4). Peripheral neuropathy was present in 67 patients and autonomic 
neuropathy was found in eight; there were no significant differences between 
the groups. 






Retinopathy 46 (96) 81 (79) N. S. 
Laser Photocoagulation 29 (62) 38 (37) N. S. 
Blind One Eye 7 (14) 6 (6) N. S. 
Blind Both Eyes 5 (11) 2 (2) N. S. 
NERVES 
Peripheral Neuropathy 23 (49) 44 (43) N. S. 
Autonomic Neuropathy 5 (11) 3 (3) N. S. 
N. O.: NOT signincant Level ot signiticance: kl-<U. uo 
Table 5A Microvascular complications in nephropathy patients 
The power of the study was calculated as 84% using the proportion of 
patients with retinopathy in each group, with P <0.05 and the harmonic mean 
of the numbers in the two groups. 
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5.5.1.3 Macrovascular Complications 
There were no statistically significant differences in macrovascular 
complications between the groups, 28 patients had evidence of IHD and 15 
had had a myocardial infarction. Six patients had experienced transient 
ischaernic attacks and 14 had had cerebrovascular accidents. Fifty-two 
patients had peripheral vascular disease, in 19 cases this was severe, 22 
had leg or foot ulcers and five had one limb amputated (Table 5.5). Total 
serum cholesterol levels were raised in both groups; Type 1: mean 6.5 (SD+ 
2.0) mmol 1-1 and Type 2: mean 6.7 (SD+ 2.0) mmol I" (PI-N. S. ). Body mass 
index indicated that both groups were overweight: Type 1: 26.1 (SD+ 5) kg 
m-2, Type 2: 28.3 (SD-+4) kg M-2 (P--N. S. ). 
There was no significant difference between the groups for family history of 
diabetes (36% v 36%: Type 1 versus Type 2), history of cigarette smoking 
(55% v 50%) or in defaulting from diabetic clinic visits (47% v 39%). 






Ischaernic Heart Disease 8 (17) 20 (20) N. S. 
Myocardial Infarction 3 (6) 12 (12) N. S. 
BRAIN 
Transient Ischaemic Attack 2 (4) 4 (4) N. S. 
Cerebrovascular Accident 6 (13) 8 (8) N. S. 
VASCULAR 
Peripheral Vascular Disease 19 (40) 33 (32) N. S. 
Ulcer Leg/Feet 5 (11) 17 (17) N. S. 
Amputation (I leg) 3 (6) 2 (2) N. S. 
N. b.: NOt significant Level of significance: 1-1_<U. ub 
Table 5.5: Macrovascular complications in nephropathy patients 
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Hypertension was found in 140 patients, yet only 64 were on anti- 
hypertensive medication at referral (Table 5.6). 
Type I Type 2 P 
n (%) n (%) 
HYPERTENSION 44 (93) 96 (94) N. S. 
ANTI-HYPERTENSIVE THERAPY 20 (45) 44 (46) N. S. 
SYSTOLIC PRESSURE (mm Hg) 
Range 70-240 120-220 
Mean (±SD) 161(+29) 168 (±25) N. S. 
DIASTOLIC PRESSURE (mm Hg) 
Range 40-120 50-150 
Mean (±SD) 90(+15) 90 (+15) N. S. 
Table 5.6: Blood pressure and treatment: Type 1 versus Type 2 nephropathy 
patients 
Both groups had systolic hypertension with a wide range in Type 1 patients 
(Figure 5.8). 













Systolic 1 Systolic 2 Diastolic I Diastolic 2 
Mean, Median, 1: Type 1,2: Type 2, N. S.. Not significant Level of significance. P<0.05 
Figure 5.8: Blood pressure: Type 1 versus Type 2 nephropathy patients 
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The mean diastolic pressure was at the upper limit of normal in both groups, 
with a wider range in the Type 2 group. Less than half of each group with 
hypertension were receiving anti-hypertensive therapy at referral. There was 
no significant difference in mean systolic or diastolic pressures between the 
groups. 
5.5.1.4 Progression of Renal Disease 
Over an eight year period, thirty-five patients reached ESRF and received 
renal replacement therapy (RRT); 16 (34%) Type 1 (11 CAPD and 5 HD) 
and 19 (19%) Type 2 (13 CAPD and 6 HD), nine patients received renal 
transplants (101--N. S. ). 
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5.5.2. Comparison of Type 2 Patients with Nephropathy and Type 2 
Patients with Non-Diabetic Renal Disease. 
Sixty-two Type 2 patients with nephropathy were compared to sixty-nine 
Type 2 patients with renal disease due to causes other than diabetic 
nephropathy (other causes were described in Chapter 4.5). Diagnosis was 
confirmed by biopsy in five nephropathy patients and in 11 patients with non- 
diabetic renal disease (P--N. S. ). Patients in both groups were predominantly 
male and White. However, there was a higher proportion of Indo-Asian and 







TOTAL NUM13ER 62 (100) 69 (100) 
GENDER 
Male 41 (66) 38 (55) N. S. 
Fernale 21 (34) 31 (45) N. S. 
ETHNic GROUP 
White 36 (58) 55 (80) 
Indo-Asian 18 (29) 8 (11) <0.05 
Black 8 (13) 6 (9) 
DIABETIC TREATMENT 
Diet 1 (1) 12 (17) 
Oral 11 (18) 40 (58) <0.001 
Insulin 50 (81) 17 (25) 
AGE (Years) 
Range 41-81 31-77 
Mean (+SD) 61 (_+8) 64L+9) N. S. 
DURATION OF DIABETES (Years) 
Range 4-28 1-40 
Mean (+SD) 15(_+6) 9L+8) <0.001 
r, i. b.: NOt significant Level of significance: Vý U-Vo bu; bianoara oeviation 
Table 5.7: Demographics of nephropathy patients compared to patients with non 
diabetic renal disease 
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More of the nephropathy group were treated with insulin (81% versus 25%) 
(P<0.001) and diabetic control was worse in the nephropathy group; the 
mean (+SD) HbAl for nephropathy patients was 11.6 (±2.6)% versus 10.6 
(+2.4)% in the other group (P--N. S. ). Both groups were overweight with the 
same mean body mass index: 29 kg M -2. 
The power of the study was calculated as 99% using the proportion of 
patients in each group receiving insulin treatment (Type 1: 0.81 and Type 2: 
0.25), P<0.05 and the harmonic mean of the numbers in each group (65). 
There was a significant difference in duration of diabetes at referral between 
the groups (Table 5.7). When duration of diabetes to the development of 
retinopathy was compared there was no statistical difference between the 
groups (Figure 5.9). 
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Figure 5.9: Time to development of complications: Type 2 nephropathy group 
versus Type 2 patients with non-diabetic renal disease 
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Duration of diabetes to onset of proteinuria was longer in the nephropathy 
group (mean: 12.8 (+6.1) years) than in the non-diabetic renal disease group 
(mean: 7.1(±8.3) years) and this was significant (P<0.001). There was also a 
significant difference in duration of diabetes to onset of hypertension 
- mean: 12.6 (+6.4) years versus non-diabetic renal (nephropathy group, 
disease; mean- -0.2 (±8.0) years) (P<0.001). 
There was a strong positive correlation between time to development of 
retinopathy and proteinuria (Figures 5.10 and 5.11) and between time to 
onset of hypertension and proteinuria in both groups (Figures 5.12 and 5.13) 
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Figure 5.10: Relationship between development of retinopathy and proteinuria 
in Type 2 nephropathy patients 
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Figure 5.11: Relationship between development of retinopathy and proteinuria 
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Figure 5.12: Relationship between development of hypertension and proteinuria in 
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Figure 5.13: Reiationship betvmen development af hypertension and prateinuria in 
Type 2 patents with non-diabetic renal disease 
Figure 5.13 indicated that the group of patients with non-diabetic renal 
disease was composed of two separate subgroups, those who developed 
hypertension before the onset of diabetes (Group A) and those in whom 
hypertension developed in the same year or after diabetes (Group B). A 
comparison of the mean time to onset of hypertension in relation to onset of 
diabetes in each group confirmed this (P<0.001) (Table 5.8). In both 
subgroups hypertension developed first followed by proteinuria. In Group A 
proteinuria developed thirteen years after hypertension but in Group B there 
was only two years between the development of these two complications. 
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Mean (+SD) -8(6) 5(5) <0.001 
Median -6 3 
PROTEINURIA (years) 
Mean (+SD) 5(8) 7(7) N. S. 
Median 4 6 
RETINOPATHY (years) 
Mean (+SD) 6(5) 10(7) N. S. 
Median 8 11 
N. S.: Not significant SID: Standard deviation Level of significance: P <0.05 
Table 5.8: Comparison of times of onset of complications in patients with non- 
diabetic renal disease 
A further analysis performed to ascertain whether the correlation between 
time to development of hypertension and proteinuria existed separately in 
these two subgroups showed a positive correlation between these two 
parameters in both groups (Figures 5.14 and 5.15). 
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Figure 5.14: Relationship between development of hypertension and proteinuria 
in patients with non-diabetic renal disease where hypertension 
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Figure 5.15: Relationship between development of hypertension and proteinuria 
in patients with non-diabetic renal disease where hypertension has 
developed in the same year or after diabetes (n=34) (Group B) 
Linear regression showed that time to development of hypertension was 
25% predictive of the variance in time to development of proteinuria in the 
entire group with non-diabetic renal disease. However, when this group was 
divided, in Group A time to onset of hypertension was 36% predictive of the 
variance in time to onset of proteinuria (P<0.05) and in Group B it was 38% 
predictive of the variance in time of onset of proteinuria (P<0.001). Linear 
regression analysis demonstrated that in nephropathy patients the time to 
development of retinopathy was 53% predictive (P<0.001) and in patients 
with non-diabetic renal disease was 70% (P<0.001) predictive of the 
variance in time to development of proteinuria (P<0.001). 
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Multiple regression analysis showed that in nephropathy patients time to 
development of hypertension and onset of retinopathy combined were 67% 
predictive (P<0.001) of the time to development of proteinuria with 
hypertension being more significant than time to onset of retinopathy 
(P<0.001 versus P<0.01). However, in the entire group of non-diabetic renal 
disease patients, the combined effect of time to onset of hypertension and 
retinopathy was 75% (P<0.001) predictive with retinopathy being the 
significant parameter (P<0.005) and hypertension being non significant. Due 
to the small numbers of patients with retinopathy in the subgroups of patients 
with non-diabetic renal disease, multiple regression analysis was not 
performed. 
5.5.2.1 Renal Function 
The ranges of serum creatinine were wide In both groups. The mean and the 
median for the non-diabetic renal disease group (all patients) was higher 
than in the nephropathy group but this was not statistically significant 
(Figures 5.16). After removal of outliers in each group, there was still no 
significant difference between the groups both In the revised and outliers 
results (Figures 5.16). The outliers represented patients In ESRF and the 
revised group represented those in chronic renal failure. There were wide 
ranges of'proteinuria in both groups although the means were the same 
(nephropathy group range: 0.09-13.30 g 24h*', mean: 2.83 g 24h" and the 
non-diabetic nephropathy group range: 0.07-21.00 g 24h": mean of 2.90 g 
24h*') (FI-N. S. ). 
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DN All NDRD All DN Rev NDRD Rev DN Out NDRD Out 
Mean: - Median: - Mean and Medium same value: 
DN: Diabetic nephropathy NDRD: Non-diabetic renal disease Rev: Results minus outliers 
Out: outliers 
Figure 5.16: Comparison of serum creatinine concentration in Type 2 patients with 
nephropathy and those with non-diabetic renal disease 
5.5.2.2 Microvascular Complications 
There were two differences in point prevalence of microvascular 
complications between the groups. Ninety-five percent of nephropathy 
patients in comparison to only 30% of patients with non-diabetic renal 
disease had retinopathy (P<0.001), while 45% of the nephropathy group had 
peripheral neuropathy in comparison to 19% of non-nephropathy patients 
(P<0.005) (Table 5.9). 








Retinopathy 59 (95) 20 (30) <0.001 
Laser Photocoagulation 26 (44) 5 (25) N. S. 
Reduced Visual Acuity 15 (24) 8 (12) N. S. 
Blind One Eye 2 (3) 3 (4) N. S. 
Blind Both Eyes 0 (0) 2 (3) N. S. 
NERVES 
Peripheral Neuropathy 28 (45) 13 (19) <0.005 
Autonomic Neuropathy 1 (2) 0 (0) N. S. 
N. S.: Not significant Level of significance: P<0-05 
Table 5.9: Microvascular complications in Type 2 nephropathy patients in 
comparison to those with non-diabetic renal disease 
5.523. Macrovascular Complications 
The only significant difference in macrovascular complications between the 
groups was that 16% of nephropathy patients in comparison to 4% of 









Ischaernic Heart Disease 12 (19) 13 (19) N. S. 
Myocardial Infarction 8 (13) 10 (15) N. S. 
BRAIN 
Transient Ischaernic Attack 2 (3) 2 (3) N. S. 
Cerebrovascular Accident 2 (3) 8 (12) N. S. 
VASCULAR 
Peripheral Vascular Disease 19(31) 16 (23) N. S. 
Ulcers (Leg/Foot) 10(16) 3 (4) <0.05 
Amputation (One Leg) 2 (3) 2 (3) N. S. 
N. Zj.: NOI signiticant Levei ot signITIcance; r ýv-va 
Table 5.10: Macrovascular complications in Type 2 nephropathy patients in 
comparison to those with non-diabetic renal disease 
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The majority of both groups had hypertension. However, only 42% of the 
nephropathy group and 52% of those with non-diabetic renal disease with 
hypertension were being treated With anti-hypertensive medication at referral 
(Table 5.11). Both groups had systolic hypertension and there was no 








HYPERTENSION 60 (97) 62 (90) N. S. 
ANTI-HYPERTENSIVE THERAPY 25 (42) 32 (52) N. S. 
SYSTOUC PRESSURE (mm Hg) 
Range 120-220 110-260 
Mean (+SD) 170L+22) 168L+28) N. S. 
DLASTOUC PRESSURE (mm Hg) 
Range 50-150 64-120 
Mean (+SD) 90L+ 15) 90L+12) N. S. 
NOT signiticant Levei of signiticance: ij5u. uo bu: bianuara aeviation 
Table 5.11: Blood pressures in Type 2 nephropathy patients in comparison 
to those with non-diabetic renal disease 
There was a significant difference between the groups in patents who 
defaulted from routine diabetic clinic appointments: 30 (48%) nephropathy 
patients versus 13 (19%) in patients with non-diabetic renal disease 
(P<0.001). Defaulting from routine clinic visits increased the risk of 
developing nephropathy (odds ratio = 4.1). However, there was no difference 
in smoking history (52% nepheopathy and 51% non-diabetic renal disease). 
Of those patients who had defaulted, 50% with nephropathy and 21% with 
non-diabetic renal disease had smoked at some time (P--N. S. ). 
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5.524. Progression of Renal Disease 
Forty-two percent of the nephropathy group and 25% of non-diabefic renal 
disease patients received RRT or died from ESRF. Forty-six percent of 
nephropathy patients on RRT had CAPD, 54%, had haemodialysis treatment 
and two received kidney transplants while 67% of the non-diabefic renal 
disease group received CAPD and 33% had haemodialysis, none received 
renal transplants (P--N. S. ). Sixteen (26%) nephropathy patients died from 
ESRF in comparison to two patients with non-diabetic renal disease 
(FI-N. S. ). 
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5.6 Discussion 
This study has shown that there was a significantly higher proporfion of Indo- 
Asian and Black patients with nephropathy in the Type 2 group. The Southall 
and Coventry studies have demonstrated that Indo-Asians living in the 
United Kingdom have an increased incidence of Type 2 diabetes in 
comparison to the indigenous population [approximately four times greater] 
(Mather and Keen, 1985; Simmons et al, 1989). There is also an Increasing 
body of evidence that Indo-Asian diabetic patients have a higher risk of 
developing nephropathy and end stage renal disease than White patents 
(Allawal et al, 1988; Burden et al, 1992; Feehally, 1995). It has also been 
demonstrated that Black Type 2 diabetic patients In the United States have 
an increased incidence of end stage renal disease [up to four times greater] 
in comparison to White patients (Cowie et al, 1989; Perneger et al, 1994). 
The shorter duration of diabetes at referral and onset of proteinuria in Type 2 
patients in this study contrasts With the result of a study In patients who 
eventually received dialysis where the duration of diabetes In both Type 1 
and Type 2 patients was 18 and 16 years respectively (Biesenbach et al, 
1994). However, the United Kingdom Prospective Diabetes Study in newly 
diagnosed Type 2 patients has demonstrated that within 9 years of diagnosis 
9% of patients had developed microvascular complications despite attempts 
to normalise glycaemic control within a research protocol (Turner et a/, 
1996). In this study the shorter duration in Type 2 patients until onset of 
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retinopathy, proteinuria and hypertension contrasts with the longer duration 
in Type 1 patients and reflects the undetermined duration of diabetes before 
diagnosis. Many Type 2 patients are unaware that they have the symptoms 
of diabetes for some time before diagnosis is made; a finding confirmed in 
the United Kingdom Prospective Diabetes Study where 2% of newly 
diagnosed Type 2 patients had microvascular complications (Jackson et al, 
1991; United Kingdom Prospective Diabetes Study Group, 1994). 
The strong association between times of onset of retinopathy and especially 
hypertension and time to development of proteinurla In Type 2 patients is 
reflective of the progression of microvascular complications and the Increase 
in blood pressure that occurs as nephropathy progresses from 
microalburninuria to proteinuria (Mathlesen et al, 1995). The longer duration 
of diabetes to development of proteinuria and accompanying complications 
in Type 1 patients is consistent with previous research (Parving et al, 1988). 
The possibility that Type 2 patients have accelerated development of 
complications is probably the result of their older age group and pre-existing 
vascular damage than to a major difference In the two groups of patients. 
The lack of difference between the two groups In prevalence of micro- and 
macrovascular complications is concerning. As the Type 2 patients were 
selected for presence of retinopathy in order to remove any query about 
diagnosis of nephropathy, the similarities in microvascular complications 
were expected. The concerning aspect Is that despite the younger age of the 
Type 1 patients, the prevalence of macrovascular complications was similar 
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between the two groups. It has been suggested that Type 1 nephropathy 
patients have an eight times higher incidence of coronary heart disease in 
comparison to Type 1 patients without nephropathy (Deckert et al, 1992). 
The positive benefits of anti-hypertensive therapy on the progression of 
nephropathy have been known for 17 years in Type I patients and more 
recently in Type 2 patients (Mogensen, 1982; Parving et al, 1983; Ahmad et 
al, 1997). Despite this, over 90% of patients in both groups had hypertension 
and less than 50% of these patients were receiving anti-hypertensive 
medication. However, a recent study in over 3000 Type 1 patients, has 
demonstrated that untreated hypertension is common in people with 
diabetes (Collada-Mesa et a/, 1999). Similarly, a German study of pre- 
dialysis diabetic patients has demonstrated that 97% had poorly controlled 
blood pressure levels (Pommer et al, 1997). In this study, systolic 
hypertension was common in both groups while diastolic pressures were 
near the upper limit of normal. This is not unique to patients In 
Wolverhampton; in France, a high proportion of hypertensive Type 2 
nephropathy patients have systolic hypertension despite receiving anti- 
hypertensive treatment (Passa, 1997). 
Over eight years, progression of renal disease to requirement for RRT 
occurred in a higher proportion of Type 1 patents: 34% in comparison to 
19% of the Type 2 group which is interesting in that a larger proportion of the 
Type I group (85%) had serum creatinine concentrations at referral below 
300 pmol 1 -1 while only 20% of Type 2 patients had serum creatinine 
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concentrations at referral above 300 pmol 1 -1 (similar to the percentage who 
required RRT). These results can be compared with those of Ritz and co- 
workers who have found that the progression to ESRF in Type 1 and Type 2 
patients is the same and that more than 50% of patients in both groups 
reach ESRF within five years of persistent proteinuria (Ritz et al, 1991). 
However, a small study (n=7 patients) by Friedman and Gross has shown 
that the decline in renal function is slower in Type 2 than in Type 1 patients, 
a finding which reflects the results of this study (Friedman and Gross, 1991). 
The comparison of Type 2 patients with diabetic nephropathy and those with 
non-diabetic renal disease has highlighted a number of differences between 
these two groups. There were more Indo-Asian and Black patients with 
nephropathy; in contrast, it has been reported that Indo-Asian people In the 
UK have an higher incidence of non-diabetic renal disease than White 
patients, and in the USA, Black patients have a seven times Increase in odds 
ratio for end stage renal disease from any cause than White diabetic patients 
(Perneger et al, 1994; Feehally, 1995). The nephropathy patients had a 
longer duration of diabetes and there were more men than women in 
comparison to the group with non-diabetic renal disease; findings which are 
consistent with the study by Perneger and co-workers, 1994. 
As expected this study has demonstrated a higher prevalence of retinopathy 
in the nephropathy group than in those patients with non-diabetic renal 
disease. A study in India in Type 2 patients has shown that the absence of 
retinopathy was a more reliable predictor of non-diabetic renal disease in 
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comparison to the presence of retinopathy in nephropathy patients; due to 
the variation in the prevalence of retinopathy in Type 2 nephropathy patients, 
the authors found that retinopathy was a less reliable predictor (John et al, 
1994). In contrast, in the USA, only 50% of patients with non-diabetic renal 
disease had retinopathy requiring laser treatment in comparison to 75% of 
patients with diabetic nephropathy (Perneger et al, 1994). In the same study 
the proportion of patients with peripheral neuropkhy was similar in both 
groups unlike the present study where the nephropathy patients had 
significantly more peripheral neuropathy than patients with non-diabetic renal 
disease (Perneger et al, 1994). 
When a comparison of the time to development of retinopathy, hypertension 
and proteinuria was made between patients with nephropathy and those with 
non-diabetic renal disease, there was a shorter time to development of 
complications in the non-diabetic renal disease group, in keeping with the 
shorter duration of diabetes at referral, and a stronger correlation between 
time to development of retinopathy and proteinuria than in the nephropathy 
patients. A possible explanation for this is that there were only 16 patients 
with non-diabetic renal disease who had retinopathy in comparison to 63 
nephropathy patients; a study with larger numbers of patients with non- 
diabetic renal disease may produce more conclusive results. The two distinct 
groups of patients with onset of hypertension pre- and post-diagnosis of 
diabetes was not surprising as a large percentage of patients had renal 
disease secondary to hypertension. This may also explain why more patients 
-169- 
with non-diabetic renal disease with hypertension were receiving anti- 
hypertensive treatment. 
A higher percentage of nephropathy patients required RRT and died of 
ESRF over the eight year period suggesting that the decline In renal function 
was more rapid in the nephropathy group. However, these results contrast 
with a Spanish study in which 53% of the patients had non-diabetic renal 
disease and were followed for less than three years, where there was no 
difference in the decline of renal function between patients with nephropathy 
and those with non-diabetic renal disease (Wagner et al, 1997). 
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5.7 Conclusions 
I Type 2 nephropathy patients were older and appeared to have a 
shorter duration of diabetes at nephrological referral and before onset 
of proteinuria, retinopathy and hypertension than Type I patients; 
however, this was probably due to the presence of diabetes for an 
undetermined period of time before diagnosis in Type 2 patients 
rather than to a real difference between the two groups. 
2 There were more Indo-Asian and Black patients with nephropathy in 
the Type 2 group than in the Type 1 group. 
3 There was a stronger relationship between the time to development of 
retinopathy, hypertension and proteinuria in the Type 2 nephropathy 
patients than in the Type 1 group. 
4 There was no difference between Type 1 and Type 2 nephropathy 
patients in prevalence of either microvascular or macrovascular 
complications. 
5 There were fewer Indo-Asian and Black Type 2 patients with non- 
diabetic renal disease and fewer on Insulin treatment than Type 2 
nephropathy patients. 
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6 Duration of diabetes at referral and at onset of proteinuria were 
shorter in patients with non-diabetic renal disease than in the 
nephropathy group. 
7 There was a stronger relationship between time to onset of proteinuda 
and hypertension in the Type 2 nephropathy group than in patients 
with non-diabetic renal disease. 
8 The nephropathy group had more retinopathy, peripheral neuropathy 
and leg/foot ulcers than patients with non-diabetic renal disease. 
9 The decline in renal function was faster in the nephropathy group than 
in patients with non-diabetic renal disease. 
10 Defaulting from routine clinic visits increased the risk of developing 
nephropathy. 
5.7.1 Summary of Conclusions 
1 The prevalence of complications were similar in Type I and Type 2 
nephropathy patients. However, the relationship between the onset of 
complications was stronger in the Type 2 patients than In the Type I 
nephropathy group. Therefore, there were similarities and differences 
between the groups and both Hý2): Diabetic complications were 
similar in Type I and Type 2 patients with nephropathy and Hi(2): 
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Diabetic complications were different in Type 1 and Type 2 patents 
with nephropathy, could be accepted. 
2 The prevalence of complications and the relationships between the 
complications were different in Type 2 nephropathy patients in 
comparison to Type 2 patients with non-diabetic renal disease. 
Therefore, accept Hi(3): Diabetic complications were different in Type 
2 nephropathy patients compared to Type 2 patients with non-di abetic 
renal disease. 
3 The decline in renal function was faster in Type 2 patients with 
nephropathy in comparison to Type 2 patients with non-diabetic renal 
disease. Therefore, accept Hi(4): The progress of renal disease in 
patients with nephropathy was faster than that of patients with non- 
diabetic renal disease. 
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Chapter 6 




Many studies have been performed to ascertain the factors that put Type 1 
diabetic patients at risk of developing nephropathy. The Diabetes Control of 
Complications Trial has demonstrated that improved glycaemic control reduces 
the development of microvascular complications in these patients (Diabetes 
Control and Complications Trial, 1993). The control of hypertension in Type I 
patients with proteinuria has long been recognised as a means of delaying the 
progression of nephropathy (Mogensen, 1982). Since then, many anti- 
hypertensive strategies have been used to find the most effective treatment in 
these patients (Parving et al, 1983; Bjorck et al, 1986). Microalbuminuria can be 
reduced and even delayed by the use of angiotensin converting enzyme 
inhibitors (ACEI) (Viberti et al, 1994; EUCLID Study Group, 1997). However, 
hypertension is still a major problem when patients have proteinuria. 
This study was performed with the aim of identifying factors in our Type I 
patients that can be used to differentiate those at risk of developing 




To identify differences in diabetes control and diabetic complications 
between Type 1 diabetic patients with and without nephropathy. 




Ho: There are no differences in diabetes control and diabetic 
complications between the groups. 
Hi: There are differences in diabetes control and diabetic 
complications between the groups. 
2 Ho: There are no factors other than poor glycaernic control, 
hypertension and duration of 'diabetes that put patents at risk of 
developing nephropathy that can be identified during routine clinical 
practice. 
Hi: There are factors other than poor glycaemic control, hypertension 
and duration of diabetes that put patients at risk of developing 
nephropathy that can be identified during routine clinical practice. 
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6.4 Methods 
Using retrospective data, a controlled, matched comparison was made between 
23 Type 1 White patients with nephropathy and serum creatinine levels <200 
pmol 1-1 who were referred for nephrological assessment and a control group of 
73 Type 1 White patients with no proteinuria and creatinine levels within the 
normal limits (60-120 pmol 1") who attended the diabetic clinic for routine 
annual review over a three year period between 1992-1995. The control group 
was matched for age, duration of diabetes and gender by identifying White 
patients whose age and duration of diabetes lay within ten year bands, to match 
with nephropathy patients, from a cohort of over 200 patients. The same type of 
data was collected as in Chapter 4: information on demographics, diabetes 
history, treatment, diabetic control and complications, and details on renal 
function. A point prevalence Le.: prevalence at a single examination, was 
determined for diabetes complications and other factors which may be 
predictive of development of nephropathy. 
All glycated haemoglobin (HbAI) results over a four-year period were collected 
from medical records and comparisons were made between the groups as well 
as a separate comparison of HbAl results at either nephrological assessment 
or annual review examination (controls). 
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Comparisons were made of clinical parameters (age, duration of diabetes, BMI, 
HbAll, diastolic and systolic blood pressures) in patents with pharmacologically 
treated and untreated hypertension, both between and within the groups. 
Descriptive statistics (means +standard deviation), Student t tests, Chi2 tests, 
Mann-Whitney U tests, Pearson correlation, linear and logistic regression 
analysis were performed using SPSS and Excel statistics packages. The 
chosen level of statistical significance was P <0.05 in two-tailed tests. 
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6.5 Results 
From the original cohort of 49 Type 1 patients referred for nephrological 
assessment, 23 White patients with nephropathy were compared with 73 
matched White controls with no evidence of renal disease on uAlbustie testing 
(routine testing for microalburninuria was not performed within the diabetic 
clinic, therefore no information was available on microalbuminuric status of the 
control group). The age and duration of diabetes were closely matched. 







Total number 23 73 
Male 17 (74) 50 (68) N. S. 
Female 6 (26) 23 (32) N. S. 
Age (years) 
Range 21-63 20-68 
Mean L+SD) 40 (12) 43 (12) N. S. 
Median 40 42 
Duration DM (years) 
Range 4-38 7-47 
Mean L+SD) 22 (9) 23 (8) N. S. 
Median 25 20 
D. M.: Diabetes Mellitus S. D. * Standard dev iation Level of si nnificance: P<O. C 5 
Table 6.1: Demography of Type 1 patients with nephropathy In comparison to 
matched controls. 
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Glycated haernoglobin (HbAl) at referral was very much higher in the 
nephropathy group: mean (±SD): 12.1 (+2.0) % in comparison to 10.7 (+1.9) % 
in the controls (P<0.005). When comparisons were made of HbAl over a four 
year period the control group had much better glycaemic control: mean (+SD): 
10.7 (+2.3) % versus 12.3(+2.6) % in the nephropathy group (P<0.001). 
Analysis of variance demonstrated that there were no statistical differences in 
HbAl over the four years within either of the groups (Figure 6.1). 
Nlaxinun 75% Quartile 26% Quartile Mnirnuim 
25 
128 10.9 12.2 10.4 12-1 10.8 
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Figure 6.1: Glycaemic control in Type 1 nephropathy patients in comparison to 
matched controls 
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The range of body mass index (BMI) was similar in both groups: 21.4-34.3 Kg 
m'2 in nephropathy patients and: 19.9-32.3 Kg M'2 in the controls. However, the 
nephropathy patients were heavier with the differences between the means 
being statistically significant: 27.9 (+3.6) Kg m-2 (nephropathy group) and 
25.8L+3.1) Kg m-2 (control group) (P<0.05). 
6.5.1 Renal Function 
Both groups had a mean serum creatinine within normal limits (60-120 Pmol 1") 
94 (+21) pmol 1-1 in the nephropathy group in comparison to controls: 91 L+ 10) 
pmol I" (P'---N. S. ). The median serum creatinine for both groups was the same: 
93 (nephropathy group) versus 93 (controls) pmol I" with the range being wider 
in the nephropathy patients: 40-139 ýtmol I" than the controls: 64-115 pmol 1". 
6.5.2. Microvascular Complications 
The nephropathy group had significantly more microvascular complications than 
the control subjects with 20 (87%) of nephropathy patients having retinopathy 
(in 12 patients this was severe) compared to only 34 (47%) of controls (in three, 
this was severe) (P<0.001) (Table 6.2). The presence of retinopathy Increased 
the risk of developing nephropathy (odds ratio: 7.6). Both peripheral and 








Retinopathy 20 (87) 34 (47) <0.001 
Severe Retinopathy 12 (60)* 3 (9)* <0.001 
Laser Photocoagulation 12 (60)* 2 (6)* <0.001 
Blind one eye 3 (13) 1 (1) N. S. 
Blind both eyes 0 (0) 1 (1) N. S. 
NERVOUS SYSTEM 
Peripheral Neuropathy 6 (26) 6 (8) <0.05 
Autonomic Neuropathy 2 (9) 0 (0) N. S. 
-: vercentage ot triose witn reunopatny Levei or signuicance; r-, j u. u; ) 
Table 6.2: Comparison of microvascular complications: Type 1 nephropathy patients 
versus controls. 
The power of the study was determined as 98% with P: 5 0.05, based on the 
proportion of patients in each group with retinopathy and using the harmonic 
mean of the number of patients in the two groups (35) (Brant, 1999). 
6.5.3 Macrovascular Complications 
There was little difference between the groups in prevalence of either ischaernic 
heart disease (angina or ECG evidence) or myocardial infarctions. However, 
nephropathy patients had a much higher prevalence of hypertension and 








Peripheral 7 (30) 3 (4) <0.001 
Ulcer 1 (4) 1 (1) N. S. 
BRAIN 
Cerebrovascular Accidents 0 (0) 0 (0) 
HEART 
Ischaemic Heart Disease 2 (9) 4 (5) N. S. 
Myocardial Infarction 3 (13) 3 (4) N. S. 
Hypertension 19 (83) 26 (36) <0.001 
i-co.; rmax signiricant LeVel ot signiticance: /-ýU-uo 
Table 6.3: Comparison of macrovascular complications: Type 1 nephropathy patients 
versus matched controls 
The presence of hypertension increased the risk of developing nephropathy 
(odds ratio: 8.6). Of those patients with hypertension only 10 (43%) of the 
nephropathy group and 11 (41%) control subjects were receiving anti- 
hypertensive medication at referral (P--N. S. ). 
The nephropathy patients had systolic hypertension: mean (+SD): 159L+25)mm 
Hg versus 134(±21) mm Hg in controls (P<0.001), median: 160 (nephropathy 
group) versus 130 mm Hg (control group). The mean, 90L+1 1) mm Hg, and 
median diastolic pressure, 90 mm Hg, in the nephropathy group were at the 
upper limit of normal in comparison to a mean of 78 (+11) mm Hg and a median 
of 80 mm Hg in controls (P<0.001) (Figures 6.2 and 6.3). 
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Fig ure 6.2: Blood pressure in Type 1 nephropathy patients 
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Figure 6.3: Blood pressure in Type I control group 
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When the groups were divided into sub-groups with treated hypertension, (10 
nephropathy patients versus 11 controls) all of the treated nephropathy patients 
were receiving angiotensin converting enzyme inhibitor (ACEI) drugs either 
singly or in combination with other types of anti-hypertensive medication but 
only 3 (27%) of treated control subjects were on ACEI (p<0.001). Control 










NUMBERTRIZATED 10 11 N. S. 2 3 
TYPE: 
ACEI (ONLY) 5 3 N. S. (1) (2) 
ACEI (+ I OTHER) 4 0 (1) 
ACEI (+ 2 OTHERS) 1 0 
Ca ANTAGONISTS (ONLY) 2 
Ca ANTAGONISTS(+ I OTHER 2 (1) 
13ETA 13LOCKERS (ONLY) 2 
DIURETICS (ONLY) 2 
-- tTrecuve i reatment: k3P: 5140/90 MmHg AL; Ll: Angiotensin convening Vj1Zy111tS 111,11LALUlb 
Ca: Calcium N. S.: Not significant Neph: Nephropathy patients Con: Controls 
Level of significance: P<0.05 ý'): Other did not Include ACEI 
Table 6.4: Comparison of anti-hypertensive treatment In Type I nephropathy patients 
and matched controls 
Only two nephropathy patients and three controls had hypertension which was 
being effectively controlled by drug treatment (Bp : 5140/90 mmHg). Seven 
control subjects and one of the nephropathy patients had systolic hypertension. 
Seven of the treated nephropathy group and one control subject had both 
systolic and diastolic hypertension. 
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The treated nephropathy patients were younger: mean age: 41L+13) years in 
comparison to the control group: mean age: 58 &) years and this difference 
was statistically significant (P<0.005) (Table 6.5). There was no statistical 
difference between the groups in BMI, creatinine, HbAl at referral, duration of 












AGE (YEARS) ___ 
RANGE 24-63 29-62 48-68 24-62 
MEAN (+SD) 41(13) 43(13) 58(7) 47(g) 
MEDIAN 41 40 55 45 
DURATION OF DM 
RANGE 14-38 B-35 17-41 9,34 
MEAN L+SD) 24(8) 22(g) 30(7) 23(8) 
MEDIAN 25 22 30 22 
CREATININE (umoi r') 
RANGE 71-139 40-122 71-115 82-114 
MEAN (+SD) 99(20) 90(24) 90(15) 93(8) 
MEDIAN 95 94 93 93 
HbAl (%) 
RANGE 10.7-13.9 7.4-13.3 8.0-14.3 6.9-13.8 
MEAN(+SD) 12.2(l. 3) 11.0(2.0) 11.2(2.0) 10.7(2.1) 
MEDIAN 11.7 11.4 11.5 10.5 
BMI (kg m2) 
RANGE 27.0-33.4 21.5-M. 3 23.7-30.4 22.8-31.2 
MEAN 29.8(2.1) 27.2(4.3) 27.6(2.7) 26.1(2.8) 
MEDIAN 29.4 26.1 28.4 25.3 
Li. m.: uaDetes mellitus SD: Standard deviation 
Table 6.5: Comparison of clinical factors in Type I nephropathy patients and 
controls with treated and untreated hypertension. 
When nephropathy patients with treated and untreated hypertension were 
compared there were no statistical differences in age, serum creatinine 
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concentration, duration of diabetes, HbAl at referral or systolic pressure 
(P--N. S. ). There was a statistical difference in diastolic blood pressure with a 
higher mean in the treated nephropathy patients (97L+9] mm Hg) in comparison 
to those with untreated hypertension: (89L+9] mm Hg) (P-0-5). 
Comparison of nephropathy and control subgroups with treated hypertension 
demonstrated that the diastolic pressure in nephropathy patients was higher 
than in the control subjects: 97 (±9) mm Hg versus 81 (+9) mm Hg (P<0.005). 
Both groups had systolic hypertension with a mean systolic pressure in 
nephropathy patients of 165 (±25) mm Hg in comparison to the control group 
where the mean was: 149 (±9) mm Hg (PI--N-S) (Figure 6.4). 












DN Systolic Controls DN Diastolic Controls 
Systolic Diastolic 
Median: DN: nephropathy subgroup N. S.: Not significant 
Figure 6.4: Blood pressure in patients with treated hypertension 
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There was a negative correlation between duration of diabetes and diastolic 
blood pressure in the treated nephropathy group (r= -0.64, n=10, P<0.05) but 
none in the treated control group (Figure 6.5). Linear regression analysis 
demonstrated that duration of diabetes was 40% predictive of variance in 
diastolic pressure in treated nephropathy patients. 
60 
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Figure 6.5: Relationship between diastolic pressure and duration of diabetes in 
Type 1 nephropathy patients with treated hypertension 
In treated control patients there was a negative correlation between age and 
diastolic pressure (r= -0.77, P<0.01) which was not seen in the nephropathy 
patients (r= -0.24, P--N. S. ). Linear regression analysis showed that age was 
predictive of 59% of the variance of diastolic pressure in treated control subjects 
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Figure 6.6: Relationship between diastolic pressure and age in Type 1 control subjects with 
treated hypertension 
In patients with untreated hypertension (8 nephropathy patients and 17 control 
subjects) there were no statistical differences between the groups in mean age, 
serum creatinine concentration, Hbal at referral, BIVII, duration of diabetes, 
diastolic or systolic pressures (Table 6.5). 
Both untreated groups had systolic hypertension: mean systolic in the 
nephropathy patients was 170(+18) mm Hg versus 159(+14) mm Hg in control 
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70 80 90 100 
Diastolic Pressure (mm Hg) 
subjects (P--N. S. ). Mean diastolic pressures in both groups were below the 
upper limits of normal: 89 (+9) mm Hg in the nephropathy group in comparison 
Nb)anun 77/6 Cmartile 291/6 Omarfile Mrinup 
Wphropaft COr*d Systollic NOOTUPa" Cor*d ClasMic 
, 
%4StdjC ic 
M3dan: - NS= Not sigificant 
Figure 6.7: Blood pressures in Type 1 nephropathy patients and controls with 
untreated hypertension 
to 87(+13) mm Hg in control subjects (P--N. S. ). The systolic range in 
nephropathy patients was wider than in the control group but the diastolic range 
was narrower than in the control subjects (Figure 6.7). 
In the sub-group of untreated nephropathy patients, there was a significant 
negative correlation between systolic pressure and HbAl at referral (r= -0.91, 
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P<0.005). Linear regression analysis showed that HbAl was 83% predictive of 
the variance in systolic blood pressure but as the untreated nephropathy group 
only contained eight patients, it is possible that in a larger group HbAl would 
not be as significant a predictor of systolic pressure. 
The comparison between treated and untreated hypertensive control subjects 
demonstrated that there were no statistical differences in serum creatinine 
concentration, HbAl at referral or diastolic pressures between the groups. 
However, there were statistically significant differences in mean age (treated: 
58 L+7) years versus untreated: 47 (+9) years, P<0.005); duration of diabetes 
(treated: 30 (±7) years versus untreated: 23 L+8) years, P<0.05) and systolic 
blood pressure (treated: 149 L+9) mm Hg versus untreated: 159 L+14) mm Hg, 
P<0.05). 
6.5.4 Other Contributing Factors 
A higher prevalence of current smokers and of people who default from routine 
diabetic clinic visits were found in the nephropathy group and a higher 
prevalence of patients who had never smoked was found in the control group. 
The differences between the groups were statistically significant for all of these 
factors (Table 6.6). 
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Current Smokers 12 (52) 17 (23) <0.01 
History of Smoking 2 (9) 1 (1) N. S. 
Never Smoked 9 (39) 55 (75) <0.005 
Defaulting from Clinic 9 (39) 10 (14) <0.0 I 
MO. = NOT signiticant Levei ot signiticance: tA_< u. u.,: ) 
Table 6.6: Other factors that may influence development of nephropathy in 
Type 1 patients. 
A number of these factors increased the risk of developing nephropathy: current 
smoking odds ratio = 4.3; a history of smoking odds ratio = 12.2 (however the 
actual numbers were very small) and defaulting from routine clinic visits odds 
ratio = 4.0 
Pearson correlation identified a number of factors in both groups which 





Nephropathy (WG) BMI and Diastolic Pressure 0.68 <0.005 47ý/o- 
Nephropathy Duration DM and Diastolic Pressure -0.64 <0.05 40% Treated HT (SG) 
Nephropathy HbAl and Systolic Pressure -0.91 <0.005 83% Untreated HT (SG) 
Controls (WG) Age and Diastolic Pressure 0.36 <0.005 13% 
Controls (WG) Age and Systolic Pressure 0.41 <0.001 1 17% 
vvta; wnoie group tia subgroup HT: Hypertension tsmi: way mass inoex 
Table 6.7: Factors which were predictive of blood pressure levels In both groups of 
patients. 
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There was a positive correlation between duration of diabetes and serum 
creatinine levels in the nephropathy group (r=0.48, P<0.05) but none in the 
control group (Figure 6.8). Linear regression analysis showed that duration of 
diabetes was 19% predictive of the variance in serum creatinine levels in 
patients who developed nephropathy. 
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Figure 6.8: Relationship between duration of diabetes and serum creatinine 
concentration in Type 1 nephropathy patients 
Logistic regression analysis using serum creatinine as the dependent variable 
and defaulting from diabetes clinic visits, hypertension treatment, retinopathy, 
current smoking, smoking history and gender as independent variables showed 
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that combined they produced a predictive value of R2=0.192 but none of these 
were statistically significant variables. 
The only other factors in the nephropathy group which correlated were body 
mass index (BMI) and diastolic pressure (r=0.68, P<0.005) (Figure 6.9). Linear 
regression analysis showed that BMI was 47% predictive of the variance in 
diastolic pressure. 
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Figure 6.9: Relationship between BMI and diastolic blood pressure in Type 1 
nephropathy patients 
In the control group as a whole there was a statistically significant positive 
correlation between age and diastolic pressure (r=0.36, P<0.005) in contrast to 
the negative correlation between age and diastolic pressure in untreated 
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nephropathy patients (see Figure 6.6) (Figure 6.10). 
There was also a positive correlation between age and systolic blood pressure 
(r=0.41, P<0.001) in the control group (Figure 6.11). Regression analysis 
showed that age was 13% predictive of the variance in diastolic pressure and 
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It has been known for many years that poor glycaemic control is directly related 
to the development of microvascular complications (Tchobroutsky, 1978). More 
recently, intensive insulin therapy has been shown to prevent the onset of these 
complications (Reichard et al, 1993; Diabetes Control and Complications Study 
Group, 1993). However, there is controversy as to whether improvement in 
glycaernic control, once microalbuminuria has occurred, can decrease the rate 
of albumin excretion (Microalbuminuria Collaborative Study Group, 1995; 
Bojestig et al, 1996). 
In this study patients with nephropathy had worse glycaemic control and more 
microvascular complications than the matched control group. Most of the 
nephropathy patients (87%) had retinopathy (in 60% this was severe) in 
comparison to controls, 47% of whom had background retinopathy (only 9% 
had severe retinopathy). These results agree with the findings of the 
EURODIAB IDDM Complications study where normoalbuminuric patients were 
found to have background retinopathy rather than proliferative and patients with 
proteinuria had both (Stephenson et al, 1995). The increased risk of developing 
nephropathy which the presence of retinopathy conferred may be a spurious 
relationship in that retinopathy develops along with nephropathy and in itself is 
not necessarily a risk but is indicative of the patient being at risk of developing 
-198- 
renal microvascular disease. In this study nephropathy patients also had more 
peripheral and autonomic neuropathy, again this is an indication of the extent of 
microvascular damage. 
There was no difference in prevalence of IHD or MI between the groups 
although the nephropathy group had significantly more PVD and hypertension. 
The high percentage of patients with hypertension in the nephropathy group 
was expected as proteinuria and hypertension co-exist in nephropathy. The 
results for prevalence of hypertension in this study are marginally higher than in 
the EURODIAB IDDIVI Complications study, where 69% of macroalbuminuric 
and 29% of normoalbuminuric patients had hypertension (Collada-Mesa et al, 
1999). The increased risk which the presence of hypertension confers on 
patients susceptible to nephropathy is well recognised and the large number of 
studies on the benefits of controlling hypertension in patents with 
microalbuminuria testifies to this (Lewis et al, 1994; Microalbuminuria 
Collaborative Study Group, 1995; EUCLID Study Group, 1997). In this study, 
nephropathy patients had systolic hypertension unlike the control group. 
Systolic hypertension has been found in previous research in Type 1 
nephropathy patients (Cooper et al, 1988). Lambert and colleagues have shown 
that Type 1 patients with microalbuminuria have stiffer carotid arteries in 
comparison to normoalbuminuric diabetic patients and normal control subjects 
(Lambert et al, 1998). The authors suggest that carotid artery stiffness leads to 
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systolic hypertension. Arterial rigidity is associated with atherosclerosis and this 
may explain the significant difference in peripheral vascular disease between 
the two groups in this study. 
It is surprising that less than half of patients with hypertension in both groups 
(47% versus 48%) were receiving anti-hypertensive medication at examination, 
especially as many studies have shown the benefit of reducing blood pressure 
in diabetic patients with nephropathy (Mogensen, 1982; Parving et al, 1983; 
Parving and Hommel, 1989). However, the results of this study are similar to 
those of the EURODIAB IDDM Complications study where they found that 
42.2% of patients with hypertension were receiving anti-hypertensive treatment 
and that only 11.3% of those patients on treatment had blood pressure levels 
which were controlled (Collado-Mesa et al, 1999). The reasons for the lack of 
effective anti-hypertensive therapy in both of these studies are likely to be a 
combination of factors. For example: 
" although the recommended upper limits for unormal blood pressure in 
diabetesm, were defined as 140/90 mm Hg by the Working Group on 
Hypertension in Diabetes in 1987, a treatment threshold of 150/90 or even a 
systolic pressure above 150 mm Hg (more in line with non-diabetic patients) 
may have been used in a clinical setting; 
" the awareness of medical staff for the need to control blood pressure at 
a relatively" low levels in patients with proteinuria may be absent or unclear; 
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the possibility of side effects from anti-hypertensive drugs (e. g.: impotence 
secondary to treatment with beta-adrenoceptor blocking drugs) may be 
regarded by medical staff as unacceptable in relatively young patients 
(Working Group on Hypertension in Diabetes, 1987). 
In the subgroup study comparing patients with treated and untreated 
hypertension, the numbers of patients in each of the groups were small 
resulting in a very low statistical power (less than 10%) therefore the sub-study 
could be regarded more as a pilot study. When patients with treated 
hypertension in both groups were compared only 20% of the nephropathy group 
and 27% of control subjects had blood pressures within normal levels Le.: were 
receiving effective anti-hypertensive treatment. One nephropathy and seven 
control patients had systolic hypertension alone, and the rest of the patients in 
both groups had both diastolic and systolic hypertension. 
All of the treated nephropathy patients were receiving ACEI either alone or In 
combination with other types of anti-hypertensive medication in comparison to 
only three of the control group. The treated nephropathy group had higher 
mean diastolic and systolic pressures in comparison to treated control subjects 
and they were also younger than the controls. The negative correlation between 
age and diastolic pressure and duration of diabetes and diastolic pressure in 
the small number of treated nephropathy patients, which was not present in 
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untreated nephropathy patients, suggests that there may be other factors which 
separate these two groups other than hypertension treatment, especially as 
there were no statistical differences in either age or duration of diabetes 
between the groups. Previous research has suggested that patients with 
nephropathy have increased total cholesterol, low density lipoprotein, 
triglyceride and reduced high density lipoprotein concentrations (Jensen et al, 
1988; Wafts et a/, 1988). This lipid profile would contribute to the development 
of atherosclerosis even at an early age affecting arterial elasticity and 
subsequently the blood pressure. 
When treated and untreated nephropathy patients were compared the only 
difference was that those with treated hypertension had higher diastolic blood 
pressures than those not receiving anti-hypertensive medication. These results, 
though based on a small sample size, suggest that blood pressure may be 
more difficult to control in younger nephropathy patients than in control subjects 
and that there may be two distinct groups of nephropathy patients Le.: one with 
more advanced nephropathy (in the treated group mean serum creatinine was 
99 timol I-' versus 90 pmol 1-1 in untreated patients; with the maximum value in 
the treated group close to 200 pmol 1-1). It may be that ACEI are not as effective 
in treating hypertension in established nephropathy than in the earlier 
microalburninuric stage of the disease. However, the small numbers of 
nephropathy patients in this study make it impossible to reach definitive 
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conclusions on this topic and indicate the need for a larger multicentre study to 
address this. 
Two meta-analyses on the effect of anti-hypertensive treatment in nephropathy 
patients have shown that treatment with ACEI does have a beneficial effect on 
renal function independently of its effects on blood pressure (Kasiske et al, 
1993; Maki et al, 1995). Early research into the effect of hypertension treatment 
in nephropathy has demonstrated that reducing blood pressure with a variety of 
anti-hypertensive agents also reduces the rate of decline of renal function 
(Parving et al, 1983; Mogensen, 1982). More recently, the EUCLID study 
showed that treatment for 24 months with lisinopril (ACEI) in 34 
microalbumin uric (AER 20-200pg min") patients, in comparison to 45 
microalburnin uric patients receiving placebo, slowed the decline In renal 
function, although the numbers in both groups were small (EUCLID Study 
Group, 1997). 
In patients with untreated hypertension both the nephropathy and control 
subjects had systolic hypertension with diastolic pressures within normal limits. 
This could indicate that systolic hypertension is regarded as a less Important 
parameter in treating hypertension than diastolic pressure despite the evidence 
that systolic hypertension is a significant factor In the progression of diabetic 
nephropathy (Cooper et al, 1988). In younger untreated control subjects with a 
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shorter duration of diabetes than treated controls, the mean systolic pressure 
was significantly higher than that in the treated control subjects. This indicates a 
need for more intensive monitoring and treatment of systolic hypertension in 
younger patients. 
In this study, the nephropathy group were more likely to have a history of 
smoking and to default from routine diabetic clinic visits than controls, both of 
which increased the risk of developing nephropathy. In 1993, Reichard and co- 
workers found no relationship between smoking and nephropathy in Type 1 
patients. However, other researchers have demonstrated a link between the 
two, (Chase et al, 1991; Sawicki et al 1994; Aldmal et al, 1994). While, strong 
independent relationships have also been demonstrated between ex-smoking 
and macroalburninuria and ex-smoking and proliferative retinopathy 
(independently of albumin excretion rate) (Chaturvedi et al, 1995). Biesenbach 
and colleagues have also shown that nephropathy patients who smoked not 
only had an increased rate of decline in renal function but also had higher 
systolic and diastolic blood pressures than non-smokers (Biesenbach et al, 
1994). In this study, peripheral vascular disease was more common in the 
nephropathy patients than controls which may also be related to smoking. 
The POSitive correlation between serum creatinine concentration and duration of 
diabetes suggested that duration of diabetes was predictive of declining renal 
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function in the nephropathy patents but not in controls. This may be more 
reflective of poor glycaemic control over many years of diabetes that has led to 
the development of nephropathy rather than be directly related to length of 
duration. 
Raised body mass index was predictive of raised diastolic blood pressure in the 
nephropathy group but again not in control subjects. It is possible that a high 
body mass index has a contributory effect on diastolic pressure that is already 
above normal secondary to nephropathy, but in control subjects where blood 
pressure is not compromised by abnormal renal function, body mass index is 
far less significant. 
In control subjects the positive correlations between age and diastolic pressure 
and age and systolic pressure were to be expected as blood pressure increases 
with age in the UK population as a whole. 
There may have been an element of bias in the selection of the control subjects 
as these were people attending for annual review examinations and might have 
excluded some patients who may have defaulted from clinic visits but who did 
not have nephropathy. Also, the selection of patients for the control study 
occurred five years after starting the collection of data in nephropathy patients. 
In those five years, changes in the approach to treating hypertension and poor 
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glycaemic control may have occurred which would have been more likely to 
impact on diabetic people who did not have advanced microvascular disease 
than on the nephropathy patients. 
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6.7 Conclusions 
I Nephropathy patents had consistently worse glycaemic control than the 
control group. Therefore, accept Hi(l): there are differences in glycaemic 
control between the groups. 
2 Nephropathy patients had a higher prevalence of microvascular 
complications, peripheral vascular disease and hypertension than control 
subjects. Theref6re, accept Hi (1): There are differences in diabetic 
complications between the group. 
3 The individual presence of retinopathy and / or hypertension both 
increased the risk of developing nephropathy. 
4 Current smoking, a history of smoking and defaulting from routine clinic 
visits all increase the risk of developing nephropathy. Therefore, accept 
Hi (2): there are factors other than poor glycaernic control, hypertension 
and duration of diabetes that put patients at risk of developing 
nephropathy that can be identified during routine clinical practice. 
-207- 
Chapter 7 




Diabetic nephropathy in Type I patients has been studied extensively but 
until relatively recently the whole topic of nephropathy in Type 2 patients 
seemed to have little attraction for researchers. The presence of 
microalbuminuria in Type 2 patents was regarded as predictive of death 
from cardiovascular disease instead of the early stages of nephropathy 
(Mogensen, 1984). As management of ischaemic heart disease and 
hypertension have improved, the prognosis for Type 2 patients with 
microalbuminuda appears to have improved in terms of survival, and 
increasingly Type 2 patients are progressing to overt proteinuria and 
onwards to end stage renal failure. This has stimulated research into the 
progression of nephropathy in Type 2 patients with microalbuminuria (Berrut 
et al, 1997). Several studies have demonstrated a raised glomerular filtration 
rate in newly diagnosed Type 2 patients (Vora et al, 1993; Ritz and 
Stefanski, 1996). 
Over the last decade people with Type 2 diabetes have increasingly 
represented a significant number of diabetic patients who receive renal 
replacement therapy (Humphrey et al, 1989; Perneger et al, 1994). In 
different countries the proportion of diabetic patients in end stage renal 
failure with Type 2 diabetes varies considerably (e. g.: Australia: 61%; New 
Zealand: 79%; Italy: 67% and Germany: 51%) as does the proportion in 
different ethnic groups: (data from USA) Black people: 29%, White: 31%; 
Pima Indians: 95%; Native American Indian: 55%; (data from Australia) 
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White: 48%; Aboriginal: 83% (Ritz and Stefanski, 1996). This would reflect 
the incidence of Type 2 diabetes in the respective population groups. 
The same clinical problems occur in Type 2 as in Type 1 diabetic patients in 
terms of preventing microvascular complications and potentially identifying 
those people who may be at risk of developing nephropathy. This 
retrospective study has been designed to identify potential risk factors for 
developing nephropathy in Type 2 patients by direct comparison with a 
matched control group with normal renal function. 
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7.2 Objectives 
To identify differences in diabetic control and complications between 
Type 2 patients Wth nephropathy and matched controls. 




1 Ho: Type 2 nephropathy patients had the same prevalence of diabetic 
complications and the same prevalence of hypertension than matched 
controls. 
Hi: Type 2 nephropathy patients had a different prevalence of diabetic 
complications and a higher prevalence of hypertension than matched 
controls. 
2 Ho: There were no factors other than poor glycaemic control, the 
presence of hypertension or duration of diabetes that put Type 2 
patients at risk of developing nephropathy that can be identified 
during routine clinical practice. 
Hi: There were factors other than poor glycaemic control, the 
presence of hypertension or duration of diabetes that put Type 2 
patients at risk of developing nephropathy that can be identified 
during routine clinical practice. 
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7.4 Methods 
From the index population of patients referred for nephrological assessment 
from the diabetic clinic, a group of 46 Type 2 patients with nephropathy and 
serum creatinine levels less than 300 gmol 1-1 were compared with 44 
matched controls with no evidence of overt proteinuria (routine testing for 
microalbuminuria was not performed in the diabetic clinic, therefore, 
microalburninuric status of control subjects was not known). Nephropathy 
patients were only included if they had a duration of diabetes greater than 
two years, had no retinopathy at presentation of diabetes and no proteinuria 
within the first three years after diagnosis of diabetes. These inclusion 
criteria were selected in order to identify a discrete group with nephropathy 
and decrease the likelihood that patients had undiagnosed diabetes for 
many years before diagnosis. Nephropathy was diagnosed on clinical 
grounds Le.: they had to have either proteinuria on "Albustix" testing plus 
diabetic retinopathy or confirmation of diagnosis by renal biopsy. 
The control group was selected from 643 Type 2 patients attending the 
diabetic clinic for routine annual review examination between 1992-1995. 
They had normal serum creatinine levels (<120 pmol 1-1) and no evidence of 
overt proteinuria. Controls were matched for age, duration of diabetes, 
gender, ethnic group and diabetes treatment where possible. 
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Data were collected as in Chapter 4 for both groups of patients Le.: 
information on diabetes history, treatment and complications, renal disease, 
hypertension and anti-hypertensive treatment; hypertension was defined as 
systolic pressure >140 mm Hg and / or diastolic pressure >90 mm Hg. 
Diabetic control was determined using glycated haernoglobin (HbAI) results 
at either nephrological assessment or annual review examination (controls). 
HbAl results over a four-year period were collected and comparisons were 
made between the groups. A point prevalence Le.: prevalence at a single 
examination, was determined for diabetes complications and other factors 
that may be predictive of development of nephropathy. 
A comparison was made between patients with treated and untreated 
hypertension in both groups to determine whether there were specific factors 
which contributed towards lack of anti-hypertensive therapy. 
Descriptive statistics (means +standard deviations), Student t-tests, Chi2 test 
and Fisher Exact test when expected frequencies were less than 5 for 2x2 
contingency tables, Mann-Whitney U tests for data with abnormal 
distributions, analysis of variance of between and within the groups was 
performed for repeated HbAl measurements over four years, Pearson 
correlation and linear and multiple regression analysis were performed using 
SPSS statistics package. Odds ratio was also calculated as a measurement 
of risk of developing nephropathy. The chosen level of significance was 
P<0.05 for one and two tailed tests. 
-214- 
7.5 Results 
The two groups were well matched for age, duration of diabetes, gender and 
ethnic group. There was a higher percentage of nephropathy patients 







NUMBERS 46 (100) 44 (100) N. S. 
GENDER 
Male 30 (66) 29 (66) 
Female 16 (34) 15 (34) N. S 
ETHNic GROUP 
Indo-Asian 15 (29) 13 (30) 
Afro-Caribbean 6 (13) 5 (11) N. S. 
Caucasian 25 (58) 26 (59) 
DIABETES TREATMENT 
Diet 1 (2) 1 (2) 
Oral 9 (22) 18 (41) N. S. 
Insulin 36 (78) 25 (57) 
AGE (Years) 
Range 41-77 42-76 
Mean(+SD) 61(+8) 62(+8) N. S. 
Median 62 63 
DuRATiON OF DM (years) 
Range 4-28 4-35 
Mean(+SD) 14(+6) 15(+7) N. S. 
Median 14 14 
DM: Diabetes mellitus N. S.: Not significant Level of significance: P50-05 
Table 7.1: Demographics of Type 2 nephropathy patients versus controls 
The range in diabetic control (HbAI) at examination was Wide in both 
groups: 6.3-15.5% (controls) and 7.4-20.0% (nephropathy group). There was 
a statistical difference (P<0.05) in mean HbAl between patients with 
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nephropathy [111.8 (+2.7)%] and controls [10.4 (+2.0)%]. Analysis of variance 
of mean HbAl over four years demonstrated that the nephropathy group had 
worse control although it was far from ideal in both groups: Mean (+SD) of 
results for all four years in the nephropathy group: 12.1 (±2.8)% versus 11.3 
(+2.4)% in control subjects (P<0.005). There was no statistical difference in 
mean HbAl between the 4 years within the nephropathy group but within the 
control group there was a significant difference in the third year (P<0.05) 
possibly due to changes in clinical policy (Figure 7.1). 







Mean: -- Median: DN: Nephropathy group 
Con: Controls Ref: at referral examination 
Figure 7.11: Glycaemic control: Type 2 nephropathy patients versus 
controls 
There was no significant difference in body mass index (BMI) between the 
groups: nephropathy patients: 28.6 (+ 2.9) kg M-2 versus 27.0 (+5.3) kg M-2 
(P-- N. S. ). 
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Year Year Year Year Year Year Year Year Ref Ref 
I DN 1 Con 2 DN 2 Con 3 DN 3 Con 4 DN 4 Con DN Con 
7.5.1 Renal Function 
The range of serum creatinine in the control group (56-120 Pmol I-) was 
within the normal reference range (60-120 pmol 1-1) with a mean of 92 ptmol 
I'. As expected, the range in the nephropathy group was wider (65-191 
pmol 1-1), with a mean just above and median within the upper limit of normal 








Maximum 75% Quartile 25%Quartile Minimum 
Mean: 122 M ean: 92 
Median: 118 M t- (I ian: 92 
Nephropathy Controls 
Figure 7.2: Comparison of serum creatinine levels in Type 2 nephropathy patients 
and control subjects 
7.5.2 Microvascular Complications 
There was a similar prevalence of microvascular complications in the two 
groups except for eye complications where there were statistically significant 
differences between the groups in background retinopathy (P<0.001) with 
the nephropathy patients having more severe retinopathy and treatment with 
laser photocoagulation (P<0.001 for both) (Table 7-2). However, it was to be 
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expected that nephropathy patients would have retinopathy, as this was part 
of the clinical criteria for diagnosis of nephropathy. 





Retinopathy 43 (93) 20 (45) <0.001 
Severe Refinopathy 24 (56) 1 (5) N. S. 
Laser Photocoagulation 20 (47) 1 (5) N. S. 
N. O.: NOT signITIcant LeVel of signiticance: P<U. U. ':) 
Table 7.2: Eye complications in Type 2 nephropathy patients compared to control 
subjects 
7.5.3 Macrovascular Complications 
The only statistical difference in macrovascular complications between the 
groups was the prevalence of hypertension: 44 (96%) of nephropathy 
patients in comparison to 31 (70%) controls (P<0.005). The presence of 
hypertension increased the risk of developing nephropathy (odds ratio = 
9.2). Of those patients with hypertension, only 19 (43%) of nephropathy 
patients in comparison to 22 (71%) of controls were receiving anti- 
hypertensive therapy (P<0.05). 
Both groups had systolic hypertension with diastolic pressures within the 
normal range. There were statistically significant differences In mean systolic 
pressures: 170L+23) mm Hg in the nephropathy group versus 146 L+20) mm 
Hg in the control group (P<0.001) and in mean diastolic pressures: 90L+13) 
mm Hg (nephropathy patients) compared to BIL+10) mm Hg (control 
subjects) (P<0.001) (Figures 7.3 and 7-4). 
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Figure 7.3: Blood pressures in Type 2 nephropathy patients 
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Figure 7.4: Blood pressure in Type 2 control subjects 
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In the nephropathy group the minimum systolic pressure was higher than in 
the control group with the maximum being well above the maximum of 200 
mm Hg in control patients. There was also a much wider inter-quartile range 
in nephropathy patients (Figure 7.5). In both groups the systolic medians 
























Figure 7.5: Blood pressure of Type 2 nephropathy patients and controls 
Regression analysis demonstrated that in nephropathy patients systolic 
pressure was 26% (P<0.001) predictive of variance in hypertension but in 
the control group it was 49% predictive of the variance in hypertension 
(P<0.001). Diastolic pressure was only 13% (P <0.05) predictive of the 
variance in hypertension in controls but not predictive in the nephropathy 
2 =0.009. group (R , 
P-- N. S. ). The higher predictive value of systolic pressure 
in the control group indicates that although this group had a lower mean 
systolic pressure than the nephropathy patients, that systolic hypertension in 
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control patients is more predominant than diastolic hypertension. However, 
in the nephropathy group, patients had both systolic and diastolic 
hypertension. 
The proportion of patients with hypertension in each group was used to 
calculate the power of the study using the method described by Lowe, 1993. 
At 90% statistical power with P<0.05,40 patents in each group would be 
needed. Therefore, the sample sizes for this study were sufficient to give a 
statistical power of 90%. 
When the groups were divided into those receiving anti-hypertensive 
treatment and those with untreated hypertension, regression analysis of the 
treated groups showed that systolic pressure was 26% (P<0.001) predictive 
of the variance in receipt of anti-hypertensive therapy in the control group 
but only 12% predictive of the variance in receipt of therapy in the 
nephropathy patients. However, in controls receiving anti-hypertension 
treatment diastolic pressure was 11 % (P<0.05) predictive of the variance in 
treatment in comparison to 1% (P--N. S. ) in the nephropathy group. Multiple 
regression analysis showed that diastolic and systolic pressures together 
were 26% predictive of anti-hypertensive therapy in treated control patients 
with only systolic pressure being significant (P<0.001). These results can be 
interpreted as showing that in both groups systolic pressure was more 
indicative of the lack of anti-hypertensive treatment than diastolic pressure. 
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Body mass index (BMI) was 22% (P<0.005) predictive of the variance in 
treatment of hypertension in the nephropathy group but only 4% (P--N. S. ) in 
the control group. Multiple regression analysis showed that systolic pressure 
and BMI together were 36% (systolic pressure: P<0.01, BMI: P<0.05) 
predictive in the nephropathy group but only 26% (systolic pressure: P<0.05, 
BMI 1: 1--N. S. ) predictive in controls. Multiple regression analysis using 
defaulting from clinic visits, presence of retinopathy, smoking history, systolic 
pressure and BMI as independent variables showed a combined predictive 
value of 39% with only the systolic pressure (P--0.01) and BMI (P<0.005) as 
significant predictors of anti-hypertensive treatment In nephropathy patients. 
In the control group these factors combined to give a predictive value of 27% 
with only systolic pressure being statistically significant (P<0.05). 
In patients with untreated hypertension there were no similarities between 
the control and nephropathy groups. In nephropathy patients systolic 
pressure was 15% (P<0.05) predictive and BMI was 22% (P<0.001) 
predictive of the variance in lack of anti-hypertensive therapy unlike the 
control group where neither of these parameters were significant. Multiple 
regression analysis demonstrated that systolic pressure and BMI together 
were 31% (systolic pressure; P--N. S., BMI: P<0.05) predictive of untreated 
hypertension in the nephropathy group. Multiple regression analysis using 
defaulting from clinic visits, presence of retinopathy, smoking history, systolic 
Pressure and BMI as independent variables showed that none of these 
variables were statistically significant predictors in controls but when 
combined were 42% predictive of lack of anti-hypertensive treatment. 
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However, in the nephropathy group these same factors were only 34% 
predictive of untreated hypertension with BMI (P<0.05) being the only 
statistically significant factor. 
7.5-4. Other Contributory Factors 
A higher percentage of the nephropathy group (47%; n=22) had defaulted 
from routine diabetic clinic follow up compared to 14% (n=6) of controls 
(P<0.001). There was no significant statistical difference in current smokers 
between the groups. However, more nephropathy patients (n=24; 52%) had 
a history of smoking in comparison to the controls (n=11; 25%) (P<0.01). 
Defaulting from clinic visits increased the risk of developing nephropathy 
(odds ratio = 5.8) as did a history of smoking (odds ratio = 3.3). 
There was a weak positive correlation (r--0.37) between age at referral for 
nephrological assessment and serum creatinine levels in the nephropathy 
group (P<0.05) but not in control patients (Figure 7.6). 
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Figure 7.6: Relationship between age and serum creatinine in Type 2 nephropathy 
patients 
Linear regression demonstrated that age at nephrological assessment 
predicted 14% towards the variance in serum creatinine concentrations. 
Similarly, there was a weak positive correlation (r=0.29) between duration of 
diabetes and serum creatinine in nephropathy patients (PI--0.05) but no 
correlation between these parameters in the controls (r=0.08, FI-N. S. ) 
(Figure 7.7). Linear regression analysis showed that duration of diabetes 
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Figure 7.7: Relationship between duration of diabetes and serum creatinine 
in Type 2 nephropathy patients 
There was no correlation between either creatinine and systolic pressure or 
creatinine and HbAl at referral in either group. 
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7.6 Discussion 
The groups were well matched for age, duration of diabetes and ethnicity 
and by studying patients in chronic rather than end stage renal failure the 
difference in renal function between the groups was not great. The control 
group had normal renal function and, despite the presence of proteinuria, 
nephropathy patients had serum creatinine levels within or just above the 
normal range. 
In this study a higher prevalence of background and severe retinopathy were 
found in the nephropathy group than in controls. This was similar to a recent 
study in Japanese Type 2 patients which showed that those with 
macroproteinuria have a higher prevalence of background and proliferative 
retinopathy than patients who are normoalbumin uric or microalburnin uric 
(Tanaka et al, 1998). 
The only differences in macrovascular complications were the high 
prevalence of hypertension, the low prevalence of anti-hypertensive 
treatment and the higher levels of mean systolic and diastolic pressures in 
nephropathy patients in comparison to controls. These findings are similar to 
a study in Korean Type 2 patients which demonstrated a higher prevalence 
of hypertension and higher systolic and diastolic blood pressures in patients 
progressing to microalbuminuria than those who remained normoalbuminuric 
(Park et al, 1998). The lack of anti-hypertensive therapy in the nephropathy 
group was disturbing as control of hypertension is recognised as the most 
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effective way of slowing the decline in renal function in patients with 
microalburninuria and overt proteinuria (Kasiske et A 1993, Ahmad et al, 
1997). 
The comparison of treated and untreated hypertensive patients 
demonstrated that not only was systolic pressure a major factor in predicting 
treatment of hypertension in both groups but also a lack of treatment In the 
nephropathy group (but not in controls) presumably because of the 
predominance of systolic hypertension in both groups. Diastolic pressure 
was only predictive in controls with treated hypertension which may be 
secondary to the lower mean diastolic pressure in this group (i. e.: as there 
were fewer patients with diastolic pressures above the upper limit of normal, 
those that were represented a significant minority in terms of uncontrolled 
hypertension). These results suggest that in control subjects with treated 
hypertension, the level of blood pressure control was poor. While In the 
nephropathy group, control of systolic pressure Is not as effective as control 
of diastolic pressure. However, the comparison of results for untreated 
hypertensive patients must be regarded with some caution as there were 
only three controls in this subgroup and larger numbers could alter the 
results and interpretation. 
Body mass index also played a significant role In predicting anti- 
hypertensive treatment and the lack of this treatment in nephropathy patients 
but not in the control group. This may reflect the significantly larger BMI In 
the nephropathy group with treated hypertension. The apparently combined 
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enhancing effects of systolic pressure and BMI on both treatment of 
hypertension and lack of the same may indicate two sides of the same 
problem Le.: patients who are overweight are more likely to be hypertensive 
and the larger the patient the more difficult it is to control blood pressure. 
A previous study in Wolverhampton has demonstrated that defaulting from 
routine diabetic clinic visits increases the chance of patients developing 
diabetic complications (Hammersley et al, 1985). Therefore, the results of 
this study showing that control subjects were less likely to default and have 
fewer microvascular complications in comparison to people with 
nephropathy was not surprising. The increaseý risk of developing 
nephropathy associated with defaulting from clinic visits confirms the 
previous findings. 
The difference between the two groups in the prevalence of current smokers 
and those with a history of smoking, and the increased risk that a history of 
smoking confers on the development of nephropathy are similar to the 
results of a study by Bruno and colleagues in 1996, who demonstrated that 
in Type 2 diabetic patients a history of smoking increased the risk of 
developing nephropathy in comparison to current smokers. This apparent 
anomaly is possibly due to ex-smokers having smoked for a longer period of 
time than current smokers. 
The correlation between age at referral and serum creatinine, and duration 
of diabetes and serum creatinine in the nephropathy group but not In control 
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subjects was particularly interesting as the groups were well matched for 
both age and duration of diabetes. There may be four factors influencing 
these results. The nephropathy patients may be more prone to vascular 
disease than the control group of the same age, and their renal disease and 
higher blood pressure levels may be reflective of this. The fact that patients 
with nephropathy were more likely to have smoked may have put them at a 
higher risk of developing vascular disease. Type 2 patents who develop 
nephropathy at the same age and duration of diabetes as matched controls 
may be more susceptible to this complication due to genetic factors 
influencing renal function or blood pressure control, or both. The link 
between age and serum creatinine levels may be due to the natural effect of 
age in reducing effective renal plasma flow and subsequent reduction in 
renal function. This effect has been observed to be greater in newly 
diagnosed Type 2 patients than in non-diabetic people (Ritz and Stephanski, 
1996). 
The real duration of diabetes in Type 2 patients is very difficult to ascertain. 
In this study the exclusion of patients presenting with microvascular 
complications within the first two years of diagnosis has decreased the 
confounding influence of undiagnosed diabetes. None the less, duration of 
diabetes is essentially an undefinable variable In Type 2 patients. However, 
bearing this in mind, duration of diabetes has been shown previously to be 
related to macroalbuminuria in Type 2 patients (Bruno et al, 1996). 
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The relatively small numbers of patients in this study make it difficult to 
access the true extent of the association between certain factors and 
nephropathy and this was one of the limiting factors to the research. Larger 
patient numbers would have undoubtedly identified factors which have a 
lesser effect but may still be very relevant. 
The possible bias in selection of control subjects previously referred to In 
relation to Type I control subjects is also relevant to Type 2 control patients 
Le.: only patients attending for annual review examination were used to 
select control subjects therefore potentially excluding patients who had 
defaulted from clinic and the collection of data on control subjects occurred 
five years after the start of collecting data on the nephropathy group during 
which time the clinical approach to hypertension treatment and glycaemic 
control may have changed. 
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7.7 Conclusions 
1 Type 2 nephropathy patients had a higher prevalence of retinopathy, 
including severe retinopathy, than controls. 
2 Type 2 nephropathy patients had a higher prevalence of 
hypertension, higher systolic and diastolic pressures and less anti- 
hypertensive treatment than controls. Therefore, accept Hi (1): 
Nephropathy patients have more diabetic complications and a higher 
prevalence of hypertension than matched controls. 
3 Duration of diabetes and increasing age are significant factors 
associated with the development of nephropathy in susceptible 
patients. 
4 The presence of hypertension was a risk factor for the development of 
nephropathy. 
5A history of smoking was a risk factor for the development of 
nephropathy in Type 2 patients. 
6 Defaulting from routine diabetic clinic follow up was a risk factor for 
developing nephropathy in Type 2 patients. Therefore, accept Ho (2): 
There are factors other than glycaemic control, the presence of 
hypertension and duration of diabetes that put Type 2 patients at risk 
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of developing nephropathy that can be identified during routine clinical 
practice. 
7 Increasing body mass index and untreated hypertension were 
associated with the presence of nephropathy. 
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Chapter 8 
A Comparison of Diabetic Nephropathy in Type 2 
Patients from Different Ethnic Groups 
-233- 
8.1 Introduction 
The 1991 census identified that 3% of the British population were of Indo-Asian 
origin (Cruickshank, 1993). However, in Wolverhampton the same census has 
shown that 13% of our population are Indo-Asian and 5% Black [Indo-Asian 
and Black refer to the definitions used in this thesis not those of the OPCS (see 
Section 7.4)] (Office of Population Censuses and Survey, 1991). In 1987, a 
survey of 549 diabetic clinics in the U. K. estimated that 4.3% of patients 
attending were of Indo-Asian origin and 2.1 % were Black (Goodwin et al, 1987). 
From data collected to find control subjects for the earlier chapters, 139 (15%) 
Indo-Asian patients and 50 (6%) Black patients attended the diabetic clinic In 
Wolverhampton for annual review examination out of 908 patients over a four 
year period, however, this represents less than half of the diabetic clinic 
population. 
The Southall and Coventry studies have demonstrated that Indo-Asian people 
have a four times increased risk of developing diabetes than the indigenous 
White population of the U. K. (Mather and Keen, 1985; Simmons et al, 1989). 
Both the Coventry study and the UK Prospective Diabetes Study have shown 
that Indo-Asian patients develop Type 2 diabetes at a younger age than White 
patients (Simmons and Powell, 1993; UK Prospective Diabetes Study Group, 
1994). In 1988, Allawi and co-workers found that Indian diabetic patients living 
in the U. K. had a higher prevalence of microalbuminuria than people of 
-234- 
European origin (Allawi et al, 1988). It has also been shown that Indo-Aslan 
men with diabetes were twice as likely to develop chronic renal failure than 
White diabetic men and that the incidence of end-stage renal failure secondary 
to diabetes in Indo-Asian people is ten times that of White diabetic patients 
(Burden et al, 1992; Gujral eta/, 1997). 
A previous study in Wolverhampton has shown that people of Black origin had 
a higher incidence of diabetes than White people living in other parts of the 
U. K. (Odugbesan, et al, 1989). In the U. S. A., Black patients with Type 2 
diabetes are known to have a 2.6 higher incidence of end stage renal disease 
than White patients (Cowie, et al, 1989). Perneger and colleagues (1994) found 
that the odds for Black patients developing end stage renal disease was 7.4 
times greater than in White patients. In one renal unit in the U. K., 45% of Type 
2 patients receiving dialysis for end stage renal failure due to nephropathy were 
either Indo-Asian or Black (Grenfell et al, 1988). 
Whether there are specific risk factors, predictors of, or indeed differences in 
the development of nephropathy in Indo-Aslan, Black or White diabetic patients 
is unclear. This study is designed to ascertain whether there are any 
differences between these three ethnic groups which may relate to the 
development of nephropathy. 
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8.2 Objectives 
1 To determine whether there were differences in the presentation of 
nephropathy between White, Indo-Asian and Black patients. 
2 To determine whether there were differences In the prevalence of 
diabetic complications between the groups. 
3 To determine whether there were risk factors for nephropathy specific to 
any of the ethnic groups. 
4 To determine whether there were factors associated with nephropathy 
specific to any of the ethnic groups. 
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8.3 Hypotheses 
I Ho: There were no differences in the presentation of nephropathy 
between White, Indo-Asian and Black Type 2 diabetic patients. 
Hi: There were differences in the presentation of nephropathy between 
White, Indo-Asian and Black Type 2 diabetic patients. 
2 Ho: There were no differences in the prevalence of diabetic 
complications between White, Indo-Asian and Black Type 2 diabetic 
patients. 
Hi: There were differences in the prevalence of diabetic complications 
between White, Indo-Asian and Black Type 2 diabetic patients. 
3 Ho: There were no risk factors for nephropathy specific to either White, 
Indo-Asian or Black Type 2 diabetic patents. 
Hi: There were risk factors for nephropathy specific to either White, 
Indo-Asian or Black Type 2 diabetic patients. 
4 Ho: There were no factors associated with nephropathy specific to either 
White, Indo-Asian or Black diabetic Type 2 patients. 
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Hi: There were factors associated with nephropathy specific to either 
White, Indo-Asian or Black diabetic Type 2 patients. 
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8.4 Methods 
From the index population of patients referred for nephrological assessment 
from the diabetic clinic, Type 2 patients with nephropathy were divided into 
three groups dependent on ethnic origin; White (defined as people with genetic 
origins in Europe, irrespective of place of birth), Indo-Aslan (defined as people 
with genetic origins from the Indian subcontinent, irrespective of place of birth) 
and Black (defined as people with genetic origins from Africa irrespective of 
place of birth) and matched according to age, gender, duration of diabetes and 
diabetes treatment. For the initial analysis patients on renal replacement 
therapy or with serum creatinine levels greater than 300 pmol I" were omitted 
from the analysis to remove bias due to advanced disease. A further analysis 
Was performed to validate the results of Chi2 tests by using larger numbers of 
patients; this included patients with serum creatinine levels above 300 Pmol I" 
and those on RRT. 
Data were collected as in Chapter 4 for both groups of patients Le.: information 
on diabetes history, treatment and complications, renal disease, hypertension 
and anti-hypertensive treatment; hypertension was defined as systolic pressure 
>140 mm Hg and / or diastolic pressure >90 mm Fig. Nephropathy was 
diagnosed on clinical grounds Le.: they had to have either proteinuda on 
'AlbustV testing plus diabetic retinopathy or confirmation of diagnosis by renal 
biopsy. Diabetic control was determined using glycated haernoglobin (HbAI) 
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results at either nephrological assessment or annual review examination 
(controls). HbAl results over a four-year period were collected and 
comparisons were made between the groups. A point prevalence Le.: 
prevalence at a single examination (nephrological assessment) was determined 
for diabetes complications and other factors that may be predictive of the 
development of nephropathy. 
Duration of diabetes to the onset of proteinuria, retinopathy and hypertension 
were also determined and compared between the groups to assess whether 
there were any differences in development of these complications. 
A comparison was made between patients with treated and untreated 
hypertension to determine whether there were factors which contributed 
towards lack of anti-hypertensive therapy which were specific to any of the 
ethnic groups. 
Descriptive statistics (means +standard deviations), Chi2 tests, analysis of 
variance between and within the groups, Pearson correlation and linear and 
multiple regression analysis were performed using SPSS statistics package. 
The chosen level of significance was P -<0.05 
for one and two-tailed tests. 
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8.5 Results 
From the original cohort of 102 Type 2 patents with nephropathy 61 patents 
were included in the comparison of ethnic groups: 17 Indo-Asian, 10 Black and 
34 White. The groups were well matched for age, sex, duration of diabetes and 
diabetes treatment. Indo-Asian patients had the shortest duration of diabetes at 
referral: mean 11 L+5) years with a median of 10 years (P--N. S. ). (Table 8.11). 
All but one of the Black patient were on insulin treatment, unlike the other two 









NUMBER 17 10 34 
MALE 10(59) 7 (70) 23 (68) 
FEMALE 7 (41) 3 (30) 111 (32) N. A. 
AGE (YEARS) 
RANGE 41-68 49-71 45-83 
MEAN L+SD) 59(7) 60(8) 64(8) N. S. 
MEDIAN 60 59 64 
DURATION DM (YEARS) 
RANGE 3-20 7-25 1-28 
MEAN L+SD) 11(5) 16(5) 14(7) N. S. 
MEDIAN 10 16 15 
DIABETES TREATMENT 
DIET 0 0 0 
ORAL 6 (35) 1 (10) 9 (26) NA 
INSULIN 11 (65) 9 (90) 25 (74) 
U. M.: Diabetes mellitus; S. D.: Standard deviamn N. O.. FIUL NUI 11116di IL 
N. A.: Not applicable (Expected frequency X2 < 5) Level of significance: PIO-05 
Table 8.1: Demographics of Type 2 nephropathy patients from different ethnic 
backgrounds. 
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There was little difference in glycaemic control (as measured by HbAl at 
referral) between the groups [mean (±SD) Indo-Asian- 12.6 (+4.2) %; Black: 
12.7 (±2.3) %; White: 11.1 (+2.2) % (P--N. S. )]. Analysis of variance showed 
that there was no difference either within or between the groups in glycaernic 
control over four years (P--N. S. ) (Figure 8.1). 
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Figure 8.11: Glycaernic control over four years in Type 2 nephropathy patients of 
different ethnic origin 
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I-All BI W1 I-A2 B2 W2 I-A3 B3 W3 I-A4 134 W4 
M en n Median I-A: Indo Asian Bý Black W: White 1,2,3,4 Years 1,2,3,4 
8.5.1 Renal Function 
Mean serum creatinine levels were similar in all three groups [Indo-Asian: 131 
(+30) ýtmol 1-1, Black: 135 (±30) ýtmol 1-1, White: 130 (+50) Pmol 1 -1; (P--N. S. )] 
although the range in the White group was wider than in the other two groups 
(Figure 8.2). 
Maximum 75'Yo Quartile 25% Quartile Minimum 
300 r 
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Figure 8.2: Serum creatnine concentrations in Type 2 nephropathy patients from 
different ethnic groups 
There was no statistical difference in mean proteinuria between the groups 
(Indo-Asian: 2.3 (+3.1) g 24h-1, Black: 2.9 (±3.5) g 24h-1, White: 1.8 (±1.1) g 
-243- 
24h-') but ranges varied and the inter-quartile range in the Black group was 
wider than the other two groups (Figure 8-3). 










8.5.2 Microvascular Complications 
l1w 
Microvascular complications were similar in all three groups (Table 8.2). 
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Indo-Asian Egack White 
Median: 









Retinopathy 15 (88) 9 (90) 34 (100) N. A. 
Severe Retinopathy* 9 (60) 4 (44) 19 (56) N. A. 





N A Blindness (one eye) 1 (6) . . 
NERVOUS YSTEM 
Peripheral Neuropathy 4 (24) 3 (30) 18 (53) NA 
Autonomic Neuropathy 1 (6) 0- 0 N. A. j 
N. A.: Not applicable (Expected frequency X2 < 5) *: Percentage of patients vvith retinopathy 
Table 8-2: Comparison of microvascular complications between ethnic groups 
8.5.3 Macrovascular Complications 
The only statistical difference in macrovascular complications between the 
groups was that White patients had a higher prevalence of peripheral vascular 
disease (n=18; 53%) than either Indo-Asian (n=O) or Black patients (n=l; 10%) 









Ischaemic Heart Disease 3 (18) 2 (20) 9 (26) N. A. 
Myocardial Infarction 1 (6) 0 5 (15) N. A. 
Hypertension 17(100) 10 (100) 33 (97) N. S. 
BRAIN 
1 (6) 0 1 (3) N. A. Transient IschaemicAttack 0 2 (20) 3 (9) N. A. Cerebrovascular Accident 
PERIPHERIES 
Peripheral Vascular Disease 0 1 (10) 18 (53) N. A. 
Ulcers (foot/leg) 1 (6) 1 (10) 9 (27) N. A 
N. S.: Not significant N. A.: Not applicable (Expected frequency %' < 
Level of significance: P <0.05 
Table 8.3: Comparison of macrovascular complications between ethnic groups 
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Blood pressure levels were similar across all three groups. Mean systolic 
pressure demonstrated that each group had systolic hypertension (Indo-Asian: 
172 (+25) mm Hg; Black: 173 (+23) mm Hg; White: 173 (+23) mm Hg 
[P--N. S. ]). Mean diastolic pressures were just above the upper limit of normal in 
all groups (Indo-Asian: 93 (±15) mm Hg; Black: 92 (+18) mm Hg; White: 94 
(±15) mm Hg (P--N. S. ]). In White patients the median systolic pressure was 
lower than the mean: 165 mm Hg in comparison to 173 mm Hg, unlike the other 
two groups where the mean and median were the same (Figure 8-4). 







Indo-Asian Indo-Asian Black Black White White 
Systolic Diastolic Systolic Diastolic Systolic Diastolic 
Mean: - Median: - Same Mean and Median: 
Figure 8A Blood pressures in nephropathy patients from different ethnic origins 
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The inter-quartile range for systolic pressure was smallest in the Black patients 
and for diastolic pressure was smallest in White patients. 
All Indo-Asian and Black patients and 97% of the White group had hypertension 
but only 44% (n=15) of White patients were receiving anti-hypertensive 
medication in comparison to 65% (n=ll) Indo-Asian patients and 50% (n=5) of 










Hypertension 17(100) 10000) 33(97) N. S. 
Anti-Hypertensive Therapy 13(76) 5(50) 15(44) N. S. 
Mono-Therapy 4(31)* 2(40)* 11(73)* N. A. 
ACEI Mono-Therapy 3(75)** 2(100)** 5(46)** N. A. 
Combination Therapy 9(69)* 3(60)* 4(27)* N. A. 
At; ti: Angiotensin converting enzyme inhibitors -: /o on anu-nypeReliblve Lnel-dPY 
*ý. % of mono-therapy patients NA: Not applicable (Expected frequency X2< 5) 
N. S.: Not significant Level of significance: F! 5 0.05 
Table 8.4: Anti-hypertensive therapy in Type 2 nephropathy patients of different ethnic 
origin 
Of those patients receiving treatment for hypertension, 73% (n=ll) of White, 
31 % (n=4) of Black and 40% (n=2) of Indo-Asian patients were receiving mono- 
therapy while the remainder were treated with a combination of different types 
of anti-hypertensive drugs (Table 8.4). Only 46% (n=5) of White patents on 
mono-therapy were receiving an ACEI in comparison to 75% (n=3) Indo-Asian 
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and 100% (n=2) Black patients. Indo-Asian patients had the greatest need for 
combination therapy (69%). All combination therapies included ACEI. 
When the groups were divided into patients with treated or untreated 
hypertension, there were only two differences within the ethnic groups. In Indo- 
Asian patients the mean L+SD) systolic blood pressure was significantly higher 
in patients with treated hypertension (184 L+241 mm Hg) than those with 
untreated hypertension (163 L+111 mm Hg) (P--0.05). In White patients mean 
L+SD) BMI was greater in treated patients (34 L+6] kg m-2) in comparison to 
untreated patients (26 L+4] kg m-2) (P<0.001). There were no differences in age, 
duration of diabetes, serum creatinine concentrations, proteinuria, HbAl at 
referral or diastolic blood pressure. Comparison of these paramaters between 
the ethnic groups of those treated and separately those untreated showed no 
statistically significant differences. However, analysis of variance of all treated 
and untreated patients combined demonstrated that mean (+SD) BMI in treated 
patients was higher (Indo-Asian: 28 (±6); Black: 30 L+2): White: 34 (±6) kg m-2) 
than in untreated patients (Indo-Asian: 27(±2); Black: 28 (+3); White: 26 (+4) kg 
M-2 (p<0.005). 
On investigation of differences in correlations between various clinical 
parameters, it was found that in White patients with treated hypertension there 
was a positive correlation between age and serum creatinine (r--0.62, P<0.05, 
R2 =38%) but there were no statistically significant correlations in untreated 
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White patients. It should be noted that the numbers were very small in groups 
of treated and untreated Indo-Asian and Black patients, and therefore, 
correlations were not performed. 
8.5.4 Other Factors 
When the length of time between diagnosis of diabetes and development of 
retinopathy, proteinuria and hypertension were compared, Indo-Asian patients 
developed all three complications at an earlier duration of diabetes than either 
Black or White patients (Table 8.5). However, the only statistically significant 
difference between the groups was that Indo-Asian patients developed 
retinopathy at an early duration of diabetes. 
Time (years) Indo-Asian Black White P 
DM-RETINOPATHY 
Range 0*-14 2-18 0-26 
Mean (+SD) 6(5) 11(6) 11(8) <0.05 
Median 6 11 13 
DM-PROTEINURIA 
Range 1-20 5-24 0-27 
Mean(+SD) 9(6) 14(6) 14(8) N. S. 
Median 8 16 is 
DM-HYPERTENSION 
Range 0-16 5-24 -3-25 
Mean(+SD) 8(5) 14(7) 12(8) N. S. 
Median 7 16 12 
DM: Diabetes mellitus. SD: Standard Devi ation. N. S.: Not siFnificant 0*: onset of complication I  
same year as diabetes was diagnosed. A minus number Diagnosed before diagnosis of diabetes. 
Table 8.5: Time to development of complications in Type 2 nephropathy patients of 
different ethnic origin. 
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Proteinuria developed after retinopathy in all three groups and after 
hypertension in Indo-Asian and Black patients. In Indo-Asian patients there 
were positive correlations between time to development of hypertension and 
development of proteinuria (r=0.78, P<0.001) (Figure 8.5) and time to 
development of retinopathy and development of hypertension (r=0.85, P<0.001) 
(Figure 8.6). However, there was a non-significant correlation between onset of 
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Figure 8.5: Relationship between developmat of prateinuda and hypertension 
in Type 2 Indo-Asian nephropathy patients 
Regression analysis demonstrated that retinopathy was 72% predictive of the 
variance in time to development of hypertension in Indo-Asian patients 
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Figure 8-6: Relationship between onset of retinopathy and hypertension in Type 2 Inclo-Asian 
nephropathy patients 
In Black patients there were very strong positive correlations between onset of 
development of proteinuria and of hypertension (r=0.97, P<0.001) (Figure 8.7), 
between development of retinopathy and of hypertension (r=0.90, P--0.001) 
(Figure 8.8) and a weaker correlation between development of retinopathy and 
proteinuria (r=0.78, P<0.05) (Figure 8.9). Linear regression analysis 
demonstrated that onset of hypertension was 94% predictive of the variance in 
time to development of proteinuria (P<0.001); onset of retinopathy was 80% 
predictive of the variance in time to development of hypertension (P--0.001), 
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Figure 8.7: Relationship between development of hypertension and proteinuria in 
Type 2 Black nephropathy patients 
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Figure 8-8: Relationship between development of retinopathy and hypertension 















Figure 8.9: Relationship between development of proteinuria and retinopathy in 
Type 2 Black nephropathy patients 
In Black patients multiple regression analysis demonstrated that time to 
development of retinopathy and hypertension combined were 97% predictive of 
the duration of diabetes at onset of proteinuria with time to development of 
hypertension being statistically more significant (P<0.001) than time to onset of 
retinopathy (P<0.05). 
In White patients there were significant correlations between time to onset of 
retinopathy and development of proteinuria (r=0.82, P<0.001) (Figure 8.10), 
time to onset of hypertension and development of proteinuria (r=0.84, P<0.001) 
(Figure 8.11) and time to development of retinopathy and hypertension (r=0.83, 
P<0.001) (Figure 8.12). 
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Figure 8.10: Relationship between the development of proteinuria and retinopathy 
in Type 2 White nephropathy patients 
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Figure 8.11: Relationship between development of proteinuria and hypertension in 











Figure 8.12: Relationship between development of retinopathy and hypertension 
in Type 2 White nephropathy patients 
Regression analysis has shown that in White nephropathy patients time to 
onset of retinopathy was 69% predictive of the variance in time to onset of 
hypertension and 79% predictive of the variance in time to onset of proteinuria 
(P<0.001). Multiple regression analysis showed that combined time to 
development of retinopathy and hypertension were 81% predictive of onset of 
proteinuria but that only time to onset of retinopathy was statistically significant 
(P<0.001). 
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Indo-Asian Retinopathy and Hypertension 0.85 <0.001 72 
Hypertension and Proteinuria 0.78 <0.001 61 
Retinopathy and Proteinuria 0.39 N. S. 
Black Retinopathy and Hypertension 0.90 <0.001 80 
Hypertension and Proteinuria 0.97 <0.001 94 
Retinopathy and Proteinuria 0.78 <0.05 61 
White Retinopathy and Hypertension 0.83 <0.001 69 
Hypertension and Proteinuria 0.84 <0.001 71 
Retinopathy and Proteinuria 0.82 <0.001 79 
Levei oT signiTicance: FI<0.05 N. S. Not significant R-: mumpie correiation Co-eTTIcient 
Table 8.6: Relationship between time to development of retinopathy, hypertension and 
proteinuria in different ethnic groups 
There appeared to be a different relationship between the onset of retinopathy 
and the other two complications in Indo-Asian patients in comparison to White 
and Black patients (Table 8.6). 
When correlations between various clinical parameters were examined to 
assess if the relationship between two factors could identify potential risks for 
specific ethnic groups the following were found: In White patients the only 
correlation found between the following parameters: age, duration of diabetes, 
serum creatinine concentration, proteinuria, diastolic and systolic blood 
pressures, body mass index, HbAl at referral and over four years was between 
age and serum creatinine (r--0.40, P<0.05). Regression analysis demonstrated 
that age was 16% predictive of the variance in serum creatinine. 
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In Indo-Asian patients there was a weak negative correlation between diastolic 
blood pressure and creatinine (r= -0.49, P--0.05) plus a positive correlation 
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Figure 8.13: Relationship between BMI and HbAl at referral in Inclo-Asian Type 
2 patients with nephropathy 
In Black patients the correlation between serum creatinine and proteinuria was 
strong and positive (r=0.89, P<0.001) (Figure 8.14) as was the correlation 
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Figure 8.14: Relationship between proteinuria and creatinine in Black 
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Figure 8.15: Relationship between duration of diabetes and diastolic blood 




There was also a negative correlation between HbAl at referral and diastolic 
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Figure 8.16: Relationship between diastolic blood pressure and HbAl at 
referral in Black Type 2 nephropathy patients 
The only other differences between the groups were in smoking history and 
speaking English. More Indo-Asian patients had never smoked (n=14,82%) 
than either Black (n=6,60%) or White (n=14,41%) patients (P<0.05) and only 
41% (n=7) of Indo-Asian patients spoke English in comparison to 100% of the 
other two groups (P<o. ooj). 
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8.5.5 Results of Analysis of Larger Numbers of Patients 
Due to the very small numbers of patients in this matched comparison which 
made it impossible to assess statistical differences using Ch12 test, a second 
analysis was performed using ninety-seven Type 2 patients Le.: 32 Indo-Asian, 
13 Black and 52 White patients (the same group included in Chapter 9). The 
results of this analysis did not differ in a major way from the matched 
comparison except that the renal function results included serum creatinine 
concentrations above 300 gmol 1-1 and slightly higher urinary protein excretion 
levels. Chi2 tests were only valid in a few cases where complication rates were 
compared, because of the small number of Black patients (Table 8.7). Fisher's 










Peripheral neuropathy 8(25) 4(31) 30(58) <0.005 
Peripheral vascular disease 2(6) 3(23) 28(54) <0.001 
Hypertension 31(97) 13(100) 47(90) N. S. 
L-wvt: i vi bignincance: P'-<U. Ub N. S.: Not significant 
Table 8.7: Statistical significance of complications from larger ethnic analysis. 
A number of correlations were performed within each ethnic group, which 
included dichotomous and continuous variables, to identify any potential 
differences between the groups. There were several correlations, all of which 
were relatively weak, but were statistically significant. Those variables in which 
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the numbers were small (< 10) were not included (all correlations in Black 
patients fitted this category) (Table 8.8). 
Group Variables Correlation 
Co-efficlent (r) 
P 
Indo-Asian Retinopathy 0.36 <0.05 
Defaulting from clinic 
Gender / Not speaking English 0.52 <0.005 
Not speaking English 
/Defaulting from clinic -0.35 <0.05 
Not speaking English 
/Diastolic Pressure 0.38 <0.05 
White Peripheral neuropathy 0.30 <0.05 
Peripheral vascular disease 
Smoking history / -0.23 <0.05 
Systolic pressure 
Smoking history Hypertension -0.28 <0.05 
Systolic pressure Hypertension 0.47 0.001 
LUVUI or signITIcance: t--<u. u: ) 
Table 8.8: Correlation between variables in different ethnic groups from larger 
analysis. 
In Indo-Asian patients the significance of not speaking English and defaulting 
from routine diabetic clinic appointments appeared to be closely linked and also 
with the presence of retinopathy and level of diastolic blood pressure. Only 41 % 
of Indo-Asian patients in the matched analysis and 46% in the larger analysis 
spoke English and the majority of those (67%) who defaulted from diabetic 
clinic visits did not speak English. A history of smoking was linked with raised 
systolic pressure and hypertension in White patients. 
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8.6 Discussion 
This study, albeit in relatively small numbers of patients, has highlighted some 
similarities and differences between the three ethnic groups. The only 
difference in prevalence of macrovascular complications between the groups 
was the small proportion of Indo-Asian (n=2; 6%) patients with peripheral 
vascular disease in comparison to White patients (n=28,54%); this finding has 
been reported in other studies (Gujral et al, 1993; UK Prospective Diabetes 
Study Group, 1994). Similarly, there was a higher prevalence of peripheral 
neuropathy in White patients compared to both the Indo-Asian and Black 
groups. 
Although the prevalence of hypertension was similar in all of the groups, a 
larger proportion of Indo-Asian patients were receiving anti-hypertensive 
medication in comparison to the other two groups. Of those patients with 
treated hypertension, fewer White (27%) received a combination of different 
anti-hypertensive medications but still had the same mean blood pressure as 
Indo-Asian and Black patients, of whom 69% and 60% respectively were on 
combination therapy. Therefore, this may indicate that (a) Indo-Asian and Black 
patients had hypertension which may be more difficult to control (b) the medical 
staff were more open to prescribing combination therapy to these two groups, 
or (c) that the high prevalence of peripheral vascular disease in White patents 
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meant that reducing blood pressure levels in this group would have 
compromised the patients' peripheral vasculature. 
The statistically significant higher mean systolic pressure in patients With 
treated hypertension in the Indo-Asian group in comparison to untreated 
patients may be reflective of clinicians concentrating on treating diastolic 
hypertension and an acceptance of systolic pressures above the upper limit of 
normal except in cases where systolic pressures were considerably raised. The 
finding that patients in all three groups with treated hypertension were heavier 
than those with untreated hypertension not only suggests that being overweight 
contributes to hypertension but that clinicians were more open to prescribing 
anti-hypertensive therapy for larger patients. In White patients although the 
correlation between hypertension and smoking history was not strong it was 
significant especially as there was also a correlation between systolic pressure 
and a history of smoking in this same group. An Italian study of Type 2 patients 
with micro- and macroalbuminuda has demonstrated an increased risk of 
developing nephropathy associated with ex-smoking and this has been 
confirmed herein (Chapter 6) (Bruno et al, 1996). The EURODIAB study has 
shown that Type I patients who were ex-smokers had a higher prevalence of 
macroalbuminuria and proliferative retinopathy than current or non-smokers 
(Chaturvedi et al, 1995). The long term effects on both large and small blood 
vessels of diabetic patients having smoked at some point in their lives appear 
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to have a cumulative effect in people who are susceptible to developing 
nephropathy. 
The shorter duration of diabetes until onset of retinopathy, hypertension and 
proteinuria found in Indo-Asian patients suggests that this group may be 
developing these complications at an earlier stage of their diabetes than either 
Black or White patients. However, it is worth remembering that in Type 2 
diabetes the exact onset of diabetes is never actually known and diagnosis can 
occur some considerable time after the disease has developed, a finding 
confirmed by the presence of diabetic complications at diagnosis of diabetes in 
2% of Type 2 patients entered-into the UK Prospective Diabetes Study (UK 
Prospective Diabetes Study Group, 1994). 
The Indo-Asian group was the only group where there was an absence of a 
statistically significant correlation between the times of onset of retinopathy and 
proteinuria although there were strong correlations between the times to 
development of hypertension and proteinuria and of hypertension and 
retinopathy. In addition, Indo-Asian patients developed retinopathy at a 
significantly earlier duration of diabetes than the other two groups. These 
findings suggests that in Indo-Asian patients there was a different pattern In the 
development process of the three complications in relation to each other which 
was not obvious in the other two groups. One explanation of this may be that 
hypertension may be the link between retinopathy and proteinuria. Klein and 
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co-workers have demonstrated that systolic blood pressure predicts the 
incidence of retinopathy and diastolic pressure predicts the progression of 
retinopathy and it has been tentatively suggested that treatment with ACEI may 
decrease the progression of retinopathy in patients with normal blood pressures 
(Klein et al, 1989; Chaturvedi et al, 1998). 
The positive correlation between increasing age and serum creatinine in White 
patients was due to this group being older than the other two groups (difference 
in mean and median of 4-5 years, with a wider range) as renal function 
deteriorates with increasing age. In Indo-Asian patients the positive correlation 
between increasing BMI and HbAl at referral was to be expected in that, the 
more overweight a patient is the more difficult it is to control blood glucose 
levels. The two correlations with diastolic blood pressure found in Black 
patients were interesting: Increasing duration of diabetes correlated with 
increasing blood pressure and decreasing HbAl at referral correlated with 
increasing blood pressure. All of these may be related, Black patients with 
longer duration of diabetes and raised diastolic pressures who developed 
proteinuria may have received aggressive medical care in the diabetic clinic 
prior to referral which included addressing poor glycaemic control. However, 
the numbers in this group were too small for any substantial conclusions to be 
drawn. 
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Less than 50% of Indo-Asian patients in this study spoke English. This 
percentage is higher than has been previously reported in Wolverhampton, 
where it was found that only 26% of Indo-Asian patients attending diabetes 
education sessions, presented in Punjabi, spoke English (Wilson et al, 1993). 
However, a survey of Asian diabetic patients in Nottingham showed that 70% 
spoke English, therefore, the difficulty in communication with health care 
professionals may not be as widespread across the UX as the Wolverhampton 
figures suggest (Hawthorne, 1990). The weak but statistically significant 
correlations between not speaking English, defaulting from clinic visits and 
diastolic pressure cannot be ignored. Being unable to communicate with 
healthcare professionals may directly influence the patient's understanding of 
the importance of regularly attending the diabetic clinic. Previous research in 
Wolverhampton has demonstrated that patients who defaulted from routine 
diabetic clinic follow up have less contact with physicians and more 
complications than those who attended on a regular basis (Hammersley et al, 
1985). The association between not speaking English, defaulting from clinic 
and diastolic blood pressure would appear to be downward spiral for Indo-Aslan 
patients which needs to be broken. Therefore, the inability to speak English, 
which can prevent patients understanding their disease and how to manage it 
and which also appears to contribute to patients defaulting from clinic visits, 
must be regarded as an avoidable risk factor for diabetic complications 
including nephropathy. 
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The small number of patients in the analysis of ethnic groups has provided a 
view of the possible differences between the three groups but in order to 
statistically prove that there are differences, a much larger study would be 
needed to increase the power of the study and which would need to include a 
larger group of Black patients (Silman, 1995; Gordis, 1996). 
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8.7 Conclusions 
I Retinopathy, hypertension and proteinuria developed earlier in Indo- 
Asian patients than in either of the other two groups. Therefore, accept 
Hi (1): There were differences in presentation of nephropathy between 
the groups. 
2 White patients had a higher prevalence of peripheral neuropathy and 
peripheral vascular disease than the other two groups. Therefore accept 
Hi (2): There were differences in the prevalence of diabetic 
complications between White, Indo-Asian and Black Type 2 diabetic 
patients. I 
3 Fewer White patients with hypertension were receiving anti-hypertensive 
medication than either Indo-Asian or Black patients. 
4 The inability to speak English found in Indo-Asian patients was a risk 
factor for development of nephropathy and was linked to defaulting from 
routine clinic visits: Therefore accept Hi (3): There were risk factors for 
nephropathy specific to Indo-Aslan patients. 
5 In White patients age at referral was predictive of serum creatinine 
concentrations. In the other two groups there were no factors which were 
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associated with nephropathy that were specific to either ethnic group. 
Therefore, accept Hi (4): There were factors associated with 




Evaluation of the Effectiveness of Routine 
Nephrological Out-Patient Clinical Care on Survival and 
Assessment of Factors Which May Influence Survival in 
Patients with Diabetic Nephropathy 
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9.1 Introduction 
Both the Diabetes Control and Complications Trial in Type I diabetes and the 
United Kingdom Prospective Diabetes Study in Type 2 patients (both studies 
with large numbers of patients) have confirmed that diabetic nephropathy can 
be delayed by tight glycaemic control (Diabetes Control and Complications Trial 
Research Group, 1993; Turner et al, 1996). In 1982, Mogensen followed by 
Parving and colleagues (1983) demonstrated in studies With small numbers of 
patients (n=6 and n=12 respectively) that control of hypertension also prevented 
the progression of nephropathy, a finding that has been confirmed subsequently 
(Mogensen, 1982; Parving et al, 1983; The EUCLID Study Group, 1997). 
Despite this knowledge, diabetic nephropathy is increasingly a major cause of 
end stage renal disease and death. Within a five year period, the percentage of 
patients with diabetes who were receiving renal replacement therapy In 
Heidelberg in Germany had increased from 36% to 59% (Ritz et al, 1999). In 
other countries the percentage of deaths from end stage renal failure (ESRF) 
secondary to nephropathy is high e. g.: in Japan, 33% of cases of diabetes 
diagnosed over a 14 year period and in Missouri, USA, 54% of Type 2 In 
comparison to 10% of Type I patients died from ESRF (Diabetes Epidemiology 
Research International Mortality Study Group, 1991; Heilman et al, 1997). 
Once persistent proteinuria is established prognosis is poor: In two Danish 
studies 35% of patients with macroalburninuria died within five years and 44% 
of patients with overt nephropathy 'died within ten years (Parving, 1999). It Is 
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worth noting that in 1989, Parving and Hommel demonstrated that anti- 
hypertensive treatment in nephropathy patients reduced the cumulative death 
rate from ESRF over ten years to 18% in comparison to much higher rates in 
previous studies (Parving and Hommel, 1989). 
There are also reported differences in the characteristics of nephropathy in 
various ethnic groups including Indo-Asian and Black Type 2 patents who have 
increased prevalence and incidence of ESRF due to nephropathy and Pima 
Indians with nephropathy who have increased mortality rates from ESRF and 
cardiovascular disease (Nelson et al, 1988; Cowie et A 1989; Gujral et al, 
1997). Similarly, there is a high incidence of nephropathy in Japanese Type 2 
patients with early-onset of diabetes (Yokoyama et al, 1998). While comparison 
of Type 1 patients in Europe and the USA has shown an increased prevalence 
of nephropathy in the USA (Lloyd et al, 1996). 
This study is designed to evaluate whether routine follow up of nephropathy 
patients in a nephrology clinic affects rates of survival and whether there are 
differences in factors which influence survival in both types of diabetes and in 
different ethnic groups. 
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9.2 Objectives 
To determine whether routine follow up of patients in a nephrology clinic 
affects survival of diabetic patients with nephropathy. 
2 To determine whether different factors affect survival in Type 1 and Type 
2 nephropathy patients. 




Ho: Routine follow up in a nephrology clinic did not improve survival 
rates in Type 1 and Type 2 diabetic nephropathy patients 
Hi: Routine follow up in a nephrology clinic did improve survival rates 
in Type 1 and Type 2 diabetic nephropathy patients 
2 Ho: Survival time was the same in patients from different ethnic 
groups with diabetic nephropathy. 
Hi: Survival time was not the same in patients from different ethnic 
groups with diabetic nephropathy. 
3 Ho: There was no difference in factors which affect survival in Type I 
and 2 diabetic patients with nephropathy. 
Hi: There was a difference in factors which affect survival In Type 1 
and 2 diabetic patients with nephropathy. 
4 Ho: There was no difference in factors which affect survival in different 
ethnic groups. 
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Diabetic patients referred for nephrological assessment were followed up over a 
maximum period of twelve years (1987-1998) to assess the effect of normal 
clinical practice on survival. Normal clinical practice was defined as treatment 
determined by consultant nephrologists for individual patients and individual 
medical problems on an "intention to treat* basis; there was no written pre- 
determined protocol for treatment which could be followed by junior medical 
staff, although individual cases were discussed with the consultant. Follow up 
was defined as regular attendance at the out-patient clinic, though the number 
of visits per year varied according to the clinical condition of the patient 
Patients were excluded from the study if they were receiving renal replacement 
therapy at the study onset or if they had only one functioning kidney, as this 
may have affected the rate of decline of renal function. As patients were 
referred at different times over the twelve year period, length of follow up time 
varied from patient to patient. 
Data were collected from patients' hospital records on blood pressure 
measurements, serum creatinine concentrations, urinary protein levels, and 
glycaernic control as measured by HbAll (both pre and post-referral), over the 
time period since referral, as well as demographic data. Information on end 
points was also collected. 'The end points were: survival without reaching 
ESRF, need for renal replacement therapy (RRT), survival on RRT, death, 
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death following RRT and lost to follow up. Cumulative survival, using Kaplin- 
Meier curves and the Log rank test were used to compare equality of survival In 
Type 1 and Type 2 patients and in different ethnic groups. Cause of death was 
also recorded. In some cases, the causes of death could not be determined due 
to inability to locate patients' hospital records after death. Data collected at 
referral were the baseline data used to compare data collected annually in 
subsequent years up to year 7, from this time point numbers of patients were 
too low to reliably perform statistical analysis. 
A number of different parameters were examined to find the potential effect of 
these on survival. Hypertension was defined as a systolic pressure > 140 mm 
Hg or diastolic pressure > 90 mm Hg and this decided the "need for treatment". 
Age at renal referral, duration of diabetes, time from onset of overt proteinuria to 
renal referral, duration of diabetes until onset of proteinuria, systolic and 
diastolic blood pressures, serum creatinine, 24 hour urinary protein excretion, 
anti-hypertensive treatment (as measured by point scale, see Appendix 1) and 
presence or absence of this at baseline. AM of the above were compared In all 
of the Type 1 and Type 2 groups and, in addition, two other analyses were 
performed: 1) in three ethnic groups: Indo-Asian (people with ethnic origins In 
the Indian subcontinent whether born there or elsewhere): Black (people with 
ethnic origins in either Africa or the Caribbean, irrespective of place of birth): 
and White patients and 2) a subgroup analysis of Type I and Type 2 patents 
With serum creatinine levels below 120 ýtmol 1-1 (upper limit of normal) to 
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remove bias due to advanced renal disease. Cox regression analysis was 
performed and the Cox proportional hazard model was used to consider the 
above parameters in terms of cumulative survival and to determine hazard 
ratios for specific parameters. As the numbers of patients were small, a limit of 
three parameters was used together as covariates. 
Numerical data were analysed using Student West, categorical data were 
analysed using Chi2 test and Fisher's Exact Test when expected frequencies 
were less than 5. Analysis of variance was used to determine differences within 
groups of repeated measures and between the groups. Standard deviation 
(SD), standard error (SE) and 95% confidence intervals (CI) were used in 
Kaplin-Meier analysis, SE were not calculated if the number of deaths was less 
than the number of censored data. The level of significance was P<0.05. As the 
number of patients in the various groups analysed decreased to less than ten 
over the years of follow up, statistical analysis was only performed, if number of 
patients was greater than 10, except when Fisher's Exact Test was used. 
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9.5 Results 
9.5.1 Demographic Data 
From the original cohort of 47 Type 1 patients with nephropathy, three were 
excluded as they were receiving renal replacement therapy at the onset of the 
study. Forty-four Type 1 and 97 Type 2 patients were included; five Type 2 
patients with only one functioning kidney were excluded. 
There was no significant difference in gender ratio between the two groups, 
however, as expected, the Type 2 group had more Indo-Asian and Black 
patients than the Type I group (P<0.05) (Table 9-1). 





TOTAL 44(100) 97(100) 
GENDER 
Male 32(73) 65(67) N. S. 
Female 12(27) 32(33) N. S. 
ETHNic GROUP 
Asian 5(11) 32(33) 
Black 5(11) 13(13) <0.05 
White 34(78) 52(54) 
DURATION OF DM (years) 
Range 8-42 0-11 
Mean L+SD) 23 &) 13(+7) <0.001 
Median 23 14 
AGE AT REFERRAL (YEARS) 
RANGE 18-73 3"3 
MEAN (+SD) 44(+13) 61 &) <0.001 
MEDIAN 45 62 
UM: Diabetes mellitus SD: Standard deviation N. O.; Not 5191111IL; d[IL 
Table 9.1: Demographic data on nephropathy patients followed over an eleven 
yearperiod. 
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Mean duration of diabetes at nephrological referral was ten years shorter in the 
Type 2 group than in Type I patients (P<0.001). The mean age of the Type 2 
group was 17 years older than that of Type 1 patients (P<0.001). The mean 
(Type 1: 3 years; Type 2: 2 years) and median (I year in both groups) time to 
nephrological assessment after the second protein uria-positive dipstick test was 
similar in both groups (P--N. S. ). However, there was a stafistically significant 
difference between the groups in the time from onset of proteinuria to 
nephrological referral with Type 2 patients being referred more quickly [range: 
0-11 years; mean: 1.6 (SE+ 0.2) years] than the Type I group [range: 0-29 
years; mean: 3.3 (SE+0.8) years] (P<0.05). 
Twenty three (52%) of the Type 1 group in comparison to 25 (26%) of Type 2 
patients were alive at the end of the study while 3 (7%) of Type I and 13 (13%) 
of Type 2 patients were lost to follow up (P<0.01) (Table 9.2). 
End Points Type I 
n (%) 
Type 2 P 
ToTALs: 44(100) 97(100) 
Alive 23(52) 25(26) 
Dead 18(41) 59(61) <0.01 
Lost to Follow Up 3 (7) 13(13) 
SUBTOTALS: 
Patients on RRT: 
Alive 8(18) 3 (3) 
Dead 7(16) 13(13) 
Patients not on RRT: 
Alive 15(34) 22(22) 
Dead 11(25) 46(47) <0.005 
RRT: Renal replacement therapy 
Table 9.2: End points reached by nephropathy patients after an eleven-year period. 
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Three of the Type 1 group were alive after 11 years of follow up and three Type 
2 patients after ten years (Figure 9-1). Fifteen (34%) Type 1 patients and 16 
(16%) of the Type 2 group had received renal replacement therapy (RRT). 
There was no significant difference in mean time to starting RRT between the 
groups: Type 1: 3(SD+3) years and Type 2: 2(SD+2) years (P--N. S. ). Seven 
Type 1 and thirteen Type 2 patients on RRT had died (P<0.005) (Table 9.2). 
One Type 1 and seven Type 2 patients had died from ESRF without receiving 
RRT within a short time of referral (Type 1 time to death: 2 years and in Type 2- 
mean: 1 (SD+ 1) year). 




















Figure 9-1: Numbers of patients still alive at the end of each year of follow up 
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Comparison of systolic blood pressure recorded annually showed that there 
was no statistical difference in systolic pressure between the groups at baseline 
[Type 1; mean: 164 (SD+28) mm Hg versus Type 2; mean- 167 (SD+27)mm 
Hg]. Systolic pressures compared between baseline and year 1, had decreased 
in both groups (P<0.001). There were significant differences in systolic pressure 
between the groups in years 2,3 and 6 (P <0.05 in all three years) (Figure 9-2). 
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From year two onwards, Type 2 patients had higher systoliC pressures than the 




Figure 9.2: Comparison between Type 1 and Type 2 patients of mean blood 
pressures during follow up period 
significant difference over seven years of follow up, in either group, in systolic 
pressure from baseline to year seven (Figure 9.2). 
There was no difference in diastolic pressures between the groups at baseline 
[Type 1; mean: 92 (SD+ 12) mm Hg versus Type 2; mean: 90 (SD+17) mm Hg]. 
However, by the end of year 1 diastolic pressures in both groups had 
decreased and the difference from baseline was significant (P<0.005), as it 
was between years 1 and 2 (P<0.01). However, analysis of variance showed 
that the difference in diastolic pressures in both groups from baseline to year 
seven was not significant (Figure 9.2). 










Baseline Yearl Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 
Median: 
Figure 9.3: Points allocated for anti-hypertensive therapy in Type 1 patients over 
seven years 
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Thirty nine (86%) Type 1 and 87 (90%) of Type 2 patients were hypertensive at 
referral (P--N. S. ) Thirteen (33%) Type 1 patients and 46 (55%) of Type 2 
hypertensive patients were not receiving anti-hypertensive therapy (P<0.05). 
Over seven years there was a wide range for points (Appendix 1) for anti- 
hypertensive treatment in both groups of patients with median values frequently 
towards the bottom of the range in Type 1 patients (Figure 9.3 and 9.4). 










Baseline Year I Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 
Median 
Figure 9.4: Points allocated for anti-hypertensive therapy in Type 2 patients over 
seven years 
In four of the years, not including the baseline, hypertensive patients in both 
groups were not receiving drug treatment, which may have contributed to the 
persistent systolic hypertension observed in Type 2 patients. Type 1 patients 
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received more anti-hypertensive treatment at baseline than the Type 2 group. 
There was no difference between the groups in type of anti-hypertensive drugs 
used in treatment (P =N. S. ). Fifteen (38%) of Type 1 and 15 (17%) of Type 2 
patients were on ACEL Multiple anti-hypertensive therapy (more than one type 
of drug) was being used in the same percentages of both groups (duo therapy: 
21% and triple therapy: 8%) except for 2% of Type 2 patients who required 
quadruple therapy. However, when points for anti-hypertensive treatment, for 
those on treatment, were compared at baseline, there was no statistical 
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Figure 9.5: Comparison of mean points allocated for anti-hypertensive therapy over 
seven years of follow up in Type 1 and Type 2 nephropathy patients 
The difference in ant-hypertensive points between baseline and year one, 
which was statistically significant, demonstrated that the number of patients 
receiving anti-hypertensive treatment had increased in both groups (P<0.001) 
(Figure 9.5). However, there was no difference between baseline and 
subsequent years when all seven years were added (P--N. S. ) (Figure 9.5). Type 
2 patients had a higher overall mean point rating for anti-hypertensive treatment 
for the majority of the seven years than the Type I group. 
The ranges of serum creatinine levels at baseline were wide: Type 1: 65-858 
pmol 1-1 and Type 2: 65-1140 l. Lmol 1-1 with similar means in both groups: [Type 
1: 197 (SD+215) pmol 1-1 versus Type 2: 204 (SD+193) pMol I'll (P--N. S. ). 
There were significant differences in mean creatinine levels between the groups 
from baseline to year I (P<0.05) and between years I and 2 (P <0.001) (Figure 
9.6). However, analysis of variance showed that over a seven year follow up 
period there was no significant difference between the groups In creatinine 
concentrations. Proteinuria levels at baseline were similar in both groups (Type 
1; mean: 2.9 (SD+2.6) g 24hr' and Type 2; mean: 2.8 (SD+3.6) g 24hr' 
(P--N. S. ). 
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Figure 9-6: Comparison of mean serum creatinine levels over a nine year period: 
Type 1 versus Type 2 patients 
In those patients where cause of death was known, congestive cardiac failure 
was the most common cause in Type 1 patients (n=4; 22%) followed by ESRF 
(n=3; 17%) and cerebrovascular accidents (n=3; 17%). In Type 2 patients, 
ESRF was the most common cause of death (n=14,24%) followed by 
myocardial infarction (n=8; 14%) and 4 (7%) died of cerebrovascular accidents. 
The cause of death could not be ascertained in 4 (22%) Type 1 and 27 (46%) 
Type 2 patients making statistical analysis unreliable. 
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9.5.2 Survival Analysis 
Comparison of cumulative survival showed that the mean survival time in Type 
1 patients was 2978 (SE+: 217; 95% Cl: 2552,3404) days [mean=8 years] with 
a median of 3522 days (SE and 95% Cl. not calculated) [10 years] and in the 
Type 2 group the mean was 2106 (SE+: 141; 95 Cl: 1829,2382) days [mean = 
6 years] with a median of 2303 days (SE+ 353; 95% Cl: 1610,2996) [6 years] 
(Figure 9.7). The distribution of survival was not equal between the groups 
(X2 Logrank. 7.55, df--1, P<0.01). Twenty-six (59%) of Type 1 patients were either 
alive or lost to follow up and were therefore recorded in Figure 9.7 as censored 









Figure 9.7: Kaplin-Meier survival analysis in Type 1 and Type 2 nephropathy patients 
0 
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Five years after renal referral 68% of Type 1 and 44% of Type 2 patients were 
still alive (Table 9.3). 
Type of Patients Survival 
Diabetes 5 Years 7 years 10 years 
nN n (%) nN 
1 30(68) 19(43) 6(14) 
2 43(44) 28(29) 3 (3) 
Table 9.3: Patient survival at different time points: main group analysis 
Five Type I and two Type 2 patients had received renal transplants. Of the 
Type 1 patients, two had survived for 11 years post-transplant, one for nine 
years, one for six and one had died after nine years. One of the Type 2 patients 
had survived for seven years and the other, the only Indo-Asian patient, had 
died seven years post-transplant. By the end of five years, 80% of Type I and 
50% of Type 2 patients receiving RRT were still alive after renal referral (Table 
9.4). 
Type of DM Patient Survival 
(n on RRT) 5 Years 7 years 10 years 
n (%) n (%) nN 
1 (15) 12(80) 10(67) I 3(20) 
2 (16) 8(50) 6(38) 1(6) 
um- uiawes meintus 
Table 9.4: Survival in Type 1 and Type 2 patients having renal replacement therapy 
over 10 year period 
The mean cumulative survival in Type I patients on RRT was 3081 (SE+: 316; 
95% Cl: 2462,3699) days [8 years] with a median of 3522 (SE+: 506; 95% Cl: 
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2530,4515) days [10 years] in comparison to a mean of 1934 (SE+ 207,95% 
Cl: 1332,2535) days [5 years] a median of 2306 (SE+1473; 95% Cl: 0,5192) 
days [6 years] in Type 2 patients receiving RRT. The distribution of survival in 
Type 1 and Type 2 patients receiving RRT was not the same (X2 Logrank: 7.39, 






Figure 9-8: Kaplin-Meier survival curve in Type 1 and Type 2 patients receiving renal 
replacement therapy 
00 
In the Type 1 group, adjusted for gender, there was no difference in cumulative 
survival in women patients, mean of 3073 (SE: + 348; 95% Cl: 2391,3755) days 
[8 years] and median: 2295 (SE and 95%Cl not calculated) days [6 years] in 
comparison to men-, mean: 2124 (SE+ 222; 95%Cl- 1689,2560) days [6 years] 
and median: 2609 (SE+883; 95% Cl: 879,4339) days [7 years] (X2 Logrank: 3.07, 
df--1, P--N. S. ) (Figure 9.9). 
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Figure 9.9: Kaplin-Meier cumulative survival, adjusted for gender, in Type 1 patients 
In Type 2 patients, cumulative survival adjusted for gender showed that in 
women both the mean and median were longer: mean: 2865 (SE+ 255; 95% Cl: 
2364,3366) days [8 years] with a median of 3522 (SE+682; 95% Cl: 2185, 
4859) days [10 years]) than in men (mean: 2068 (SE+172; 95% Cl: 1730,2406) 
days [6 years]) with a median of 2247 (SE+282; 95% Cl: 1695,2799) days [6 
years] (X2 Logrank: 0.72, df=1, P--N. S. ) (Figure 9.10). 
P--N. S. 
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Figure 9.10: Kaplin-Meier cumulative survival, adjusted for gender, in Type 2 patients 
The data for all patients indicated that current smoking status was not a 
significant potential factor affecting survival when adjusted for type of diabetes. 
9.5.3 Other Factors Affecting Survival 
A number of variables were assessed for significance in terms of survival and 
hazard using the Cox proportional hazards model in individual groups and when 
adjusted for type of diabetes. Table 9.5 lists the results for those variables, 
which were significant, or where the hazard ratio was increased, these will be 
discussed individually within this results section. 
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Type DM - Variable P SE Wald 
0 
P exp P 
(HR) 
95% Cl 
Type I Age 0.0609 0.0212 8.2822 0.0040 1.0628 1.0196.1.1079 
Type 2 Age 0.0512 0.0175 8.6028 0.0034 1.0525 1.0171.1.0892 
Adjust TDM Creat. Base 0.0020 5.338xlO'4 13.999 0.0002 1.0020 1.0010.1.0030 
Type 2 Creat. Base 0.0032 6.43xl 0'4 24.00 0.0000 1.0032 1.0019.1.0044 
Adjust TDM Age + 0.0553 0.0142 15.2549 0.0001 1.0569 1.0280.1.0869 
Creat. Base 0.0020 5.538xlO'4 12.6518 0.0004 1.0020 1.0009.1.0031 
Adjust TDM Dur. DM 0.332 0.0168 3.9215 0.0477 1.0338 1.0003.1.0683 
Adjust TDM Dur. DM + 0.0255 0.0166 1.8383 0.1752 1.0228 0.9900,1.0566 
Age 0.0520 0.0135 14.7839 0.0001 1.0524 1.0258,1.0817 
Type I Time to Prot. 0.0556 0.0285 3.8164 0.0508 1.0578 0.9998.1.1178 
Adjust TDM Prot. Base 0.0819 0.0302 7.3301 0.0068 1.0853 1.0229.1.1516 
Type I Prot. Base 0.2766 0.0891 9.6659 0.0019 1.3187 1.1077.1.5700 
Type I Untreated HT. 0.1712 0.3765 0.2067 0.6493 1.1867 0.5673.2.4824 
Type 1 Systolic Yr. 3 0.0623 0.0274 5.1564 0.0233 1.0643 1.0086,1.1231 
Type 2 Current Smoke 0.2268 0.2868 0.6252 0.4291 1.2546 0.7151,2.2012 
I JF%. nct4dru rauO I um: I ype of diabetes ureat: ureatinine uoncentration uur uuration 
Base: baseline DM: Diabetes mellitus Prot: Proteinuda Cl: Confidence Intervals 
HT: Hypertension 
Table 9.5: Cox proportional hazards model: Assessment of Influence of variables on 
survival in Type 1 and Type 2 nephropathy patients 
Cox regression analysis showed that age at referral was a statistically 
significant factor in cumulative survival in both Type I and Type 2 (P<0.005 
both groups) with the hazard ratio (HR) being similar In both groups (1.06 
versus 1.05) (Table 9.5). 
When data were adjusted for type of diabetes, duration of diabetes was a 
statistically significant factor for cumulative survival (HR=1.03, P<0.05) (Table 
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9.5). The addition of age as a covariate, resulted in durafion of diabetes 
becoming non-significant (HR=1.02, P--N. S. ) but age was highly significant 
(HR=1.05, P<0.001) (Table 9.5). The individual addition of systolic or diastolic 
pressures at baseline, as covariates, did not change the statistical significance. 
Serum creatinine at baseline was another factor that was significant for 
cumulative survival when data were adjusted for type of diabetes (1-111=11.0, 
P<0.001) (Table 9.5). When the groups were analysed separately, it was still 
significant in Type 2 patients (HR=1.00, P<0.001), but not in the Type I group 
(P--N. S. ) (Table 9.5). Separate addition of systolic and diastolic pressures at 
baseline as covariates to creatinine levels at baseline, resulted In creatinine 
being the only significant factor for survival (P<0.001). 
When adjusted for type of diabetes, proteinuria at baseline was a significant 
factor for survival (HR=1.09, P<0.01), but when the groups were investigated 
separately, proteinuria at baseline was very significant in Type I patents 
(HR=1.3, P<0.005) but not in the Type 2 group (P =N. S. ) (Table 9.5). 
In those patients with hypertension, the absence of anti-hypertensive therapy 
was not a significant factor on cumulative survival but in Type I patients the 
hazard ratio was increased (HR=1.2) (Table 9.5). In Type I patients systolic 
pressure in year 3 after referral was a significant factor in survival (P<0.05) 
although the HIR was only slightly raised (1-111=11.06). Current smoking also 
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increased the hazard ratio (HR=1.25) in Type 2 patients although this was not 
significant (P--N. S. ) (Table 9.5). 
Hypertension, systolic (except in year 3) and diastolic pressures at baseline and 
for the seven subsequent years, a history of smoking, glycaemic control (HbAl) 
at baseline, and for 5 years pre- and 5 years post-baseline, or defaulting from 
clinic visits were not significant factors in cumulative survival in either group. 
9.5-4. Comparison of Data Between Ethnic Groups 
The maximum survival time in White patients was 11 years in Type 1 patients 
(n=3) and 10 years in the Type 2 group (n=l) (Figure 9.11). One Indo-Asian 
and one Black patient survived for 10 years (both Type 2), two Black Type 1 
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Figure 9.11: Numbers of patients surviving at the end of each year in each ethnic 
group 
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Analysis of variance demonstrated that duration of diabetes in Type 1 White 
patients was significantly longer (mean: 25(SD+8) years] than in Indo-Asian 
[mean: 17 (SD+4) years] and Black [mean: 18(SD+5) years] Type 1 patients 
(P<0.05) but there was no difference in Type 2 patients (Figure 9.12) 











I-A: Indo-Asian T: Type of diabetes Mean: 
Figure 9.12: Comparison of duration of diabetes in different ethnic groups 
There was no statistical difference in mean age, gender, systolic and diastolic 
pressure at baseline or in time to onset of proteinuria between the ethnic groups 
in either Type 1 or Type 2 patients. 
Analysis of variance showed that there was no difference in serum creatinine 
concentration at baseline between the three ethnic groups (P--N. S. ). However, 
there was a statistically significant difference, in all three groups, between 
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I-A TI I-A T2 Black TI Black T2 White TI White T2 
creatinine at baseline and year 1 (P<0.001) and when year 2 creatinine was 
added as a covariate, between baseline and year 2 (P<0.05) (Figure 9.13). By 
year 6 there were no differences from baseline in creatinine levels. By year 
seven, the number of patients was low in both the Black and Indo-Asian groups, 
thus making analysis unreliable. Black patients tended to have the highest and 
Indo-Asian patients the lowest creatinine levels. 








Figure 9.13: Mean serum creatinine levels over seven years: Comparison of ethnic 
groups 
Comparison of systolic blood pressure between baseline and year 1, showed 
that this significantly decreased (p<0.001), and there was no difference due to 
ethnicity (Figure 9.14). When year 2 was added as a covariate, again there was 
a significant difference in all three groups (f)---o. 01) as there was when year 3 
was added (P<0.05). There were no significant differences in systolic pressure 
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after year 3, possibly due to the small numbers of Indo-Asian and Black 
patients. There was a statistically significant difference between diastolic 
pressure at baseline and at year 1 (F'--0.001) but not between baseline and year 
2, although by year 3 the difference had again become significant (P'--0.05) 
(Figure 9.14). There was no data for Black patients in year seven. None of 
these differences were due to ethnicity although Black patients had higher 
systolic pressures over the first four years. After year 3, there were no statistical 
differences in diastolic blood pressure at baseline and subsequent years. 
Indo-Asian: Mean Systolic Black: Mean Systolic 
--&-White: Mean Systolic Indo-Asian: Mean Diastolic 
-Black: 











Figure 9.14: Systolic and diastolic blood pressures over seven years: Comparison of 
ethnic groups 
Thirty one (84%) of Indo-Asian, all 18 (100%) Black and 75 (87%) of White 
patients were hypertensive at baseline (P<0.05) with 13 (42%) Indo-Asian, 8 
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(44%) Black and 36 (49%) of White hypertensive patients not receiving anti- 
hypertensive treatment (P--N. S. ). Of those with treated hypertension, 19 (40%) 
White, 8 (32%) Indo-Asian and 3 (30%) Black patients were on ACEI while 7 
(70%) Black, 13 (52%) Indo-Asian and 18 (38%) White patients required more 
than one type of anti-hypertensive drug. 
At baseline less than 25% of each of the groups had systolic pressures below 
or equal to the upper limit of normal (<140 mm Hg) (Figure 9.15). From years 1 
to 4, Black patients had the worst controlled systolic pressure but this improved 
as the numbers of patients decreased in years 5 and 6, due to the deaths of 
patients with the highest systolic pressures. Indo-Asian patients, had the best 
control With up to 47% having normal systolic pressures during the first four 
years. In year 5,50% of white patients, the maximum percentage achieved in 
this group, had controlled systolic hypertension (Figure 9.15). 
Diastolic pressure was better controlled than systolic pressure. Over 60% of 
Indo-Asian and White patients and 47% of Black patients had diastolic 
pressures below or equal to the upper limits of normal (< 90 mm Hg) at baseline 
(Figure 9.16). From year 1 onwards, the lowest percentage with diastolic 
pressures within the normal limits was 60%. 
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Figure 9.15: Percentage of patients with systolic pressures within normal limits over 
seven years: Comparison of ethnic groups 
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Figure 9.16: Percentage of patients with diastolic pressures within normal limits over seven 
years; comparison of different ethnic groups 
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JO Indo-Asian 13 Black 0 White 
When points for blood pressure treatment at baseline were compared (for those 
receiving anti-hypertensive treatment) Indo-Asian and Black patients had higher 
mean point ratings (31) than White patients (21) although this was not 
statistically significant. Indo-Asian patients had a wider range of points over 
seven years in comparison to White patents (Appendix 1). In both groups there 
were patients who required anti-hypertensive therapy who did not receive any 
for four out of the seven years. Black patients had the smallest range for points 
of anti-hypertensive therapy. By year 1, the points rating had increased in each 
group [Indo-Asian: 42; Black: 39; White: 36 (P'--N. S. for ethnicity)] however, this 
was a statistically significant increase from baseline (P<0.001) and explains the 
decrease in both systolic and diastolic pressures in year 1. There were no 
significant differences in points rating from baseline in years 2 and 3 (years 4 
onwards were not analysed due to small numbers). 
Mean proteinuria at baseline was similar in all three ethnic groups: Indo-Asian: 
2.8 (SD+2.9) g 24hr', Black: 3.6 (SD+2.4) g 24hr' and White: 2.7 (3.4) g 24hr' 
patients (P--N. S. ). 
Cause of death was not known in 21 (24%) White and 10 (27%) Indo-Asian 
patients. End stage renal failure was the commonest known cause of death in 
White patients: n=13 (15%) in comparison to 2 (11%) Black and 2 (5%) Indo- 
Asian patients. Three (16%) Black patients died of myocardial infarctions in 
comparison to 5 (6%) White and 1 (5%) Indo-Asian patients. Three (16%) Black 
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patients died of congestive cardiac failure in comparison to 2 (2%) White and 2 
(5%) Indo-Asian patients. Cerebrovascular accidents were responsible for 2 
(11 %) deaths in Black patients, 3 (3%) in White patients and 2 (5%) Indo-Asian 
deaths. Statistical analysis was not performed due to the large number of 
deaths from unknown cause. 
9.5.5 Comparison of Survival in Dderent Ethnic Groups 
There was no statistical difference in cumulative survival in Indo-Asian Type 1 
and Type 2 patients (X2 Logrank: 0.18, df=l, P--N. S. ) (Figure 9.17). 
1.0 




Figure 9.17: Kaplin-Meier cumulative survival in Indo-Asian (I-A) nephropathy 
patients 
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The mean for the Type 1 Indo-Asian group was 2598 (SE: 215; 95% Cl: 2178, 
3019) days [7 years] in comparison to Type 2 patients; mean: 2360 (SE. 246; 
95% Cl: 1878,2842) days [6 years] with medians of 2768 (SE+O [n=5,2 deaths 
and 3 censored)) days [7years] (Type 1) versus 2765 days (SE+489; 95% Cl: 
1825,3705) [7 years] (Type 2). 
Similarly, there was no statistical difference between the groups in cumulative 
survival in Black patients (X2 Logrank: 0.02, df=l, P--N. S. ) (Figure 9.18). The mean 
for Type 1 patients was 2093 (SE: + 582; 95% Cl- 953,3233) days [6 years] in 
comparison to the mean for the Type 2 group of 2107 (SE+ 387; 95% Cl: 1260, 
2775) days [6 years] with medians of 2086 (SE+1084; 95% Cl: 0,4212) days [6 
years] (Type 1) versus 1616 days (SE+501; 95% Cl- 635,2597) [4 years] (Type 
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Figure 9.18: Kaplin-Meier cumulative survival in Black nephropathy patients 
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However, the cumulative survival in Type 1 White patients was significantly 
longer; mean: 3050 (SE+ 248; 25% Cl: 2565,3535) days [8 years] than in the 
Type 2 group; mean: 1950 (SE+ 184; 95% Cl: 1589,2310) days [5 years] with 
medians of 2240 days [6 years] (Type 1) and 2247 (SE+416; 95% Cl: 1431, 
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Figure 9.19: Kaplin-Meier cumulative survival in White nephropathy patients 
When adjusted for ethnic group, there was a significant difference in equality of 
survival distribution (X2 Logrank: 7.97, df=l, P--0.005) presumably due to the 
differences in survival time between Type 1 and Type 2 White patients. 
Six (16%) Indo-Asian, four Black (22%) and 21 (24%) White patients received 
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RRT (F'--N. S. ). There was no statistical difference in equality of survival 
distributions when adjusted for RRT and ethnic group (X2 Logrank: 0.22, df--lq 
P--N. S. ) or when compared with patients who did not receive RRT (x2uvrar*: 
0.30, df=I, P--N. S. ) (Table 9.6). 
Ethnic Group Cumulative Survival 
On RRT (days) 
Cumulative Survival 
Without RRT (days) 
P 
INDO-ASLAN 
Mean (+SE) 1924(535) 2565(245) 
[95% Cl] [875,2972] [2084,3046] 
Median L+SE) 2306(1817) 3217(579) 
[95% Cl] [0,2867] 12083,4351) 
Black 
Mean (+SE) 1505(345) 2142(385) 
[95% Cl] [828,2182] [1388,2896] N. S. 
Median L+SE) 890(668) 1616(1184) 
[95% Cl] [0,2199] [0,3937] 
White 
Mean (+SE) 2802(292) 2236(183) 
[95% Cl] [2230,33731 11707,2787] 
Median L+SE) 3052(410) 2247(272) 
[95% Cl] [2249,3857] [1879,25941 
KK 1: Renal replacement therapy SE: Stanclara trror u. %, onnuencu 'Intavd1b 
N. S.: Not significant 
Table 9.6: Cumulative survival for different ethnic groups dependent on treatment with 
renal replacement therapy 
After five years of follow up, 67% of Indo-Asian, 25% of Black and 76% of White 
patients were still alive. By ten years of follow up, 17% of Indo-Asians, 25% of 
Black and 43% of White patients were still alive. 
In Black patients who were current smokers the mean survival time was 889 
(SE+269; 95% Cl: 362,1417) days [2 years] With a median of 1096 (SE+891, * 
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95% Cl: 0,2842) days [3 years] in comparison to non-current smokers where 
mean survival time was 2529 (SE+ 376; 95% Cl: 1791,3267) days [7 years] 
with a median of 2550 days [7 years]. The equality of survival distribution was 
(X2 found not to be equal Logrank: 5.99, df=1, P<0.05) (Figure 9.20). There was no 
difference in survival time between current smokers and non-smokers in the 
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Figure 9.20: Kaplin-Meier cumulative survival in Black patients due to current smoking 
habits 
Cox regression analysis showed that Black patients who were current smokers 
had an increased hazard ratio (HR) of 4.57 (P=0.25) (Table 9.7). A history of 
smoking was also a significant factor in reducing survival in black patients 
(H R=4.62, P=O. 0 17) (Ta ble 9.7). 
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9.5.6 Other Factors Affecting Survival 
Several variables were assessed fbr significance in terms of survival and 
hazard using the Cox proportional hazard model in individual groups, when 
adjusted for ethnicity and when adjusted for type of diabetes. Table 9.7 lists the 
results for those variables which were significant or where the hazard ratio was 
increased, and these will be discussed individually within this results section. 
When adjusted for ethnicity. serum creatinine at baseline was a significant 
factor in survival (P=0.001) however when adjusted for type of diabetes as well, 
this parameter was more significant in Type I patents (P<0.01) than in the 
Type 2 group (F'--0.01). When ethnic groups were assessed separately, serum 
creatinine at baseline was more statistically significant in Black patients 
(HR=1.01; P--0.004) than in either Indo-Asian (HR=1.00; P--0.015) or White 
patients (HR=1.00-, Fl--0.046) (Table 9.7). Despite the significance of these 





Variable SE Wald 
o? ) 
P e-xp P 
(HR) 
95% Cl 
ADJUST E Creat. Base 0.0017 -5. -12xl 0' 10.3826 0* 0013 1.0017 1.0006,1.0027 
WHrrE Creat. Base 0.0012 5.88x1O *4 3.9958 0.0456 1.0012 1.0000,1.0023 
BLACK Creat. Base 0.0075 0.0026 8.29 0.004 1.0075 1.0024,1.0126 
INDO-ASLAN Creat. Base 0.0035 0.0015 5.8753 0.0154 1.0035 1.0007,1.0064 
WHrrE Age Referral 0.0627 0.0143 19.2289 0.0000 1.0647 1.0353,1.0950 
ADJUST E 
TYPE 1 Age Referral 0.0471 0.0176 7.1956 0.0073 1.0483 1.0128,1.0850 
ADJUST E 
TYPE 2 Age Referral 0.0541 0.0211 6.5753 0.0108 1.0556 1.0128.1.1001 
WHrrE Age Referral 0.0627 0.0143 19.2289 0.0000 1.0647 1.0353,1.0950 
ADJUST TDM Age Refer+ 0.0640 0.0186 11.7941 0.0006 1.0001 1.0279,1.1058 WHrrE Creat Base 0.0018 6.726xl 0-4 6.8547 0.0088 1.0018 1.0004,1.0031 
AojUSTTDM Age Refer + 0.0331 0.0311 1.1313 0.2875 1.0337 0.9725.1-0987 BLACK Creat Base 0.0091 0.0035 6.5924 0.0102 1.0091 1.0022,1.0162 
ADJUST TDIVI Age Refer + 0.0204 0.0356 0.3285 0.5666 1.0206 0.9518,1.0944 INDO-ASLAN Creat Base 0.0029 0.0015 3.6165 0.0572 0.0572 0.9999,1.0060 
INDO-ASIAN Time to Renal 0.2238 0.9260 5.843 0.0156 1.2508 1.0432.1.4997 
Referral 
ADJUST E Not Speak 0.5433 0.2460 4.8770 0.0272 1.7217 1.0630.2.7884 (INDO-ASIAN) English 
ADJUST TDM Not Speak INDO-ASLAN English 0.5573 0.2604 4.5823 0.0323 1.7460 1.0482.2.9084 
ADJUST SEx Not Speak INDO-ASLAN English 0.8324 0.3158 6.9491 0.0084 2.2989 1.2380,4.2688 
MALE Not Speak INDO-ASIAN English 0.9676 0.3468 7.7826 0.0053 2.6316 1.3335,5.1934 
FEMALE Not Speak INDO-ASIAN English 0.3595 0.5484 0.4297 0.5121 1.4326 0.4890.4.1967 
INDO-ASIAN Prot. Base 0.2857 0.0997 8.2114 0.0042 1.3307 1.0945,1.6180 
13LACK Prot. Base 0.1752 0.0882 3.9441 0.0470 1.1915 1.0023,1.4165 
BLACK CUrrent Smoke 1.5194 0.6793 5.0028 0.0253 4.5697 1.2068,17.303 
13LACK 
L 
Smoke History 1.5323 0.6421 5.6954 0.0170 4.6290 1.3151.16.294 
a--tio E. Ethnicity -TDW. Ty Haz-a-rd-Rt pe of diabetes Creat Serum creatinine Concentration l3ase*R. q4zPiin= D-+-D, +. ýmwita rl- rnnfidpnna intervals 
Table 9.7: Cox proportional hazards model assessing influence of variables on survival in 
ethnic groups. 
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Age at referral was also a statistically significant factor for survival in both 
groups (P<0.01) when adjusted for ethnicity, (HR=1.05 in both groups). In White 
patients age at referral was very significant (P<0.001, HR=1.06). Age and 
creatinine at baseline together, adjusted for type of diabetes, were significant 
covariates in White patients (age: P<0.001; creatinine: P<0.01; although the HR 
was very close to 1.00) unlike Black patients (age: HR=1.03, P--N. S.; creatinine: 
HR=1.01, P<0.01, ) and Indo-Asian patients (age: HR=1.02, P--N. S.; creatinine: 
HR=1.00, P--N. S. ). 
In Indo-Asian patients, time between onset of proteinuria and nephrological 
referral was a significant factor in cumulative survival (HR=1.25, P<0.05, ) unlike 
White and Black patients, although the median time to referral in all three 
groups was I year. The inability to speak English was also a significant hazard 
for survival in Indo-Asian patients (HR=1.7, P<0.05). When gender was added 
as a covariate to inability to speak English in Indo-Asian patients, male patients 
had an increased HR=2.63 (F'--0.005) in comparison to women (HR=1.43, 
F'-N. S. ) 
When adjusted for ethnic group, proteinuria level at baseline was a statistically 
significant factor for survival (P<0.005) posing a greater hazard in Indo-Asian 
(HR=1.33, P<0.005) and Black patients (HR=1.19, P<0.05) than in White 
patients (P--N. S. ) (Table 9.7) 
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When adjusted for ethnicity and when systolic pressure at baseline was added 
as a covariate to proteinuria at baseline, the statistical significance of 
proteinuria decreased (P<0.05) while systolic pressure had no significant effect 
on survival. Removal of systolic pressure as a covariate and addition of diastolic 
Pressure at baseline maintained the significance of proteinuria at baseline 
(P<0.005) but diastolic pressure was not significant. The addition of both 
systolic and diastolic pressure as covariates resulted in the significance of 
proteinuria decreasing (F'--0.01). In the individual ethnic groups, both systolic 
and diastolic pressures at baseline (added as separate covariates) decreased 
the significance of proteinuria in Indo-Asian patients (systolic: P<0.05; diastolic: 
P<0.01). 
Defaulting from routine clinic visits, systolic and diastolic pressures at baseline 
up to year 3 after referral or MAI results either at baseline, for 5 years pre, or 5 
years post-baseline examination were not significant as factors in survival. 
9.5.7 Subgroup Analysis of Type I Versus Type 2 Patients 
To remove any potential bias due to the presence of advanced renal disease at 
referral, a further analysis was performed. From the original 141 patients 
included in the survival analysis, all patients with serum creatinine levels above 
the upper limit of the normal range (120 gmol 1-1) and those who had received 
RRT Were excluded leaving 22 Type I and 42 Type 2 patients. The 
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demographic data were still very similar to the original cohort of patients 
described in Table 9.1, except that the percentage of White Type 2 patients had 
decreased from 54% to 45% in the subgroup (Table 9-8). 





Number 22 42 
Male 15(68) 26(62) N. S. 
Female 7(32) 16(38) 
Indo-Asian 3(14) 19(45) 
Black 2(9) 4(10) <0.05 
White 17(77) 19(45) 
Duration of DM (years) 
Range 8-39 1-26 
Mean (+SD) 22(8) 13(7) <0.001 
Median 20 14 
Age (years) 
Range 21-73 39-83 
Mean (+SD) 43(14) 60(9) <0.001 
Median 42 60 
N-S.: not significant SD: Standard deviation um: ummes memm 
Table 9.8: Demographic data for subgroup analysis Type I versus Type 2 nephropathy 
patients 
As expected from results in preVious chapters, duration of diabetes at onset of 
Proteinuria was shorter in the Type 2 group [mean: 12 (SD_+7) years versus 
Type 1: 20 (SD+9) years] (P<0.001). However, there was no statistical 
difference between the groups in the time to nephrological referral from the 
diabetic clinic; Type 1 mean: 2 (SD+2) years versus Type 2 mean: 1(SD+I) 
year (FI-N. S. ). 
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The groups were well matched for creatinine concentrations at referral; the 
range in both groups was 65-120 ýt mol 1-1 with a mean in Type 1 patients of 93 
(SD+15) ýt mol 1-1 and median of 92 ýt mol 1-1 in comparison to the Type 2 group: 
mean: 98 (SD+ 14) g mol 1-1 and median of 98 g mol I-'. 
Twelve (55%) Type 1 and 15 (36%) Type 2 patientS had defaulted from routine 
diabetic clinic visits (PI--N. S. ). A smaller proportion of Type 2 patients were 
current smokers (Type 2: n=14,33% versus Type 1: n=9,41%) (P--N. S. ) and 
55% of both groups had never smoked. 
Three (14%) of the Type 1 group and 1 (2%) of the Type 2 patients had 
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At the end of the twelve year follow up period, 13 (59%) of Type 1 and 16 (38%) 
of Type 2 patients were still alive (Table 9.9) but each patient had been followed 
up for different lengths of time. 
End Point Typi- -1 Type 2 P 
n (%) n M) 
Alive 13(59) 16(38) 
Dead 7(32) 18(43) N. S. 
Lost to Follow up 2(9) 8(19) 
Table 9-9: End points reached in subgroup analysis 
Analysis of variance showed that there was a statistically significant difference 
between baseline creatinine levels and year 1 (P<0.05) and in each subsequent 
year until year 4 to year 5 (Figure 9.22). 






0123 Year 4 Creat: Mean Creatinine 
Figure 9.22: Subgroup analysis: Mean serum creatinine concentration over 7 
years of follow up 
-313- 
However, when the change between baseline and year 5 was compared, this 
was not statistically significant. Due to the small, number of patients in the Type 
2 group from year 5 onwards, further analysis was not performed. The decline 
in renal function, as assessed by mean inverse creatinine against time, was 
similar in both groups (P--N. S. ). 
Mean systolic blood pressure at baseline was similar in both groups [Type 1: 
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Analysis of variance showed that there was a statistical difference in systolic 
pressure between baseline and year 1 in both groups (P<0.001). However, 
there was no difference between baseline up to and including year 5 or 
between the groups (P--N. S. ). There was no statistical difference in diastolic 
pressure at baseline between the groups (F'---N. S. ). However, there was a 
statistically significant difference between diastolic pressure between baseline 
and year 1 (P<0.01) but no difference between baseline up to and including 
year 5 (F'---N. S. ). Nineteen (86%) Type I and 34 (81%) Type 2 patients were 
hypertensive at baseline (P--N. S. ); 4 (21%) Type 1 and 17 (50%) Type 2 of 
those with hypertension were not receiving anti-hypertensive medication. 
Analysis of variance showed that there was a significant difference between 
those who needed anti-hypertensive treatment and those who actually received 
it (P <0.01). 
At baseline only 9 (41%) Type I patients and 11 (27%) of the Type 2 group had 
systolic pressures within the normal range (< 140 mm Hg) (Figure 9.24). Over 
the next seven years, systolic pressure remained poorly controlled in Type 2 
patients; the maximum percentage of Type I patients achieving normal systolic 
Pressures was 78% in year 5 (Figure 9.24). There was a higher proportion of 
patients in both groups with diastolic pressures within the normal limits L< 90 
mm Hg); Type 1: n=13 (59%) and Type 2: n=26 (63%). The minimum 
percentage of patients in both groups with diastolic pressures within normal 
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Figure 9.24: Percentage of Type I and Type 2 subgroup patients with systolic pressures 
below the upper limit of normal (<140 mm Hg) 
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Figure 9.25: Percentage of Type 1 and Type 2 subgroup patients with diastolic pressure 
below the upper limit of normal (<90 mm Hg) 
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IN Type 1 Systolic M Type 2SptolhIc] 
9.5.8. Survival Analysis of the Subgroup 
The mean survival time in the subgroup analysis for Type 1 patients was 3039 
(SE+231; 95% Cl: 2587,3491) days [8 years] (median 2626 days (SE not 
calculated: 7 years) and for the Type 2 group was 2676 (SE+190,, 95% Cl: 
2304,3048) days [7 years] (median 3217 (SE + 684; 95% Cl, 1877,4577) days: 
9 years); there was no difference in survival distribution between the groups 
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Figure 9.26: Kaplin-Meier cumulative survival in subgroups of Type 1 and Type 2 
patients 
Five and seven year survival was better in the subgroup analysis than in the 
main study (Table 9.10). 
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Type of DIVI Patient Survival 
(Group) 5 Year 7 Year 10 Year 
n (%) n (%) n (%) 
1 (Main) 30(68) --- 19(43) 6(14) 
1 (Subgroup) 16(73) 11(50) 3(14) 
2 (Main) 43(44) 28(29) 3(3) 
2 (Subgroup) 26(62) 15(38) 1(2) 
um: uiames menitus 
Table 9.10: Comparison of survival in main and subgroup over 5,7 and 10 years 
Female patients survived for one year longer (mean: 3103 (SE+241; 95% Cl: 
2630,3575) days [8 years] than male patients (mean: 2727 (SE+ 188; 95% Cl: 
2358,3096) days [7 years] 
Wugrank: 1.46, df=l, P--N. S. ) There was no 
significant difference between the groups in surVival time for each sex. 
9.5.9 Other Factors Affecting survival of Subgroup Patients 
When adjusted for type of diabetes, duration of diabetes, time to onset of 
proteinuria, time to renal referral, defaulting from routine diabetic clinic visits, 
current smoking, history of smoking, hypertension, presence of and lack of anti- 
hypertensive therapy in hypertensive patients at baseline and points for blood 
pressure treatment were not significant factors on survival. 
A number of variables were assessed for their influence on survival. Those 
which were statistically significant or increased the hazard ratio are listed in 
Table 9.12. Age at referral was a significant factor for survival when adjusted for 
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type of diabetes (HR=1.1, P<0.001) and separately for each group (Type 1: 
HR=1.1, P<0.05; Type 2: HR=1.1, P<0.005) (Table 9.11). When adjusted for 
type of diabetes, serum creatinine at baseline was also a significant factor in 
cumulative survival (HR=1.1, P <0.05), despite all values being within the 
normal limits (Table 9.11). On individual group analysis, creatinine levels at 
baseline were sig nificant for survival in Type 1 patients (H R= 1.1, P<0.0 1) only. 
Type -DM 
- - - - - 
Variable SE Wald 
(X2) 
P Exp 0 
(HR) 
95% Cl 
9d YJ u Fst T DM Age 0.1014 -0.0262 15.006 0.0001 1.1067 1.0514,1.1650 
Type 1 Age 0.0906 0.0374 5.8577 0.0155 1.0949 1.0174,1.1783 
Type 2 Age 0.1102 0.0351 9.8341 0.0017 1.1165 1.0422,1.1961 
Adjust TDM Systolic Yr 1 0.0347 0.0123 8.0117 0.0046 1.0353 1.0107.1.0605 
Type 1 Systolic Yr 1 0.0644 0.0230 7.8166 0.0052 1.0665 1.0194,1.1158 
Type 2 Systolic Yr 2 -0.0340 0.0152 5.0233 0.0250 0.9666 0.9383.0.9957 
Type 1 Diastolic Yr 1 0.0679 0.0301 5.0913 0.0240 1.0702 1.0090,1.1352 
Type 2 Diastolic Yr 2 -0.912 0.0344 7.0284 0.0080 0.9128 0.8533,0.9765 
Type I Creat. Base 0.0731 0.0280 6.8163 0.0090 1.0759 1.0184.1.1366 
Type I Creat. Base + 0.0947 0.0347 7.4432 0.0064 1.0993 1.0270.1.1767 
Systolic Base 0.0248 0.0156 2.5278 0.1119 1.0251 0.9942.1.0561 
Type 1 Hypertension 0.2055 0.5417 0.1439 0.7044 1.2281 0.4248,3.5510 
Adjust TDM Untreated HT. 0.2354 0.4285 0.3019 0.5827 1.2655 0.5464,2.9310 
Type I Untreated HT. 0.2033 0.5408 0.1414 0.7069 1.2255 0.4246,3.5373 
Type 2 Time to Refer. 0.3692 0.1536 5.7537 0.0165 1.4465 1.0699.1.9558 
- .. -- -ýGmlu I OUU I UIVI* , ype or ujames TV Tear LFedL.. %., I WCILII III I- HT: Hypertension Refer Referral Cl: Confidence intervals 
Table 9.11: Cox proportional hazards model assessing influence of variables on 
survival in subgroup analysis. 
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When creatinine at baseline was added as a covariate to age at referral, neither 
factor was significant in Type 1 patients although age was still statistically 
significant in Type 2 patients (HR=1.1, P<0.005). Creatinine levels in year 1 
were also statistically significant for survival in Type I patients (HR=. 1.05, 
P<0.05) but not in the Type 2 group. 
Systolic pressure over six years was assessed on an annual basis for its effect 
on survival in each of the groups. Systolic pressure at baseline was not a 
significant factor affecting survival in either group, however, in year 1 it was a 
significant factor in Type 1 patients (HR=1.1, P<0.01) [mean systolic pressure 
year 1: 149(SD+25) mm Hg; 5% decrease from baseline mean (four patients 
had either died or were lost to follow up)] but not in the Type 2 group. In year 2, 
systolic Pressure was significant in Type 2 patients (HR=1.00, P<0.05) (mean 
systolic pressure: 158 (SD+27) mm Hg; 5% increase from mean in year 1 (nine 
patients had either died or were lost to follow up)], however, patients with 
Systolic pressures below the mean had a slightly decreased HR (0.97). When 
systolic pressures from baseline to year 3 were added as covariates, none of 
these were significant factors on survival. The mean systolic pressure in Type 1 
patients decreased to below 140 mm Hg by year 2 and remained below this 
level until year 7. In contrast, in Type 2 patients the mean systolic pressure 
remained above 150 mm Hg from year 2 onwards (Figure 9.23). The addition of 
Systolic pressure in year 1 to creatinine concentrations in year 1 as a covariate 
showed that in Type 2 patients systolic pressure was a significant factor 
-320- 
affecting survival (HR=1.1, P<0.05) and that creatnine was not but in the Type 
I group only creatinine, was statistically significant (HR=1.1, P<0.01) (Table 
9.11). 
Diastolic pressure over six years was also assessed on an annual basis for 
effect on survival in each of the groups. Diastolic pressure at baseline, in both 
groups, was not significant in terms of survival. In year 1, diastolic pressure in 
Type I patients was significant (HR=1.1, P<0.05) [mean diastolic pressure: 86 
(SD+12) mm Hg; 4% decrease from baseline mean (four patients had either 
died or were lost to follow up)] but in Type 2 patients it was not. In year 2, 
diastolic pressure was a significant factor in survival in Type 2 patients (P<0.01) 
[mean diastolic year 2: 81 (SD+13) mm Hg; 2% decrease on mean in year I 
(nine patients had either died or were lost to follow up)], patients with a diastolic 
below the mean had slightly decreased HR (0.91) (Table 9.11). When diastolic 
Pressure at baseline and in years I and 2 were added as covariates, none of 
these were significant factors in survival in Type I patients. However, in the 
Type 2 group the significance of diastolic pressure in year 3 increased 
(F'--0.005) while diastolic pressures in the other two years were not significant. 
In Type 1 patients the mean diastolic pressure dropped from 90 mm Hg at 
baseline to 86 mm Hg by year 1 and remained at or beneath this level until year 
7. Mean diastolic pressure in Type 2 patients was lower at baseline than in 
Type 1 patients (85 mm Hg) and by year 2 had gone up to 89 mm Hg and 
decreased until year 5 (Figure 9.25). 
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Assessment of systolic and diastolic pressures, as covariates in year 2 showed 
that in Type 1 patients systolic pressure was a significant factor on survival 
(P<0.05) but diastolic pressure was not. Neither systolic nor diastolic pressures 
were statistically significant to survival in Type 2 patients. A similar analysis was 
performed for systolic and diastolic pressures in year 3 which showed that 
neither parameter was statistically significant for survival in either Type I or 
Type 2 patients. 
Glycaemic control (HbAI) was assessed as a factor in survival using data from 
baseline, years 1-4 pre-baseline and years 1-4 post baseline. When adjusted 
for type of diabetes, no individual year was a significant factor. However, when 
years 1-4 pre-baseline were analysed together as covariates, HbAl in year 3 
before referral was a significant factor (F'--0.05) as was HbAl in year 4 before 
referral (F"-0.01). Mean HbAl for years 1 to 4 pre-baseline were 12% for each 
year. Neither the baseline nor post baseline HbAl readings were significant 
factors in survival. 
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9.6 Discussion 
9.6.1 Differences Between Type I and Type 2 Patients in Terms of Survival 
In the main analysis, 32% of Type 1 and 56% of Type 2 patients had died by 
the end of year five of follow up and 86% Type 1 and 97% of Type 2 by the end 
of year 10. In contrast, the five year survival in the subgroup analysis (patients 
with baseline creatinine levels within the normal range) was higher with only 
27% of Type 1 and 38% of Type 2 patients having died, in Type 1 patients, 10 
year Survival was the same as the main analysis (86%) and in Type 2 patients 
98% had died. Although seven year survival was better in the subgroup 
analysis (50% of Type 1 versus and 43% in main group and 38% of Type 2 
subgroup versus 29% in main group). These results can be compared to the 
Danish studies described by Parving (1999) where 35% of Type 2 patients with 
macroalburninuria had died within 5 years and 44% of Type 1 patients with 
overt nephropathy had died within 10 years (Parving, 1999). In the subgroup 
analysis, Type 2 survival was similar over five years but in both the subgroup 
and main studies Type I survival was worse over ten years than the Danish 
studies. However, it is worth noting that numbers of patients in this study were 
considerably smaller than either of the Danish studies. These results do 
highlight two important points, firstly the main analysis included patients with 
advanced renal disease many of whom required RRT or died from ESRF within 
the first few years of follow up and secondly, that patients with proteinuria and 
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normal creatinine levels appear to have an increased chance of survival for up 
to seven years following renal referral but from then onwards there was no 
difference in survival between the groups. In those patients who received RRT, 
five year survival was 80% in Type 1 and 50% in Type 2 patients, results which 
appear to be favourable in comparison to a study in Germany where 40% of 
Type 1 and 10% of Type 2 patents had survived on RRT for five years and a 
study in Italy where 5 year survival for all diabetic patients on dialysis was 34% 
again, the small numbers in the present study may make comparisons 
unrealistic (Marcelli et al, 1996; Ritz et al, 1999). 
The main analysis has shown that Type 1 patients have a longer mean survival 
time than the Type 2 group. However, the subgroup analysis has shown that 
there was no difference in survival time between Type I and Type 2 patients. 
This implies that nephropathy patents with serum creatinine levels above the 
normal limits have a reduced survival rate in comparison to those with normal 
creatinine levels. It is also worth noting that a higher proportion of Type 1 
patients received RRT and thus survival time may have been extended. Type I 
patients receiving RRT also had a longer survival time than Type 2 patients on 
RRT, Possibly due to more Type 2 patients dying from renal failure, despite 
receiving dialysis. Female Type 2 patients survived for longer in the main 
analysis but there was no difference in the survival times between the sexes in 
either group in the subgroup analysis. This may have been secondary to there 
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being similar proportions of female patients in each group in the subgroup 
analysis, unlike the main analysis where there was a preponderance of men. 
Type 2 patients in the main analysis were referred more quickly for 
nephrological assessment than Type 1 patients, but this was not true in the 
subgroup analysis. There were two explanations for this a) some Type 1 
patients had developed proteinuria long before the referral process started plus 
treatment with ACEI for nephropathy patients started in the diabetic clinic in 
1984 therefore Type I patients would already have been receiving appropriate 
treatment and b) that once the referral process was in place, Type 2 patients 
were referred as soon as persistent proteinuria was diagnosed rather than 
waiting until the patients' renal function had significantly deteriorated. 
The Type 1 group were younger than Type 2 patients in both the main and 
subgroup analysis. Age at referral was a significant factor on survival in both 
groups and in both analyses despite the almost twenty year age difference 
between the groups. Duration of diabetes was longer in the Type 1 group but 
was not a significant factor on survival in either analysis, unlike the Type 2 
group where duration was shorter and was a significant factor on survival in the 
main analysis only. However, when age was added to duration, duration was no 
longer a factor in survival but age was. A Japanese study of early-onset Type 2 
patients, where the duration of diabetes was longer (mean: 23 years) than 
patients in this study (mean: 13 years), has shown that duration was a 
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significant independent factor in survival but this may be secondary to the fact 
that Type 2 diabetes is common in young Japanese people whose extended 
duration of diabetes is similar to that of Type I patients at the onset of 
Proteinuria (Yokoyama et al, 1998). The results of this study also contrast with 
an age stratified study of survival in Pima Indians with Type 2 diabetes on RRT 
where Nelson and co-workers demonstrated that duration of diabetes was an 
independent risk factor for survival (Nelson et A 1996). In the shorter duration 
Type 2 patients in the present study, there may have been other pre-existing 
risks Le.: risk factors for cardiovascular disease which were present even 
before diagnosis of diabetes. 
In the main analysis, creafinine concentrations at baseline were significant in 
the Type 2 group only, possibly due to the wider range of values than in Type 1 
patients, but in the subgroup analysis baseline creatinine levels (within normal 
limits) were significant only in Type 1 patients despite the close matching of this 
parameter in both groups. It could be postulated that the younger age of these 
patients may have been relevant to the significance of serum creatinine levels 
Le.: the levels may have been higher than the norm for younger people, 
however, there was no confirmation of this using the Cox proportional hazard 
model. In a Chinese study of Type 2 patients, plasma creatinine was found to 
be a predictive factor for mortality despite the mean value at the start of the 
study being within normal limits, although the range was wide, however, in 
those patients who died mean plasma creatinine was raised (Chan et al, 1995). 
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The comparison of these two studies again highlights the difference between 
the main and subgroup analysis in this study, reinforcing the advantage for 
survival in Type 2 patients with normal creatinine levels at baseline. 
At referral, the majority of patients (86%) in both groups were hypertensive with 
one third of Type 1 patents and 55% of Type 2 who needed anti-hypertensive 
treatment not receiving treatment. Hypertension both contributes to and is 
caused by renal disease, therefore the need to control blood pressure is all 
important in delaying the progression of nephropathy and improving survival; 
the efficacy of various anti-hypertensive drugs in nephropathy patients has 
been extensively researched (Sawicki et al, 1995; Leese and Vora, 1996; 
Parving, 1999). It would appear despite this knowledge that our cohort of 
patients were not being treated appropriately. However, the EURODIAB IDDM 
Complications study has shown that in a large European cohort of Type 1 
patients, of those with hypertension only 42% were on anti-hypertensive 
treatment and that only 11 % of those With hypertension had blood pressures 
which Were treated and controlled (Collada-Mesa et al, 1999). The authors have 
suggested that this is due to the lack of understanding that physicians have of 
the vital importance of controlling blood pressure in patients with diabetes, 
despite the evidence from research and the clear guidelines on treatment of 
hypertension in diabetes which exist in many countries. 
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In this study both groups had systolic hypertension at baseline, although this 
was not a significant factor in survival. Between baseline and the first year, anti- 
hypertensive treatment increased which produced a decrease in both systolic 
and diastolic pressures. However, in the subgroup analysis only, the systolic 
pressures in year 1 became a significant factor for survival in Type 1 patients. 
This poses an interesting question because systolic pressure in the Type 1 
subgroup remained below the upper limit of normal (140 mm Hg) from year I 
onwards. Possibly, deaths and patients lost to follow up during this first year, 
may have influenced the significance of systolic pressure by the end of the first 
year in the Type I group. In year 2 having a systolic pressure below the mean 
value conferred a slightly reduced hazard for survival in Type 2 patients. 
In the Type 2 group the mean systolic pressure was above the upper limit of 
normal throughout the whole study. There was also an increase in both mean 
Systolic and diastolic pressures in the Type 2 subgroup from the initial decrease 
from baseline to year 1, from year 2 onwards both remained virtually 
unchanged probably due to some patients who were hypertensive not receiving 
treatment. However, it could also be that a) anti-hypertensive treatment was not 
effective, b) dose levels were too low, c) the medical staff were aiming to treat 
diastolic hypertension without considering systolic hypertension, d) blood 
pressure was resistant to treatment, or e) that because these were older Type 2 
patients the need to aggressively reduce blood pressure was not thought to be 
as important as in younger Type 1 patients or 0a combination of these factors. 
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In the subgroup analysis, diastolic pressures were better controlled than in the 
main analysis and the levels in each group reflected changes in the systolic 
Pressures previously discussed. A number of studies have shown associated 
systolic hypertension with nephropathy while Vestbo and colleagues have 
shown that systolic blood pressure was related to urinary albumin excretion in 
diabetic and non-diabetic subjects (Cooper et al, 1987; Klein et al, 1988; 
Nielsen et al, 1993; Vestbo et al, 1995). These previous studies indicate that 
Type 2 patents in Wolverhampton are not unique in having raised systolic 
pressure in connection with nephropathy. The lack of anti-hypertensive therapy 
at baseline was a significant factor for survival in Type 2 subgroup patients 
increasing the hazard ratio to 1.5. However, in the Type 1 group, although lack 
of anti-hypertensive treatment increased the hazard ratio to 1.2, this was not 
significant; these results also underline the need for aggressive treatment of 
hypertension in nephropathy but more especially in Type 2 patients. 
In the main analysis, other parameters were not significant as independent risk 
factors for survival Le.: a history of smoking, defaulting from routine diabetes 
clinic follow up and HbAl levels over five years pre- and post referral. Current 
smoking although it was not a significant factor in survival was a hazard in Type 
2 patients. 
However, in the subgroup analysis, HbAl levels at years 3 and 4 pre-referral 
were significant when adjusted for type of diabetes and in combination with 
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other pre-referral HbAl values. It may be possible that the turning point in terms 
of changes in renal function occurred around three to four years before renal 
referral especially as the median time between onset of proteinuria and referral 
was one year in both groups. Patients may have developed microalbuminuria 
up to three years before developing overt proteinuria. Cooper and co-workers 
found that in both Type 1 and Type 2 patients the mean duration of the 
microalbuminuric phase of nephropathy was 3 to 4 years which correlates with 
the Significance of MAI in years 3 and 4 pre-referral as a factor in survival in 
this study (Cooper et al, 1987). 
In those patients where cause of death was known, a higher proportion of Type 
2 patients died from ESRF (24%) than Type 1 (17%). However, 22% of Type I 
patients died from cardiac failure and it would have been useful to know how 
many of these patients were in renal failure. ESRF results in congestive cardiac 
failure and it has been reported that many patients in renal failure have cardiac 
failure recorded in Part I of the death certificates (Joint Working Party of Renal 
Association et al, 1989). The large percentage of deaths in each of the groups 
where the cause was not known highlights the problem of tracking patients' 
hospital notes following death. 
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9.6.2 Dderences Between Ethnic Groups in TerTns Of Survival 
Type 2 diabetes is more common in Indo-Asian and Black patients than Type I 
and in this study the numbers of Type 1 patients in these two ethnic groups was 
low (Mather and Keen, 1985; Simmons et al, 1989; Cowie et al, 1989; Simmons 
and Powell, 1993; Perneger et al, 1994). Several studies have shown that both 
Black and Indo-Asian patients have an increased risk of developing ESRF. It 
could be assumed that this is secondary to the higher incidence of Type 2 
diabetes in both groups; however, Cowie and co-workers have found a higher 
incidence of Black patients reaching ESRF even after adjusting for the high 
incidence of Type 2 diabetes in Black people (Cowie et al, 1989; Burden et al, 
1992; Roderick et al, 1994). 
In this study, the three ethnic groups were well matched in terms of age, sex, 
systolic and diastolic pressures and duration of diabetes in Type 2 patents. 
However, Type 1 White patents had a longer duration of diabetes than either 
Type 1 Indo-Asian or black patients, which may be secondary to the small 
numbers of Type 1 patients in the other two ethnic groups rather than to a real 
difference. Previous studies in Leicester have shown an increased incidence of 
nephropathy in Indo-Asian men in comparison to Indo-Asian women and White 
patients which was not confirmed in this study where there was a higher ratio of 
men: women (2.9) in the White group while the ratio in both Black and Indo- 
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Asian groups was lower and similar (1-6 and 1.5 respectively) (Burden et a/, 
1992; Koppiker et al, 1998). 
White patients with Type 1 diabetes survived for longer after renal referral than 
Type 2 patients but there was no difference in survival in either Indo-Asian or 
Black patients when type of diabetes was compared. However, there was a 
significant difference in survival, when adjusted for ethnic group, possibly due to 
the longer survival time in Type 1 White patients. This longer survival time in 
Type 1 White patients cannot be explained by some of those patients having 
received RRT because there was no difference between the groups in mean 
survival of patients on RRT or between survival in those patients receiving RRT 
and those not. This increased survival time in White Type 1 patients reflects the 
Poor prognosis for Type 2 patients with nephropathy, as discussed previously. It 
is worth noting that Cowie and co-workers (1994) have shown in the USA that 
survival of Black patients on dialysis is longer than that of White patients unlike 
the present study. 
The dramatic difference in survival in Black patients who were current smokers 
(mean 2 years) in comparison to those who were not (mean 7 years) and the 
Substantially increased hazard ratio (4.6) probably reflects the increased risk of 
death from cardiovascular disease and in particular from hypertensive disease 
in Black people, in conjunction with increased mortality risk in these diseases 
associated with smoking; in the present study 73% of known causes of death in 
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Black patients were due to cardiovascular disease (Raleigh et a/, 1996). This 
view is reinforced by the observations that 100% of Black patients in the 
present study were hypertensive at baseline, that 56% of those were not 
receiving anti-hypertensive therapy and that for the first few years of the study 
Black patients had persistent systolic hypertension (less than 30% had 
controlled systolic pressures) while 30% also had uncontrolled diastolic 
pressures. 
The significance of serum creatinine concentration at baseline in all three 
groups, but with hazard ratios close to 1.0, suggests that although serum 
creatinine was a factor in survival, as expected because these patients were 
known to have renal disease, in itself it did not contribute a serious hazard. The 
addition of age to serum creatinine showed that both were factors in survival in 
White patients although together neither were in Indo-Asian patients and only 
creatinine was in Black patents although the mean age for all three groups was 
similar. Interestingly, Cowie and co-workers found that age in Black patients 
reaching ESRF was higher than in White patients, a finding that would be 
difficult to extrapolate to the cohort in the present study based on age at referral 
(Cowie et al, 1989). Serum creatinine was lower in Indo-Asian patients for the 
first two years which may explain the decrease in significance of this factor 
when age was added. 
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Despite the similarities in mean proteinuria at baseline, proteinuria was a more 
significant factor in survival in Indo-Asian patients than in Black patients, with 
increased hazard ratios in both, but was not significant in White patients. When 
this is considered, along with the lower mean serum creatinine levels in Indo- 
Asian patients at baseline and the significance of time to renal referral after 
development of overt proteinuria as an independent factor in survival in this 
group only (despite the mean time to referral being similar in all three groups), 
these factors suggest that proteinuria is a major risk factor in Indo-Asian 
patients in comparison to the other two groups. The increased risk posed by 
Proteinuria may be related to the increased prevalence of nephropathy, 
Previously demonstrated in this ethnic group (Gujral et al, 1997). 
The inability to speak English in Indo-Asian patients, a factor which may 
considerably disadvantage patients in terms of understanding how to monitor 
and care for their diabetes, was a significant hazard for survival especially in 
men. This was not surprising as many Indo-Asian patients in Wolverhampton 
neither speak nor read English (Wilson et al, 1993). It was perhaps not 
surprising that it was more of a hazard in men than women, given that 83% of 
male patients in comparison to 60% of females who died did not speak English. 
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9.6.3 Comments on the Methodology 
This study was based entirely on normal clinical practice without any 
predetermined criteria for commencing anti-hypertensive therapy at specific 
blood pressure levels. Instead, physicians made decisions based on the 
patients condition at each clinic visit (as they normally would). This resulted in a 
useful insight into how blood pressure control is managed in nephropathy 
patients over a number of years in a clinical setting. However, a protocol 
detailing examination techniques, biochemical investigations and the levels of 
diastolic and systolic blood pressure at which treatment should be instigated as 
well as anti-hypertensive drugs and dosages may have improved blood 
Pressure control, assuming that declining renal function was not the reason that 
hypertension was not controlled, it is likely that this would also have improved 
survival as other research has shown (Rossing et al, 1996). 
The difficulty in locating the medical records of patients who had died resulted 
in a distinct lack of information on the cause of death in many patients. This 
could have been avoided if the patients' records had been marked in advance 
as being part of a research project. 
The relatively small number of patients in this study provide information on 
survival in people with nephropathy in wolverhampton but made it difficult to 
compare these results with results from much larger studies elsewhere. 
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9.7 Conclusions 
I Early referral of patients with proteinuria and serum creatinine 
concentrations within normal limits appeared to increase seven year 
survival in both Type 1 and 2 diabetic patients with nephropathy. 
However, this may reflect the natural progression of nephropathy in that 
people with serum creatinine levels within the normal limits would take a 
longer time to reach end stage renal failure than those with creatinine 
concentrations above the upper limit of normal. 
2 Five year survival on RRT was better than in other studies in both types 
of diabetes. 
3 Age at referral in both the younger Type 1 and the older Type 2 patents 
was a significant factor in survival. 
4 Creatinine concentration at referral, even when within normal limits, was 
a significant factor for survival in Type 1 patients (HR=1.1). 
5 Untreated hypertension at renal referral increased the risks for survival in 
Type I patients (HR=1.2). 
-336- 
6 Blood pressure levels over the two years after referral were significant for 
survival in patients with creatinine concentrations within normal limits at 
referral. 
7 In Type 2 patients systolic hypertension remained uncontrolled 
throughout the entire follow up period. 
8 Type 1 White patents survived for longer than White Type 2 patients. 
9 Current smoking was a significant risk to survival in Black patients 
(HR=4.6) 
10 There was no difference in survival time following RRT between the 
ethnic groups. 
11 Black patients had the worst controlled systolic hypertension. 
12 ProteinUria at baseline was a hazard for survival in Black patients 
(HR=1.2). 
13 Indo-Asian patients had lower serum creatinine levels for the first two 
years, had an increased risk to survival from proteinuria levels at 
baseline (HR=1.3) and from the length of time to renal referral after 
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developing persistent proteinuria (HR=1.3). These suggest a major 
difference in nephropathy in Indo-Asian patients which cannot be further 
explained by this study. 
14 The inability to speak English was a significant hazard to survival in Indo 
-Asian patients (HR=1.7), especially in men (HR=2.6). 
9.7.1 Summary of Conclusions 
1 Routine follow up of patients in a nephrology clinic appeared to improve 
survival in Type I and 2 nephropathy patients with serum creatinine 
levels within the upper limit of normal, however, without performing a 
controlled trial to assess survival in patients with the same creatinine 
concentrations either attending a nephrology clinic or not, it would be 
inappropriate to either accept or reject Ho(l). 
2 Survival time was not the same in patients from different ethnic groups, 
therefore, accept Hi(2). 
3 There was a difference in factors which affect survival in Type 1 and 2 
nephropathy patients as well as similarities, therefore, accept Hi (3). 
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There was a difference in factors which affect survival in patients from 
different ethnic groups, therefore, accept Hi (4). 
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Chapter 10 
Review of the Thesis 
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10.1 , Novel Aspects of the Research 
This - project specifically studied nephropathy in the diabetic population of 
Wolverhampton, a subject which has not been researched previously in this 
town. Wolverhampton has a mixed ethnic population, with a higher percentage 
of Indo-Asian (12%, 1995) than Black people (5%, 1995), high levels of 
unemployment and social deprivation [using the Townsend score of material 
deprivation: 35% of the wards in Wolverhampton had the highest Townsend 
Score Le.: severe deprivation, with only 10% having a score in minus figure Le.: 
an indication of affluence (Hutchby et al, 1996)]. 
All of these factors contribute to poor health and an increased burden on health 
care services in that Indo-Asian people have a higher incidence of coronary 
artery disease, diabetes and nephropathy than the indigenous population, Black 
people have a high incidence of diabetes, nephropathy and a higher death rate 
from hypertension related causes, while low income and social deprivation can 
lead to poor nutrition, amongst many other things, which in turn may exacerbate 
the difficulties in controlling diet in people with diabetes (Allawi et al, 1988; 
Odugbesan et a/, 1989; Cowie et al, 1989; Burden et al, 1992; Perneger et al, 
1994; Raleigh et al, 1996; Shaukat, 1995; Gujral et A 1997). Thus in 
Wolverhampton, the population is potentially more at risk of developing both 
diabetes and nephropathy than in an affluent town with a predominantly White 
employed population. Added to this are the difficulties in communicating with 
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Indo-Asian patients who neither speak nor read English and the cultural 
differences between White and Indo-Asian and possibly Black patients which 
influence the approach and perceptions of each of these ethnic groups to 
diabetes (Wilson et al, 1993; Greenlaugh, 1997). Other places with populations 
containing substantially sized ethnic groups have been well researched in terms 
of diabetes (Coventry and Southall) and nephropathy (Leicester) but this has not 
been done previously in Wolverhampton (Mather and Keen, 1985; Simmons et 
al, 1989; Gujral etal, 1997). 
The data collected for this project reflected normal clinical practice rather than a 
formal research protocol. A research project performed Within the limitations of a 
structured protocol detailing methods of examination, upper limits of blood 
Pressure for treating hypertension etc. would have provided results which would 
certainly have differed from those obtained; there is individual variation in the 
decision -making processes of clinicians during normal clinical practice in 
comparison to decisions made when implementing a structured research 
Protocol. The evidence provided by this project on the lack of anti-hypertensive 
therapy received by nephropathy patients in Wolverhampton has highlighted the 
difficulties of maintaining blood pressure control within a clinical setting despite 
the widespread knowledge that effective anti-hypertensive treatment can delay 
the Progression of nephropathy (Mogensen, 1982; Parving et al. 1983). It was 
reassuring that in the EURODIAB study the same lack of effective hypertension 
management was observed across Europe and that this was not a problem 
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specific to Wolverhampton (Collada-Mesa et A 1999). However, these results, 
which cover eight years of treatment, have identified an area of clinical care that 
needs to be addressed and improved. 
The concept of combined diabetes and nephrological clinical management of 
patients with nephropathy was new in Wolverhampton in 1987 and the medical 
care provided by this combined approach has been assessed during this project. 
Combined clinical care has been encouraged by both diabetic physicians and 
nephrologists with the belief that it would lead to improved prognosis for 
nephropathy patients. However, in this study, the overall benefits in terms of 
survival were similar to previous reports, primarily due to the difficulties in 
controlling hypertension. 
The Study of nephropathy in different ethnic groups, although only a "snap-shot" 
of the problem due to the small sample sizes, has identified that difficulty in 
speaking English in Indo-Asian patients is linked to defaulting from routine 
diabetic clinic follow up, the presence of retinopathy, raised diastolic pressure 
and ultimately the risk of death from nephropathy. The results of the present 
study highlight the need to provide health care which can meet the needs of all 
people in the population by ensuring (a) adequate numbers of health care 
Professionals who speak the languages of minority groups and (b) that health 
promotion/education is presented in languages that people understand. 
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10.2 This Research in the overall Perspective of Research into Diabetic 
- Nephropathy 
The study of mortality in diabetic and non-diabetic people in Wolverhampton 
aimed to provide an insight into the conditions which were responsible for deaths 
in both groups of people and to place nephropathy, as a fatal complication of 
diabetes, into context within the Wolverhampton diabetic population. The 
increased risk of death from cardiovascular disease in diabetic women in 
comparison to diabetic men and non-diabetic women found in the present study 
has been identified in previous research (Kannel and McGee, 1979; Moss et al, 
1991). An interesting aspect of this part of the study was the consistently high 
mortality over ten years from cardiovascular disease in non-diabetic people in 
Wolverhampton, results which reflect the high levels of cardiovascular disease in 
the general population (Kelleher et al, 1994; Hutchby et al, 1996). Diabetic 
nephropathy accounted for only 4% of deaths in diabetic people but it is likely 
that patients With nephropathy died from cardiovascular disease as has been 
shown in other research (Wong et al, 1991). 
One aim of this research project was to identify factors which were associated 
with diabetic nephropathy in both Type I and Type 2 patients from information 
routinely collected during medical consultations at out-patient clinic visits. An 
enormous amount of research has been performed on diabetic nephropathy; an 
initial literature search using Medline identified thousands of references to this 
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tOPic. Most of these studies have been in Type 1 patients and many risk factors 
for nephropathy in this group have been identified; predominantly poor glycaemic 
control, the presence of microalbuminuda, raised blood pressure, duration of 
diabetes and a high incidence of microvascular complications (Andersen et al, 
1983; Parving et al, 1983; Parving et al, 1988; Vora, et al, 1993; Mathiesen et al, 
1995). The present study was designed to identify any other factors associated 
with nephropathy in Type I patents and specifically to study Type 2 nephropathy 
Patients in depth. 
This research has demonstrated that a history of smoking was associated with 
the presence of nephropathy in both Type 1 and Type 2 patients compared to 
control subjects, similar to the results of other studies (Microalbuminuria 
Collaborative Study Group, UK, 1993; Chaturvedi et al, 1995; Bruno et al, 1996). 
Defaulting from routine diabetic clinic visits was also a factor associated with 
nephropathy in both Type I and Type 2 patients in comparison to controls and to 
Type 2 patients with non-diabetic renal disease; confirming the results of 
Previous research in Wolverhampton which showed that defaulting from clinic 
was associated with all microvascular complications (Hammersley et al, 1985). 
The present study of Type I patients compared to control subjects identified the 
known risk factors: poor glycaemic control, the presence of retinopathy and 
hypertension but did not identify any unknown factors associated with 
nephropathy. This was not surprising as nephropathy in Type 1 patients has 
been studied extensively for over two decades and factors associated With 
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nephropathy which could be identified using observational data have been 
documented in previous research (Andersen et al, 1983; Parving et al, 1983; 
Parving et al, 1988; Mathiesen et al, 1995). Ongoing and future research into the 
molecular and genetic causes of nephropathy in Type 1 diabetes will produce 
new data that will hopefully lead to ways of preventing or at least effectively 
treating nephropathy. 
Over the last decade interest has grown in nephropathy in Type 2 patients 
probably due to the increasing numbers of people developing Type 2 diabetes 
throughout the world and to the higher numbers of Type 2 patients surviving long 
- enough to'reach end stage renal failure (Ritz and Stephanski, 1996). When the 
present research started there was less known about nephropathy in Type 2 
diabetes than there is now. Similarities in the factors associated with 
nephropathy in Type 2 patients from different countries have been demonstrated 
(Italy, Korea and, apart from the earlier age of onset of Type 2 diabetes, in 
Japan) (Bruno et al, 1996; Park et al, 1998; Tanaka et al, 1998). However, 
different ethnic groups with Type 2 diabetes are more susceptible to nephropathy 
than others (Pima Indians, Indo-Asians and Aborigines) (Ritz and Stephanski, 
1996). This suggests that the factors associated with nephropathy are only part 
of the problem and that unknown genetic factors may be responsible for the 
development of nephropathy in Type 2 as well as in Type I diabetes. 
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In the present study, Type 2 nephropathy patients had more retinopathy and 
peripheral neuropathy than control subjects and patients with non-diabetic renal 
disease, therefore, the presence of microvascular complications was associated 
With nephropathy in Type 2 patients similar to Type 1 patients (Parving et A 
1988). Age and duration of diabetes were both predictive of renal function in 
Type 2 nephropathy patients. The presence of hypertension was a risk factor in 
this group and in addition increased body mass index was associated with 
untreated hypertension. 
There were fewer Indo-Asian and Black Type 2 patients with non-diabetic renal 
disease which may suggest that ethnicity was also a factor associated with 
nephropathy. However, previous research has shown that both Indo-Aslan and 
Black people have a high incidence of non-diabetic as well as diabetic renal 
disease (Perneger et al, 1996; Gujral et al, 1997). The onset of retinopathy and 
hypertension at an early duration of diabetes in Indo-Asian patients was 
interesting in that the exact duration of diabetes in Type 2 patients before 
diagnosis is never known and many Type 2 patients present with established 
microvascular complications (UK Prospective Diabetes Study Group, 1994). It 
could be assumed that for some reason, possibly cultural, that Indo-Asian people 
take longer to have their diabetes diagnosed than White and Black people. 
However, so far there is no evidence of this and there may be a genuine 
difference in the progression of microvascular complications in Indo-Asian people 
which requires further investigation. 
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Early referral of patents with proteinuria and serum creatinine concentrations 
within the upper limit of normal appeared to improve seven year survival in this 
group, although this may have reflected the natural progression of the disease in 
these patients. In addition five year survival of patients on RRT was better than in 
other studies (Marcelli et al, 1995; Ritz et al, 1999). 
The Positive effects on renal function in nephropathy patients of controlling 
hypertension are well documented (Mogensen, 1982; Parving et al, 1983; 
Sawicki et al, 1995; the EUCLID study group, 1997; Mogensen, 1999). In this 
study, uncontrolled systolic hypertension was present in both Type 1 and Type 2 
patients at renal referral and in many patients during the follow up period; 
hypertension was also identified as a hazard to survival. Many patients with 
hypertension were not receiving anti-hypertensive medication at nephrological 
referral. Initial attempts at controlling hypertension in the first year following 
referral improved blood pressure levels but this was not sustained in some 
patients Possibly due to declining renal function. Therefore, treatment of 
hypertension as a preventative strategy prior to and following renal referral was 
not as effective as it could have been. 
Future preventative strategies in Type I and Type 2 patients should include 
aggressive anti-hypertensive treatment of (a) all diabetic patients to prevent the 
Progression of nephropathy and other complications of diabetes and specifically 
(b) Black and Indo-Asian patients before the onset of proteinuria as proteinuria 
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was shown to be a hazard for survival in both of these groups. Aggressive anti- 
hypertensive treatment should occur as soon as any level of proteinuria is 
detected on "Albustick" testing for both Type 2 and Type 1 patients, especially as 
creatinine concentration at referral was a hazard even in Type 1 patients with 
anormal" serum creatinine levels. These are pragmatic suggestions as the ideal 
would be to routinely test for microalbuminuria and start anti-hypertensive 
_ 
treatment when microalburninuria is detected. This routine testing is presently not 
performed in the diabetic clinic and is unlikely to be started due to financial 
constraints. 
Finally, Indo-Asian patients must be regarded as an "at risk" group due to (a) the 
increased risk of developing nephropathy and (b) to survival posed by not 
speaking English and the apparent impact this has had on their attendance at the 
diabetic clinic. Based on the lack of knowledge about the symptoms of diabetes 
found by Jackson and colleagues (1991), a town wide health education 
programme, presented in ethnic languages with the aim of informing Indo-Asian 
people about the symptoms of diabetes, and encouraging them to proactively 
care for their own health along with readily available language translation 
facilities in hospital, may reduce the risk of developing nephropathy and other 
complications that not speaking English confers in this group. 
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10.3 Proposed Future Research 
10-3.1 A Mulficentre, Randomised, Controlled Study of the Management of 
Hypertension in Diabetic Nephropathy 
Back3round: The effective management of hypertension in patients with 
microalbuminuda can slow down the progression of renal disease (Ravid et al, 
1996; Mogensen, 1999). Patients with overt proteinuria (but not in end stage 
renal failure) should also benefit from an aggressive approach to controlling 
blood Pressure as hypertensive damage to the kidneys compounds the disease 
process already caused by nephropathy. The present study has shown that 
routine clinical management of hypertension in nephropathy is not as consistent 
or effective as it could be. The proposed study assesses the efficacy of a 
structured approach to the management of hypertension in nephropathy patients 
in comparison to normal clinical practice. A multicentre study is required as the 
numbers of patients with nephropathy in one diabetic clinic would not be 
sufficient to provide statistical power for the study. 
Aim: To assess the efficacy of a structured interventive method of managing 
hypertension in diabetic patients with nephropathy by means of a multicentre, 
randomised, controlled study. 
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2WtgjjMK To compare a structured interventive approach to the management of 
hypertension with the normal clinical management of hypertension in patients 
With diabetic nephropathy over a ten year period. 
Patients and Methods: 
Definitions- 
Mý 
Proteinuria (>200 pg min"') as determined by presence of urinary albumin 
excretion (AER) measured by radioimmunoassay of samples from two overnight 
urine collections (American Diabetes Association, 1997). 
Hypertension: Systolic pressure >130 mm Hg and diastolic >85 mm Hg 
determined as the mean of two sifting blood pressure measuremen s using a 
digital sphygmomanometer (more accurate than the random zero variety) 
(American Diabetes Association, 1997). 
Type 1 diabetes: Diagnosis before 35 years of age requiring insulin treatment. 
Type 2 diabetes: Diagnosis after 35 years of age requiring oral or diet ther apy 
for at least one year after. 





1) All Type 1 and Type 2 diabetic patients With established nephropathy Le.: 
Proteinuria on measurement of AER, Vith normal serum creatinine 
concentrations and blood pressure levels > 130/85 mm Hg- 
2) Presence of diabetic retinopathy 
3) Confirmation of diagnosis of diabetic nephropathy on renal biopsy in the 
absence of diabetic retinopathy. 
Exclusion Criteria: 
1) Serum creatinine concentrations above 120 jimol I-'. 
2) History of hypertension prior to onset of microalbuminuria or overt proteinuria. 
3) Evidence of raised blood pressure only during clinic visits (as measured be 24 
hour blood pressure monitoring). 
4) Evidence of renal disease due to causes other than nephropathy. 
5) Evidence of hypertension due to other causes. 
Methods: 
Patients will be screened for proteinuria by measuring AER using two overnight 
urine saves. Creatinine concentrations, blood pressure measurements (x2 In 
sifting position and 24 hour blood pressure monitoring x 1; to exclude patients 
with "White coat syndrome") and assessment of inclusion and exclusion criteria 
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will be performed at screening. The screening visit will be the baseline 
measurement for the above parameters 
Patients meeting the inclusion criteria will be entered into the study or control 
group depending on randomisation. Centralised randomisation will be performed 
following development -of a system for randomisation using random number 
tables. Each diabetic clinic will be randomised to be either in the study group or 
the control group in order to reduce any potential alterations to normal clinical 
management of hypertension which could occur if some patients in the clinic 
were in the study group and others were in the control group. 
There will be two separate methods used in this study. The control group will 
receive the normal clinical management of hypertension provided in individual 
diabetic clinics Le.: at the discretion of the physician, this will include normal clinic 
follow up times and the usual approach to hypertension management for each 
clinic. At clinic visit, details of two sifting blood pressure measurements, anti- 
hypertensive therapy and serum creatinine concentrations will be assessed as 
well as glYcaemic control (HbAl c). Each year AER (assessed from two overnight 
urine saves) will be determined after the initial baseline assessment. 
The study group will receive an interventive approach to hypertension 
management. As soon as blood pressure levels are detected above 130 mm Hg 
for systolic or 85 mm Hg for diastolic pressure, anti-hypertensive medication will 
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commence. In Type 1 patients first line treatment will be an ACEI, with the 
dosage increased until blood pressure returns to <130/85 mm Hg. If the 
ma)(imum dosage of ACEI does not achieve this target, treatment may be 
supplemented by a calcium channel antagonists or other anti-hypertensive 
therapy to achieve the target blood pressure. In Type 2 patients ACEI may be 
used as Previously described in suitable patients but renal function should be 
assessed very regularly or calcium channel antagonists should be used as first 
line treatment. Other anti-hypertensive medication may be used instead of or to 
supplement the first line treatment to reach either a target blood pressure of 
,: ý130/85 mm Hg or if original systolic pressure is >180 mm Hg to achieve a 
reduction in systolic to 160 mm Hg or if systolic pressure is between 160-179 mm 
Hg to lower this by 20 mm Hg (American Diabetes Association, 1997). 
Patients will have regular assessment of blood pressure at nurse led clinics e. g.: 
every four weeks until blood pressure levels fall to < 130/85 mm Hg. The initial 
prescription of anti-hypertensive medication will be made by the physician and 
subsequent increases in dose may be performed by the nurse using a protocol 
for treatment which has been approved by the Study Steering Committee. If 
nurse Prescribing were approved by the United Kingdom Central Council for 
nursing, this would facilitate hypertension control in a diabetic clinic setting and in 
this study. However, nurse prescribing in the UK is still in its infancy with only 
limited Prescribing by a relatively few number of nurses. 
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The study group will continue to be assessed at visits every eight weeks once 
blood pressure control has been achieved. Serum creatinine concentrations will 
be measured every six months. Following the baseline measurement, AER 
(assessed from two overnight urine saves) will be determined every six months 
through out the study. 
Outcomes- 
The following outcomes will be assessed in each group: effective maintenance of 
blood pressure control, renal function, time to reaching end stage renal failure 
and survival. The interventive treatment in the study group and normal clinical 
practice will be compared to determine if the interventive approach is more 
effective in (a) controlling hypertension, (b) delaying the decline in renal function 
(assessment of AER) (c) prolonging survival. 
Descriptive statistics will be performed. Ch 12 tests will be used to compare 
categorical data. Comparison of blood pressure measurements, AER, serum 
creatinine levels and HbAlc at baseline will be made using Student t-test or 
Mann-Whitney U test (if appropriate). Subsequent comparisons of these 
parameters (i. e.: over the following years) will be made using analysis of 
variance. Percentage differences in numbers of patients with controlled 
hypertension, reaching end stage renal failure and dying in each group will be 
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assessed using Chi2 . Kaplin Meier survival curves will 
be used to show 
differences in survival between the groups. 
Based on the results of a study by Sawicki and co-workers (1995) where they 
achieved 2% reduction in systolic pressure over 5 years of intensified 
hypertension control in the study group of Type 1 patients (n=34) in comparison 
to 11% increase in systolic pressure in the control subjects (n=25) (P<0.01), in 
order to detect a reduction of 10% in systolic pressure with a power of 80% and a 
statistical significance level of P<0.05,199 patients would be needed in each 
group in this study (i. e.: 2 groups of Type 1 patients [study and control] and 2 
groups of Type 2 patients [study and control]). 
at9kManagment 
The study will last for a maximum of ten years to give an accurate indication of 
the effects of the interventive strategy on survival. Interim analysis of results will 
be undertaken at years 2,5, and 7 to determine the effect of the interventive 
strategy on blood pressure and AER. If results indicate that either of those 
parameters in patients in the control group are poorly controlled, to the detriment 
of Potential patient survival, and in comparison to the study group, the study may 
be terminated early to allow control subjects to receive more intense blood 
pressure control, although follow up of patients will be needed to asses renal and 
survival outcomes. A Steering Committee of investigators and experts in the field 
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Will be formed to monitor the progress of the study with the power to prematurely 
terminate the study if this is appropriate 
A CO-ordinating centre will be established to manage the study, collect all data 
from centres and to monitor and validate the data. A study co-ordinator will be 
appointed to act as primary contact for the study and to liase with the study 
centres, the Steering Committee and ethical committees. 
Ethical Considerations- 
The study will be performed in accord with the guidelines of the Declaration of 
Helsinki (1996 revision). As this is a multicentre study, approval will be sought 
from a Multicentre Regional Ethics Committee in the first instance and then from 
the Local Research Ethics Committee for each centre. 
Patients will be required to give fully informed written consent prior to the 
screening visit. Information about the study will be provide orally and in writing 
and Patient Information leaflets will be produced for this purpose. Confidentiality 
will be maintained by use of patient identification codes rather than using patients 
names. 
The study will be conducted to the standards of the ICH good clinical research 
practice guidelines. Monitoring and data validation will be performed by the co- 
ordinafing centre. 
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10-3.2 Outline of a Study to Detennine the Natural History of Diabetic 
Nephropathy in People from Different Ethnic Groups 
Alm: To determine whether there are specific differences in the onset and 
progression of nephropathy in Indo-Asian, Black and White Type 2 
diabetic patients. 
ObLectives: 
(1) To identify all new cases of Type 2 diabetes in several centres with large 
populations of Indo-Asian and Black patients over a period of one year. 
(2) To follow the progress of patients in each ethnic group over a minimum 
period of fifteen years. 
(3) To determine the onset of microalbuminuria, retinopathy and hypertension 
in patients in each ethnic group. 
(4) To monitor the progression of nephropathy in patients in each ethnic 
group. 
(5) To determine the quality of life of patients with newly diagnosed diabetes 
and in subsequent years. 
Studv Design-, 
A multi-centre, cohort study of Type 2 diabetic patients followed-up for a 
minimum of fifteen years into which all newly diagnosed Type 2 patents would 
be entered unless they had evidence of microvascular complications at diagnosis 
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of diabetes (including microalbuminuria). The power of the study would of 
necessity be large enough to identify small differences between the groups. 
Methods: 
Patients would attend for study visits once/year in addition to normal diabetic 
clinic visits. Details of ethnicity group, place of birth, gender, age, dietary type 
and whether English was spoken would be recorded at the start of the study. 
At each visit the following parameters would be assessed: 
Sifting blood pressure x2 
Microabluminuria / Proteinuria status 
Albumin excretion rate (timed overnight urine saves) 
Serum creatinine concentration 
MAI c 
Diabetic, anti-hypertensive, lipid lowering and other treatments would be 
recorded (including dosages, changes to dose and treatment and if possible 
compliance). 
Assessment of diabetic complications 
Quality of life assessment (once/year). 
Determination of language/s spoken, regular attendance at clinic visits, smoking 
habits, cultural and social differences Le.: religion, country of birth, employment 
status and dietary habits. 
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Statistical Analysis: 
Incidence will be determined. Analysis of variance will be used to assess 
between and within group differences. Chi2 tests will be used to assess 
differences between categorical variables. Correlation and linear regression will 
be used to determine relationships between different variables. Multiple and 
logistic regression will be used to assess the effects of multiple variables on 
specific parameters. Relative risk of developing nephropathy and other end 




Agardh E, Tallroth G, Bauer B, Cavallin-Sjoberg U, Agardh C-D. Retinopathy 
and nephropathy in insulin-dependent diabetics: An inconsistent 
relationship? Diabetic Medicine, 1987; 4: 248-250. 
Agardh E, Torffvit 0, Agardh C-D. Putative risk factors associated with 
retinopathy in patients with diabetes diagnosed at or after 30 years of age. 
Diabetic Medicine, 1989; 6: 724-727. 
Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic 
nephropathy with enalapril in normotensive Type 2 diabetic patients with 
microalburninuria. Diabetes Care, 1997; 20: 1576-1580. 
Aldmal T, Norgaard K, Feldt-Rasmussen B, Decked T. The predictive value 
of microalburninuria in IDDM. Diabetes Care, 1994; 17 (2): 120-125. 
Allawi J, Rao PV, Gilbert R, Scott G, Jarrett RJ, Keen H, Viberti C-G, Mather 
HM. Microalburninuria in non-insulin-dependent diabetes: its prevalence in 
Indian compared with Europid patients. British Medical Journal, 1988; 296: 
462-464. 
American Diabetes Association. Position statement on diabetic nephropathy. 
Diabetes Care, 1999; 22(supplement 1): S66-S69. 
Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Decked T. Diabetic 
nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological 
study. Diabetologia, 1983; 25: 496-501. 
Anderson S, Brenner BM. Influence of anti hypertensive therapy on 
development and progression of diabetic glomerulopathy. Diabetes Care, 
1988; 11(10): 846-849. 
Anonymous. The role of free radical mechanisms in the pathogenesis of 
atherosclerosis and microvascular disease. Current Debates on Diabetes, 
April 1992; 207. 
Aron DC, Rosenzwieg JL, Andersen HA. Synthesis and binding of Insulin- 
like growth factor I by human glomerular mesangial cells. Journal of Clinical 
Endocrinology and Metabolism, 1989; 68(3): 585-591. 
B 
Bain SC. The British Diabetic Association-Warren Repository. Practical 
Diabetes International, 1995; 12(l): 11-13. 
-361- 
Barmett AH, Dodson PIVI. Hypertension and Diabetes, edited by Sharyn Wong; 1990: Published by Scientific Press Limited, London: Chapter 2: 2.8. 
Berrut G, Bouhanick B, Fabbri P, Guilloteau G, Bled F, Le Jeune JJ, 
Fressinaud P, Marre M. Microalbuminuria as a predictor of a drop in 
glomerular filtration rate in subjects with non-insulin-dependent diabetes 
mellitus and hypertension. Clinical Nephrology, 1997; 48 (2): 92-97. 
Betteridge DJ. Lipids, diabetes, and vascular disease: The time to act. Diabetic Medicine, 1989; 6: 195-218. 
Biesenbach G, Janko 0, Zazgomik J. Similar rate of progression in 
predialysis phase in type I and type 11 diabetes mellitus. -Nephrology, DialYsis, Transplantation, 1994; 9: 1097-1102. 
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial 
effects of angiotensin converting enzyme inhibitors on renal function in 
patients %With diabetic nephropathy. British Medical Journal, 1986; 293: 471- 474. 
Bliss M. Theodore Ryder the last living link to the discovery of insulin. 
Practical Diabetes International, 1995; 12(4): 187-188. 
Bojestig M, Arnquist HJ, Kadberg BE, Ludvigsson J. Glycaemic control and 
Prognosis in Type I diabetic patents with microalbuminuda. Diabetes Care, 1996; 19 (4): 313-317. 
Boulton AN Knight G, Drury J, Ward JD. The prevalence of symptomatic 
diabetic neuýýpathy in an insulin-treated population. Diabetes Care, 1985; 8 (2): 125-128. 
Brant R. Power/Sample Size Calculator 
www. health. ucalgary. cal-rollin/stats/Ssize/b2. htmi 
Brenner BM and Rector FC. The Kdney. 3rd Edition, Published by Arnold 
Medical Books, WB Saunders, Philadelphia. 1986; Volume 1, Chapter 1: 7- 
11. 
Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in 
tissue and the biochemical basis of diabetic complications. Now England Joumal of Medicine, 1988; 318 (20): 1315-1322. 
Bruckdorfer KR. Non-enzymatic oxidation of lipids and lipoproteins: the role 
of metals and nitric oxide. Cuffent Opinion on UpidologY, 1993; 4(3): 238- 243. 
-362- 
Bruno G, Cavallo-Perrin P, Bargero G, Borra M, Calvii V, DErdco N, 
Deambrogio P, Pagano G. Prevalence and risk factors for microalbuminuria 
and macroalbuminuria in an Italian population-based cohort of NIDDM 
subjects. Diabetes Care, 1996; 19: 43-47. 
Burden AC, McNally PG, Feehally J, Walls J. Increased Incidence of end- 
stage renal disease secondary to diabetes mellitus in Asian ethnic groups In 
the United Kingdom. Diabetic Medicine, 1992; 9: 641-645. 
C 
Cameron JS and Challah S. Treatment of end-stage renal failure due to 
diabetes in the United Kingdom, 1975-1984. The Lancet, 1986; 11: 962-966. 
Castiglioni A, Savazzi GM. Physiopathology and clinical aspects of diabetic 
nephropathy. Nephron, 1988; SO: 151-163. 
Cerami A, Vlassara H, Brownlee M. Glucose and Ageing. Scientific 
Amefican, 1987; 256(5): 82-88. 
Chan JCN, Cheung C-K, Cheun MYF, Swaminathan R, Critchley JAJH, 
Cockram CS. Abnormal albuminuria as a predictor of mortality and renal 
impairment in Chinese patients with NIDDM. Diabetes Care, 1995; 18(7): 
1013-1016. 
Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, Harriman 
RE. Cigarette Smoking increases the risk of albuminuria among subjects 
with Type 1 diabetes. JAMA, 1991; 265(5): 614-617. 
Chaturvedi N, Stephenson JM, Fuller JH, The EURODIAB IDOM 
Complications Study Group. The relationship between smoking and 
microvascular complications in the EURODIAB IIDM Complications Study. 
Diabetes Care, 1995; 18 (6): 785-791. 
Chaturvedi N, Sjolie A-K, Stephensen JM, Abrahamian H, Kelpes M, 
Castellarin A, Rogulija-Pepeonik Z, Fuller A and the EUCLID study group. 
Effect of lisinopril on progression of retinopathy In normotensive people with 
type 1 diabetes. The Lancet, 1998; 351: 28-31. 
Chauffert M, Cisse A, Chievenne D, You JF, Michel S, Trivin F. Susceptibility 
to Type 1 diabetes in the Sengalese population is linked to HLA-DQ and not 
TAP and LMP genes. Diabetes Care, 1997; 20(8): 1299-1303. 
Chowdhury TA, Kumar S, Barnett AH, Bain SC. Nephropathy In Type 1 
diabetes: the role of genetic factors. Diabetic Medicine, 1995; 12: 1059-1067. 
Christensen PK, Rossing P, Nielsen FS, Parving HH. Natural course of 
kidney failure in Type 2 diabetic patients with diabetic nephropathy. Diabetic 
Medicine, 1999; 16(5): 388-394. 
-363- 
Collada-Mesa F, Colhoun HM, Stevens LK, Boavida J, Ferris JB, Karamanos 
B, Kempler P, Michel G, Roglic G, Fuller JH and the EURODIAB IDDM Complications Study Group. Prevalence and management of hypertension in 
Type I diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabetic Medicine, 1999; 16: 41-48. 
Consensus Statement. Treatment of hypertension in diabetes. Diabetes 
Care, 1993; 16(10): 1394-1401. 
Cooper ME, Frauman A, O'Brien RC, Seeman E, Murray RML, Jerums G. 
Progression of proteinuria in Type 1 and Type 2 diabetes. Diabetic Modkine, 
1988; 5: 361-368. 
Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. 
Disparities in incidence of diabetic end-stage renal disease according to race 
and type of diabetes. Now England Journal of Medicine, 1989; 321(16): 
1074-1079. 
Cowie CC, Port FK, Rust KF, Harris Mi. Differences In survival between 
Black and White patients with diabetic end-stage renal disease. Diabotos 
Caro, 1994; 17 (7): 681-687. 
Cruickshank JK. Diabetes in people of Indian subcontinent origin. Practical 
Diabetes Supplement, 1993; 10 (5): S2-S3. 
D 
Davies JL, Kawaguchi Y, Bennett ST, Copernan JB, Cordell JB, Codell HJ, 
Protchard Le, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balgour KM, 
Rowe BR, Farrall M, Barnett AH, Bain SC, Todd JA. A genome-wide search 
for human type I diabetes susceptibility genes. Nature, 1994; 371: 130-136. 
Davidson AM, Cameron JS, Grunfield J-P, Kerr DNS, Ritz E, Wineads CG 
(Editors). Clinical investigation of the renin-angiotensin-aldosterone system. 
Oxford Textbook of Clinical Nephrology, 2' Edition, 1998; Chapter 9.3: 
PP1425-1427. 
Deckert T, Jensen T, Feldt-Rasmussen B, Kofoed-Enevoldsen A. Borch- 
Johnsen K, Stender S. Albuminuda as a risk marker of atherosclerosis in 
insulin dependent diabetes mellitus. Cardiovascular Risk Factors, 1991; 
IM: 347-360. 
Decked T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt- 
Rasmussen B, Jensen T. Microalbuminuria: Implications for micro-and 
macrovascular disease. Diabetes Care, 1992; 15(9): 118 1 -119 1. 
DECODE Study Group. Will new diagnostic criteria for diabetes mellitus 
change phenotype of patients with diabetes? Reanalysis of European 
epidemiological data. British Medical Journal, 1998; 317: 371-375. 
-364- 
DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. 
Diabetes Care, 1992; 15(3): 318-368. 
de Grauw WJC, van de Lisdonk EH, van der Hoogen HJIVI, van Weel C. 
Cardiovascular morbidity and mortality in Type 2 diabetic patients: a 22-year 
historical cohort study in Dutch general practice. Diabetic Medicine, 11995: 
12: 117-122. 
Department of Clinical Chemistry. Standard operating Procedures, Edition 
1.0,1997. Copyright, Royal Wolverhampton Hospitals NHS Trust. 
Diabetes Control and Complications Trial Research Group. The effect on the 
development and progression of long-term complications In Insulin- 
dependent diabetes mellitus. Now England Joumal of Medicine, 1993; 329: 
977-986 
Diabetes Epidemiology Research International Mortality Study Group. 
International evaluation of cause-specific mortality and IDDM. Diabetes 
Care, 1991; 14(1): 55-60. 
Drury Mi. Diabetes Melfitus. Blackwell Scienfific Publicafions, Oxford. 1979: 
pp 2-3. 
Dudley CRK, Keavney B, Stratton IM, Turner RC, Ratcliffe PJ. UX 
Prospective Diabetes Study XV: Relationship of renin-angiotensin system 
gene polymorphism with microalburninuria in NIDDM- Kidney Intemational, 
1995; 48: 1907-1911. 
E 
Eckel RH, McLean E, Albers A Cheung MC, Bierman EL. Plasma lipids and 
microangiopathy in insulin-dependent diabetes mellitus. Diabetes Care, 
198 1; 4(4): 447-453. 
Euclid Study Group. Randomised placebo-controlled trial of lisinopril In 
normotensive patients with insulin-dependent diabetes and 
normoalburninuria or microalbuminuda. Lancet, 1997; 349: 1787-1792. 
F 
Feehally J. Nephropathy in Indo-Asians. Practical Diabetes International 
Supplement, 1995; 12(3): S6-S7. 
Feldt-Rasmussen B, Mathiesen ER, Decked T. Effect of two years of strict 
metabolic control on progression of Incipient nephropathy In Insulin 
dependent diabetes. The Lancet, 1986; il: 1900-1904. 
-365- 
Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective 
study of coronary heart disease in relation to fasting insulin, glucose and 
diabetes. Diabetes Care, 1997; 20(6): 935-942. 
Forrester JM, editor. A Companion to Medical Studies, Anatomy, 
Biochemistry and Physiology. 1985 Published by Blackwell Scientific 
Publications, Oxford; 31: 10-13. 
Franklin GM, Khan LB, Baxter J, Marshall JA, Harriman RF. Sensory 
neuropathy in non-insulin-dependent diabetes mellitus. American Journal of 
Epidemiology, 1990; 131(4): 633-643. 
Frayn K N. Insulin resistance and lipid metabolism. Current Opinion on 
Upidology, 1993; 4 (3): 197-204 
Friedman R and Gross JL. Evolution of glomerular filtration rate in proteinuric 
NIDDM patients. Diabetes Care, 1991; 14(5): 355-358. 
Fujii J, Myint T, Okado A, Kaneto H, Taniguchi N. Oxidative stress caused by 
glycation of Cu, Zn-superoxide dismutase and its effect on Intracellular 
Components. Nephrology, Dialysis and Transplantation, 1996; 
11 (Supplement 5): 34-40. 
Fuller JH, Elford J, Goldblatt P and Adelstein AM. Diabetes mortality: New 
light on an underestimated public health problem. Diabetologia, 1983; 24: 
336-341. 
Fuller JH- European Community Concerted Action on the Epidemiology and 
Prevention of Diabetes: EURODIAB- final report 1988-1991. Published by 
the European Community; 1991. 
G 
Gatling W, Turfail S, Mullee MA, Westacott TA, Hill RD. Mortality rates In 
diabetic patients from a community-based population compared to local 
age/sex matched controls. Diabetic Medicine, 1997; 14: 316-320. 
Greenhalgh PM. Diabetes in British South Asians: Nature, Nurture and 
Culture. Diabetic Medicine, 1997; 14: 10-18. 
Grenfell A, Bewick M, Parsons V, Snowden S, Taube D, Watkins PJ. Non- 
Insulin-dependent diabetes and renal replacement therapy. Diabetic 
Medicine, 1988; 5: 172-176. 
Goodwin AM, Keen H, Mather HM. Ethnic minorities In British diabefic 
clinics: A questionnaire survey. Diabetic Medicine, 1987; 4: 266-269. 
Gordis L, Epidemiology. Published by W. B. Saunders Company, 
Philadelphia, 1996: pp 140-149. 
-366- 
Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Medicine, 1991; 8: 898-905. 
Gujral JS, McNally PG, O'Malley BP, Burden AC. Ethnic differences In the 
incidence of lower extremity amputation secondary to diabetes mellitus. 
Diabetic Medicine, 1993; 10: 271-274. 
Gujral JS, Burden AC, lqbal J, Raymond NT, Botha JL. The prevalence of 
chronic renal failure in known diabetic and non-diabetic White Caucasians 
and South Asians. Practical Diabetes International, 1997; 14(3): 71-74. 
H 
Harnmersley MS, Holland MR, Walford S, Thom PA. What happens to 
defaulters from a diabetic clinic? British Medical Joumal, 1985; 291: 1330- 
1332. 
Hawthorne K. Asian diabetics attending a British hospital clinic: a pilot study 
to evaluate their care. British Journal of General Practice, 1990; 40: 243-247. 
Heilman R, Regan J, Rosen H. Effect of intensive treatment of diabetes on 
the risk of death or renal failure in NIDDM and IDDM. Diabetes Care, 1997; 
20(30): 258-264. 
Holland M. Standing Operating Procedures, Clinical Chemistry Department, 
New Cross Hospital. 1997, copyright Royal Wolverhampton Hospitals NHS 
Trust. 
Hommel E, Mathiesen E, Edsberg B, Bahnsen M, Parving H-H. Acute 
reduction of arterial blood pressure reduces urinary albumin excretion In Type I (insulin-dependent) diabetic patents with incipient nephropathy. 
Diabetologia, 1986; 29: 211-215. 
Humphrey LL, Ballard DJ, Frohnert PP, Chu C-P, O'Fallon M, Palumbo PJ. 
Chronic renal failure in non-insulin dependent diabetes mellitus. A 
Population-based study in Rochester, Minnesota. Annals of Internal 
Medicine, 1989; 1111(110): 788-796. 
Hutchby P, Austin D, Birt C, Clayton R, Davies A, Gray M, Jarvis C. Jones P. 
Packer C, Patel D, Saffrey P. Report on the Public Health of 
Wolverhampton, 1996. Published by the Wolverhampton Health Executive. 
Page 46. 
Ido Y, Kilo C, Williamson JR. Interactions between the sorbitol pathway, 
non-enzymatic glycation, and diabetic vascular dysfunction. Nophrology, 
Dialysis and Transplantation, 1996; 11 (Supplement 5): 72-75. 
-367- 
i 
Jackson DMA, Wills R, Davies J, Meadows K, Singh BM, Wise PH. Public 
awareness of the symptoms of diabetes mellitus. Diabetic Medicine, 1991; 8: 
971-972. 
Jennings PE and Barnett AH. New approaches to the pathogenesis and 
treatment of diabetic microangiography. Diabetic Medicine, 1988; 5,111- 
117. 
Jensen T, Stender S, Decked T. Abnormalities in plasma concentrations of 
lipoproteins and fibrinogen in Type I (insulin-dependent) diabetic patients 
with increased urinary albumin excretion. Diabetologia, 1988; 31; 142-145. 
John GT, Date A, Korula A, Jeyaseelan L, Shastry JCIVI, Jacob CK. Non 
diabetic renal disease in non insulin-dependent diabetics in a South Indian 
hospital. Nephron, 1994; 67: 441-443. 
Johnson RA and Tsui K-W. Statistical Reasoning and Methods. Published by 
John Witley and Sonsjnc, New York, 1998: pp 107-117. 
Joint Working Party of the Renal Association, British Diabetic Association 
and the Research Unit of the Royal College of Physicians. Treatment of and 
mortality from diabetic renal failure in patients identified In the 1985 United 
Kingdom survey. British Medical Joumal, 1989; 299: 1135-1136. 
Jokl R, Klein RL, Lopes-Virella MF, Colwell JA. Release of platelet 
plasminogen activator inhibitor 1 in whole blood is Increased In patients with 
Type 11 diabetes. Diabetes Care, 1995; 18 (8): 1150-1155. 
Jones SL, Close CF, Mattock IVIB, Jarrett RJ, Keen H, Viberti GC. Plasma 
lipid and coagulation factor concentrations in Insulin dependent diabetics 
with microalbuminuria. British Medical Journal, 1989; 298: 487-490. 
Jones RL, Peterson CM. Hernatological alterations In diabetes mellitus. 
American Journal of Medicine, 198 1; 70: 339-352. 
Julier C, Hyer RN, Davies J, Merlin F, Soularue P. Briant L. Cathenlineau G, 
Deschamps L, Rotter Jl, Groguel P, Boitard C, Bell JI, Lathrop GM. Insulin- 
IGF2 region encodes a gene implicated in HLA-Dr4-dependent diabetes 
susceptibility'. Nature, 1991; 354: 155-159. 
K 
Kannel WB, McGee DL. Diabetes and cardiovascular disease. JAMA, 1979; 
241(19): 2035-2038. 
-368- 
Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of a nti hypertensive 
therapy on the kidney in patients with diabetes: a meta-regression analysis. Annals of Internal Medicine, 1993; 118 (2): 129-137. 
Keen H, Jarret J. Complications of diabetes. 2nd Edition. 1982, Edward 
Arnold Publishers Ltd., London. Chapter 4: 139-143. 
Kelleher K, Armitage L, Birt C, Clayton R, Dougan H, Howell J, Jarvis C, 
Jones P, Linnane J. Report on Public Health in Wolverhampton 1994. 
Published by Wolverhampton Health Executive. Editor Kelleher K.: p6l. 
Kessler 11. Mortality experience of diabetic patients. A twenty-six year follow- 
up study. American Journal of Medicine, 1971; 51: 715-724. 
King GI, Wakasaki M. Theoretical mechanisms by which hyperglycaemla 
and insulin resistance could cause cardiovascular disease In diabetes. Diabetes Care, 1999; 22(Supplernent 3): C31-C37. 
Kinnear PR and Gray CD. SPSS for Windows made simple. Published by 
Lawrence Erlbaurn Associates, Trowbridge, UK, 1994; ppl52-155. 
Klein R, Klein BEK, Moss S, DeMets DL. Proteinuria in diabetes. Archives of 
Internal Medicine, 1988; 148: 181-186. 
Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Is blood pressure a 
predictor of the incidence or progression of diabetic retinopathy? Archives of 
Internal Medicine, 1989; 149: 2427-2432. 
Kohner EM, McLeod D, Marshall J. Diabetes eye disease. From 
Complications of Diabetes, 2' Edition. Editors Keen H and Jarret J. 
Published by Edward Arnold, 1982. Chapter 2: pp 19-108. 
Kojima 1, Matsumaga H, Kurokawa K, Ogata E, Nishimoto 1. Calcium Influx: 
an intracellular message of mitogenic action of Insulin-like growth factor-1. 
The Journal of Biochemical Chemistry, 1988; 263 (32): 16561-16567. 
Koppiker N, Feehally J, Raymond N, Abrams KR, Burden AC. Rate of 
decline in renal function in Indo-Aslans and Whites with diabetic 
nephropathy. Diabetic Medicine, 1998; 15: 60-65. 
Krolewski AS, Warram JH, Christleb AR, Busik Ej, Khan CR. The changing 
natural history of nephropathy in Type I diabetes. American Journal of 
Medicine, 1985; 78: 785-794. 
L 
Lambert J, Smulders RA, Aarsen M, Donker AJM, Stehouwer CDA. Carotid 
artery stiffness is increased in microalbuminuric IDDM patients. Diabotos 
Care, 1998; 21 (1): 99-103. 
-369- 
Leese GP and Vora JP. The management of hypertension in diabetes* with 
special reference to diabetic kidney disease. Diabetic Medicine, 1996; 13: 
401-410. 
Leahy A. Natural history of P-cell dysfunction in NIDDM. Diabetes Care, 
1990; 13(9): 992-1010. 
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study 
Group. The effect of angiotensin-converting-enzyme Inhibition on diabetic 
nephropathy. New England Joumal of Medicine, 1993; 329(20): 1456-1462. 
Liang JC and Goldberg MF. Treatment of diabetic retinopathy. Diabetes, 
1980; 29: 841-851. 
Lloyd C, Stephenson J, Fuller JH, Orchard TJ. A comparison of renal 
disease across two continents. Diabetes Care, 1996; 19(3): 219-225. 
Lowe D. Planning for Medical Research. Published by Astraglobe Limited, 
Cardiff, 1993: 140-147. 
M 
Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of 
antihypertensive agents on proteinuria and renal function. Archives of 
Internal Medicine, 1995; 155: 1973-1079. 
Makino H, Shikata K, Kushiro M, Hironaka K, Uamasakl Y, Sugimoto H, Ota 
Z, Araki N, Horiuchi S. Roles of advanced glycation end-products In the 
progression of diabetic nephropathy. Nophrology, Dialysis and 
Transplantation, 1996; 11 [Supplement 5]: 76-80. 
Manson E, Colditz GA, Stampfer MJ, Willett WC, Krolewskl AS, Rosner 
Arky RA, Speizer FE, Hennekens CH. Prospective study of maturity-onset 
diabetes mellitus and risk of coronary heart disease and stroke In women. 
Archives ot Internal Medicine, 199 1; 151: 1141-1147. 
Marcelli D, Spottl D, Conte F, Tagliaferro A, Urnido A, Lonati F, Malberti F, 
Locatelli F. Survival of diabetic patients on peritoneal dialysis or 
haernodialysis. Peritoneal Dialysis Intemational, 1996,16 (Supplement 1): 
S283-S287. 
Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. 
Prevention of diabetic nephropathy with enalapril In normotensive diabetics 
with microalburninuria. British Journal of Medicine, 1988; 297: 1092-1095 
Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud P. 
Small doses of ramipril to reduce microalburninuria In diabetic patients with 
incipient nephropathy independently of blood pressure changes. Joumal of 
CardiovascularPhannacology, 1991; 18 (Supplement 2): S165-S168. 
-370- 
Marshall SM. Blood pressure control, microalburninuria and cardiovascular 
risk in Type 2 diabetes mellitus. Diabetic Medicine, 1999; 16: 358-372. 
Mather HM and Keen H. The Southall Diabetes Survey: prevalence of known 
diabetes in Asians and Europeans. British Medical Journal, 1985; 291: 
1081-1084 
Mathiesen ER, Ronn B, Storm B, Foght H, Decked T. The natural course of 
microalbuminuria in insulin-dependent diabetes: a 10 year-prospective study. 
Diabetic Medicine, 1995; 12: 483-487. 
Microalbuminuria Collaborative Study Group, United Kingdom. Risk factors 
for development of microalbuminuria in insulin dependent diabetic patients: a 
cohort study. British Medical Joumal, 1993; 306: 1235-1239. 
Microalbuminuria Collaborative Study Group, United I(ingdom. Intensive 
therapy and progression to clinical alburninuria In patients with Insulin 
dependent diabetes mellitus and microalburninuria. British Medical Joumal, 
1995; 311: 973-977. 
Mogensen CE. Long-term antihypertensive treatment Inhibiting progression 
of diabetic nephropathy. British Medical Joumal, 1982; 285: 685-688. 
Mogensen CE. Microalburninuria predicts clinical proteinuria and early 
mortality in maturity-onset diabetes. Now England Journal of Medicine, 1984; 
310 (6): 356-360. 
Mogensen CE. Diabetic renal disease: the quest for norMotension and 
beyond. Diabetic Medicine, 1995; 12: 756-769. 
Mogensen CE, Hansen KW, Osterby R, Damsgaard EM. Blood pressure 
elevation versus abnormal albuminuda In the genesis and prediction of renal 
disease in diabetes. Diabetes Care, 1992; 15(9): 1192-1204. 
Mogensen CE. ACE inhibitors and diabetic nephropathy; evidence for 
renoprotection and practice. Practical Diabetes Intemational, 1999; 16 (8): 
S4-S5. 
Moriya T, Nakazawa K, ltoh N, Shigematsu H, Okada N, AJzawa T, Yamada 
T, Yajima Y. Loss of glomerular anionic sites and the development of 
alburninuria in rats with streptozotocin-induced diabetes. Nephron, 1993; 64: 
444-448. 
Moss SE, Klein R, Klein BEK. Cause-specific mortality In a population-based 




Nelson RG, Pettitt DJ, Carraher MJ, Baird R, Knowler WC. Effect of 
proteinuria on mortality in NIDDM. Diabetes, 1988; 37: 1499-1504. 
Nelson RG, Hanson RL, Pettift 13.1, Knowler WC, Bennett PH. Survival during 
renal replacement therapy for diabetic end-stage renal disease In Pima 
Indians. Diabetes Care, 1996; 19(12): 1333-1337. 
Nielsen S, Schmitz A, Rehling M, Mogensen CE. Systolic blood pressure 
relates to the rate of decline of glomerular filtration rate In Type 11 diabetes. 
Diabetes Care, 1993; 16(11): 1427-1432 
Noth RH, Krolewski AS, Kaysen GA, Meyer TW, Schambelan M. Diabetic 
nephropathy: Haemodynamic basis and implications of disease 
management. Annuls of Internal Medicine, 1989; 110 (10): 795-813. 
Nyberg G, Blohme G, Norden G. Impact of metabolic control In progression 
of clinical diabetic nephropathy. Diabetologia, 1987; 30: 82-86. 
0 
O'Donnell IVIJ, Le Guen CA, Lawson N, Gyde 01-113, Barnett AH. Platelet 
behaviour and haemostatic variables in type 1 (Insulin-dependent) diabetic 
patients with and without albuminuria. Diabetic Medicine, 1991; 8: 624-628. 
Odugbesan 0, Rowe B, Fletcher J, Walford S, Barnett AH. Diabetes In the 
UK West Indian community - the Wolverhampton Survey. Diabetic Medicine, 1989; 6: 48-52. 
Office for National Statistics. 1995 Mortality Statistics. Published HIVISO, 
1997. 
Office of Population Censuses and Surveys: Distdct Health Authodtles. 
HMSO, 1990 
Office of Population Censuses 
Wolverhampton MBC-Summary 
HMSO, 1992. 
and Surveys: 1991 Census of Population, 
P from West Midlands County Monitor. 
Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y, 
Yonemoto T, Nishikawa M, Fukuhara S, Inada M. Significance of platelet- 
derived mircoparticles and activated platelets In diabetic nephropathy. 
Nephron, 1999; 81: 271-277. 
Osbakken, M. RAS System, 1995; copyright Bristol-Myers Squibb Company, 
Princeton, New Jersey: pp 3-12. 
-372- 
p 
Padfield, PL. The Renin-angiotensin-aldosterone System. Clinician, 1988; 
6(2): 2-5. 
Panzram G. Mortality and survival in Type 2 (non-insulin-dependent) 
diabetes mellitus. Diabetologia, 1987; 30: 123-131. 
Park J-Y, Kim H-K, Chung YE, Kim SW, Hong SK, Lee K-U. Incidence and 
deterninants of microalburninuria in Koreans with Type 2 diabetes. Diabetes 
Care, 1998; 21: 530-534. 
Parmar MK13 and Machin D. Survival analysis -a practical approach. John Wiley and Sons, 1995; pp 65-115 
Parving H-H, Smidt UM, Andersen AR, Svendsen PA. Early aggressive 
antihypertensive treatment reduces rate of decline in kidney function In 
diabetic nephropathy. Lancet, 1983; 1: 1175-1178. 
Parving H-H, Hommel E, Mathiesen E, Skott P, Edsberg 13, Bahnsen M, 
Lauritzen M, Hougaard P, Lauritzen E. Prevalence of microalbuminuda, 
arterial hypertension, retinopathy and neuropathy In patients with Insulin 
dependent diabetes. British Medical Jourual, 1988; 296: 156-160. 
Parving H-H, Hommel E. Prognosis in diabetic nephropathy. British Medical 
Joumal, 1989; 299: 230-233. 
Parving H-H. Diabetic hypertensive patients: is this a group In need of 
particular care? Diabetes Care, 1999; 22 (2): 1376-1379. 
Passa P. Diabetic nephropathy In the NIDDM patient on the Interface 
between diabetology and nephrology. What do we have to Improve? 
Nephrology, Dialysis and Transplantation, 1997; 12: 1316-1317. 
Pedersen MM, Schmitz A, Pedersen EB, Danielsen H, Christiansen JS. 
Acute and long-term renal effects of anglotensen converting enzyme 
inhibition in normotensive, normalburninuric Insulin-dependent diabetic 
patients. Diabetic Medicine, 1988; 5: 562-569. 
Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease 
attributable to diabetes mellitus. Annals of Intemal Medicine, 1994,121(12): 
912-918. 
Pommer W, Bressel F, Chen F, Molzahn M. There Is room for Improvement 
of preterminal care In diabetic patients with end-stage renal failure-The 
epidemiological evidence from Germany. Nephrology, Dialysis and 
Transplantation, 1997; 12: 1318-1320. 
-373- 
lil 
Raleigh VS, Kiri V, Balarajan R. Variations in mortality from diabetes 
mellitus, hypertension and renal disease in England and Wales by country of birth. Health Trands, 1996; 28(4): 122-127. 
Ravid M, Long R, Rachmani R, Lishner M. Long-term renoprotective effect of 
angiotensin-converting enzyme inhibition in non-Insulin-dependent diabetes 
mellitus. Arch Intern Med, 1996; 156: 286-289. 
Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril Improves 
albuminuria by preventing glomerular loss of heparan sulphate In diabetic 
rats. Biochemical Medicine and Metabolic Biology, 199 1; 45: 119-13 1. 
Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term Intensified 
insulin treatment on the development of microvascular complications of diabetes mellitus. New England Journal of Medicine, 1993; 329 (5): 304-309. 
Remuzzi G, Rossi EC. Haemostasis and the kidney. Butterworths and Co. (Publishers) Ltd, London; 1989: Chapter 1: pp 6-17. 
Ritz E, Nowack R, Fliser D, Koch M, Tschope W. Type 11 diabetes mellitus: Is 
the renal risk adequately appreciated? Nephrology, Dialysis and 
Transplantation, 1991; 6: 679-682. 
Ritz E, Keller CK, Siebels M, Berqis KH. Renal Involvement In Type 11 
diabetes. Advances in Nephrology, 1995; 24: 131-143. 
Ritz E and Stefanski A. Diabetic nephropathy in Type 11 diabetes. American 
Journal of Kidney Disease, 1996; 27(2): 167-194. 
Ritz E, Koch M, Fliser D, Schwenger V. How can we Improve prognosis In 
diabetic patients with end-stage renal disease? Diabetes Caro, 1999; 22(2): 
1380-1383. 
Roderick PJ, Jones 1, Raleigh VS, McGeown M, Mallick N. Population need 
for renal replacement therapy In Thames regions: ethnic dimension. British 
Medical Journal, 1994; 309: 1111-1114. 
Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of 
cardiovascular risk factors on coronary heart disease and mortality among 
middle aged diabetic men: a general population study. British Medical 
Journal, 1989; 299: 1127-1130. 
Rosenstock J, Strowig S, Cercone S, Raskin P. Reduction In cardiovascular 
risk factors with Intensive diabetes treatment In Insulin-dependent diabetes 
mellitus. Diabetes Care, 1987; 10(6): 729-734. 
-374- 
Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of 
mortality in insulin dependent diabetes: 10 year observational study. British 
Medical Joumal, 1996; 313: 779-784. 
Rylance PB, Gordge MP, Dodd NJ, Grenfell A, Watkins PJ, Parsons V. 
Enhanced platelet function and high fibrinogen in uremic diabetics: a 
hypercoagulable state. Transplantation Proceedings, 1986; Vol XVIII(6): 
1609-1610. 
S 
Sakai H, Jinde K, Suzuki D, Yagame M, Nomoto Y. Localization of glycated 
proteins in the glomeruli of patients with diabetic nephropathy. Nephrology, 
Dialysis and Transplantation, 1996; 11 [Supplement 5]: 66-71. 
Sawicki PT, Didjurgeit U, Muhlhauser 1, Bender R, Heinemann L, Berger M. 
Smoking is associated with progression of diabetic nephropathy. Diabetes 
Care, 1994; 17 (2): 126-131. 
Sawicki PT, Muhlhauser 1, Didjurgeit U, Baumgarten A, Bender R, Berger M. 
Intensified anti hypertensive therapy is associated with Improved survival In 
type 1 diabetic patients with nephropathy. Journal of Hypertension, 1995; 13 
(8): 933-938. 
Schmidt-Nielsen K. Animal Physiology., Adaptation and Environment. 
Cambridge University Press, Cambridge. 1983; 3rd edition: pp 513-514. 
Schmitz A and Vaeth M. Microalbuminuda: a major risk factor In non-insulin- 
dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic 
Medicine, 1987; 5: 126-134. 
Seghied G, Alviggi L, Caselli P, De Giorgio LA, Breschl C, Gironi A, Niccolal 
M, Bartolomei CG. Serum lipids and lipoproteins In Type 2 diabetic patients 
with persistent microalburninuria. Diabetic Medicine, 1990; 7: 810-814. 
Selby JV, FitzSimmons SC, Newman JIVI, Katz PP, Sepe S, Showstack J. 
The natural history and epidemiology of diabetic nephropathy. JAMA, 1990; 
263 (14): 1954-1960. 
Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic 
kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. 
New England Joumal of Medicine, 1989; 320 (18): 1161-1165 
Shaukat N. Coronary heart disease In Indo-origin people. Practical Diabetes 
International, 1995; 12 (3): S3-S5. 
Silman AJ. Epidemiological studies., a practical guide. Published by 
Cambridge University Press, Great Britain, 1995: pp16-18. 
-375- 
Simmons D and Powell MJ. Metabolic and clinical characteristics of South Asians and Europeans in Coventry. Diabetic Medicine, 1993; 10: 751-758. 
Simmons D, Williams DRR, Powell MJ. Prevalence of diabetes In a 
predominantly Asian community: preliminary findings of the Coventry 
diabetes study. British Medical Joumal, 1989; 298: 18-21. 
Singh 13M, Jackson DMA, Wills R, Davies J, Wise PH. Delayed diagnosis In 
non-insulin dependent diabetes. British Medical Journal, 1992; 304: 1153. 
Sjolie A-K, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller 
J, the EURODIAB IDDM Complications Study Group. Retinopathy and 
Vision Loss in Insulin-Dependent Diabetes in Europe. Ophthalmology, 1997; 
104 (2): 252-259. 
Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes 
Care, 1999; 22(supplement 3): C14-C20- 
Sprafka JM, Pankow J, McGovern PG, French LR. Mortality among Type 2 
diabetic individuals and associated risk factors: the three city study. Diabetic 
Medicine, 1993; 10: 627-632. 
SPSS inc. SPSS Base 9.0, Applications Guide. Printed by SPSS Inc. 
Chicago, 1999: p 84. 
Stephenson J, Swerdlow AJ, Devis T, Fuller JH. Recent trends In diabetes 
mortality in England and Wales. Diabetic Medicine, 1992; 9: 417-42 1. 
Stephenson J, Fuller JH, EURODIAB IDDM Complications Study Group. 
Microvascular and acute complications In IDDM patients: The EURODIAB 
IDDM Complications Study. Diabetologia, 11994; 37: 278-285. 
Stephenson J, Fuller JH, EURODIAB IDDM ComplicatIons Study Group, 
WHO Mulfinational Study Group. Microalbuminuda Is not rare before 5 years 
of IDDM. Journal of Diabetic Complications, 1994; 8: 166-173. 
Stephenson JM, Fuller JH, Viberti G-C, Sjolie A-K, Navalesi R, the 
EURODIAB IDDM Complications Study Group. Blood pressure. retinopathy 
and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications 
Study. Diabetologia, 1995; 38: 599-603. 
Striker U and Striker GE. Administration of AGEs in vivo induces 
extracellular matrix gene expression. Nephrology, Dialysis and 
Transplantation, 1996; 11 [Supplement 51: 62-65. 
Striker GE, Eastman RD, Striker U. Diabetic nephropathy: molecular 
analysis of extracellular matrix and clinical studies update. Nephrology, 
Dialysis and Transplantation, 1996; 11 [Supplement 5]: 58-61. 
-376- 
Sugiyarna S, Miyata T, Horie K, Lida Y, Tsuyuki M, Tanaka H, Maeda K. 
Advanced glycation end-products in diabetic nephropathy. Nephrology, 
Dialysis and Transplantation, 1996; 11 [Supplement 51: 91-94 
T 
Tabachnick BG and Fidell LS. Using multivariate Statistics, 3d edition, 
published by Harper Collins College Publishers, New York, 1996: pp 7-8.30- 
32,127-156,575-594. 
Tariso JF, Reger LA, Furcht LT. Molecular mechanisms In basement 
membrane complications of diabetes: alterations in heparin, laminin and type 
IV collagen association. Diabetes, 1988; 37: 532-539. 
Tarnow L. Genetic patterns in diabetic nephropathy. Nephrology, Dialysis 
and Transplantation; 1996: 11: 410-412. 
Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role 
of glycaemic control and blood pressure in the development and progression 
of nephropathy in elderly Japanese NIDDM patients. Diabetes Care, 1998; 
21: 116-120. 
Tattersall RB and Gill GV. Unexplained deaths In Type I diabetic patients. 
Diabetic Medicine, 1991: 8: 49-58. 
Tchobroutsky G. Relation of diabetic control to development of 
microvascular complications. Diabetologla, 1978; IS: 143-152. 
Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ward JD, 
Nuber A, lonescu-Tirgoviste C, Pozza G and the EURODIAB IDDM 
Complications Study Group. The prevalence of diabetic neuropathy and Its 
relation to glycaemic control and potential risk factors: the EURODIAB IDDM 
Complications Study. Diabetologia, 1996; 39: 1377-1384. 
The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus. Report of the Expert Committee on the Diagnosis and Classification 
of Diabetes Mellitus. Diabetes Care, 1999; 22 (Supplement 1): S5-S19. 
Todd JA, Bell JI, McDevitt HO. HLA-DQbdB gene contributes to susceptibility 
and resistance to insulin-dependent diabetes mellitus. Nature, 11987; 4: 189- 
196. 
Tomlinson DR. Aldose reductase: its Importance In diabetes. Practical 
Diabetes, 1994; 11 (2): 51-55. 
Tooke JE. The microcirculation in diabetes. Diabetic Medicine, 1987; 4: 189- 
196. 
-377- 
Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study: A 
9-year update of a randomized, controlled trial of the effect of Improved 
metabolic control on complications in non-insulin-dependent diabetes 
mellitus. Annals of Intemal Medicine, 1996; 124(1): 126-145. 
Turnbridge WMG, Medical Services Study Group and British Diabetic 
Association. Factors contributing to the deaths of diabetics under fifty years 
of age. Lancet, 198 1; 11: 569-572. 
U 
UCLA. www. stat. ucla. edu/calculators/powercaic/normaVn-2-equaVn-2eq-var- 
power. html. Normal power calculations, 1999. 
UK Prospective Diabetes Study Group. UK prospective diabetes study XII: 
Differences between Asian, Afro-Caribbean and white Caucasian Type 2 
diabetic patients at diagnosis of diabetes. Diabetic Medicine, 1994; 111: 670- 
677. 
V 
Veglio M, Borra M, Stevens L, Fuller JH, Cavallo-Perin P, and the 
EURODIAB IDDIVI Complications Study Group. The relationship between 
QTC interval prolongation and diabetic complications. The EURODIAB IDDIVI 
Complications Study. Diabetologia, 1999; 42: 68-75. 
Vestbo E, Damsgaard EM, Froland A, Mogensen CE. Urinary albumin 
excretion in a population based cohort. Diabetic Medicine, 1995; 12: 488- 
493. 
Viberti GC. Aetiology and prognosbc significance of albuminuda In diabetes. 
Diabetes Care, 1988; 11(10): 840-845. 
Viberti GC, Mogensen CE, Groop LC, Pauls JF for the European 
Microalbuminuria Captopril Study Group, Effect of captopril on progression 
to clinical proteinuria in patients with insulin-dependent diabetes mellitus and 
microalbuminuria. JAMA, 1994; Vol 271, No 4: 275-279. 
Vlemming U, van der PijI JW, Lemkes HHPJ, Westendorp RGJ, Maassen 
JA, Daha MR, van Es LA, van Kooten C. The DD genotype of the ACE gene 
polymorphism is associated with progression of diabefic nephropathy to end 
stage renal failure in IDDM. Clinical Nephrology, 1999; 51 (3): 133-140. 
Vora JP, Dolben J, Williams JD, Peters JR, Owens DR. Impact of Initial 
treatment on renal function In newly diagnosed Type 2 (non-insulin- 
dependent) diabetes mellitus. Diabetologia, 1993; 36: 734-740. 
-378- 
w 
Waine C, The diabetic and coronary heart disease. Cardiology in 
Practice, 1989; 7: 36-44. 
Wagner A, Ballarin J, Calero F, Algaba F, Pou JM. Non-diabetic renal 
disease in Type 2 (non-insulin dependent) diabetic patients. Nephrology. 
Dialysis and Transplantation, 1997; 12(9): 1998. 
Waitzman MB. Proposed metabolic dysfunctions in diabetic microthrombosis 
and microangiopathy. Metabolism, 1979; 29 (4, Supplement 1): 401-406. 
Waldherr R, Ilkenhans C, Ritz E. How frequent Is glomerulonephritis In 
diabetes mellitus type II? Clinical Nephrology, 1992; 37(6): 271-273. 
Wang S-L, Head J, Stevens L, Fuller JH and World Health Organization 
Multinational Study Group. Excess mortality and Its relation to hypertension 
and proteinuria in diabetic patients: The World 'Health Organization 
Multinational Study of vascular Disease in Diabetes. Diabetes Care, 1996; 
19(4): 305-311. 
Ward JD. Improving prognosis in Type 2 diabetes: Diabetic nephropathy Is In 
trouble. Diabetes Care, 1999; 22(Supplement 2): 1384-1388. 
Watanabe Y, Yuzawa Y, Mizurnoto D, Tamai H, Itoh Y, Kumon S, Yamazakl 
C. Long-term follow-up study of 268 diabetic patients undergoing 
haemodialysis, with special attention to visual acuity and heterogeneity. 
Nephrology, Dialysis and Transplantation, 1993; 8: 725-734. 
Watts GF, Naumova R, Slavin BM, Morris RW, Houlston R, Kubal C, Shaw 
KM. Serum lipids and lipoproteins in Insulin-dependent diabetic patients with 
persistent microalbuminuria. Diabetic Medicine, 1988; 6: 25-30. 
Williams R. Mortality: is it an indicator of quality of care? Practical Diabetes, 
1993; 10(4): 139-140. 
Wilson E, Wardle EV, Chandel P, Walford S. Diabetes education: an Asian 
perspective. Diabetic Medicine, 1993; 10: 177-180. 
Wong JSK, Pearson DWM, Murchison LE, Williams MJ, Narayan V. Mortality 
in diabetes mellitus: Experience of a geographically defined population. 
Diabetic Medicine, 1991; 8: 135-139. 
World Health Organization. International Classitication ot Disease. Ninth 
Revision, 1975, published 1977 by World Health Organization. 
Working Group on Hypertension In Diabetes. Statement on hypertension In 
diabetes. Diabetes Care, 1987; 10(6): 764-776. 
-379- 
Wolverhampton Diabetes Register, 1990, New Cross Hospital, 
Wolverhampton. 
V 
Yokoyama H, Okudaira M, Otani T, Watanabe C, Takaike H, Miuira J, 
Yamada H, Mutou K, Satou A, Uchigata Y. Iwamoto Y. High Incidence of 
diabetic nephropathy in early-onset Japanese NIDDIVI patients. Diabetes 
Care, 1998; 21(7): 1080-1085. 
z 
Zatz R, Dunn R, Meyer TW, Anderson S, Rennke HG, Brenner BM. 
Prevention of diabetic glomerulopathy by pharmacological amelioration of 
glomerular capillary hypertension. Joumal of Clinical Investigation, 1986,77: 
1925-1930 
Zevaco-Mattei C, Reviron D, Atlan-Gepner C, BoW G, Simonin G, 
Lassmann-Vague V, Vague P, Mercier P, Vialettes B. Relabonship between 
HDL-DQ and -DR genotypes and clinical charactedsUcs In a French 
population of Type 1 diabetic patients. Diabetic Medicine, 1999; 16: 201- 
206. 
Zmirou D, Benhamou P-Y, Cordonnier D, Borgel F, Balduccl F, Papoz L, 
Halimi S. Diabetes mellitus prevalence among dialysed patients In France 








A small pilot study was performed to determine changes In anti-hypertensive 
drugs and dosages defined as a point scale, the aim of which was to produce a 
quantitative method for assessing levels of treatment based on type of 
medication and dosage. 
A2 Methods 
Five consultant physicians were asked retrospectively to complete a 
questionnaire (AM) on preferred drugs and dosages for the treatment of 
hypertension in Type I and Type 2 patients with nephropathy. The consultants 
were asked to assess a range of different anti-hypertensive drugs and allocate 
points on a scale from 1-10 (10 being the most preferred treatment) dependent 
on whether they were treating Type 1 or Type 2 patients. Points allocated by 
each consultant for type of drug were added together, the total was then 
averaged by dividing by the number of consultants. The drugs were 
subsequently graded according to treatment preference Le: grade I was the 
most preferred. Finally, points were allocated with the highest points equalling 
the highest grade e. g.: Grade 1=22 points, Grade 22=1 point (Tables A3.1- 
A3.3). 
The consultants were also asked to allocate points for dosages of these drugs 
again on a scale from 1-10 (10 being the most preferred dosage for maximum 
-382- 
effect) depending on type of diabetes. However, as only two consultants 
completed this section of the questionnaire, an average was determined for 
those drugs chosen as preferred drugs by both consultants. As one consultant 
had allocated points, as requested, to each dose of each drug, this InformaVon 
was used to determine points for the remaining drugs and dosages for each 
patient from baseline (at renal referral) until the end of the follow up period. 
A2.1 Questionnaire 
Instructions 
I am trying to develop and validate a point system for determining the 
effectiveness of anti-hypertensive medication in patients with diabetic 
nephropathy. I have listed the different drugs and dosages which patients have 
been treated with. I would like you to: 
A Award each dose of each drug a point between 1-10 depending on your 
own clinical judgement of the effectiveness of the dosage. 
13 Comment in the preference section which dose you would be likely to 
prescribe initially in patients with: 
a) Systolic = 140-160 mm Hg + Diastolic = 90-110 mm Hg 
b) Systolic> 1 60<200 mm Hg + Diastolic = 90-110 mm Hg 
C) Systolic > 160<200 mm Hg + Diastolic >120 mm Hg 
d) Systolic > 200 mm Hg + Diastolic =120 mm Hg 
Please mark comments with a), b), c) and d). 
-383- 
C Comment on which type of drugs are your preferential and second 
choice of treatment in Type 1 patients with nephropathy and Type 2 
patients with nephropathy. 
Scoring System for Hypertension Treatments 
Drug Total Daily Dose Point Preference in 
Diabetic Nephropathy 




Bisoprolol (mg) 5 
10 
Celiprolol (gg) 200 
300 
400 

















vage i OT questionnaire 
The following drugs were also listed in the questionnaire on subsequent pages: 
Nifedipine retard, nicardipine, amlodipine, diftiazam, doxazosin, hydralazine, 
enalapril, captopdl, lisinopdl, pedndopril, ramipril, fosinopril, trandolapril, 
cilazop(ii With a vadety of dosages. 
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A3 Results 
Four questionnaires were completed (80%), two by diabetologists and two by 
nephrologists. Only one of the four consultants completed the questionnaire on 
his own, the other three required detailed explanation from the author. From the 
questionnaires on preferred choice of anti-hypertensive therapy in Type I and 
Type 2 nephropathy patents, enalapril (an angiotensin converting enzyme 
inhibitor [ACEI]) was the preferred choice in both Type 1 and Type 2 patients 
with other ACEI coming about half way between enalapril and the least 
preferred treatment in both groups and other types of treatment varying in 
preference depending on the type of diabetes (Tables A3.1 and A3.2). 
Amlodipine was the calcium antagonists of choice used in both type of diabetes. 
Points were allocated for dosage of drugs as described in Table A3.3. 
All four consultants added information on an algorithm for treatment with a 
consensus that ACEI are the first line of choice in patients with Type I diabetes 
and with caution in Type 2 patents, followed by either beta blockers, calcium 
channel blockers, alpha blockers or diuretics. One consultant favoured 
verapamil in Type 2 patents and two recommended doxazosin for uncontrolled 
systolic hypertension. 
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Drug Average Mark Grade Points 
ENALAPRIL 8.5 1 22 
BISOPRILOL 7.0 2 21 
ATENOLOL 6.8 3 20 
DoxAzosIN 6.5 4 19 
LISINOPRIL 6.0 5 18 
FRUSEMIDE 5.0 6 17 
DmAzEm 5.0 6 17 
AMLODIPINE 5.0 6 17 
BUMETAMIDE 4.3 9 14 
NIFEDIPINE 4.0 10 13 
PERINDOPRIL 4.0 10 13 
P%AMIPRIL 3.3 12 11 
CAPTOPRIL 2.8 13 10 
CELIPROLOL 2.5 14 9 
VERAPAMIL 2.0 15 8 
NICARDIPINE 1.8 16 7 
CILAZOPRIL 1.8 16 7 
TRANDOLAPRIL 1.8 16 7 
FosINOPRIL 1.8 16 7 
INDAPAMIDE 1.3 20 3 
HYDRALAMNE 1.3 20 3 
AMILORIDE 0.5 22 1 
Table A3.1: Points for different anti-hypertensive drugs in Type 1 nephropathy 
patients 
Drug Average Mark Grade Points 
ENAIAPRIL 6.50 1 22 
DoxAzosIN 5.25 2 21 
AMLODIPINE 5.25 2 21 
ATENOLOL 5.00 4 19 
FRUSEMIDE 4.25 5 its 
UsINOPRIL 3.75 6 17 
BUMETAMIDE 3.25 7 16 
DmAzEm 3.25 7 16 
NIFEDIPINE 2.75 9 14 
BISOPROLOL 2.50 10 13 
VERAPAMIL 2.00 11 12 
PERINDOPRIL 2.00 11 12 
CAPTOPRIL 1.50 13 10 
RmPRIL 1.25 14 9 
CEUPROLOL 0.75 15 8 
INDAPAMIDE 0.50 16 7 
HYDRALAZINE 0.50 16 7 
NICARDIPINE 0.50 16 7 
AmILORIDE 0.25 19 4 
CILAZOPRIL 0.25 19 4 
TRANDOLAPRIL 0.25 19 4 
FoslNOPRIL 0.25 19 4 
Table A3.2: Points for different anti-hypertensive drugs in Type 2 nephropathy 
patients 
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Drug Dose Points Drug Dose Points 
ENALAPRIL (Mg) 2.50 2 ATENOLOL (Mg) 25.00 4 
5.00 4 50.00 8 
10.00 6 100.00 8 
15.00 7 
20.00 8 FRUSEMIDE (Mg) 20.00 3 
30.00 10 40.00 5 
40.00 10 80.00 4 
CAPTOPRIL (Mg) 120.00 6 
12.50 2 160.00 6 
25.00 4 
50.00 7 BISOPROLOL (Mg) 5.00 5 
100.00 10 10.00 5 
PERINDOPRIL (rng) 2.00 3 BUMETAMIDE (Mg) 1.00 3 
4.00 5 2.00 6 
8.00 8 6.00 8 
DITLAZEM ( g) 60.00 2 
USINOPRIL (Mg) 2.50 2 120.00 3 
5.00 3 180.00 5 
7.50 4 360.00 10 
10.00 5 
15.00 6 CELIPROLOL filg) 200.00 5 
20.00 7 300.00 7 
40.00 10 400.00 10 
RAMIPRIL (Mg) 1.25 3 INDAPAMIDE (Mg) 2.50 2 
2.50 4 5.00 3 
5.00 7 
10.00 10 HYDRALAZINE (Mg) 25.00 2 
50.00 5 
NIFEDIPINE RETARD 10.00 1 75.00 7 
(rng) 20.00 3 100.00 9 
30.00 6 150.00 10 
40.00 8 NICARDIPINE (Mg) 
60.00 8 40.00 3 
90.00 10 60.00 5 
90.00 7 
DOXAZOSIN (Mg) 1.00 1 120.00 10 
2.00 3 AMILORIDE (Mg) 
4.00 4 5.00 1 
5.00 6 10.00 2 
8.00 9 15.00 0 
20.00 0 
AMLODIPINE (Mg) 5.00 5 
7.50 7 
10.00 10 
Figure AM: Points allocated for individual doses. 
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The mean points for anti-hypertensive treatment have been used in Chapter 8 
to illustrate the differences between Type I and 2 patients. The following box 
Plots of points in different ethnic groups show that this method has been useful 
in comparing anti-hypertensive treatment over several years, for identifying lack 
of treatment and for comparing different groups of patients (Figures Al-A3). 








Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Median: 
Year 7 
Figure Al : Points for anti-hypertensive therapy in Indo-Asian patients over seven years 
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Figure A2 : Points for anti-hypertensive therapy in Black patents over four years 









Baseline Year I Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 
Wdian: 
Figure A 3: Points for anti-hypertensive therapy in White patients over seven years 
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Baseline Year 1 Year 2 Year 3 Year4 
Wdian: 
A4 Discussion 
The questionnaire was completed retrospectively which made it more difficult 
for consultants to allocate points to drugs which were used at the start of the 
treatment and have since been replaced by newer drugs e. g.: angiotensin 11 
receptor antagonists. It is impossible in retrospect to know whether the 
similarities between the preferred drugs of choice as determined now, rather 
than at the start of the study, reflects any change in practice over the last twelve 
years. It would have useful to have performed the pilot study at the start of the 
main project and repeated it towards the end to assess whether there have 
been any changes in practice. 
The questionnaire design could be improved in that three out of the four 
consultants who completed it needed detailed explanation on what was being 
asked for and all four added additional information on algorithms for treatment. 
As only one person completed the full section on drug dosages this has 
certainly biased the results for the allocation of points to Individual dosages. 
As a pilot study, it was a useful concept to provide a quantitative means of 
comparing changes in hypertension therapy over several years despite the 
limitations previously discussed and certainly the box plots have provided a 
useful illustration of differences in groups of patients as have the graphs In 
Chapter 8 of mean point scales over different years. 
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Collecting information from a larger number of consultants would have provided 
a method that was a statistically sound quantitative tool. 
A5 Conclusion 
As a means of quantitatively determining anti-hypertensive therapy, the method 
used in this pilot study gives indications rather than definitive answers. It could 
easily be modified further for use in future studies if required. 
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Appendix 2 
Definition of Terms 
Alpha blockers: Alpha-adrenoceptor blocking drugs 
Black: People of African origin irrespective of place of birth. 
Beta blockers: Beta-adrenoceptor blocking drugs 
Defaulting from routine clinic visits: Patients missed more than two consecutive 
clinic visits in more than one year since diagnosis. 
Diabetic nephropathy: Presence of persistent proteinuria plus diabetic 
retinopathy (Clinical diagnosis) or confirmed by renal biopsy. 
Hypertension: Systolic pressure > 140 mm Hg and / or diastolic pressure > 90 
mm Hg or receiving anti-hypertensive therapy as defined by the Working Group 
on Hypertension in Diabetes, 1987. 
Indo-Asian: People with origins from the Indian sub-continent Le.: India, 
Pakistan and Bangladesh, irrespective of place of birth. 
Ischaernic heart disease: Documented evidence of angina symptoms or 
electrocardiographic evidence. 
Lost to follow up: Patient stopped attending nephrology and diabetic clinics 
plus no information available on the patient having died. 
Peripheral vascular disease, severe: Presence of intermittent claudication or 
amputation. 
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Renal disease: Presence of persistent proteinuria on 'stick" testing (confirmed 
by measurement of 24 hour urinary protein excretion) and / or raised serum 
creatinine concentrations (> 120 Itmol 1-1). 
Retinopathy, background: Presence of new blood vessels, cotton wool spots 
and dot or blot haemorrhages 
Retinopathy, severe: Presence of proliferative changes, haemorrhage or loss 
of visual acuity not due to other conditions. 
Type I diabetes: Diabetes mellitus diagnosed before age 35 years and 
requiring insulin treatment vvithin the first year of diagnosis. 
Type 2 diabetes: Diabetes mellitus diagnosed after 35 years of age. 
White: People of European origin irrespective of place of birth. 
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Appendix 3 
Specimen Death Certificate 
From: 1995 Mortality statistics (Office for National Statistics, 1997) 
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World Health Organization 
International Classification of Disease 
Ninth Edition 
ICD-09 Code: 250: Diabetes Mellitus 
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148 TABWAR UST 
246.2 Cyst of thyroid 
Exdudes: cystadenoma (226) 
2464 - Haemorrhage and infarction of thyroid 
246.9 Other 
Abnormality of thyroid-binding Atrophy of thyroid 
globulin 
246.9 Unspecified 
Disum OF OTHER ENDOCIUNZ GLANDS (25(ý259) 
250 Diabetes meMtus 
Ile following fifth-digit subclassification may be used, if desired, with 
category 250: 
.0 adult-onset type 
.1 juveae type 
.9 unspecified whethq adult-onset or 
juvenile type 
Clinical informadon should be obtained when choosing the fifth digit. If 
irnpssiblcý. 9 should be usedL 
Excludes: neonatal diabetes mellitus, (775.1) 
nonclinical. diabetes (790.2) 
when complicating pregnanM childbirth or the puerpen'um 
* (649.0) 
250.0 Diabetes meffilus without mention of complication 
Diabetes mellitus without mention of complication or manifestation 
classifiable to 250.1-250.9 
Diabetes (mellitus) NOS 
1.4ale. tium tetiosckrosis; unless ketoacidosis or corna is ncndoned. widr 49)9. 
DlIftWill) 
-I. 
250.1 Diabeles with keloacidwir 
Diabetic: 
acidosis without mention of coma 
ketosis 
I 
2501 Diabetes, wuh coma 
Diabetic coma (with ketoacidosis) Diabetes with hyperosmolar coma 
250.3 t Diabetes wirh renal manyestations (581.8.582.9.593.9*) 
Diabetic nephropathy Kimmelstiel-Wilson syndrome 
Intracapiflary glomcrulosclerosis 
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250.5 t Diabetes with neurological manifestations 
Diabetic: 
amyotrophy (358.1*) Diabetic polyneuropathy (357.20) 
mononeuropathy (354. -, 351-4) 
250.6 t Diabetes with peripheral circulatory disorders 
Diabetic: 
gangrene (785.4*) 
peripheral angiopathy (443.8*) 
250.7 t Diabetes with other specified manifestations 
Excludes: intercurreni infections in diabetic patients 
250.9 Diabetes with unspecified complications 
251 Other disorders of pancreatic Internal secretion 
251.0 Hypoglycaemic coma 
latrogenic hyperinsulinism, Insulin coma 
Use additional E code, if desired, to identify cause if drug induced 





Hyperplasia or pancreatic islet beta cells NOS 
251.2 Hypoglycaemia, unspecfied 
251.3 Postsurgical hypoinsulinaemia 
Postpancreatectomy hyperglycaemia 
251.4 Abnormality of secretion ofglucagon 
Hyperplasia of pancreatic islet alpha cells with Slucagon excess 
251.5 Abnormality of secretion of gastrin 




Islet-cell hyperplasia NOS 
252 Disorders of parathyroid &land 
252.0 Hyperparathyroidism 
Hypirplasia of parathyroid 
Osteitis fibrosa cystica gencralisata (von Recklinghausen's disease of bone) 
Excludes: secondary hyperparathyroidism, (of renal origin) (588.8) 
Appendix 5 




Biomen 8140 Analyser measures HbAlc by ffigh Pressure Liquid Chromatography. When 
operated in the batch mode, the analyser will produce a result in about four minutes. The use 
of the prehaernolysed feature enables the department to offer up to the minute results on 
Patients attending the paediatric diabetic chnic. 
'14bAlc is well established as an indicator of diabetic control over a period of about 3 months, 
the average life span of a red blood cell being about 100 days. The system does not detect ýbnbrmal haernoglobins, thus patients with these variants can be difficult to recognise and they 
are better monitored by fructosamine estimation. 
XlAINTENANCE AND SEMPLE DIAGNOSTICS 
The 8140 has proven to be a very reliable analyser. it is vital that the maintenance as described 
on the maintenance sheet is absolutely adhered to. This will keep problems to a minimum. 
'Fuming the column regularly will approximately double the life of the column to about 5000 
tests. Filters may need changing more often than every 500 samples as they are prone to 
blockage. It is crucial to empty the waste container after each run: if the waste reaches a 
c! ýain level, the analyser will automatically shut down. Failure to close the manifold screw 
vAll cause the waste bottle to fill rapidly and again shutdown will occur. The usual operating 
Pressure is 57. Changing the filter or turning the column will not affect this by more than 2 if it 
has been done correctly. When working on the system never use excessive force, as it is 
possible to shear the precision fittings. Frequently the fiits that form seals become deformed 
and can be difficult to remove. The solution is to carefully prise them out with thin scissors, 
thin scalpel blades etc. The 8140 is supplied with a comprehensive handbook particular has. If 
a problem proves difficult, the technical backup provided by the company is immaculate. 
REAGENTS 





2 level 'Glyco BB Control' code U 8312 supplied by Menari Diagnostics. 
BATCH MODE OPERATION 
Introduction 
A worksheet is automatically generated when 100 unknowns have been reached. If desired, a 
wok list can be forced to be printed using 'EDT' and 'worksheet'. The analysis of a batch has 
been considerably simplified by the use of a PC to link generation of information from the 
8121 to the LDM. The stages involve downloading a worksheet, creating a load list, 
Performing the batch run and uploading the data to LDM. 
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Method 
On the 'speedmaster' click on the flame icon. The LAIX/HbAl Analyser Interface will be 
displayed. Click on 'Get Worksheet'. A box will be displayed asking for the number of the 
worksheet to be downloaded. Enter the number and click OK. An acknowledgement will 
appear in the Biomen window and a few seconds later the worksheet will be scrolled upwards 
in the LDM window. When downloading is complete, it is necessary to close the application 
before attempting to create the load list. Re-open the application by clicking on the flame icon. 
In a few seconds the Analyser Interface will be displayed. Create the load list by clicking on 
'Create Load List'. You will be asked for the total number of samples you wish to analyse. 
Enter the number in the run plus one to allow for the batch check. Click on create, wait for 
five seconds then click on done and close. The load list will be printed. 
IA)ad the samples on according to the load list, checking each sample carefully. The probe is 
cap piercing. Mistakes at this stage can he impossible to unraveL Press start and click on 
C receive data'. If you forget this last step and do it when some results have gone across, the 
data comes across in an avalanche and is usually garbled; do not forgetl 
ANALYSIS OF CONTROLS AND CLINIC SAMPLES 
Controls and clinic samples are run pre-haemolysed. The haemolysate is prepared by adding 
20ul of whole blood to 2.7mIs of haemolysing solution an a sugar tube mixing to ensure an 
even haemolysant. The 8140 will recognise samples as pre haemolysed if the first four tube 
wells in a sample rack are lect empty. All six remaining sample wells will be treated as 
Prehaemolysed. The results will be printed with a '999" preceeding the result, thus 
Prehaemolysedsample number one will be printed as '9991', sample two as '9992' etc. Before 
uPlOading the results to LMX it is necessary to remove the pre-haemolysed results. 
Removal of Pre-haemolysed samples 
Click on Files. 
Click on Edit Biomen Data. 
Find 9991 and 9992 lines by scrolling, highlight them and press delete twice to delete them 
and remove an unwanted carriage return. 
Click on Files. 
Click on Save Biomen Data. 
Click on Files. 
Click on Regenerate Results. 
At the end of the run, click on 'stop analyser link, and then click on 'upload to LMY. The 
process of uploading is relatively slow and it is prudent to allow half an hour for this process, 
if LDM is busy. The data are sent to individual patient files by using EFr, ERFT and the 
relevant work list number. The results will scroll rapidly up the page. If any analyses have not 
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produced results, a space will occur and you may enter a result manually or send the analysis 
to another worksheet using 'replig'. 
HEALTH and SAFETY 
Refer to COS SH Assessment Ref No. COA 18 
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INTRODUCTION 
The RA 1000 is basically a combined pipetting station and spectrophotometer with 
temperature control. It is both accurate and precise, typical cvs being < 3%. It performs a 
wide range of tests, the mode of operation is similar for each. Consequently this procedure 
consists of some specific details about the individual methods and a flow chart explaining how 
to run the instrument, with details of how to calibrate and simple troubleshooting. 
The methods fall into two groups.... 
I Methods using manufacturers Idts. 
2 Methods using reagents prepared in the laboratory. 
The Parameters for each test are stored in the RA, the parameter list contains the settings that 
are stored in the RA 1000 to enable analyses to be performed. Each set of parameters is 
unique. Parameters can be fisted using 94 function and the RA chemistry number. One 
example is given below. 
Glucose Parameters Chemistry 13 
NAMEGLuc 
TYPE i 
% SUIP VOL 6 
FILTER POS 4 WL 500 
DELAY 030 
INCUBATION 100 
% RGT VOL 74 
UNITS4 MMOLA, 
UNIT FAC 1.0000 
DECIMALPTI 
RBL LOW 0.000 
RBL 111 0.200 
RANGE LOW 0 
RANGE HI 25 
CAL FACTOR 188.68 
RGT RATE 0.0000 
STD VAL 16.3 
NORMAL LO 2.0 
NORMAL 1-11 8.0 
SLOPE 1.000 
INTERCEPT 0.00 
LIN FACT 1.00 
I ST LIM 1.000 
REFERENCE 
Technicon RAIOOO handbooks. 
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STANDARD OPERATING PROCEDURE FOR THE RA 1000 
EDITION No: Edition 1.0 
OPERATIVE DATE: 01/01/1997 
R. EVIEW DATE: 01/01/2000 
EDITION N/A 
REPLACED: 
FILE NAME: rasop. doc 








Edition Date Comment 
1 l/l/97 
REFERENCES 
The wide range of tests offered by the RA 1000 have extensive clinical utility, which is 
described in several textbooks. 'Clinical Chemistry' by Marshall has excellent clinical 
information, whilst 'Clinical Chemistry in Diagnosis and Treatment' by Mayne is more 
biochemically based. 
QUALITY CONTROL 
Bio-rad 2 level control supplied by Bio-rad Laboratories, Maylands Avenue, Hemel 
Hempstead, HP2 7TD. Add 10ml of deionised water to each level and mix for 30 minutes. 
Stable for 3 days at 4*C 
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HDL'CHOLESTEROL &TOTAL CHOLESTEROL 
1.5g glycine' 
Make up to 100ml with water. Store 
Reagents supplied by Bayer Diagnostics Product number IMI 1684 01 
Standard : Randox Level 1, diluted 1/2 with distilled water. Ile dilution does not 
affect the results , as the samples are diluted by the same factor-during-pre-treatment QC material: HIQC 17. 
Working reagent stability : One month at rC 
Calibration frequency : Calibrate before, each run. 
Normal range : Male 0.7 - 1.9 mmol/I Fernale 0.7 - 2.0 mmol/I 
Add 200ul PEG, vortex mix. 
0 Analyse the supernatant for cholesterol. 
Cholesterol esterase hydrolyses cholesterol esters to free cholesterol, which in the presence 
of oxygen and cholesterol oxidase produces hydrogen peroxide, which in turn products a 
quinoneimine dye. A red colour is produced which is measured at 525nin 
Cholesterol esterase 
Cholesterol esters 4 Cholesterol and fatty acids 
- Cholesterol oxidase. Cholesterol + o2 4 Cholest -4 en -3- one 4- 
H202 
Peroxidase 
H202+ 4- Aminoantipyrene. + p-Hydroxybenzoate 4H20 + C(h 
Quinoneimine dye 
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CREATININE 
N. B. Where the following symbol A occurs next to a reagent, look up the hazards and 
Piecautions; to be taken in the BDH Hazard Data Sheets. 
Reagents supplied by Bayer Diagnostics. 
Picric Acid. Product number T21-1928-Al ENPLOSIVE WHEN DRY). 
NaOH. Product number T21-1929-Al. 
Working reagent. Mix equal volumes of Picric acid reagent and NaOH reagent Add I 
drop of wetting agent for every 7ml of reagent. Stable for I month at room temperature. 
" Standard Randox Level II 
" QC Material Nycomed three level controls. 
" Calibration frequency As judged by control values 
" Normal range 60 - 120 umol/l. 
qreatinine reacts with picric acid in an alkaline medium to produce a red coloured complex, in 
a selected time interval, is proportional to the original creatinine concentration. The 
absorbance of the analytical mixture is measured at 500 nm on a first order reaction curve. The 
reaction is initiated by addition of sample to the reagent. Interference may result from 
extremely jaundiced samples. 
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PLASMA LACTATE 
" RA chemistry number 32 
" Tray 4: Position 1. 
" Normal Range 1.0 - 1.8 mmol/I 
" QC material: Batch check from previous analysis. 
" Standard : Lactate Standard (Sigma 51h 6151) .A working standard, 4.44 mmot/l is, ' prepared by diluting this stock standard 1/3 with 0.6 mmot/l HCI04- 
" Calibration frequency: Standardisation is necessary each time. 
Reagents 
N. B. Where the following symbol A occurs next to a reagentý look up the hazards and 
Precautions to be taken in the BDH Hazard Data Sheets. 
1 OAM HCI 04 A (EXPLOSIVE WHEN DRY) 64.5 n-A 60-62% perchloric acid (BDH) 
diluted to I litre with distilled water. 
2 Lactate Buffer, PH 9.15.40g glycine A (BDI-1), 20ml AnalaR Hydrazine Hydrate A 
(BDH), 4g EDTA, disodium salt AS (BDI-1). Adjust to PH 9.15 with 10% UOH A (l3DH) 
and make up to I fitre with distilled water. 
3B- NAD 'A (Sigma 12H7843). Store at less than OOC. 
4 LDH solution A (Sigma IOH96150). Store at 4"C. 
Working lactate reagent and stability 
Make up as follows in a 25ml universal container 
0 55mg NAD 
0 10 ul ILDH solution 
0 25 ml Lactate buffer 
This reagent will last if stored at 4"C for one week. However the LDH needs topping up each 
time, as it will gradually lose activity. Add I ul each time the reagent is used. 
Method 
Plasma from a fluoride oxalate tube is required. Lactate is stable in this tube for at least 4 hr. 
The sample must be prepared for analysis immediately upon receipt. Centrifuge the sample for 
5 min at 3000 rpm. Make a 1/3 dilution of plasma in cold 0.6M HC104 using 0.2 ml plasma 
and 0.4ml acid in a plastic bullet tube. Vortex and allow to stand for 5 minutes. Centrifuge in 
the micro centrifuge for I minute at 13,000rpm. Collect the supernatant into a new bullet tube. 
The lactate is now stable. 
LDH catalyses the reversible conversion of lactate to pyruvate; 
LDH 
L -Lactate + NAD 4 pyruvate, + NADH 
The reaction is driven to the right by using excess NAD and hydrazine which removes 
pyruvate, as soon as it is formed. 
URINE PROTEIN 
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L= i Department of ainical Chemistry '? 
RA chemistry number 33 Work station number 2. 
.. 
Tray 4: Position 6. 
, 
Normal range: Up to 100mg/24 hr. NB values >2.0 g/I require dilution. 
Reagents 
N. B. Where the foflowing symbol A occurs next to a reagent, look up the hazards and 
precautions to be taken in the BDH Hazard Data Sheets. 
Pyrogallol red .91.5mmoVI . Dissolve 60mg Pyrogallol red (Sigma product 8759) in I 00ml methanol BDH (GPR). 
Sodium Molybdate. Dissolve 0.24g disodium molybdate. 21420 A in l0ml distilled 
water. 
Buffer. Dissolve 5.9g succinic acid A (BDH), 0.14g sodium oxalate 33. (BDH) and 0.5g 
sodium benzoate J' 19, (BDH) in 900ml distilled water. Working reagent To the 900ml of buffer, add 40n-d pyrogallol solution, 4ml of the 
sodium molybdate solution. Adjust to pH 2.50 with O. IM HO and dilute to I litre with 
distilled water. Add I ml/l of 3 0% Brij solution. Stable for 6 months at 4*C. 
Standard 
Aqueous human albumin (BDIi) concentration 1.60g/l. 
QC Material 
Aqueous human albumin (BDH) concentration 1.60SA. 
Calibration frequency 
As judged on the basis of control values. 
Under acidic conditions and in the presence of molybdate ions, proteins form a blue coloured 
complex with pyrogallol red. The absorbance is measured at 600nm. 
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OPERATION OF THE RA 1000 
Check that the daily maintenance has been performed. Check that there is sufficient reagent for 
the number of tests that you wish to perform. Ensure that you have installed the correct 
reagent ray. These are stored in the RA! s memory and for convenience are also displayed on a 
card between the machines. The RA is a 'random access' analyser enabling any combination of 
tests on a selected reagent tray to be performed. Results are printed on the paper roll and may 
also be sent directly to the main computer. 
Periodic calibration of certain analyses may be required. Calibrating the RA is described 
subsequently as a sub routine of running a work list. Individual analyses are performed in 
separate cuvettes of the plastic rotor tray. There are 100 cuvettes, per tray. When the last 
cuvette has been filled the alarm will sound and the LED will display RT FULV. 
C11UNGING THE TRAY 
Press 'clear entry' to switch the alarm off Remove the tray and empty the contents into 
VIRKON tank 1, then immerse the tray in VIRKON tank 2, CARE II Introduce a clean tray 
and press '30 function. This will command the RA to scan the cuvettes. The number of 
unsatisfactory cuvettes will be displayed on the IED e. g. '2 bad cups',, these will not be used 
for analyses. Press'O operate entee; the RA will perform the rest of the tests. 
ROTOR TRAY WASHING WTM VIRKON 
Virkon Medical Disinfectant is obtained from the hospital pharmacy. The 5kg tin is stored in 
the fume cupboard in the weighing room. N. B. Always wear gloves and glasses when 
working with virkon. 
Every Monday, empty the two virkon tanks. Tank I contains 180g of virkon in 4 litres, of 
water. This tank receives the contents of the used tray. tank 2 contains 360g of virkon in 8 
litres of water in which the rotors are soaked for at least 8 hours to disinfect. A measuring cup 
is provided with the virkon. it is important to void the rotors completely into tank 1, to 
minimise precipitation in tank 2. 
Tank 2 should be emptied each day. To minimise time - consuming washing at weekends, it is 
prudent to build up a stock of' W1 V trays. Trays that have been used twice should be 
discarded. Rinse trays thoroughly in tap water, then place the tray in the Biostat washer and 
wash twice with distilled water. Do not allow trays to dry out before the distilled water wash. 
After washing, dry the trays on the oven in the wash - up room. When dry, inspect each 
cuvette, polishing if necessary with a clean cloth. Dirty cups should be blacked out so that they 
will not be used. Mark the number of washes on the tray, e. g. Wl'or W1 1'. Place the tray in a 
plastic bag and store in the cardboard box provided. 
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Edition Date Comment 
1 08/04/98 
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PRINCIPLE 
The Technicon DAX multichannel analyser has the capability to perform up to 24 tests on a 
sample, e. g. Sodium, potassium, bicarbonate, urea, creatinine, albumin, total protein, 
bilirubin, alkaline phosphatase, alanine transaminase, lactate dehydrogenase, magnesium, 
urate, calcium, phosphate, cholesterol and triglycerides. Sodium and potassium are measured 
Using ion - selective electrodes. Other analyses depend on changes in ultra - violet and visible light. 
REFERENCES 
The wide range of tests offered by the DAX have extensive clinical utility, which is described 
in several textbooks. 'Clinical Chemistry' by Marshall has excellent clinical information, 
whilst 
'Clinical Chemistry in Diagnosis and Treatment' by Mayne is more biochemically based. 
Specific information about the methods is available in the DAX methods manual. 
REAGENTS SUPPLIED BY BAYER DIAGNOSTICS 
Dax Reagent Part Number Reagent Stability 
Albumin 011377113 Expiry date as per container, stored at R. T. 
Alk Phos (DEA) 01 1902AO Expiry as per bottle, 7 days reconstituted 4-8 deg 
ALT 01 1760AO Expiry as per bottle, 7 days reconstituted 4-8 deg 
AIT Reagent 2 11 1762CO Ditto 
AST 011750135 Ditto 
AST Reagent 2 11 1752CO Ditto 
Creatinine Individual components expiry as container, 10 
days at R. T. once mixed 
Calcium 01 1476AO Expiry date as per container, stored at 4-8 deg 
Calcium Reagent 2 211516CO Ditto 
Cholesterol 01 1684AO Expiry as per container, 10 days at 4-8 deg 
reconstituted 
PSI, 11336262 
Total Bilirubin 01 1963AO 
Total Protein 011301113 Expiry as per container, store at R. T. 
Triglyceride 011863115 
Urea 011823AO 
Uric Acid 012577135 
ISE Acid Wash 013164AI Expiry as per container, store at R. T. 
ISE Alkaline Wash 013165AI Ditto 
Bath Additive 013163AI Ditto 
ISE Buffer 013161AI Ditto 
ISE Detergent 01358554 Ditto 
Md - Control Calib 033162AI Ditto 
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CALIBRATORS 
Three calibrators are used: - 
10 ISE standards as supplied by Bayer Diagnostics. Part numbers-Low 03-3166-AO, 
High 03-3067-AO. 
20 DAX calibrator supplied by Bayer Diagnostics. Part number 03321762. 
3 El In house bicarbonate standard (25 mmol/1) 
QUALITY CONTROL 
Biorad two level control. Details of analytical performance can be found in the DAX 
methods manual. 
METHOD 
Start Up and Reagent Preparation 
" Most of the maintenance and start up can be done setting the DAX to come on 
automatically at 8am. The instrument will be ready for use about 45 minutes later. 
" Log on touch screen. 
" Ensure that both green lights at the back of the water supply unit are on. 
" Reagent status is checked at the end of the previous days work, as some reagents need 
special preparation. Add reagents as required. For enzyme tests, dissolve given quantities 
of powder with the diluent provided. These reagents can be used as soon as they have 
dissolved. 
" Non refrigerated liquid reagents are ready for immediate use. 
" Triglyceride reagent is prepared 24 hours before use. 
" Urea is prepared 24 hrs before use. 
" ALT reagents are made up in special bottles, as those supplied are too small to hold the 
required volume. 
" Working bilirubin reagent is prepared by mixing reagents I and 2. The bilirubin blank is 
ready for use. 
" Activate U1W screen. 
Reagent Base Lines, Calibration and Loading of Controls 
" Prime as necessary. 
" Load a blue rack with one empty z 10 tube for RBL- 
" Load a green rack with DAX calibrant in position 1, ISE low calibrant in position 2 and 
ISE high calibrant in position 3. Single channels can be calibrated via menu 4 result 
validation 4 run condition. 
" Load a yellow rack with controls and one AO containing water for creatinine blank in 
position one. 
" To commence RBL and calibration, press start/stop, run, yes. 
" N. B. Dax does not do an automatic RBL when calibrating. Individual RBLs can be 
performed by highlighting those desired. 
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Analysing samples 
" Load the control rack (yellow) at the beginning, followed by sample racks (white). 
" Ensure the spout part of the insert is directly behind the bar code. 
" Ensure that the bar codes face the reader. 
" To start a run, press START/STOP, then RUN. 
RESULTS 
Calculation Include all calculations even if LMX does them for you. 
Dilutions 
The autodilution levels are pre-set by the manufacturers. There are four levels; Neat, 1: 2,1: 4, 
1: 8 
Action Limits 
A list of action limits is kept alongside the analyser, and results limits are set in the UIW so 
that results outside the limits appear in the incomplete file for the operator to view them. 
LIMITATIONS 
The following analytes are affected by haemolysis and should not be reported on haemolysed 
samples (or samples which have been left on cells for excessive periods of time: - 
Sodium, Potassium, Bicarbonate, ALT, Alk Phos. 
Analytes on lipaemic samples should not be reported except for triglyceride and cholesterol. 
If electrolytes are required on suh samples, they should be analysed on the direct reading 
ISEs of the Opera. 
Very jaundiced samples i. e. specimens with bilirubin greater than 100 umoul should not have 
their creatinine reported. 
HEALTHandSAFETY 
Refer to COSSH Assessment Ref No. COAI 1, C024 and COA25 
Authors Month, Year 
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RISK FACTORS FOR DEVELOPING NEPHROPATHY AND 
COMPLICATIONS IN PATIENTS WITH TYPE Il DIABETES 
EV McLelland, PB Rylance, J Odum, MA Jackson, S Walford, BM 
Singh, JD Phillips, C Padgharn. - 
Renal & Diabetic Units, New Cross Hospital, Wolverhampton & 
Division of Clinical Science, University of Wolverhampton, UX 
Prevention of diabetic nephropathy and complications requires 
control of risk factors. A study was therefore performed to identify 
the risk factors in patients with Type 11 diabetes. 
85 Type 11 patients with diabetic nephropathy were compared, at 
referral for nephrological assessment, with 76 Type If control 
patients without nephropathy, controlled for age (62 +8 years), sex 
(68% male, 32% female), duration of diabetes (13 +7 years) and 
ethnic group (Caucasian, Asian, Afro-Caribbean). 
Type 11 nephropaths, when compared with controls, had increased 
retinopathy (95% v 54%, p<0.001), reduced visual acuity (25% v 
9%, p<0.001), peripheral neuropathy (46% v 28%, p<0.02) and leg 
ulcers (20% v 1%, p<0.001). Nepbropathy patients were more 
commonly hypertensive (2: 140/90) (96% v 58%.. p<0.001), and 
blood pressure was higher (mean. systolic 173mmHg v 150, 
p<0.0001) diastolic 90 v 81, p<0.005). Howeveronly 45% of 
nephropaths were on anti hypertens iv es, compared with 91% 
controls (p<0.001). In addition more nephropaths had defaulted 
from clinic visits (44% v 8%, p<0.001). Diabetic control over a9 
year period was poor (HbAlc 10.2-12.2%) but there was no 
differepce between the two groups. More nephropaths had 
previously smoked (51% v 24%, p<0.001), and still smoked (27% 
v 12%, p<0.02). 
Type II diabetics with nephropathy have increased diabetic 
complications. Whilst diabetic control does not appear to be a risk 
factor, uncontrolled hypertension, failure to prescribe or take 
antihypertensives, defaulting from clinic and smoking are associated 
with the development of diabetic nephropathy in Type 11 patients. 
Clinical management of Type 11 diabetics should address these 
risk factors, in order to reduce development of nephropathy and 
other diabetic complications 
It 
-INCREASED PREVALENCE AND ACCELERATED ONSET OF 
RENAL DISEASE IN PATIENTS WITH TYPE 11 DIABETES 
EV McLelland, PB Rylance J Odum, MA Jackson, S Walford, BNj 
Singh, JD Phillips, C Padgham. 
Renal & Diabetic Units, New Cross Hospital, Wolverhampton & 
Division of Clinical Science, University of Wolverhampton, U. K 
There has been a progressive increase in referral of older diabetic 
patients with end-stage renal disease (ESRF), associated with 
increased morbidity. This study has assessed and prospectively 
followed 220 diabetics (7% of diabetic clinic patients) referred with 
proteinuria &/or raised creatinine over an 8 year period. Type I 
patients were compared with Type 11. 
78% of diabetics with renal disease were Type 11, and were 
predominantly male (61%). * 
49% of Type 11 had become insulin- 
dependant. Development of renal disease was accelerated in Type 
11 (11+8 years), compared with Type 1 (2ý+10, p<0.001). Type If 
were 20 years older than Type 1 (63+8 v 43+12 years, p<0.001). 
96% Type I had diabetic nephropathy bu .t only 60% Type 11 had 
diabetic nephropathy, the remainder had predominantly 
hypertension and reno-vascular disease, which correlated with the 
41% with no diabetic retinopathy. There was a- high incidence of 
macrovascular complications, particularly Ischaemic Heart Disease 
(16% v 19%, NS) and Peripheral Vascular Disease (39% v 29%, 
NS). Hypertension (? J40/90) was present in 90% Type I (mean 
160190) and 92% Type 11 (168/90), but only 46% Type I and 48% 
Type 11 were on antihypertensive therapy at referral. Diabetic control 
was poor in both groups (HbAlc 11.1% v 10.9%, NS), and 
cholesterol was similar (6.8 v 6.6mmol/l, NS). 26 Type 11 developed 
ESRF compared with 16 Type 1.40 died (18%), 17. (43%) from 
cardiovascular disease. 
There is an increased prevalence of Type 11 diabetics with renal 
disease compared with Type 1. Uncontrolled hypertension may be 
a factor in development of renal disease in both groups. In Type If 
patients age and renovascular disease may result in accelerated 
development of renal disease. 
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